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introduction and outline of the thesis 1
Meningococci are new pathogens. evolutionary speaking brand-and-shining-new 
pathogens, which emerged probably as recently as 200 years ago. They appeared 
when harmless neisserial commensals in our nasopharynx obtained the ability to 
cause invasive disease, possibly due to accidentally acquiring a polysaccharide 
capsule from another bacterium. in contrast, our immune systems are old. Very 
old, probably nearly as old as multicellular life itself. in spite if its age however, our 
immune system is perfectly fit to deal with the multitude of micro-organisms that 
threaten us from our environment. 
so, how does our ancient immune system battle a new pathogen such as Neisseria 
meningitidis? some people, often previously perfectly healthy, young children, may 
be left utterly defenseless. When they become infected, and get meningococcal 
septic shock, they develop rapidly progressive disease that kills one out of five 
patients, leaving another third with severe sequelae. fortunately, only a minority 
of people will acquire invasive meningococcal disease. also, not all people exhibit 
the same type of illness, there are multiple clinical manifestions associated with 
meningococcal infections. in sharp contrast to the dreadful manifestation of 
meningococcal septic shock, there even are some patients that present with 
chronic 'benign' meningococcal bacteraemia. This is a disease in which patients 
can have meningococci in their blood for weeks and still recover completely with 
simple antibiotic treatment. 
although great progression has been made previously, many children are still 
killed or severely disabled by meningococcal infections. We still cannot prevent 
children from being infected. Therefore, we need to study pathogenesis. What if we 
could turn - using our knowledge of pathogenesis - the clinical course of fulminant 
meningococcal septic shock into benign meningococcal bacteraemia?!
The present thesis studies the interplay between meningococci and the innate 
immune system. The focus is on the role of cytokines and the complement system. 
The questions are straightforward and simple: what happens during invasive 
disease, how does it happen and are there ways to stop it from happening? The 
answers are complex but will increase our knowledge, hopefully leading to new and 
better treatments for this dreadful disease. 
lipopolysaccharide (lPs) has always been regarded as the principle cytokine 
inducing element of N. meningitidis and other gram-negative bacteria, and lPs 
is also thought to be important for the activation of complement. in chapters 2 - 
4 we made use of a genetically modified meningococcus that was deficient for 
lPs, addressing the question how important lPs versus non lPs components of 
12
1meningococci are in the induction of cytokines and the activation of complement.
cytokines are crucial mediators of the inflammatory response during meningococcal 
disease. excessive production of these cytokines is held responsible for 
the development of tissue damage and shock. The relative contribution of 
lipopolysaccharide (lPs) and non-lPs of Neisseria meningitidis to the pro-
inflammatory cytokine response in human cells and to mortality in a murine model 
of meningococcal sepsis is addressed in chapter 2. in chapter 3 we dealt with the 
question which role cD14 and TlR4 play in the induction of cytokines by lPs or 
non lPs components of meningococci. 
The complement system is crucial in the initial defense against Neisseria meningitidis. 
in contrast, uncontrolled activation in meningococcal sepsis contributes to the 
development of tissue damage and shock. Whether complement activation and 
complement dependent inflammation in whole blood by meningococci is dependent 
or independent of lPs is studied in chapter 4.
for E. coli lPs it has been reported that lipoproteins inhibit cytokine production, 
opening new options for future therapies. However, meningococcal lPs is 
structurally different from E. coli lPs and intact gram-negative bacteria are 
composed of more cytokine inducing elements then solely lPs. in chapter 5 we 
questioned whether lipoproteins also neutralize meningococcal lPs or complete 
gram-negative bacteria.
another way to inhibit cytokine production by lPs is to use lPs antagonist 
molecules. Recently, novel variant lPs species derived from N. meningitidis have 
been created with a lipid a portion consisting of five or four fatty acids in the lipid 
a part of the lPs. Because penta- or tetra-acylated lPs from other bacterial 
species is reported to be antagonistic, in chapter 6 we explored whether these 
meningococcal lPs variants show antagonism for lPs induced TlR4 dependent 
cytokine production.
a bridge between cytokine production and the complement system is found in 
chapter 7, where we study the influence of mannose binding lectin (MBl), the key 
molecule of the lectin pathway of complement activation on cytokine production by 
non-lPs components of meningococci. 
in chapters 8 - 12 we addressed in vitro, in a whole blood model, as well as in vivo, 
in patients with meningococcal disease, the issue how complement is activated 
systemically during meningococcal septic shock. in addition, we also investigated 
ways to stop the consequences of systemic activation of complement. chapter 8 
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we asked whether an anti-c5a molecule is able to inhibit complement dependent 
inflammation in whole blood. in addition, in this chapter, the mechanism by which 
complement is activated by meningococci is studied. in chapter 9, we report a family 
deficiency for complement factor D with meningococcal infections and addressed 
the question to what extent factor D deficiency affects complement activation 
by meningococci. in chapter 10 we dealt with the question to what extent the 
alternative and lectin pathways of complement contribute to the systemic activation 
of complement and the ensuing tissue damage. a restriction fragment length 
polymorphism (RflP) assay to genotype the X/Y polymorphism in the promotor 
region of the MBl-gene is presented in chapter 11. chapter 12 provides a concise 
review of the current knowledge on complement activation during septic shock.
in chapters 13 - 15 we study so far unexplored new mediators activated in patients 
with meningococcal infections, in order to find new possible targets for adjuvant 
treatment and early diagnosis of the disease. in chapter 13 vascular endothelial 
growth factor (Vegf), a molecule that mediates vascular permeability as well as 
angiogenesis is investigated. We questioned whether Vegf can contribute to 
the development of shock by mediating increased capillary leakage. chapter 14 
addresses the role of macrophage migration inhibitory factor (Mif), an important 
mediator of the inflammatory cytokine response. We asked how this molecule is 
induced both in a human lPs model of sepsis and during meningococcal sepsis, 
and investigated whether it could be responsible for the development of shock. The 
kinetics of pentraxin 3 (PTX3) - a molecule that is important for the activation of 
complement - and its use as an early marker for shock is investigated in chapter 
15.
in chapters 16 and 17 the results of genetic and functional analysis in a large group 
of patients with meningococcal disease are presented. We asked the question how 
we can explain disease susceptibility and clinical manifestation of the disease. in 
chapter 16 the consequences of polymorphisms in gene for MBl for susceptibility 
to and clinical manifestation of meningococcal disease is investigated. in chapter 
17 we questioned whether innate cytokine production capacity in whole-blood 
influences clinical manifestation of meningococcal disease and disease severity.
finally, chapter 18 provides summary, general discussion and recommendations 
for future research.  
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contributions of Neisseria meningitidis lPs and non-lPs to 
proinflammatory cytokine response 2
aBsTRacT
To determine the relative contribution of lipopolysaccharide (lPs) and non-lPs 
components of Neisseria meningitidis to the pathogenesis of meningococcal sepsis, 
this study quantitatively compared cytokine induction by isolated lPs, wild-type 
serogroup B meningococci (strain H44/76), and lPs-deficient mutant meningococci 
(strain H44/76lpxA). stimulation of human peripheral-blood mononuclear cells with 
wild-type and lPs-deficient meningococci showed that non-lPs components of 
meningococci are responsible for a substantial part of tumor necrosis factor (Tnf)-α 
and interleukin (il)-1β production and virtually all interferon (ifn)-γ production. 
Based on tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis 
of lPs in proteinase K-treated lysates of N. meningitidis H44/76, a quantitative 
comparison was made between the cytokine-inducing capacity of isolated and 
purified lPs and lPs-containing meningococci. at concentrations of >107 bacteria/
ml, intact bacteria were more potent cytokine inductors than equivalent amounts of 
isolated lPs, and cytokine induction by non-lPs components was additive to that 
by lPs. experiments with mice showed that non-lPs components of meningococci 
were able to induce cytokine production and mortality. The principal conclusion 
is that non-lPs parts of N. meningitidis may play a role in the pathogenesis of 
meningococcal sepsis by inducing substantial Tnf-α, il-1β, and ifn-γ production. 
18
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inTRoDUcTion
it is generally accepted that the induction of cytokine synthesis and the subsequent 
pathophysiological events during gram-negative septic shock are primarily elicited 
by the lipopolysaccharide (lPs) component (endotoxin) of the bacterial outer 
membrane 1. Purified lPs is able to induce a proinflammatory cytokine pattern and 
a clinical condition that resembles, at a first glance, the symptoms encountered 
in gram-negative septic shock. The lPs-molecule is composed of a lipid-a part 
harboring its toxic properties, a saccharide part, and one or more molecules of 
2-keto-3-deoxy-octanate (KDo) connecting the lipid-a and the saccharide part 2. 
anti-lPs strategies explored so far have failed to ameliorate the clinical course of 
gram-negative sepsis 3-6, which raises the question whether lPs is the sole toxic 
element in gram-negative sepsis 7. 
fulminant meningococcal sepsis is considered the prototypical human gram-
negative septic shock, characterized by extremely high endotoxin and cytokine 
concentrations 8-11. Thus, the causative bacterium Neisseria meningitidis is a 
suitable subject for the study of cytokine induction by gram-negative bacteria. 
Recently, a viable N. meningitidis mutant was constructed that is devoid of lPs 
but still contains all other outer membrane constituents 12. This mutant has made 
it possible to assess the cytokine-inducing potency of the non-lPs parts of this 
gram-negative bacterium in a quantitative fashion. 
The principal aim of the present study is to determine the contribution of lPs and 
non-lPs components of N. meningitidis to the pathogenesis of meningococcal 
sepsis. Therefore, we compared quantitatively the cytokine production induced by 
meningococcal lPs, wild-type meningococci, and lPs-deficient meningococci.
MaTeRials anD MeTHoDs
Bacterial strains and lipopolysaccharides
The wild-type serogroup B N. meningitidis H44/76 strain was isolated from a 
patient with invasive meningococcal disease 13. Meningococcal strain H44/76lpxA 
is a viable isogenic mutant, completely devoid of lPs in its outer membrane. This 
mutant was constructed by insertional inactivation of the lpxA gene, essential for 
the first committed step in biosynthesis of lPs 14,15. The absence of lPs in this 
strain was confirmed by tricine sodium dodecyl sulfate (sDs)-polyacrylamide gel 
electrophoresis (TsDs-Page) with silver staining of lPs 16,17, whole-cell enzyme-
linked immunosorbent assay (elisa) with lPs-specific monoclonal antibodies, 
and gas-chromatographic/mass-spectrometric detection of lPs-specific 3-oH 
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fatty acids 12. furthermore, absence of lPs activity in the lpxA batch suspension 
was confirmed by nonreactivity in the limulus amebocyte lysate assay. Heat-killed 
(1 h, 56°c) bacteria washed in phosphate-buffered saline (PBs) were used in 
all experiments. The amount of bacteria in the suspensions used was measured 
by spectrophotometry; an optical density (oD) of 0.2 at 620 nm appeared to be 
equivalent to approximately 109 bacteria/ml. 
outer membrane complexes (oMcs) of both meningococcal strains were prepared 
by sarcosyl extraction as described previously 18. These oMcs consist primarily of 
Pora (class 1), PorB (class 3), and the RmpM (class 4) outer membrane proteins. 
The H44/76lpxA oMcs contain no lPs and express increased amounts of an opa 
protein 19, H44/76 oMcs contain 10–20% lPs. Protein content was determined by 
a bicinchoninic acid assay (Pierce chemical co., Rockford, il) with bovine serum 
albumin as a standard. 
The molecular mass of meningococcal strain H44/76 lPs is 4,044 Da 20; one 
molecule of lPs contains two molecules of KDo (molecular mass, 238 Da). lPs 
was isolated by the phenol/water extraction method as described by Westphal and 
Jann 21. after isolation, lPs was treated with proteinase K (sigma-aldrich co.) and 
with Dnase and Rnase (Roche Diagnostics) for additional purification, recovered by 
ultracentrifugation, freeze-dried, and solved in sterile PBs. The amount of protein 
contamination in this purified lPs solution was determined by bicinchoninic acid 
assay. Dna and Rna contamination was determined by spectrophotometry using a 
genequant Rna/Dna calculator (Pharmacia Biotech aB, Uppsala, sweden). 
The KDo content of the purified H44/76 lPs solution and of the bacterial 
suspensions was measured spectrophotometrically by the method described by 
Weissbach and Hurwitz 22.
TsDs-Page followed by silver staining of lPs was used for quantification of lPs 
in N. meningitidis H44/76. cell lysates of H44/76 meningococci were made by 
suspending 1.35 x 1010 bacteria in 500 µl of sDs-buffer (7.5% glycerol, 1.25 M Tris/
Hcl, 1.5% sDs) and incubating this for 5 min at 100°c. Proteins in this suspension 
were digested by incubation with proteinase K (0.5 mg/ml) for 4 h at 56°c 23. serial 
dilutions of purified H44/76 lPs were used as a standard. after silver staining, the 
polyacrylamide gel was analyzed by densitometry. 
Human peripheral blood mononuclear cells
Blood for the isolation of human peripheral blood mononuclear cells (PBMcs) was 
drawn in 10-ml eDTa-anticoagulated tubes (Vacutainer system; Beckton Dickinson, 
20
2Rutherford, nJ) from healthy volunteers. PBMcs were isolated by density gradient 
centrifugation on ficoll-Hypaque (Pharmacia Biotech aB). The cells from the 
interphase were aspirated, washed three times in sterile PBs, and resuspended 
in culture medium RPMi 1640 (Dutch modification; flows lab, irvine, scotland) 
supplemented with l-glutamine (2 mmol), pyruvate (1 mmol), and gentamycin (50 
mg/ml) and 5% freshly pooled human serum. PBMcs (5x106/well) were incubated 
with various stimuli in 200-µl 96-well plates (greiner BV, alphen a/d Rijn, The 
netherlands) at 37°c and 5% co2 for 4 and 24 h. The supernatant was obtained 
by centrifugation and stored at -20°c until the cytokine assay was performed. 
Murine experiments
c57Bl/6J mice, obtained from the Jackson lab (Bar Harbor, Me), were bred in 
our local facility. The animals were fed standard laboratory food (Hope farms, 
Woerden, The netherlands) and housed under specific pathogen-free conditions; 
6- to 8-week-old mice weighing 20 to 25 g were used for the experiments. Resident 
peritoneal macrophages were harvested by rinsing the peritoneal cavity aseptically 
with sterile PBs (4°c), 105 cells/well were incubated with the different stimuli for 
24 h. for lethality experiments, mice were pretreated with galactosamine (10 mg/
mouse) 30 min before the pathogen was injected into an orbital vein. 
cytokine assays
Tumour necrosis factor  (Tnf-) and interleukin-1ß (il-1ß) were determined by 
radioimmunoassay as described previously 24. interferon- (ifn-) was determined 
by enzyme-linked immunosorbent assay with a commercially available kit (Pelikine 
compact Human ifn- elisa kit, central laboratory of the netherlands Red cross, 
amsterdam, The netherlands). The lower detection limit was 80 pg/ml for both 
Tnf- and il-1ß and 4 pg/ml for ifn-. Murine Tnf- (mTnf-) and murine il-1ß 
(mil-1ß) were determined by radioimmunoassay as described by netea et al. 25. 
Detection limits were 40 pg/ml for mTnf- and 20 pg/ml for mil-1ß. 
statistics
Results were compared by a Wilcoxson-Mann-Whitney test for unpaired, 
nonparametrical data. spearman’s rank correlation coefficient was calculated 
to quantify the correlation between study parameters. P values of >0.05 were 
considered significant.
ResUlTs
Quantification of lPs in N. meningitidis H44/76 bacteria
To enable a quantitative comparison between cytokine induction by isolated lPs 
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and H44/76 meningococci, the purity of N. meningitidis H44/76 lPs was analyzed, 
and the amount of lPs in N. meningitidis H44/76 bacteria was determined. 
Protein contamination in the purified H44/76 lPs was <2.5%, and Dna and Rna 
contamination was 3.0% and 2.7%, respectively. This indicates that the H44/76 lPs 
used was at least 92% pure. The amount of KDo that was detected in 1 mg/ml of 
H44/76 lPs solution was 0.091 mg/ml. assuming an average molecular mass for 
lPs of 4,044 Da, the amount of lPs in this solution based on the KDo assay was 
(0.091x4,044)/(238x2)  0.8 mg of lPs/ml. 
TsDs-Page with silver stain of lPs was used to determine the amount of lPs 
in cell lysates of N. meningitidis H44/76 (figure 1) 17,23,26. Density analysis of the 
silver stain of lPs in different dilutions of cell lysates of N. meningitidis H44/76 
bacteria and of serial dilutions of purified lPs showed that 7 x 105 bacteria contain 
approximately 1 ng of lPs. 
as an alternative approach to determine the amount of lPs in the lPs-containing 
H44/76 strain, the amount of KDo detected in the lPs-deficient lpxA suspension 
was subtracted from that in the H44/76 suspension. Because the only difference 
between these isogenic strains is the presence of lPs, the difference in KDo 
content reflects lPs-associated KDo. in this way, it was calculated that 10 x 105 
H44/76 bacteria contain approximately 1 ng of lPs, a result rather similar to that 
obtained by TsDs-Page analysis. 
Quantitative comparison of cytokine induction
The dose-response relationship of meningococcal lPs, wild-type N. meningitidis 
H44/76, and lPs-deficient n. meningitidis H44/76lpxA for cytokine production by 
PBMcs after 24 h is shown in figure 2. in this figure the x-axis was calibrated 
for lPs together with the number of H44/76 bacteria that contained an equivalent 
amount of lPs, based on the above-presented TsDs-Page results. Therefore, the 
effect of all three stimuli could be compared quantitatively. 
it can be seen that at concentrations higher than 107 bacteria/ml, lPs-containing 
meningococci were more potent inductors of Tnf- and il-1β than equivalent 
amounts of isolated lPs (P<0.05). Below these concentrations, lPs was a more 
potent inductor of Tnf- and il-1β production. lPs-deficient lpxA meningococci 
were able to induce substantial amounts of Tnf-α, il-1β, and ifn-γ production. for 
Tnf-α and il-1β, approximately 10-fold-higher amounts of lPs-deficient bacteria 
were required to induce the same level of cytokine production as that in wild-type 
bacteria. of interest, significant ifn-γ production occurred after stimulation with 
both the wild-type and the lPs-deficient meningococci, but only minute amounts 
22
2of ifn-γ were produced after stimulation with isolated lPs (P<0.05). experiments 
(n=8) performed with 4 h of incubation showed a similar pattern for Tnf-α and il-
1β (data not shown). 
To assess whether the ifn-γ production induced by lPs-containing or lPs-deficient 
meningococci is secondary to the Tnf-α or il-1ß production, a series of induction 
experiments with 6 x 108/ml of H44/76 and lpxA bacteria was performed with cells 
from 30 donors. in these experiments, the Tnf-α and il-1β production appeared 
to be correlated (r=0.061 (P<0.01) and r=0.70 (P<0.001) for wild-type and lPs-
deficient meningococci, respectively). However, ifn-γ production did not correlate 
with the Tnf-α or il-1β production values for r between -0.12 and 0.22 (P=not 
Figure 2. 
Production of TNF-α (left panel), iL-1ß (middle panel), and IFN-γ (right panel) after 24 h by human PBMCs 
stimulated with different concentrations of H44/76 LPS (•), wild-type H44/76 meningococci (█), and lPs-
deficient H44/76lpxa meningococci (□). Values on the x-axis are calibrated for H44/76 lPs and the number 
of H44/76 bacteria that contain the same amount of lPs (1 ng of lPs ~7x105 bacteria). Mean values ± se 
are presented (n=5).
Figure 1. 
TsDs-Page silver staining of 0.1 µg (lane 1), 0.19 µg (lane 2), 0.39 µg (lane 3), and 0.77 µg (lane 4) of 
purified H44/76 lPs and lPs in proteinase K-treated lysates of 5x108 (lane 5) and 2.5 x 108 (lane 6) N. 
meningitidis H44/76 bacteria. insert: standard curve as calculated by linear regression for contour density 
(oD xmm2) of the purified lPs samples. contour density of the lysates corresponds with 0.7 µg of lPs in 
sample 5 and 0.34 µg of lPs in sample
23
significant). in addition, it could be seen that ifn-γ production showed a striking 
interindividual variety [range, 56–7,800 pg/ml (median, 555 pg/ml) and 40–6800 
pg/ml (median, 660 pg/ml) for H44/76 and lpxA bacteria, respectively]. Thus, ifn-γ 
is probably not produced in response to Tnf-α or il-1β, and the individual response 
in ifn-γ production after stimulation with meningococci differs considerably. 
The time course for Tnf-α and il-1β production by PBMcs showed a similar 
pattern for meningococcal lPs and both meningococcal strains. in brief, Tnf-α 
became detectable after 2 h, reached a maximum after 8 h, and declined thereafter 
whereas il-1β was detectable after 4 h and reached a plateau phase after 12 h 
(data not shown). 
The relative contribution of non-lPs structures to the total induction of Tnf-α 
and il-1β induction by N. meningitidis was assessed in a series of combination 
Figure 4. 
Production of il-1ß after 24 h by human PBMcs stimulated 
with different concentrations of oMcs isolated from the wild-
type H44/76 meningococci (█) containing 10–20% lPs and 
from mutant H44/76lpxA meningococci (□) devoid of lPs. oMc 
concentration is expressed as protein content in micrograms per 
milliliter. Mean values (n=5) are presented ± se
Figure 3.
il-1ß production after 24 h by human PBMcs stimulated with 
6 x 106 or 6 x 108/ml of wild-type H44/76 meningococci (open 
bars) (n=25), the same amounts of lPs-deficient H44/76lpxA 
meningococci (light-gray bars) (n=25), or the same amounts 
of lPs-deficient lpxa meningococci substituted with equivalent 
amounts of lPs (0.0085 and 0.85 µg/ml, respectively) as present 
in wild-type H44/76 meningococci (dark-gray bars) (n=5). Mean 
values are presented ± se. **, P < .01 compared with wild-type 
meningococci as well as lPs-deficient meningococci substituted 
with lPs
24
2experiments. in these experiments, meningococci were supplemented with 
approximately the same amount of lPs as present in the wild-type strain. figure 3 
shows the results of this experiment for il-1β after 24 h of incubation. it can be seen 
that il-1β production induced by lPs-deficient bacteria was approximately half of 
that induced by lPs-containing bacteria, whereas after addition of lPs, the il-
1β induction by lPs-deficient bacteria was restored to the level of lPs-containing 
bacteria. Results for Tnf-α and for experiments (n=5) with 4 h of incubation showed 
a similar pattern (data not shown). This additive effect of lPs to the non-lPs-
induced cytokine synthesis suggests that both stimuli may use different pathways 
for the induction of Tnf-α and il-1β.
cytokine induction by outer membrane complexes
To determine whether the non-lPs components responsible for cytokine induction 
reside in the outer membrane, cytokine induction by oMcs isolated from the wild-
type H44/76 meningococci and the lPs-deficient lpxA meningococci was assessed. 
figure 4 shows the results for il-1β after 24 h of incubation. it appeared that the 
wild-type H44/76 oMcs were potent inductors of cytokine synthesis, whereas the 
cytokine-inducing capacity of lpxA oMcs was 1,000- to 10,000-fold less than that of 
H44/76 oMcs. Results for Tnf-α and for experiments (n=5) with 4 h of incubation 
showed a similar pattern (data not shown). Taken together these results indicate 
that the outer membrane components present in oMcs like Pora, PorB, RmpM, or 
opa make a minimal contribution to cytokine induction.
cytokine induction and lethality in mice
in mice we assessed whether the observed cytokine induction by non-lPs 
components of meningococci coincides with the capacity to provoke disease. 
Results in Table 1 indicate that lPs-deficient meningococci were able to induce 
cytokine production in murine peritoneal macrophages in vitro. Table 2 demonstrates 
dosage of bacteria / mouse 
107 108 109
N. meningitidis H44/76 60 100 100
N. meningitidis H44/76lpxA 0 0 60
Table 2. 
Table 1. 
stimulus MTnfα (ng/ml) mil-1α(ng/ml)
N. meningitidis H44/76 (2 x 109/ml) 1.85 ± 0.39 4.67 ± 1.09
N. meningitidis H44/76lpxA (2 x 109/ml) 0.86 ± 0.54 1.96 ± 0.77
Production of murine tumour necrosis factor-α (mTnfα) and murine interleukin-1α (mil-1α) after 24 hours 
by murine peritoneal macrophages stimulated with wild-type H44/76 meningococci and lPs-deficient 
H44/76lpxA meningococci. Mean data ± sD are presented (n = 4 for H44/76 meningococci, n = 5 for 
H44/76lpxa meningococci). 
Mortality at 24 hours (%) in galactosamine pre-treated mice after i.v. injection of heat-killed N. meningitidis 
(5 animals per group). 
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that lPs-deficient meningococci were able to induce lethality in galactosamine-
sensitized mice in vivo. The dose needed for lPs-deficient meningococci to induce 
mortality was approximately 100-fold higher than for lPs-containing meningococci.
DiscUssion
The principal finding of the present study is that lPs is not the sole cytokine-
inducing element of N. meningitidis. Using a meningococcal mutant completely 
devoid of lPs, it was shown that non-lPs components of this bacterium were 
responsible for a substantial part of the Tnf-α and il-1β production, that non-
lPs components induced ifn-γ, and that non-lPs parts could provoke disease. 
Based on TsDs-Page analysis of lPs in proteinase K-treated cell lysates of N. 
meningitidis H44/76, a quantitative comparison between the cytokine-inducing 
capacity of lPs and that of lPs-containing bacteria became possible. it was shown 
that concentrations of >107/ml of bacteria were more potent inductors of cytokine 
synthesis than equivalent amounts of isolated lPs and that cytokine induction by 
non-lPs components was additive to that by lPs. furthermore, it was demonstrated 
that the non-lPs components responsible for the cytokine induction do not reside 
in sarcosyl-extracted outer membrane complexes. 
non-lPs components of bacteria can induce cytokine production 7, as has been 
shown by experiments with gram-positive bacteria 27-31 and with various isolated 
elements of these bacteria like peptidoglycan 32-34, lipopeptides 28, lipoproteins 28, 
lipoteichoic acid 35, and capsular polysaccharides 36. However, so far studies trying 
to assess quantitatively the contribution of these non-lPs structures to cytokine 
induction by gram-negative bacteria were hampered by the inevitable copresence 
of lPs, outflanking the cytokine induction by non-lPs structures. To circumvent 
this problem we used a meningococcal mutant that is entirely deficient of lPs. With 
this strain we demonstrated that approximately half the amount of Tnf-α and il-
1β induced by meningococci in human PBMcs or murine peritoneal macrophages 
was elicited by non-lPs structures. similarly, lPs-deficient meningococci could 
cause lethal disease in galactosamine-pretreated mice, albeit the dosages of lPs-
deficient meningococci required to induce mortality were approximately 100-fold 
higher than for wild-type meningococci. 
Tnf-α, il-1β, and ifn-γ are pivotal mediators in the pathogenesis of gram-negative 
septic shock. after infusion of lPs in human volunteers or primates, Tnf-α and il-
1β appear within 1 to 2 h 37, but no ifn-γ seems to appear 38. However, after the 
infusion of whole bacteria, ifn-γ is induced and can be detected in the circulatory 
system after 6–8 h 38,39. During meningococcal infections, ifn-γ is increased in 
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2plasma or cerebrospinal fluid and correlates with the severity of disease 40,41. in our in 
vitro study, meningococcal lPs stimulated only minimal ifn-γ production, whereas 
both lPs-containing and lPs-deficient bacteria induced significant amounts of 
ifn-γ. in addition, ifn-γ was not produced in response to Tnf-α or il-1β, which 
indicates that non-lPs components of meningococci were primarily responsible for 
ifn-γ induction. Because the primary source of ifn-γ is the lymphocyte and marked 
differences occur between individuals, it is tempting to speculate that certain non-
lPs components of meningococci can act as superantigens. 
in this study we used the widely employed KDo assay to determine the amount of 
lPs in the H44/76 lPs preparation 22,42,43. With this method (0.8/0.92) x 100% (i.e., 
85%) of the lPs was detected. limitations of this assay are conversion of a fraction 
of KDo during acid hydrolysis to entities inert to the thiobarbituric acid reaction and 
incomplete hydrolysis, both leading to an underestimation of the amount of KDo. 
on the other hand, contaminants in the lPs may coreact in the assay, which leads 
to overestimation of the amount of lPs 44,45. The relatively accurate yield of KDo in 
the present study showed that these limitations of the KDo assay are likely to be of 
minor importance for determination of H44/76 lPs. 
By TsDs-Page analysis of lPs in lysates of N. meningitidis H44/76, the amount 
of lPs in H44/76 bacteria was determined. it appears that 7 x 105 bacteria 
corresponded to approximately 1 ng of lPs, which fits rather well with the results 
obtained by KDo analysis in H44/76 and lpxA bacteria. This estimate is in good 
accordance with reported estimates of 1 ng of lPs for 105 bacteria with Escherichia 
coli 1,46-50, taking into account that the MW of meningococcal lPs is 2- to 10-fold 
lower than that of E. coli lPs. in addition, our estimate compares fairly well to 
clinical data of Brandtzaeg et al. 51, Mariani-Kurkdjian et al. 52, and Bingen et al. 
53, who detected lPs values up to 500 ng/ml and bacterial numbers up to 5 x 108 
cfU/ml in cerebrospinal fluid during meningococcal meningitis. 
Based on the estimate that 7 x 105 bacteria correspond to 1 ng of lPs, we could 
compare the cytokine-inducing potency of isolated lPs with that of meningococci 
containing the same amount of lPs. it was found that at concentrations below 
107 bacteria/ml or equivalent amounts of lPs, lPs induced more Tnf-α and 
il-1β, but at higher concentrations, complete meningococci were more potent. 
Because at these higher concentrations the Tnf-α and il-1β-inducing capacities 
of lPs-deficient meningococci increased in a parallel fashion, the higher activity of 
bacteria at these higher concentrations is likely to have been caused by the non-
lPs components of the bacterium. 
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fulminant meningococcal sepsis is characterized by high plasma concentrations 
of endotoxin that range from 0.75 to 170 ng/ml 8,10,54-56. Based on our estimation of 
1 ng of lPs per 7 x 105 bacteria, the reported range of endotoxin concentrations 
corresponds to 5 x 105 to 1.2 x 108 bacteria/ml. We speculate that strategies 
designed to block lPs-induced cytokine synthesis alone are of limited value, 
because at this degree of bacteremia, a substantial part of the proinflammatory 
cytokine response is elicited by non-lPs parts of the meningococcus 57. 
Because several outer membrane proteins of N. meningitidis are known to 
interact with human cell receptors 58,59, we examined whether sarcosyl-extracted 
outermembrane complexes are able to induce cytokine production. lPs-deficient 
oMcs primarily composed of the major outer membrane proteins Pora, PorB, 
RmpM, and opa did not induce cytokines. Thus, other meningococcal components 
not retained after sarcosyl extraction, for instance certain lipoproteins, chromosomal 
Dna, the polysaccharide capsule 60, or the peptidoglycan cell wall 32-34, must have 
been responsible for the observed cytokine induction by the lPs-deficient mutant. 
further research is needed to identify which of the non-lPs components are 
responsible for cytokine induction and to quantify their relative contribution to the 
pathogenesis of invasive meningococcal disease
28
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Neisseria meningitidis can induce pro-inflammatory cytokine production 
via pathways independent from cD14 and toll-like receptor 4 3
aBsTRacT
fulminant meningococcal sepsis (fMs) is considered the prototypical gram-
negative sepsis. lipopolysaccharide (lPs) is thought to be the main toxic element 
that induces pro-inflammatory cytokine production after interaction with cD14 
and toll-like receptor 4 (TlR4). However, there is increasing evidence that lPs is 
not the sole toxic element of meningococci. The aim of the present study was to 
determine the role of cD14 and TlR4 in pro-inflammatory cytokine induction by 
meningococci. To this end, cytokine induction by isolated meningoccal lPs, wild-
type N. meningitidis H44/76 (lPs+ meningococci) matched for concentrations of 
lPs and lPs-deficient N. meningitidis H44/76lpxA (lPs- meningococci) was studied 
in human PBMcs and murine peritoneal macrophages (PMs). Pre-incubation of 
PBMcs with WT14, a monoclonal antibody against cD14, abolished Tnf-α and 
il-1β induction by E. coli lPs, while cytokine induction by meningococcal lPs was 
only partially inhibited. When lPs+ and lPs- meningococci at higher concentrations 
were used as stimuli, anti-cD14 had a minimal effect. in c3H/HeJ murine PMs, 
devoid of a functional TlR4, minimal il-1α, il-6 and Tnf-α production was seen 
after stimulation with 10 ng/ml E. coli or meningococcal lPs. However, at higher 
concentrations (1000 ng lPs/ml) the production of Tnf-α, but not il-1α or il-6, 
occurred also independently of TlR4. The expression of a functional TlR4 in murine 
PMs had no effect on the cytokine induction by lPs+ or lPs- meningococci. it is 
concluded that pro-inflammatory cytokine induction by N. meningitidis can occur 
independently of cD14 and TlR4. 
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inTRoDUcTion
invasive infections with the gram-negative bacterium Neisseria meningitidis are 
an important cause of morbidity and mortality worldwide 1. Particularly fulminant 
meningococcal sepsis (fMs), considered to be the prototypical gram-negative 
septic shock, is feared for its high fatality rate. lipopolysaccharide (lPs, endotoxin), 
an important structural and functional component of the outer membrane of gram-
negative bacteria, is thought to be responsible for the major pathophysiological 
events during meningococcal septicaemia 2. lPs induces the synthesis of 
interleukin-1β (il-1β) and tumour necrosis factor-α (Tnf-α), pro-inflammatory 
cytokines pivotal in the development of septic shock 3,4.
Recently, the principal pattern-recognition receptors for lPs have been 
characterised more precisely. after the interaction of lPs with lPs-binding protein 
(lBP), lPs is shuttled to cD14, a glycophosphatidyl-inositol (gPi) - linked cell-
surface glycoprotein present on cells of the myeloid lineage5 6. as cD14 lacks a 
transmembrane domain, association with the toll-like receptor 4 (TlR4) and its 
co-factor MD-2 is required for transmembrane signalling 7-9. TlR4 imparts ligand 
specific recognition of lPs and binding of lPs induces physical proximity between 
CD14 and TLR4 prior to nuclear translocation of NF-κB 10,11. in addition to its role 
in the recognition of lPs, cD14 has also been shown to mediate responses after 
stimulation with other bacterial components 12.
in spite of the importance of lPs in the pathogenesis of fMs, there is convincing 
evidence that lPs is not the sole toxic element. anti-lPs strategies have failed 
to ameliorate the clinical course of fMs 13-16, and it was recently shown in various 
laboratories that a mutant strain of N. meningitidis devoid of lPs is able to induce 
cytokine production 17-19. Thus, bacterial components other than lPs, i.e. non-lPs 
components, may have an important role in the pathogenesis of fMs.
The aim of the present study was to determine the role of cD14 and TlR4 in pro-
inflammatory cytokine induction by the meningococcus.
MaTeRials anD MeTHoDs
Neisseria meningitidis strains
The wild-type serogroup B N. meningitidis H44/76 strain (designated as lPs+ N. 
meningitidis) was isolated from a patient with invasive meningococcal disease 20. 
The meningococcal strain H44/76lpxA (designated as lPs- N. meningitidis) is a 
viable isogenic mutant, completely devoid of lPs in the outer membrane. This 
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mutant was constructed by insertional inactivation of the lpxA gene, essential 
for the first committed step of the biosynthesis of lPs. The absence of lPs in 
this strain was confirmed as described previously 21. absence of lPs-activity in 
the lPs- N. meningitidis batch-suspension was assessed by non-reactivity in the 
limulus amebocyte lysate assay.
Bacteria were grown overnight in liquid medium, heat-inactivated (1 h, 56°c) 
and washed in phosphate buffered saline (PBs). Bacteria were quantified by 
spectrophotometry.
lipopolysaccharides (lPs)
a commercially available Tca extracted E. coli 055:B5 lPs was purchased 
from sigma-aldrich co (Rutherford, nY). Meningococcal lPs was isolated in 
our laboratory by phenol/water extraction according to Westphal and Jann 22. 
after extraction, this meningococcal lPs was treated with Proteinase K (sigma-
aldrich co), Dna-ase and Rna-ase (Roche diagnostics) for additional purification, 
recovered by ultracentrifugation, freeze-dried and solved in sterile PBs.
The commercial E. coli lPs preparation was found to be contaminated with protein 
(8.5%) (by lowry-assay) and nucleic acids (6.1%) (by spectrophotometry). The N. 
meningitidis lPs preparation was free of protein (< 1.0%), nucleic acid content was 
(4.4%).
Quantification of lPs in N. meningitidis H44/76 bacteria was performed by TsDs-
Page followed by silverstaining of lPs and assay for 2-keto-3-deoxyoctanate as 
described previously 17; 1 ng of lPs correlated with 0.7x106 lPs+ N. meningitidis 
H44/76 bacteria.
anti-cD14 antibody
The monoclonal anti-cD14 antibody WT14 was produced as described previously 
23. Binding of lPs to human macrophages was determined by flow cytometry using 
fluorescein isothiocyanate (fiTc) labelled E. coli 055:B5 lPs. fiTc labeling of lPs 
was performed as described by Pollack et al. 24. Purified human monocytes were 
preincubated with control antibody (which did not bind monocytes), WT-14 antibody 
or an excess of unlabelled lPs. The cells were washed and fiTc-labelled lPs 
was allowed to bind the monocytes in the presence of 10% pooled human serum 
(as a source of lPs-binding protein). Monocytes were identified based on size and 
granularity. in stimulation experiments with PBMcs, WT14 alone did not induce 
cytokines.
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Mice
Murine c57Bl/6J peritoneal macrophages (PMs) were used to study cytokine 
induction by meningococcal lPs and lPs+- or lPs- meningococci. The role of 
TlR4 in cytokine induction by meningococcal lPs and non-lPs components was 
assessed in PMs isolated from c3H/HeJ or c3H/Hen mice. The mice were obtained 
from the Jackson laboratories (Bar Harbour, Me, Usa) and were bred in our local 
facility; 6 to 8 weeks old mice, weighing 20 to 25 grams were used. The animals 
were fed standard laboratory food (Hope farms, Woerden, the netherlands) and 
housed under specific pathogen-free conditions. c3H/HeJ mice have a non-
functional TlR4, owing to a base-transversion in the gene coding for TlR4. The 
parent strain c3H/Hen possesses the normal functional TlR4.
Human and murine cells; culture conditions
Blood for the isolation of human peripheral blood mononuclear cells (PBMcs) 
was drawn in 10-ml eDTa anti-coagulated tubes (Vacutainer system, Beckton 
Dickinson, Rutherford, nJ) from healthy volunteers. PBMcs were isolated after 
density gradient centrifugation on ficoll-Hypaque (Pharmacia Biotech aB). The 
cells from the interphase were aspirated and washed 3 times in sterile PBs. 5x105 
cells per well were incubated in 200 ml 96 wells plates (greiner BV, alphen a/d 
Rijn, the netherlands) with the various stimuli for 24 hours at 37 °c and 5% co2. 
The anti-cD14 antibody WT14 was preincubated (20 mg/ml) with the PBMcs for 2 
hours at 37 °c and 5% co2.
Resident peritoneal macrophages (mPMs) of c3H/Hen or c3H/HeJ mice were 
harvested by rinsing the peritoneal cavity aseptically with sterile PBs (4 °c). 1x105 
cells per well were incubated with the various stimuli. culture conditions were 
similar to those for human PBMcs.
RPMi 1640 (Dutch modification, flows lab, irvine, scotland) supplemented with 
l-glutamine (2 mMol), pyruvate (1 mMol) and gentamycin (50 mg/ml) was used 
as culture medium. for experiments with human PBMcs, 5% fresh pooled human 
serum obtained from 5 healthy volunteers was added.
cytokine assays
Human il-1β and Tnf-α were determined by radioimmunoassay (Ria) as described 
previously 25. The lower limit of detection was 0.08 ng/ml. Murine il-1α (mil-1α) 
and mTnf-α and were determined by Ria as described 26. mil-6 was determined 
by elisa (Pelikine compact murine il-6 elisa kit, central laboratory of the 
netherlands red cross). The lower limit of detection was 0.04 ng/ml.
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calculations and statistics
for calculations and graphs, the net cytokine production, i.e. the cytokine 
concentration in the stimulated sample minus the concentration in the unstimulated 
sample, was used. Median cytokine production was used to calculate the % 
decrease in cytokine production. Data were analysed using the Mann-Whitney test 
for unpaired, non-parametrical data (graphPad Prism, graphPad software inc.); a 
p-value <.05 was considered significant.
ResUlTs
cytokine production after stimulation with meningococcal lPs, 
lPs+ and lPs- meningococci
cytokine production by human PBMcs and murine c57Bl/6J PMs was studied using 
a low or a high concentration of meningococcal lPs (6 or 600 ng/ml for human 
PBMcs and 10 or 1 000 ng/ml for murine PMs) and matched concentrations of lPs-
containing (lPs+) or lPs-deficient (lPs-) meningococci. figure 1 shows the results 
for il-1β in human PBMcs. at these concentrations, lPs+ meningococci induced 
3 - 4 fold more il-1β than equivalent amounts of purified meningococcal lPs. 
The lPs- meningococci induced sizeable amounts of pro-inflammatory cytokines, 
however less than the wild-type strain. Tnf-α production followed a similar pattern 
(data not shown). in murine PMs, the pattern of the production of il-1α, Tnf-α and 
il-6 after stimulation with the three different stimuli was similar to that observed in 
human PBMcs for il-1β and Tnf-α, although a higher concentration of stimulus 
was needed to obtain measurable cytokine production.
effect of anti-cD14 on the binding of E. coli lPs to monocytes 
and cytokine induction by E. coli lPs
flow-cytometric (facs) analysis of the binding of fiTc-labeled E. coli lPs to 
human monocytes showed that the anti-cD14 antibody WT14 completely abrogated 
the binding of E. coli lPs to monocytes (figure 2). as expected, anti-cD14 inhibited 
the E. coli lPs (10 ng/ml) induced il-1β and Tnf-α production with > 95% (figure 
3).
effect of anti-cD14 on cytokine induction by meningococcal lPs, 
lPs+ and lPs- meningococci
figure 4 shows the effect of anti-cD14 on the il-1β and Tnf-α production by human 
PBMcs after stimulation with isolated meningococcal lPs, lPs+ meningococci 
and lPs- meningococci. Meningococcal lPs and both bacterial strains were used 
at matched concentrations as described above. anti-cD14 showed a trend towards 
inhibition of il-1β and Tnf-α production at both low and high concentrations of 
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Figure 3 
il-1β and Tnfα production by human 
PBMcs preincubated for 2 hours with 
RPMi (white bars) or 20 µg/ml anti-cD14 
(hatched bars) prior to stimulation for 24 
hours with 10 ng/ml E. coli lPs. Median 
values are presented +/- iQR, n = 5. 
P-values apply to the comparison between 
preincubation with or without anti-cD14. 
Figure 2
Binding of fiTc-labelled E. coli lPs to 
human monocytes after preincubation with 
a control antibody, the anti-cD14 antibody 
WT14 or an excess of unlabelled lPs. 
Results are given as the mean percentage 
of positive cells +/- sD, n = 4,  performed on 
the same batch of frozen monocytes.
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Figure 1
il-1β production by human PBMcs 
after stimulation with low (panel a, 6 
ng/ml meningococcal lPs or 6 x 106 
meningococci/ml ) and high dose (panel 
B, 600 ng/ml meningococcal lPs or 
6 x 108 meningococci/ml) purified 
meningococcal lPs (hatched bars), lPs+ 
N. meningitidis H44/76 (black bars) or 
lPs- N. meningitidis lpxA (white bars). 
Median values are presented, error bars 
indicate inter-quartile range (iQR). n = 
15 for the lPs experiments, n = 25 or 30 
for the experiments with the low or high 
bacterial concentration respectively.
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meningococcal lPs. However, in contrast to E. coli lPs (figure 3), inhibition 
was incomplete (64% for il-1β and 45% for Tnf-α) and did not reach statistical 
significance. after stimulation with the high concentration of meningococcal lPs 
(600 ng/ml), the production of il-1β and Tnf-α was even less inhibited (53% and 
24%, respectively).
il-1β and Tnf-α production after stimulation with the low concentration (6x106/
ml) of lPs+ meningococci was inhibited by anti-cD14 (78% for il-1β and 61% 
for Tnf-α, p <.05). after stimulation with lPs- meningococci this reduction was 
55% for both cytokines (p =.08 and .03 for il-1β and Tnf-α, respecively). at the 
high concentration of both bacterial strains (6x108 meningococci/ml), no significant 
inhibition of cytokine production occurred, however, an inhibiting trend on Tnf-α 
production was present.
cytokine induction by meningococcal lPs, lPs+ meningococci 
and lPs- meningococci in c3H/HeJ and c3H/Hen mice
as a reference, PMs of c3H/Hen and c3H/HeJ mice were stimulated with E. coli 
lPs (10 ng/ml). figure 5 shows the results for il-1α and Tnf-α. in accordance 
with previous studies, production of il-1α and Tnf-α by c3H/HeJ PMs was reduced 
LPS N. Men
LPS+
N. Men
LPS-
0
5
10
15
20
5
10
IL
-1
β
(n
g/
m
L)
LPS N. Men
LPS+
N. Men
LPS-
TN
Fα
(n
g/
m
L)
P =.08
P =.03
P =.08
P =.50
P =.50
P =.11
P =.08
P =.03
P =.02
P =.11
P =.21
P =.35
5
10
15
20
10
20
30
A
A
B
B
0
0 0
Figure 4
il-1β and Tnfα production in human PBMcs preincubated for 2 hours with RPMi (white bars) or 20 µg/ml 
anti-cD14 (hatched bars) prior to stimulation for 24 hours with meningococcal lPs, lPs+ N. meningitidis 
H44/76 and lPs- N. meningitidis lpxa. Panels a : 6 ng/ml meningococcal lPs or 6 x 106 meningococci/
ml, panels B : 600 ng/ml meningococcal lPs or 6 x 108 meningococci/ml. Median values are presented, 
+/- iQR, n = 5 for all stimuli. P-values apply to the comparison between preincubation with or without anti-
cD14.
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to values approximately equivalent to the blank. The il-6 production was similarly 
affected (data not shown).
figure 6 shows the il-1a and Tnf-a production by mPMs of c3H/Hen and c3H/
HeJ mice after stimulation with meningococcal lPs, or matched concentrations of 
lPs+ or lPs- meningococci. similar to the pattern for E. coli lPs, minimal il-1α 
production occurred in c3H/HeJ mPMs after stimulation with the low or high dose 
dose of meningococcal lPs. The il-6 production was similarly affected (data not 
Figure 5
il-1α and Tnfα production in murine 
peritoneal macrophages of c3H/Hen 
mice (white bars) and c3H/HeJ mice 
(hatched bars) after stimulation for 
24 hours with 10 ng/ml E. coli lPs. 
Median values are presented +/- 
iQR, n = 5. net cytokine production 
(cytokine level in stimulated sample 
minus cytokine level in blank) is 
presented. P-values apply to the 
comparison between c3H/HeJ and 
c3H/Hen mPMs.
Figure 6
il-1α and Tnfα production in murine peritoneal macrophages of c3H/Hen mice (white bars) and c3H/
HeJ mice (hatched bars) after stimulation with meningococcal lPs, lPs+ N. meningitidis H44/76 or lPs- N. 
meningitidis lpxA. Panels a : 10 ng/ml meningococcal lPs or 107 meningococci/ml, panels B : 1000 ng/
ml meningococcal lPs or 109 meningococci/ml. Median values +/- iQR, n = 10, of net cytokine production 
(cytokine level in stimulated sample minus cytokine level in blank) are presented. P-values apply to the 
comparison between c3H/HeJ and c3H/Hen mPMs.
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shown). However, Tnf-α production was only affected after stimulation with the 
low dose (10 ng/ml) of meningococcal lPs, while after stimulation with the high 
dose (1000 ng/ml) only 18% reduction occurred as compared with the production 
in c3H/Hen PMs.
lPs+ meningococci in low concentrations induced 58% less il-1a in c3H/HeJ mice 
as compared to c3H/Hen mice (p =.08). il-6 showed a similar pattern (data not 
shown). at high concentrations however, virtually equal amounts of il-1α and il-6 
were produced by c3H/HeJ and c3H/Hen mPMs. Remarkably, Tnf-α production 
was not affected in c3H/HeJ mice. lPs- meningococci induced equal amounts of 
il-1α, il-6 and Tnf-α in murine PMs of c3H/HeJ and c3H/Hen mice.
DiscUssion
in the present study we demonstrated that N. meningitidis can induce cytokines in 
human PBMcs or murine peritoneal macrophages by pathways independent from 
cD14 and TlR4.
The finding that anti-cD14 did not completely inhibit the production of pro-
inflammatory cytokines after stimulation with meningococcal lPs is in contrast with 
the findings for E. coli lPs. in accordance with previous studies we found that il-
1β and Tnf-α induction by E. coli lPs is completely cD14-dependent 6. Because 
our meningococcal lPs preparation appeared to be less contaminated than the 
commercially purchased E. coli lPs, the observed cD-14 independent cytokine 
production in experiments with meningococcal lPs is rather explained by the 
specific molecular characteristics of meningococcal lPs than contaminants. indeed, 
recently gangloff et al. showed that lPs molecules with a short polysaccharide tail 
that lacks the typical o antigen, such as meningococcal lPs, may engage cD14-
independent pathways for the induction of Tnf-α 27.
cD14 has been shown to bind a range of microbial components other than lPs 
such as peptidoglycan, lipoproteins, lipoteichoic acid, lipoarabinomannan and 
various other components 12,28. gram-negative bacteria contain some of these 
non-lPs components (peptidoglycan, lipoproteins) which are proficient to engage 
cD14. Recently, ingalls et al. identified cD14 as a principal ligand for cytokine 
induction by lPs-deficient meningococci 19. our finding that, after stimulation with 
the low dose (6x106 bacteria/ml) lPs-free meningococci, anti-cD14 considerably 
(55%) inhibited il-1β and Tnf-α production is in accordance with this role for cD14. 
However, as inhibition was incomplete, the non-lPs components of N. meningitidis 
may engage also cD14-independent pathways. at higher concentrations (6x108 
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bacteria/ml), we found that pro-inflammatory cytokine production was completely 
cD14-independent. We presume that at these concentrations, non-specific 
receptors like the β2-integrins or scavenger receptors are engaged 29,30.
TlR4 has been shown to confer ligand-specific recognition of lPs. However, there is 
recent evidence that TlR2, and not TlR4, is involved in recognition of lPs isolated 
from Porphyromonas gingivalis or Leptospira spp. Thus, probably various types 
of lPs may interact differentially with TlRs 31,32. in the present study we showed 
that in mice, TlR4 is the principal signal transferring receptor for meningococcal 
lPs at lower concentrations (10 ng/ml). at higher concentrations (1 \000 ng/ml) 
however, Tnf-α - but not il-1α or il-6 - was also produced independently of TlR4. 
Hirschfeld et al. 31 reported that engagement of TlR4 and TlR2 will result in the 
differential expression of cytokine genes. combined with our recently published 
suggestion that the molecular conformation of the lipid-a moiety in meningococcal 
lPs, with six symmetrically distributed fatty-acids, favors the engagement of TlR2 
33, we speculate that the TlR4 independent induction of Tnf-α by meningococcal 
lPs, is mediated by TlR2.
our experiments with lPs-free and lPs-containing meningococci indicate that TlR4 
is not exclusively engaged in cytokine induction by the gram-negative bacterium 
N. meningitidis. Using TlR4-nonfunctional c3H/HeJ mPMs, il-1α production after 
stimulation with the wild-type lPs+ meningococci was only moderately decreased 
compared to the parent c3H/Hen murine PMs, and Tnf-α production was not 
decreased at all after stimulation with low dosages of lPs+ meningococci. as 
cytokine production after stimulation with lPs- meningococci in c3H/HeJ mPMs 
was not affected, it is likely that the signaling via non-TlR4 pathways by lPs+ 
meningococci occurs by non-lPs components of the meningococcus. This 
is underscored by the finding of Massari et al., who found that isolated outer 
membrane porins of the meningococcus can signal via TlR234.
it should be noted that our data on the role of TlR4 in proinflammatory cytokine 
induction by N. meningitidis are derived from experiments with murine peritoneal 
macrophages. However, recent studies with cells transfected with human receptors, 
i.e. chinese hamster ovary fibroblasts transfected with human TlR4 and TlR2 19 or 
with Hela cells transfected with human TlR2 35, suggest that for the response to 
meningococci non-TlR4 pathways are also of importance in the human situation.
Recently, we and others provided evidence for a role of non-lPs components of 
N. meningitidis in cytokine induction and therefore in the pathogenesis of fMs 17-
19. in the present study we show that pro-inflammatory cytokine induction by N. 
meningitidis can occur independently of cD14 and TlR4. Therefore, it can be 
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speculated that therapeutic strategies designed to block either lPs, cD14 or 
TlR4 are likely to be insufficient for the complete abrogation of the harmful pro-
inflammatory cytokine response during fMs.
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Complement activation and complement-dependent inflammation by 
Neisseria meningitidis are independent of lipopolysaccharide. 4
aBsTRacT
fulminant meningococcal sepsis has been termed the prototypical lipopolysaccharide 
(lPs)-mediated gram-negative septic shock. systemic inflammation by activated 
complement and cytokines is important in the pathogenesis of this disease. We 
investigated the involvement of meningococcal lPs in complement activation, 
complement-dependent inflammatory effects, and cytokine or chemokine production. 
Whole blood anticoagulated with lepirudin was stimulated with wild-type Neisseria 
meningitidis H44/76 (lPs+), lPs-deficient N. meningitidis H44/76lpxA (lPs–), 
or purified meningococcal lPs (nmlPs) at concentrations that were relevant to 
meningococcal sepsis. complement activation products, chemokines, and cytokines 
were measured by enzyme-linked immunosorbent assays, and granulocyte cR3 
(cD11b/cD18) upregulation and oxidative burst were measured by flow cytometry. 
The lPs+ and lPs– N. meningitidis strains both activated complement effectively 
and to comparable extents. Purified nmlPs, used at a concentration matched to 
the amount present in whole bacteria, did not induce any complement activation. 
Both cR3 upregulation and oxidative burst were also induced, independent of lPs. 
Interleukin-1β, tumor necrosis factor alpha, and macrophage inflammatory protein 
1α production was predominantly dependent on LPS, in contrast to il-8 production, 
which was also markedly induced by the lPs– meningococci. in this whole blood 
model of meningococcal sepsis, complement activation and the immediate 
complement-dependent inflammatory effects of cR3 upregulation and oxidative 
burst occurred independent of lPs.
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4inTRoDUcTion
invasive disease caused by the gram-negative bacterium Neisseria meningitidis is a 
life-threatening infection in children and young adults. Meningococcal septic shock 
(or fulminant meningococcal sepsis [fMs]), the prototype of overwhelming gram-
negative sepsis, is feared especially because it is able to cause devastating disease 
with a high case fatality rate. The pathogenic mechanisms leading to fMs are 
thought to be the uncontrolled growth of meningococci in the circulation, resulting 
in a massive activation of diverse inflammatory systems, such as the complement 
system, the cytokine network, and the coagulation cascade 1,2. 
in fMs, high lipopolysaccharide (lPs) levels are correlated with an increased 
bacterial load, high levels of pro- and anti-inflammatory cytokines, increased 
complement activation, the induction of intravascular coagulation, and a poor 
outcome. Therefore, meningococcal lPs is regarded as the principal bacterial 
pathogenic element during fMs 3. 
The complement cascade plays a dual role in the pathogenesis of meningococcal 
infections. a complement deficiency predisposes some individuals to meningococcal 
infection 4-6, but on the other hand, with fMs, extensive complement activation 
is correlated with severe disease and a poor outcome 7,8. Thus, the complement 
system plays an important role in the first line of defense against meningococcal 
infection, whereas massive activation of the complement system contributes to the 
development of shock. 
complement is activated on the meningococcal surface by one or more of the 
three initial complement-activating pathways, i.e., the classical, the lectin, and the 
alternative pathways (figure 1). after the activation of complement factor 3 (c3) by 
any of these pathways, a c5 convertase is formed, which cleaves the pivotal c5 
molecule into c5a and c5b. c5b is the initial molecule in the formation of the terminal 
c5b-9 complement complex (Tcc). Membrane-associated Tcc, also designated 
the c5b-9 membrane attack complex, leads to lysis of the bacterium, whereas c5a 
is a potent anaphylatoxin 9. experimentally, the role of the complement system 
in inflammation by N. meningitidis and Escherichia coli was recently given more 
emphasis by our observation that granulocyte cR3 (cD11b/cD18) upregulation and 
the formation of reactive oxygen species in human whole blood, key elements in the 
induction of vascular damage during sepsis, are highly dependent on c5a 10,11.
Recent in vitro studies suggested that components of N. meningitidis other 
than lPs may also contribute to the inflammatory response of the host. Using a 
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meningococcal mutant that was deficient for lPs in the outer membrane, we and 
others have shown that proinflammatory cytokines can be induced independent of 
lPs in cultured human cells 12-14. in addition, we showed that purified meningococcal 
lPs (nmlPs) is a poor activator of complement, whereas experiments with outer 
membrane vesicles that were depleted of or completely lacking lPs suggested that 
non-lPs components in the bacterial outer membrane are the principal complement 
activators in a whole blood model 15. 
for the present study, lPs-containing N. meningitidis, LPS-deficient N. meningitidis, 
and purified meningococcal LPS were used in a human whole blood model of 
meningococcal sepsis to determine the role of lPs in complement activation, the 
complement-dependent inflammatory processes of CR3 upregulation and oxidative 
burst, and cytokine production. 
MaTeRials anD MeTHoDs
equipment and reagents. 
all materials used in the stimulation experiments were endotoxin-free. The 
polypropylene tubes used were either nunc cryotubes (nalgene nunc, Roskilde, 
Denmark) or falcon tubes (Becton Dickinson, franklin lanes, n.Y.). Phosphate-
buffered saline (PBs) was produced in the laboratory, Dulbecco’s medium was 
obtained from invitrogen corporation (Paisley, scotland), and lepirudin (Refludan) 
was purchased from Hoechst (frankfurt am Main, germany). flow cytometry was 
performed with a facscalibur instrument (Becton Dickinson san Jose, calif.), 
and optical densities were determined with an MRX microplate reader (Dynex 
Technologies, Denkendorf, germany). 
Bacterial strains.
N. meningitidis H44/76 (lPs+) is an isolate from a patient with invasive 
meningococcal disease 16. This strain is the production strain for the norwegian 
group B oMV vaccine and is an international reference strain 17, serologically 
classified as B:15:P1.7,16, immunotype l3,7,9, as determined by the use of anti-
lPs monoclonal antibodies (Mabs) in a dot blotting assay for immunotyping 18. 
The lPs-deficient strain N. meningitidis H44/76lpxA (lPs–) is a viable isogenic 
mutant of strain H44/76 that lacks lPs in the outer membrane and was a kind gift 
from Peter van der ley and liana steeghs (Dutch Vaccine institute, Bilthoven, 
The netherlands). it was constructed by insertional inactivation of the lpxA gene, 
which is essential for the first committed step of biosynthesis of lPs, as described 
by steeghs et al 19. for the present study, batch suspensions of H44/76lpxA were 
tested and showed no reactivity in a Limulus amebocyte lysate (lal) assay, a highly 
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4specific and sensitive test for lPs. as shown by steeghs et al., the expression level 
of the integral outer membrane proteins by the lPs-deficient mutant is similar to 
that of the wild-type strain; however, the outer membrane phospholipid composition 
is altered, with a switch to mostly short-chain, saturated fatty acids 20. lPs-deficient 
mutant meningococci were grown overnight on Kellog’s medium and resuspended in 
Hanks’ balanced salts solution (invitrogen). Bacteria were heat inactivated at 60°c 
for 40 min. The concentration of the bacteria was determined by measuring the 
optical density at 630 nm. nmlPs was isolated from strain H44/76 by phenol-water 
extraction 21 followed by Dnase, Rnase, and proteinase K treatment. The batch of 
lPs used for this study was previously shown to be highly reactive in the lal assay 
and a potent inducer of cytokine production 22. Quantification of the amount of lPs 
in lPs+ N. meningitidis H44/76 bacteria was performed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (sDs-Page) followed by silver staining of lPs. 
The lPs level was determined by digital scanning, with purified H44/76 lPs used 
as the standard 13,23. 
Whole blood model
a recently developed whole blood model for the study of N. meningitidis-induced 
inflammation was used 11. The model is based on anticoagulation with lepirudin, 
a recombinant hirudin which is a highly specific thrombin inhibitor that minimally 
influences complement activation or cytokine production. Whole blood from healthy, 
adult volunteers was collected in polypropylene tubes containing lepirudin (50-
µg/ml final concentration). informed consent was obtained from all donors prior 
to the experiments, and the human experimentation guidelines of the local ethics 
committee were followed in conducting the research. immediately after being drawn, 
the whole blood (1 ml) was incubated with the stimulants (0.1 ml). 
for the determination of granulocyte cR3 (cD11b/cD18) expression and oxidative 
burst, samples were incubated for 10 min at 37°c in a water bath, followed by 
immediate processing for flow cytometry. 
for the detection of complement activation, samples were incubated for 1 h at 37°c 
in a coulter mixer (coulter, luton, england). complement activation was stopped 
by the addition of eDTa to a final concentration of 20 mM, after which samples were 
centrifuged at 1,400 x g for 10 min. The plasma was collected and stored at –70°c 
until samples were assayed in one batch. 
Samples for the measurement of tumor necrosis factor alpha (TNF-α), interleukin-
1β (IL-1β), IL-8, and macrophage inflammatory protein 1α (MIP-1α) were processed 
as described for complement activation, but the incubation time was increased to 2 
h. 
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oxidative burst
oxidative burst was measured by using a commercially available Burst-test kit 
(orpegen Pharma, Heidelberg, germany). after incubation as described above, 
samples were treated according to the manufacturer’s instructions and assayed by 
flow cytometry. granulocytes were identified in a forward scatter-side scatter plot by 
their typical patterns. 
cR3 (cD11b/cD18) expression
after being incubated as described above, cells were washed once in sterile PBs 
and fixed with 0.5% (vol/vol) paraformaldehyde in an equal volume of PBs for 4 min 
at 37°c. cells were stained with an anti-CD11b-PE or isotype control (γ2a) (Becton 
Dickinson) antibody for 15 min at room temperature. an anti-cD14-fiTc (Becton 
Dickinson) antibody and the nuclear dye lDs-751 (Molecular Probes inc., eugene, 
oreg.) were used to discriminate granulocytes in washed whole blood. 
enzyme immunoassays. complement activation was measured in plasma by 
enzyme immunoassays based on Mabs that were highly specific for the activation 
products; the native, nonactivated components did not interfere in the assays. 
activation of the three initial pathways was selectively detected. 
(i) c1rs-c1inh complexes. activation of the classical complement pathway was 
determined as described previously 24. c1rs-c1 inhibitor (c1rs-c1inh) complexes 
were measured by using Mab Kok-12, specific for a neoepitope exposed only when 
c1inh is in complex with its substrates. in brief, microtiter plates were coated with 
the Kok-12 antibody, the antibody was reacted with plasma or controls, and the 
complex was detected with a cocktail of anti-c1r and anti-c1s antibodies. Human 
serum activated with heat-aggregated immunoglobulin g was used as a standard 
and was defined to contain 1,000 arbitrary units (aU)/ml. 
(ii) c4bc. activation of the classical and lectin pathways was determined by an assay 
using a Mab specific for a neoepitope that is exposed in activated c4 25. The c4bc 
assay detects the sum of the activation products c4b, ic4b, and c4c. The same 
standard was used as for the c1rs-c1inh assay, defined to contain 1,000 aU/ml. 
Both the Mab for this assay and Kok-12 were a kind gift from c. e. Hack, Department 
of immunopathology, sanquin Research, amsterdam, The netherlands. 
(iii) c3bBbP complexes. activation of the alternative pathway was detected by 
measuring the alternative convertase c3b-Bb-properdin (c3bBbP), as recently 
described 10. The capture antibody used was an antiproperdin antibody, and the 
detection antibody was a polyclonal anti-c3 antibody. The standard was normal 
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4human serum activated with zymosan and defined to contain 1,000 aU/ml. 
(iv) Tcc. activation of the terminal pathway was quantified by using Mab ae11, 
specific for c9 incorporated in the fluid-phase sc5b-9 complex, as described 
previously 26. The assay was modified, with a biotinylated anti-c6 antibody used 
as the detection antibody. Human serum activated with zymosan was used as the 
standard. 
an overview of the complement activation markers measured is illustrated in 
figure1. 
cytokines and chemokine
commercially available enzyme-linked immunosorbent assay (elisa) kits were 
used according to the manufacturers’ instructions to quantify TNF-α, IL-1β, IL-8 
(Duo set elisa development system [R&D systems, Minneapolis, Minn.] for all 
three), and MIP-1α (MIP-1α Cytoscreen [Biosource International, Cammarillo, 
Calif.]). The lower limits of detection were 8 pg/ml for TNF-α, IL-1β, and IL-8 and 2 
pg/ml for MIP-1α. 
Figure 1.
schematic overview of the complement system.
Boxes indicate specific complement activation products measured in the present study and their relation to 
specific complement activation pathways. c1rs-c1inh complexes reflect classical pathway activation, c4bc 
reflects both classical and lectin pathway activation, and c3bBbP reflects alternative pathway activation. 
Tcc is an activation product of the final common and terminal pathways.
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lal assay
Quantification of the biological activity of lPs in the bacterial strains was performed 
as described previously 27. E. coli o55:B5 lPs was used as a reference. The lower 
limit of detection was 0.25 endotoxin units/ml. 
statistics
a two-way analysis of variance (anoVa) for repeated measures was used to test 
the data for statistically significant differences. P values of <0.05 were considered 
statistically significant
ResUlTs
complement activation by lPs+ and lPs– N. meningitidis or 
purified nmlPs.
assays for c1rs-c1inh (classical pathway), c4bc (classical and lectin pathways) 
and c3bBbP (alternative pathway) complexes were used to determine the initial 
complement activation pathways, whereas soluble Tcc, the final product of the 
terminal pathway, was used as an indicator of total complement activation (figure 
1). 
The amount of lPs per 106 N. meningitidis cells was estimated by sDs-Page 
analysis; this showed that 106 bacteria contained approximately 5 ng of lPs. in 
figures 2 and 3, the x axes are calibrated for the numbers of lPs+ N. meningitidis 
cells as well as the amounts of lPs that are present in the bacteria. in this way, the 
activities of the bacteria and purified lPs can be compared quantitatively. 
The levels of the markers of initial pathway activation, c1rs-c1inh, c4bc, and 
c3bBbP, as well as that of Tcc from the terminal pathway, were all increased from 
the baseline after stimulation with lPs+ or lPs– N. meningitidis (figure 2). The 
activation of initial complement activation products was seen at concentrations of 
106 meningococci/ml or higher, which correspond to approximately 5 ng of nmlPs 
or more/ml. in contrast, purified nmlPs did not induce complement activation at 
concentrations up to 1,000 ng/ml. The combination of purified nmlPs and lPs– 
N. meningitidis induced complement activation to a similar extent as lPs+ or 
lPs– N. meningitidis (not shown). These data indicate that complement activation 
by N. meningitidis in human whole blood occurs independently of the lPs outer 
membrane component. 
granulocyte cR3 upregulation and oxidative burst by lPs+ and 
lPs– N. meningitidis or purified nmlPs.
Recently, the cR3 upregulation and oxidative burst induced by N. meningitidis in 
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4granulocytes were shown to be complement dependent. Therefore, we investigated 
the role of lPs in these processes. 
Both lPs+ and lPs– N. meningitidis at concentrations of 106/ml induced marked 
granulocyte cR3 upregulation and oxidative burst. The addition of purified nmlPs 
to lPs-deficient N. meningitidis did not influence the cR3 upregulation or oxidative 
burst (not shown). notably, purified nmlPs did not induce significant cR3 
upregulation or oxidative burst at concentrations up to 1,000 ng/ml (figure 3). These 
results indicate that the upregulation of cR3 expression and the oxidative burst in 
whole blood granulocytes after stimulation with N. meningitidis are not dependent 
on nmlPs. 
cytokine and chemokine induction by lPs+ and lPs– n. 
meningitidis.
cytokine and chemokine induction in a human whole blood model of meningococcal 
sepsis was assessed after 2 h of incubation with lPs+ or lPs– N. meningitidis 
(figure 4). no cytokine or chemokine production was seen in this whole blood 
model in the absence of a stimulus. lPs+ N. meningitidis was a potent inducer 
of IL-1β, TNF-α, IL-8, and MIP-1α production, as it was able to induce cytokine 
Figure 2. 
complement activation 
by lPs+ and lPs– N. 
meningitidis and by 
purified nmlPs.
The results are for the 
formation of c1rs-c1inh 
(classical pathway), 
c4bc (classical and 
lectin pathways), 
c3bBbP (alternative 
pathway), and Tcc 
(final common pathway) 
after the stimulation of 
lepirudin-treated human 
whole blood for 1 h 
with lPs+ (diamonds) 
or lPs– (squares) N. 
meningitidis or purified 
nmlPs (circles). The x 
axes are calibrated for 
the numbers of lPs+ 
N. meningitidis cells as 
well as the amounts of 
nmlPs that are present 
in the lPs+ bacteria, 
according to sDs-Page 
analysis. Medians and 
upper quartiles are 
presented from four 
separate experiments. *, 
P < 0.05; **, P < 0.01, by 
two-way anoVa. Dashed 
lines indicate baseline 
complement activation.
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and chemokine production at concentrations higher than 104 meningococci/ml. il-
1β, TNF-α, IL-8, and MIP-1α production by LPS– meningococci was significantly 
reduced compared to that by lPs+ N. meningitidis (P < 0.05 for all cytokines and 
chemokines measured). However, marked IL-8, and to a lesser extent, TNF-α and 
MIP-1α production was also induced by lPs– N. meningitidis, suggesting that these 
mediators can also be induced in the absence of lPs (figure 4).
Figure 3. 
granulocyte cR3 upregulation 
and oxidative burst by lPs+ 
and lPs– N. meningitidis and 
by purified nmlPs. 
The results are for cR3 
(cD11b/cD18) upregulation 
and oxidative burst in human 
granulocytes after the 
stimulation of lepirudin-treated 
human whole blood for 10 
min with lPs+ (diamonds) or 
lPs– (squares) N. meningitidis 
or purified nmlPs (circles). 
The x axes are calibrated 
for the numbers of lPs+ N. 
meningitidis cells as well as 
the amounts of nmlPs that 
are present in the bacteria, 
according to sDs-Page 
analysis. one representative 
of three separately performed 
experiments is shown. Dashed 
lines indicate baseline cR3 
expression or oxidative burst.
Figure 4. 
cytokines and chemokines 
induced by lPs+ and lPs– N. 
meningitidis.
The results are for the 
production of IL-1β, TNF-α, 
IL-8, and MIP-1α after the 
stimulation of lepirudin-treated 
human whole blood for 2 h 
with lPs+ (diamonds) or lPs– 
(squares) N. meningitidis. 
Mean cytokine or chemokine 
production levels from three 
separate experiments are 
presented. *, P < 0.05, by 
two-way anoVa
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4DiscUssion
The principal finding of the present study was that complement activation and the 
complement-dependent inflammatory events of cR3 upregulation and oxidative 
burst are independent of lPs in a whole blood model of meningococcal sepsis. 
The construction of the lPs-deficient meningococcal mutant H44/76lpxA has 
made it possible to study the relative importance of the lPs moiety of a gram-
negative bacterium in diverse inflammatory processes 19. We used lPs-deficient 
N. meningitidis to assess the involvement of meningococcal lPs in complement 
activation, complement-dependent inflammatory effects, and cytokine or chemokine 
production in a human whole blood model of meningococcal sepsis. The lack of 
reactivity of the lPs– strain in a lal assay confirmed the absence of lPs in the 
batch used for the experiments. The estimate that 106 lPs+ meningococci contained 
approximately 5 ng of meningococcal lPs was in line with previous estimations 
13,22. 
N. meningitidis is exclusively a human commensal or pathogen, and none of the 
animal models available accurately simulate fMs. Therefore, we used an in vitro 
experimental system approaching, as closely as possible, the human in vivo situation 
10,11. The principle of this model is to keep all ambient inflammatory systems intact 
so that they can be activated and mutually interact but still to avoid coagulation. 
Because most anticoagulants, such as eDTa, citrate, and heparin, interact with 
critical steps in the inflammatory network, this model uses the highly specific 
thrombin inhibitor lepirudin, a recombinant hirudin analogue, as an anticoagulant. 
cR3 upregulation and oxidative burst were found to be induced to a similar extent 
by live or heat-inactivated bacteria in this model. since these processes are 
highly complement dependent, this indicates that complement activation is also 
not affected by inactivation of the bacteria. Therefore, heat-inactivated bacteria 
were used because of practical considerations, as live meningococci constitute a 
significant health hazard 11. 
lPs is present in solution in the form of micellar structures, which is quite distinct 
from its organization when it is present in the outer membrane. Hypothetically, the 
physicochemical presentation of lPs could affect the complement-activating ability, 
favoring membrane-bound lPs as the stronger complement activator. However, 
the observation that lPs-containing meningococci activate complement to a similar 
extent as lPs-deficient meningococci suggested that this is not the case, as did 
the absence of an increase in the complement-activating ability when isolated lPs 
was added back to the lPs-deficient strain. This is supported by a previous study in 
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which neisserial outer membrane vesicles (oMVs) containing lPs were equipotent 
to oMVs deficient for lPs 15. 
complement activation by lPs+ or lPs– N. meningitidis was seen at concentrations 
of 106/ml or higher. This is a concentration of meningococci that is frequently found 
during fMs 3,28; 106 lPs+ N. meningitidis cells contain approximately 5 ng of lPs. 
in contrast, complement was not activated by purified lPs at concentrations up 
to 1,000 ng/ml. This suggests that during meningococcal sepsis, complement 
activation is not induced by lPs, but by other constituents of N. meningitidis. 
Members of our laboratory previously reported that the upregulation of cR3 and 
the induction of oxidative burst in granulocytes in this whole blood model are 
dependent on complement activation 10,11. When complement is activated, c5a is 
formed, and this anaphylatoxin reacts with the c5a receptor on granulocytes and 
monocytes to induce the upregulation of cR3. cR3 is the principal receptor involved 
in the phagocytosis of c3b-coated bacteria, and when upregulated, it will enhance 
phagocytosis of the bacteria and in this way stimulate the oxidative burst process. 
our results indicate that cR3 expression and oxidative burst are mediated by non-
lPs components of N. meningitidis. 
it is commonly accepted that lPs extracted from diverse gram-negative bacteria 
activates complement readily via classical and alternative pathway-dependent 
mechanisms 29,30. in addition, lPs has been shown to be able to upregulate cR3 
expression and to prime neutrophils for oxidative burst 31-34. However, for the 
experiments presented in these studies, very high concentrations of lPs were 
applied (>5 to 10 µg/ml), incubation times of longer than 30 min were employed for 
granulocyte activation, or isolated cell cultures or plasma were used. in addition, 
it was recently shown that a contaminating substance of commercially available 
lPs is, at least in part, responsible for the upregulation of neutrophil responses 
35. We claim that the conditions used in our study more closely resemble the in 
vivo situation than those used in previous studies. in our model, purified nmlPs 
was tested in whole blood at concentrations that are relevant for the situation 
encountered during fMs. The relatively short incubation times mimic the function of 
the complement cascade system, the components of which are present in plasma 
and able to be immediately activated by an invading pathogen, in this way avoiding 
the contribution of activation processes secondary to other inflammatory events. 
We propose that the observed weak complement-activating property of nmlPs is 
not specific for this type of lPs, as it has a relatively short saccharide side chain, 
but that other types of lPs are also weak complement activators at relevant 
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4concentrations. Preliminary data from our laboratory suggest that this is the 
case for E. coli lPs in the same in vitro model. in addition, in primate models, 
complement is not activated after E. coli lPs infusion, but after whole E. coli cell 
infusion, marked complement activation occurs within 15 min 36,37. also, in a human 
endotoxemia model, no complement activation is observed, whereas significant 
cytokine production, endothelial cell activation, and activation of the coagulatory 
and fibrinolytic systems are found 38. 
The bacterial components that are involved in the activation of complement, the 
upregulation of cR3 expression, and oxidative burst remain elusive and will be 
subjected to further investigation. it was previously reported that oMVs isolated 
from lPs-deficient N. meningitidis induce substantial complement activation 15. This 
suggests that the non-lPs components that induce complement activation reside 
in the outer membrane. The lectin pathway seems to be an important player in 
complement activation by meningococci when they are grown on Kellog’s medium 
and studied in the whole blood model 11. since mannose-binding lectin binding to 
the bacteria occurs via the outer membrane proteins porin and opacity protein 
(opa) independently of lPs 39, it is reasonable to suggest that the porins and 
opa are responsible, at least in part, for the observed complement activation and 
subsequent cR3 upregulation and oxidative burst. 
The proinflammatory cytokines TNF-α and IL-1β are primary cytokine mediators 
during meningococcal sepsis, whereas il-8 and MIP-1α are important chemotactic 
proteins that are important for pathogenesis 40-42. We found that lPs– N. meningitidis 
induced marked IL-8, and to a lesser extent, TNF-α and MIP-1α production in 
the whole blood model, indicating that bacterial components other than lPs are 
also proficient at inducing cytokine or chemokine production. However, lPs+ N. 
meningitidis was more potent in the induction of these proinflammatory mediators, 
in particular TNF-α and MIP-1α, indicating that LPS is an important factor involved 
in the regulation of these processes, which is in agreement with previous reports 12-
14. it is tempting to speculate that the observed lPs-independent induction of il-8, 
and possibly also TNF-α and MIP-1α, is mediated or potentiated by the activation of 
complement factor c5a, as has been suggested previously 10,43,44. 
We conclude that complement activation occurs independently of the lPs moiety 
of N. meningitidis. Therefore, cR3 upregulation and oxidative burst, previously 
shown to be highly complement dependent, are also independent of lPs. cytokine 
and chemokine production can be induced via lPs-dependent as well as lPs-
independent mechanisms. 
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Human lipoproteins have divergent neutralizing effects on E. coli lPs, N. 
meningitidis lPs, and complete gram-negative bacteria. 5
aBsTRacT
The use of lipoproteins has been suggested as a treatment for gram-negative 
sepsis because they inhibit lipopolysaccharide (lPs)-mediated cytokine production. 
However, little is known about the neutralizing effects of lipoproteins on cytokine 
production by meningococcal lPs or whole gram-negative bacteria. We assessed 
the neutralizing effect of lDls, HDls, and VlDls on lPs- or whole bacteria-
induced cytokines in human mononuclear cells. a strong inhibition of Escherichia 
coli LPS-induced interleukin-1β (IL-1β), tumor necrosis factor-α, and IL-10 by 
lDl and HDl was seen, whereas VlDl had a less pronounced effect. in contrast, 
Neisseria meningitidis lPs, in similar concentrations, was neutralized much less 
effectively than E. coli lPs. effective neutralization of meningococcal lPs required 
a longer interaction time, a lower concentration of lPs, or higher concentrations of 
lipoproteins. The difference in neutralization was independent of the saccharide tail, 
suggesting that the lipid a moiety accounted for the difference. Minimal neutralizing 
effects of the lipoproteins were observed on whole E. coli or N. meningitidis bacteria 
under all conditions tested. These results indicate that efficient neutralization of 
lPs depends on the type of lPs, but a sufficiently long interaction time, a low lPs 
concentration, or high lipoprotein concentration also inhibited cytokines by the less 
efficiently neutralized N. meningitidis lPs. irrespective of these differences, whole 
bacteria showed no neutralization by lipoproteins. 
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5inTRoDUcTion
lipopolysaccharide (lPs), a major structural and functional component of the outer 
membrane of gram-negative bacteria, is considered to be a major pathogenic 
element in gram-negative septicemia 1. lPs interacts with a variety of cells to 
induce a wide array of inflammatory mediators. among these, the proinflammatory 
cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) and the 
antiinflammatory cytokine il-10 are key factors in the development of shock and 
disseminated intravascular coagulation 2. 
fulminant meningococcal sepsis (fMs) is an important cause of morbidity and 
mortality worldwide, especially in children and young adults. in addition, it is the 
prototypical gram-negative sepsis syndrome, in which lPs concentrations may 
become extremely high and correlate with cytokine levels, morbidity, and mortality 
3,4. 
lPs is composed of a polysaccharide tail to which the lipid portion (lipid a) is 
attached via 2-keto-3-deoxyoctanate (KDo). lipid a, a glucosamine-derived 
phospholipid, is considered to be the toxic moiety of lPs and is responsible for 
many of the biological effects of lPs 5. 
in the past, various strategies have been explored to combat the deleterious effects 
of lPs during sepsis. However, none of these anti-lPs strategies has shown a 
benefit on outcome 6-9; thus, the search for a lPs-neutralizing treatment modality 
continues. lipoproteins have been shown to bind lPs and to neutralize lPs-
induced cytokine production 10. also, in animal models of sepsis, the administration 
of lipoproteins was found to be beneficial 11,12, and lPs infusion experiments 
in humans showed that the inflammatory response is inhibited by infusion of 
lipoproteins 13,14. for these reasons, lipoprotein infusion during septicemia has 
been advocated as an adjunctive therapy. fMs especially, being the prototypical 
lPs-mediated disease, has been suggested as a candidate disease for treatment 
with lipoproteins. 
To date, most investigators assessing the effect of lipoproteins have used 
lPs derived from enterobacteriaceae species (Escherichia coli or Salmonella 
typhimurium). However, the lPss are a heterogeneous group of molecules with 
interspecies differences in the length and position of the acyl chains in the lipid 
a portion of the lPs, the length and polarity of the polysaccharide tail, and the 
formation of supramolecular structures 5,15,16. These differences in lPs have been 
shown to modulate the capacity to induce cytokines 17-19, and it is likely that these 
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differences also affect the interaction with lipoproteins. in addition, lPs is not the 
only component of gram-negative bacteria that induces cytokines 20-22. Therefore, 
the question is to what extent an adjunctive therapy that targets only lPs, such as 
lipoproteins, will inhibit cytokine production by complete bacteria. 
in the present study, we addressed these questions by comparing the inhibitory 
effect of lipoproteins on cytokine induction by lPs of E. coli and Neisseria 
meningitidis in human mononuclear cells. in addition, we assessed the cytokine-
inhibiting capacity of lipoproteins on whole E. coli and N. meningitidis bacteria. 
MaTeRials anD MeTHoDs
lPss and meningococci
E. coli 055:B5 Tca and phenol-extracted lPs were obtained from sigma chemical 
co. (st. louis, Mo). e. coli K12, D31m4 rough (Re) lPs consisting of lipid 
a(KDo)2 and lacking the polysaccharide tail was purchased from list Biological 
laboratories (campbell, ca). The lipid a of e. coli lPs is a hexaacyl phospholipid 
with the fatty acyl acids asymmetrically distributed 23. Meningococcal lPs was 
isolated by the phenol/water extraction method as described by Westphal and Jann 
24. H44/76 lPs was isolated from strain H44/76 25. Meningococcal H44/76rfaC lPs 
[lipid a(KDo)2] was isolated from the isogenic mutant rfaC of strain H44/76, as 
described by stojiljkovic et al. 26. similar to E. coli lPs, meningococcal lPs has a 
hexaacyl lipid a; however, in the lipid a of the meningococcal lPs, the fatty acids 
are symmetrically distributed 27. Whereas E. coli lPs has a polysaccharide tail, 
meningococcal lPs has an oligosaccharide tail (Table 1).
The commercial E. coli lPs was contaminated with protein (8.5%, by lowry assay) 
and nucleic acid (6.1%, by spectrophotometry). The meningococcal lPs was 
not contaminated with protein, and the nucleic acid content was 4.4%. lPs was 
suspended in culture medium before use. 
E. coli aTcc 35218 is an international reference strain. N. meningitidis H44/76 was 
isolated from a patient with invasive disease 25. stationary-phase bacteria grown in 
liquid medium were used, and bacteria were heat-inactivated (1 h, 56°c). 
lPs lipid a - acyl chains lipid a - molecular 
conformation
saccharide tail
e. coli 055:B5 Hexaacyl asymmetrical polysaccharide
e. coli K12, D31m4 Hexaacyl asymmetrical absent
n. men H44/76 Hexaacyl symmetrical oligosaccharide
n. men H44/76rfac Hexaacyl symmetrical absent
Table 1. characteristics of the different lPs-types. Modified from Refs 19,23,27. 
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5Molarity of the lPs solutions
Measurement of KDo was used to estimate the molarity of the lPs solutions. KDo 
was measured by spectrophotometry, as described by Weissbach and Hurwitz 28. 
lipoproteins and lipoprotein-depleted plasma
lipoproteins (VlDl, lDl, and HDl) and lipoprotein-depleted plasma (lPDP) were 
prepared from fresh eDTa plasma by sequential ultracentrifugation as described 
previously 29 under pyrogen-free conditions using pyrogen-free materials. 
lipoproteins prepared in this manner were previously shown to be endotoxin-free by 
limulus amebocyte lysate (lal) assay. lipoproteins were dialyzed for 24 h against 
0.05 M phosphate buffer, pH 7.4, containing 5 µM eDTa, with one exchange of 
the buffer (lPDP is the fraction of plasma that is obtained after removing the lipid 
fractions). lipoproteins were isolated before each experiment from different donors. 
The concentration of total lipid in the lipoprotein fractions was determined based 
on total cholesterol as a quantitating unit. cholesterol in the different lipoprotein 
fractions was measured by spectrophotometry using a commercially available kit 
and a Hitachi 747 apparatus (Roche Diagnostics, almere, The netherlands). Before 
use, the lipoproteins were diluted 1:1 in lPDP (unless otherwise stated). average 
concentrations of lipoprotein in which the lPs or bacteria were preincubated were 
376 mg/l (0.60 mmol/l cholesterol) for lDl, 130 mg/l (0.22 mmol/l cholesterol) 
for HDl, and 378 mg/l (0.20 mmol/l cholesterol) for VlDl. for experiments 
using a higher concentration of lipoproteins, the lipoproteins were concentrated 
approximately five times by additional ultracentrifugation of the separate lipoprotein 
fractions. 
Human peripheral blood mononuclear cells
Blood for the isolation of peripheral blood mononuclear cells (PBMcs) was drawn 
in 10 ml eDTa anti-coagulated tubes (Vacutainer system; Becton Dickinson, 
Rutherford, nJ) from healthy human volunteers. informed consent was obtained 
before each experiment, and the guidelines of the local ethics committee were 
followed in the conduct of these experiments. PBMcs were isolated by density 
gradient centrifugation over ficoll-Hypaque (Pharmacia Biotech aB, Uppsala, 
sweden). The cells from the interphase were aspirated, washed three times in 
sterile PBs, and resuspended in culture medium RPMi 1640 (Dutch modification; 
flow labs, irvine, UK) supplemented with l-glutamine (2 mmol), pyruvate (1 mmol), 
and gentamicin (50 mg/ml). 
assay procedure
fifty microliters of the lipoprotein diluted in lPDP or lPDP alone was preincubated 
with the stimuli (50 µl) for a certain time period. Then, the preincubated mixture 
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was added to 100 µl of 5 x 106 PBMcs on 200 µl 96-well plates at 37°c and 5% 
co2 and incubated for 24 h. The supernatant was obtained by centrifugation and 
stored at -20°c until required for the cytokine assays. lPDP alone significantly 
enhanced lPs or whole bacteria-induced cytokine production in PBMcs compared 
with culture medium. 
cytokine assays
Levels of IL-1β and TNF-α were determined by radioimmunoassay as described by 
Drenth et al. 30. The lower limit of detection was 80 pg/ml for both cytokines. il-10 
was determined by a commercially available elisa kit (Pelikine compact; sanquin, 
amsterdam, The netherlands). 
statistics and calculations
statistical analysis was performed using an unpaired two-sided t-test; P < 0.05 was 
considered significant. Two-way anoVa was performed to compare concentration 
curves (graphPad Prism; graphPad software, inc.). To calculate the inhibition of 
cytokines by the lipoproteins, cytokine production in the presence of the lipoprotein 
diluted in lPDP was expressed as a percentage of production in the presence of 
lPDP alone.
ResUlTs
cytokine induction by N. meningitidis lPs and E. coli lPs 
a molarity-based comparison of cytokine induction by N. meningitidis and E. 
coli lPs (Tca-extracted) in PBMcs, based on assay for KDo, showed that 
meningococcal lPs is more potent in the induction of IL-1β and TNF-α than is E. 
coli lPs, especially at concentrations of less than 1 pmol/ml (figure 1). The minimal 
concentrations to induce significant IL-1β and TNF-α production were 0.0001 pmol/
ml for meningococcal lPs and 0.001 pmol/ml for E. coli lPs. Phenol-extracted E. 
coli lPs was approximately as potent in the induction of IL-1β and TNF-α as TCA-
extracted lPs (data not shown). Based on these data, in subsequent experiments 
lPs was used at concentrations of 0.14 pmol/ml (equivalent to ⁓0.6 ng/ml 
meningococcal lPs and 1 ng/ml E. coli lPs) unless otherwise stated
effect of lipoproteins on cytokines by E. coli and N. meningitidis 
lPs
The effect of the preincubation of equimolar concentrations of E. coli or N. 
meningitidis LPS with the lipoproteins LDL, HDL, and VLDL for 8 h on IL-1β, TNF-α, 
and il-10 production in PBMcs is shown in figure 2. lipoproteins did not induce 
cytokine production in the absence of stimulus, suggesting minimal contamination 
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5of the lipoprotein fractions with lPs. E. coli lPs-induced cytokine production was 
diminished by lDl to values of 20% of production in lPDP; HDl was slightly less 
effective in the inhibition of cytokine production, whereas VlDl had only a minimal 
effect. notably, meningococcal lPs-induced cytokine production was inhibited to 
a significantly lesser extent by lDl and HDl than cytokine production by E. coli 
lPs. lDl reduced the N. meningitidis lPs-induced cytokine production to only 50–
Figure 2. 
inhibition of lPs-induced cytokines by lipoproteins.
effect of pre-incubation of lPs (0.14 pmol/ml) with lDl, HDl or VlDl for 8 hours on il-1β, Tnfα and il-10 
by human mononuclear cells. lDl and HDl effectively inhibited E. coli lPs, but not N. meningitidis lPs. 
Results are expressed as a percentage of production in lipoprotein depleted plasma (lPDP).  Means and 
standard error of the mean (seM) are presented, n = 5, * = P < .05, for the comparison of E. coli lPs with 
N. meningitidis lPs, by unpaired t-test.  
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Figure 1. 
Cytokines by E. coli and N. 
meningitidis LPS. 
Dose-response curve of il-1β and 
Tnfα by E. coli and N. meningitidis 
lPs in human mononuclear cells 
based on molar concentrations of 
lPs (KDo-assay). N. meningitidis 
lPs was more potent in the induction 
of il-1β and Tnfα than E. coli lPs. 
Medians and interquartile ranges 
(iQR) are presented, n = 5. 
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60% of control production for IL-1β and IL-10, whereas TNF-α production was not 
inhibited at all. HDl inhibited N. meningitidis-induced cytokines less efficiently than 
lDl, and the effect of VlDl was minimal. 
next, we investigated the kinetics of lPs neutralization by lDl or HDl using 
different preincubation times of lipoprotein with lPs and different lipoprotein 
concentrations (figure 3) . We found that inhibition of E. coli LPS-induced IL-1β 
by lDl was dependent on the preincubation time and that for maximal inhibition, 
4–8 h of preincubation was required. of importance, the inhibition of N. meningitidis 
lPs-induced IL-1β production by LDL, compared with E. coli lPs, required much 
longer preincubation times to achieve noticeable inhibition, and maximal inhibition 
was seen only after 24 h of preincubation (figure 3). The results for TNF-α and HDL 
showed a similar pattern, although inhibition by HDl was less efficient.
for lDl, we investigated the importance of lPs concentration on lipoprotein 
neutralization (figure 4) . The experiments showed that TNF-α production was 
inhibited significantly better by E. coli lPs than by N. meningitidis lPs (P < 0.05 by 
two-way anoVa). However, the effectiveness of inhibition by lDl is dependent on 
the concentration of lPs; at high concentrations, both lPs types showed minimal 
inhibition, whereas at the lowest concentration tested, both lPs types were inhibited 
to a large extent. Results for IL-1α showed a similar pattern
in addition, the influence of preincubation with lipoproteins at concentrations 
encountered in normal physiological, nonseptic conditions was investigated. By 
Figure 3.  
effect of pre-incubation of the lPs (0.14 pmol/ml) 
with lDl (0.6 mmol/l) for various time periods on il-
1β production in human mononuclear cells.
inhibition of lPs-induced cytokine by lDl was time-
dependent, the interaction of N. menigitidis lPs with 
lDl was slower than that of E. coli lPs, and relatively 
high lDl concentrations were necessary to inhibit il-
1β production. Results are expressed as a percentage 
of production in lipoprotein depleted plasma (lPDP). 
Means and seM are presented, n = 3. 
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5additional ultracentrifugation, lipid concentrations of 1.1 mmol/l for VlDl, 3.43 
mmol/l for lDl, and 1.18 mmol/l for HDl were achieved. concentrated lDl and 
HDL inhibited TNF-α by both LPS types effectively and to the same extent, whereas 
concentrated VLDL also inhibited TNF-α but to a lesser extent than LDL or HDL 
(figure 5) . Results for IL-1β showed a similar pattern
influence of lipid a composition and the saccharide tail
To investigate whether the observed differences in lipoprotein-dependent inhibition 
of E. coli and N. meningitidis lPs-induced cytokines were dependent on the lipid 
a part or the saccharide tail of the lPs molecule, variants of the lPs lacking the 
Figure 4. 
inhibition of Tnfα at various lPs 
concentrations
inhibition of lPs-induced Tnfα 
production in human mononuclear cells 
by lDl (0.6 mmol/l) after stimulation 
with a concentration range of E. coli 
or N. meningitidis lPs (0.014 to 140 
pmol/ml). lDl was preincubated 
with the different lPs-types for 
8 hours. Results are expressed 
as a percentage of production in 
lipoprotein depleted plasma (lPDP). 
N. meningitidis was significantly (P < 
.05) better inhibited by lDl than E. 
coli lPs (Two-way anoVa). Means 
and seM are presented, n = 3.
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Figure 5. influence of concentrated lipoproteins on lPs-induced 
cytokine production. 
effect of pre-incubation of E. coli or N. meningitidis lPs for 
8 hours with concentrated lipoprotein fractions on cytokine 
induction in human mononuclear cells. lipoproteins were 
concentrated approximately 5 times, lipid concentrations in 
which the lPs was preincubated after concentration were 1.1 
mmol/l for VlDl (VlDl-c), 3.43 mmol/l for lDl (lDl-c) and 
1.18 mmol/l for HDl (HDl-c). Means and seM are presented, 
n = 3.
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polysaccharide tail were used. E. coli Re K12, D31m4 lPs was approximately 
equipotent to E. coli 055:B5 lPs, and N. meningitidis H44/76rfaC lPs was 
approximately equipotent to N. meningitidis H44/76 lPs. IL-1β, TNF-α, and IL-10 
produced by E. coli Re K12, D31m4 lPs were inhibited by lDl (figure 6) and HDl 
(data not shown) to a similar extent as that produced by E. coli 055:B5 lPs. no 
difference was found in the weak inhibitory effect of lDl on cytokine production 
between N. meningitidis H44/76 and N. meningitidis H44/76rfaC lPs. Thus, these 
data suggest that the differences in lipoprotein-dependent inhibition of cytokine 
production between E. coli lPs and meningococcal lPs are not caused by the 
different lengths of the saccharide tails of the lPs but by differences in the lipid a 
part of the lPs molecule.
effect of lipoproteins on cytokines by   or N. meningitidis whole 
bacteria
Because lPs is not the only cytokine-inducing moiety of gram-negative bacteria, we 
assessed whether the lipoprotein fractions were capable of inhibiting the cytokine 
response by PBMcs to complete gram-negative bacteria. in these experiments, the 
E. coli lPs-induced cytokine response was inhibited by lDl or HDl. in contrast, 
IL-1β, TNF-α, and IL-10 induced by E. coli and N. meningitidis complete bacteria 
were not, or were only minimally, inhibited by the lipoproteins lDl, HDl, or VlDl 
(figure 7) . Because the amount of cytokines induced by these whole bacteria 
was significantly higher than the amount induced after stimulation with lPs, we 
tested the capacity of lipoproteins to inhibit a lower concentration of bacteria or 
the capacity of a higher concentration of lDl to inhibit cytokine production. even 
Figure 6.
effect of the saccharide tail of lPs on inhibition by lipoproteins
effect of pre-incubation of various types of lPs (≈ 0.14 pmol/ml) with lDl (0.6 mmol/l) for 8 hours on 
il-1β, Tnfα and il-10 by human mononuclear cells. E. coli 055:B5 and E. coli K12, D31m4 Re lPs were 
inhibited equally by lDl, whereas both meningococcal lPs were less effectively inhibited. Results are 
expressed as a percentage of production in lipoprotein depleted plasma (lPDP). Means and seM are 
presented, n = 5. Differences were tested for significance using unpaired t-test. 
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5Figure 9.
influence of concentrated lipoproteins on whole bacteria-
induced cytokine production
effect of pre-incubation of e. coli or n. meningitidis (0.6 x 
106 bacteria/ml) lPs for 8 hours with concentrated lDl on 
cytokine induction in human mononuclear cells. lDl was 
concentrated approximately 5 times, lDl concentration 
in which the lPs was preincubated was 3.43 mmol/l. 
lDl is unconcentrated lDl (0.6 mmol/l), lDl-c indicates 
concentrated lDl (3.43 mmol/l).Means and seM are 
presented, n = 3.
0
20
40
60
80
100
120
LDL LDL-C
%
 o
f c
on
tro
lp
ro
du
ct
io
n
TNF
E. coli bacteria
N. meningitidis bacteria
Figure 8
inhibition of lPs-induced Tnfα production in human 
mononuclear cells by lDl (0.6 mmol/l)after stimulation with 
a concentration range (104 to 107 bacteria/ml) of whole E. 
coli or N. meningitidis bacteria.
lDl was preincubated with the different bacteria for 8 
hours. Results are expressed as a percentage of production 
in lipoprotein depleted plasma (lPDP). no effect of lDl on 
Tnfα production by E. coli or N. meningitidis bacteria was 
seen. Means and seM are presented, n = 3.
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Figure 7. 
inhibition of whole bacteria induced cytokines by lipoproteins.
effect of pre-incubation of lPs (0.14 pmol/ml) or E. coli and N. meningitidis complete bacteria (0.6 x 106) 
with lDl, HDl or VlDl for 4 hours on il-1β, Tnfα and il-10 by human mononuclear cells. lDl and HDl 
effectively inhibited E. coli lPs, but not E. coli or N. meningitidis whole bacteria. Results are expressed as 
a percentage of production in lipoprotein depleted plasma (lPDP).  Means and seM are presented, n = 5, * 
= P < .05 for the comparison of E. coli lPs with the complete bacteria, by unpaired t-test. 
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at the lowest concentration of bacteria tested (104/ml), no effect of VlDl, lDl, or 
HDl was seen on Tnf-, il-1ß, or il-10 production (figure 8 shows the results for 
LDL and TNF-α). In addition, concentrated LDL (3.43 mmol/l) did not lead to more 
inhibition of bacteria-induced cytokines (figure 9)
DiscUssion
in the present study, we showed that at equimolar concentrations of E. coli or 
N. meningitidis lPs, the in vitro neutralizing effect of lipoproteins on cytokine 
production by N. meningitidis lPs was reduced in comparison with that by E. coli 
lPs. The neutralizing effect on E. coli lPs was shown to be time-dependent and 
saturable. By increasing the interaction time between the lipoproteins and lPs, 
increasing the lipoprotein concentration, or increasing the lPs concentration, the 
dissimilarity in the neutralizing effect of the lipoproteins disappeared. The difference 
in the extent of inhibition of lDl and HDl on both types of lPs is likely to be 
caused by the difference in the lipid a portion of the lPs molecule. of importance, 
cytokine induction by whole E. coli or N. meningitidis bacteria was not influenced 
by lipoproteins. 
a quantitative comparison of the biological effects of different lPs types on a weight 
basis may yield incorrect results because lPs from different bacteria have different 
molecular weights, largely because of the highly variable length of the saccharide 
tail. To avoid this pitfall, we assessed the molar concentration of the E. coli lPs 
and meningococcal lPs batches by determination of KDo, a highly conserved part 
of lPs (molecular mass 238 Da) 5,28, and used equimolar concentrations of lPs 
in all comparative experiments. in accordance with previously reported data on 
the bioactivity of lPs 31,32, the molarity-based dose-response curve showed that at 
concentrations of less than 1 pmol/ml, meningococcal lPs is 10 times more potent 
in the induction of IL-1β and TNF-α than is E. coli lPs. 
The protective effect of the lipoproteins lDl and HDl in models of gram-negative 
infection and lethal endotoxemia is well documented, and the inhibition of lPs-
induced proinflammatory cytokine production, through binding of lPs by the 
lipoproteins, is thought to be a key element in this process 10-14. in the present study, 
we tested whether cytokine induction by the lPs isolated from N. meningitidis, the 
bacterium that causes the prototypical gram-negative sepsis syndrome, is inhibited 
by lipoproteins in a similar manner as the prototypical lPs isolated from E. coli. 
The concentrations of lPs used in the current in vitro experiments (0.14 pmol or 
0.6 ng/ml) were chosen to be in the range of concentrations of lPs (as determined 
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5by lal assay) seen in the bloodstream during meningococcal sepsis, which range 
from 0.05 ng/ml to more than 10 ng/ml 4. in E. coli sepsis, lPs levels are generally 
lower 33,34. as earlier determinations showed that meningococci contain 1 ng 
lPs/106 bacteria in the outer membrane 20, the concentration of bacteria (0.6 x 106) 
was chosen to match the concentrations of lPs used. This bacterial concentration 
is in agreement with the amount of bacteria found during meningococcal sepsis 
(2.2 x 104/ml to 1.6 x 108/ml) 35. 
lipoprotein plasma concentrations are altered during sepsis or meningitis: lDl and 
HDl cholesterol decreased (to 0.8–1.4 mmol/l for lDl and 0.2–0.4 mmol/ml for 
HDl), whereas VlDl cholesterol was increased to a median concentration of 2.3 
mmol/ml 36,37. Thus, the concentrations of lDl and HDl used for this study are in 
range with the concentrations of these lipoproteins as they occur in septic conditions. 
for some experiments, the lipoproteins were further concentrated approximately 
five times to also investigate their detoxifying capacity at concentrations that are 
seen under normal physiological, nonseptic conditions. as VlDl increases during 
sepsis, we could only study this lipoprotein at concentrations that are seen in 
healthy individuals. 
confirming earlier observations 38, we found that preincubation of E. coli lPs with 
lDl as well as HDl inhibited the cytokine response, whereas VlDl had a less 
pronounced effect. However, at identical molar concentrations and incubation 
times, N. meningitidis lPs was neutralized much less efficiently than E. coli lPs. 
The neutralizing effect of lDl and HDl was dependent on the preincubation time of 
the lPs with the lipoproteins and the concentration of lPs or lipoproteins. Whereas 
E. coli was inhibited significantly after relatively short preincubation times of 1–4 h, 
for meningococcal lPs, maximal inhibition was only seen after 24 h of preincubation. 
Using a fixed preincubation time (8 h) and a fixed concentration of lDl, the extent 
of inhibition was influenced by the concentration of lPs. over the complete range 
of concentrations tested, E. coli lPs was significantly better neutralized by lDl 
than was N. meningitidis lPs (as assessed by two-way anoVa). However, at the 
highest concentration tested, E. coli lPs also showed minimal inhibition, whereas 
at the lowest concentration tested, both lPs types were neutralized to a large 
extent. To investigate the impact of higher concentrations of lipoproteins on lPs 
detoxification, we maximally concentrated the lipoprotein fractions by additional 
ultracentrifugation. in this way, lipoprotein fractions approximately five times more 
concentrated were obtained, and the final concentration of lipoprotein in the PBMc 
system now equaled concentrations seen under physiological, nonseptic conditions. 
at these higher concentrations of lipoprotein, both lPs types were inhibited equally 
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and to a large extent by lDl and HDl after 8 h of preincubation. Thus, irrespective 
of the difference in neutralization seen at low concentrations of lipoproteins, this 
suggests that at physiological concentrations both E. coli and N. meningitidis 
lPss are neutralized by the lipoproteins effectively. VlDl had a less pronounced 
neutralizing effect on cytokines, although it cannot be excluded that at even higher 
concentrations, as seen during sepsis, the effect of VlDl is also increased. Taken 
together, these results indicate that the efficient neutralization of lPs depends 
on the type of lPs, but a sufficiently long interaction time, a low concentration of 
lPs, and a high concentration of lipoproteins will also inhibit cytokines by a less 
efficiently neutralized lPs. our results emphasize the concept that lipoproteins 
might be important for E. coli lPs-mediated disease. However, because during 
severe meningococcal sepsis, lPs concentrations are much higher, the time period 
from the onset of disease to admission is very short 4, and concentrations of lDl 
and HDl are decreased, it is unlikely that lipoproteins play an important role in 
neutralizing lPs during this type of infection. 
The main molecular differences between E. coli lPs and N. meningitidis lPs are 
the size and structure of the saccharide tail and the position and distribution of 
the six acyl chains on the glucosamine backbone. To investigate which of these 
differences determine the neutralization by lipoproteins, we measured the effect 
of lipoproteins on cytokine induction by two types of E. coli and N. meningitidis 
lPs that are completely devoid of a saccharide tail, i.e., E. coli Re K12, D31m4 
lPs and N. meningitidis H44/76rfac lPs. This showed that the neutralizing action 
of lipoproteins is independent of the presence of the saccharide tail. Thus, the 
lipid a part, with its asymmetrical hexaacylated conformation in E. coli lPs and 
its symmetrical distribution of the six acyl chains in N. meningitidis lPs, accounts 
for the divergent effect. The bioactivity and receptor affinity of an lPs molecule is 
suggested to be determined by the three-dimensional conformation of the lipid a, 
possibly altering the bioactivity and receptor affinity of the lPs molecule 19. for 
lPs-lipoprotein interactions, levine and colleagues 12 have proposed the “leaflet 
insertion” model, in which the fatty acyl acids of the lipid a portion of lPs are 
inserted into the lipid monolayer of the lipoproteins, inactivating the “toxic moiety” of 
lPs. We presume that the lower degree of neutralization of meningococcal lPs by 
lipoproteins is caused by the symmetrical lipid a structure interacting more slowly 
with the lipoprotein lipid monolayers. 
lPs is generally considered to be the pathogenic component of gram-negative 
bacteria 1. However, recently, it has been shown that non-lPs components of 
gram-negative bacteria also highly influence cytokine production 20-22. Therefore, 
we studied whether lipoproteins affect cytokine production after stimulation with 
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5whole bacteria, even at relatively low bacterial concentrations or high (physiological, 
nonseptic) lipoprotein concentrations. This was not the case. This finding 
indicates that whole bacteria, in contrast to isolated lPs, in which neutralization 
by lipoproteins depends on the interaction time and concentration of lPs or 
lipoprotein, are impervious to neutralization by lipoproteins. We assume that lPs, 
anchored tightly in the outer membrane of the gram-negative bacterium, interacts 
less easily with the lipoproteins than isolated lPs. in addition, it can be speculated 
that bacterial components, other than lPs, of E. coli or N. meningitidis that are 
not inhibited by lipoproteins may account for the absent cytokine-inhibitory effect 
of lipoproteins on whole gram-negative bacteria. The data presented seemingly 
contradict the findings in animal models, in which lipoprotein administration did 
reduce cytokines and outcome after the administration of whole E. coli or after 
cecal ligation and puncture 39,40. Therefore, further investigation is needed on the 
immune-modulating mechanisms of lipoproteins during gram-negative sepsis. 
in conclusion, lDl and HDl inhibit cytokines by E. coli lPs, but N. meningitidis lPs 
shows reduced neutralization by human lipoproteins. However, a sufficiently long 
interaction time, a low lPs concentration, or higher lipoprotein concentration also 
inhibits cytokines by this less efficiently neutralized lPs. in contrast, lipoproteins 
do not have a neutralizing effect on whole E. coli or N. meningitidis bacteria. This 
raises questions about the rationale for adjuvant treatment of meningococcal and 
other types of gram-negative sepsis with lipoproteins. 
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N. meningitidis lipid a mutant lipopolysaccharides (lPs) function as lPs 
antagonists in humans by inhibiting toll-like receptor 4 (TlR4) dependent 
cytokine production 6
aBsTRacT
lipopolysaccharide (lPs) is a major constituent of the outer membrane of gram-
negative bacteria and important in the induction of pro-inflammatory responses. 
Recently, novel lPs species derived from Neisseria meningitidis H44/76 by 
insertional inactivation of the lpxL1 and lpxL2 gene have been created with a lipid 
a portion consisting of five (pentaacylated lpxL1) or four (tetraacylated lpxL2) fatty 
acids connected to the glucosamine backbone instead of six fatty acids in the wild-
type lPs. We show that these mutant lPs-types are poor inducers of cytokines 
(Tnfα, il-1β, il-10, il-Ra) in human mononuclear cells. Both penta- and tetra-
acylated meningococcal lPs were able to inhibit cytokine production by wild type E. 
coli or meningococcal lPs. Binding of fiTc-labelled E. coli lPs TlR4 transfected 
chinese hamster ovary (cHo) cells was inhibited by both mutant lPs-types. 
experiments with cHo fibroblasts transfected with human cD14 and TlR4 showed 
that the antagonizing effect was dependent on the expression of human TlR4. in 
contrast to the situation in humans, lpxL1 lPs has agonistic activity for cytokine 
production in peritoneal macrophages of DBa mice, and exacerbated arthritis 
in murine collagen induced arthritis model. in conclusion, N. meningitidis lipid a 
mutant lipopolysaccharide (lPs) lpxL1 and lpxL2 function as lPs antagonists in 
humans by inhibiting toll-like receptor 4 (TlR4) dependent cytokine production but 
have agonistic activity in mice. 
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6inTRoDUcTion
lipopolysaccharide (lPs) is a major constituent of the outer membrane of gram-
negative bacteria and is important in the induction of inflammatory responses and a 
potent adjuvant in vaccine development 1-3. in Neisseria meningitidis, the molecule 
consists of an oligosaccharide tail, a conserved saccharide inner core and a hexa-
acylated lipid a portion. The lipid a portion is considered the toxic-moiety of lPs, 
responsible for the induction of pro-inflammatory signalling, that binds the cellular 
receptor complex for lPs.
The cellular receptor complex for lPs is well established, consisting of cD14, 
TlR4 and MD-2 4-8. after binding of lPs to this complex, a cascade of intracellular 
molecules is engaged ultimately leading to the release of nuclear factor (nf)-κB 
and the induction of cytokine genes. However, not all lPs function as agonists for 
TlR4. lPs with a penta or tetra-acylated lipid a such as Rhodobacter spaeroides 
lPs 9, Porphyromonas gingivalis lPs 10, lPs from the E. coli msbB strain 11 or 
synthetic lPs such as lipid a-like compound e5531 12 are poor pro-inflammatory 
stimuli and can even act as antagonists of lPs-induced signals. curiously, it has 
been shown previously that some of these lPs-antagonists in humans are lPs 
agonists in rodent cells, inducing a normal inflammatory response 13. 
Recently, by insertional inactivation of the lpxL1 and lpxL2 gene of N. meningitidis 
H44/76, mutant meningococci have been created expressing mutant lPs with a 
lipid a portion consisting of five (pentaacylated lpxL1) or four (tetraacylated lpxL2) 
fatty acids connected to the glucosamine backbone instead of six fatty acids in the 
wild-type H44/76 lPs. These mutant meningococcal strains have previously been 
shown to have reduced toxicity in comparison with the wild-type H44/76 strain, as 
shown by a decreased potency for the induction of Tnfα in a human macrophage 
cell-line 14. in addition, a lPs mutant (msbB) structurally equal to the lpxL1 lPs 
has been shown to inhibit il-8 production in TlR4  transfected  HeK293 cells 15. in 
the present study we investigated the ability of the lpxL1 and lpxL2 lPs mutants to 
inhibit cytokine responses mediated by human TlR4. in addition, we tested these 
lPs mutants in mouse macrophages and a mouse model of arthritis.   
MaTeRials anD MeTHoDs
Bacterial strains and lipopolysaccharides 
construction and characterization of the meningococcal H44/76 lpxL1 and lpxL2 
mutants have been described in detail elsewhere 14. The parent strain N. meningitidis 
H44/76 is an international reference strain, isolated from a patient with invasive 
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meningococcal disease 16, serologically classified as B:15:P1.7,16, immunotype 
l3,7,9 17. as analysed by mass-spectometry, lpxL1, makes lipopolysaccharide 
(lPs) with penta- instead of hexa-acylated lipid a, in which the secondary lauroyl 
chain is missing from the nonreducing end of the glcn disaccharide. insertional 
inactivation of the other (lpxL2) gene was not possible in wild-type strain H44/76 
expressing full-length immunotype l3 lipopolysaccharide (lPs) but was achieved in 
a galE mutant expressing a truncated oligosaccharide chain. structural analysis of 
lpxL2 mutant lipid a showed a major tetra-acylated species lacking both secondary 
lauroyl chains and a minor penta-acylated species 14. for isolation of lPs, the 
N. meningitidis strain H44/76 and its derivatives with inactivated lpxL1 or lpxL2 
genes, were grown at 37°c in liquid medium supplemented with isoVitaleX (Becton 
Dickinson) in a humid atmosphere containing 5 % co2. Bacterial suspensions were 
heat inactivated for 30 min at 56 °c. lPs was isolated by the phenol/water extraction 
method as described by Westphal and Jann 18. after extraction, lPs was treated 
with Proteinase K (sigma-aldrich co), Dna-ase and Rna-ase (Roche diagnostics) 
for additional purification, recovered by ultracentrifugation, freeze-dried and solved 
in sterile PBs. lPs purified and isolated in this way has previously been shown to 
be free of protein contamination (< 1.0 %) (determined by lowry-assay), whereas 
nucleic acid contamination is approximately 5 % 19. E. coli 055:B5 lPs and fiTc 
labeled E. coli lPs was obtained from sigma-aldrich chemical co.
cells and culture conditions
Human peripheral blood mononuclear cells (PBMcs)
Blood for the isolation of PBMcs was drawn in 10 ml eDTa anti-coagulated tubes 
(Vacutainer system, Beckton Dickinson) from healthy human volunteers. informed 
consent was obtained before each experiment, and the guidelines of the local 
ethics committee were followed in the conduct of these experiments. PBMcs were 
isolated by density gradient centrifugation over ficoll-Hypaque (Pharmacia Biotech 
aB). The cells from the interphase were aspirated, washed 3 times in sterile 
phosphate buffered saline (PBs) and resuspended in culture medium RPMi 1640 
(Dutch modification, flow labs) supplemented with l-glutamine (2 mMol), pyruvate 
(1 mMol) and gentamicin (50 mg/ml). cells were incubated with the different 
stimuli for 24 hours, unless otherwise indicated, where after the supernatants were 
collected and stored at -80°c until assay in one batch. 
chinese hamster ovary fibroblasts (cHo) stably transfected with 
human cD14 (3e10) or cD14 and TlR2 (3e10-TlR2) or cD14 
and TlR4 (3e10-TlR4)
chinese hamster ovary fibroblasts (cHo) stably transfected with human cD14 
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6(3e10) or human cD14 and hTlR4 (3e10-TlR4), described previously in detail 5, 
were a kind gift from Dr. Robin ingalls and Dr. Douglas T golenbock. it is important 
to note that 3e10 expresses also hamster TlR4 on the outer membrane, and is 
capable of lPs-mediated signaling. These cell-lines express inducible membrane 
cD25 under control of a region from the human e-selectin (elaM-1) promoter 
containing NF-κB binding sites; this promoter element is absolutely dependent 
on NFκB 13. cells were maintained at 37°c and 5% co2 in HaM’s f12 medium 
(Gibco™, Invitrogen) supplemented with 10 % FCS, 0.01 % L-glutamine, 50 μg/mL 
gentamycin and 400 U/ml hygromycin and 0.05 mg/ml of puromycine for 3e10-
TlR4 as additional selection antibiotics. TlR4 expression was confirmed by flow-
cytometry (coulter facs-scan) using Pe-labelled or anti-TlR4  (clone HTa125) 
(Immunosource). For stimulation experiments, 500 μl of cells in culture medium 
at a density of 1 x 105/ml were plated in 24-well culture plates. after an overnight 
incubation cells were incubated with the various stimulants for 20 hours, whereafter 
the cells were harvested using trypsin/eDTa (cambrex) and prepared for flow-
cytometry (coulter facs-scan). cD25 expression of the cHo-cells was measured 
using fiTc labelled anti-cD25 (DaKo). 
fiTc-lPs binding experiments
LpxL1 and lpxL2 LPS (1 μg/mL) were preincubated with CHO 3E10-TLR4 
for 15 minutes whereafter fiTc labelled E. coli lPs was added at increasing 
concentrations. cells were incubated for 1 hour at RT in the dark, harvested using 
trypsin/eDTa and washed with sterile PBs. Read out was by flow cytometry (coulter 
facs-scan). 
Murine model of arthritis
collagen-induced arthritis (cia) was induced in DBa-1 mice between 10 and 12 
weeks of age. Bovine type ii collagen was dissolved in 0.05 M acetic acid to a 
concentration of 2 mg/ml and emulsified in an equal volume of freund’s complete 
adjuvant (2 mg/ml of M. tuberculosis strain H37Ra; Difco laboratories, Usa). Mice 
were immunized by intradermal injection of 100 µl of the emulsion at the base of 
the tail and were given an intraperitoneal booster injection of 100 µl of cii dissolved 
in phosphate-buffered saline without any adjuvant on day 21. clinical onset and 
progression of arthritis was macroscopically evaluated by two blinded observers 
and scored on a scale between 0 and 2 for each paw as described previously 
20. Mice were treated using three i.p. injections of lpxL1 (400 µg/kg body weight) 
once in two days started on day 22 of immunization before the clinical onset of the 
disease.
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stimulation of murine peritoneal macrophages
Murine macrophages were isolated from naïve DBa/1 mice by the lavage of the 
peritoneal cavity using 10 ml cold medium (DMeM + 10% fcs). adherent cells 
were harvested and cultured for four days before use. cells were incubated with e. 
coli lPs (10 ng/ml), lpxL1  (100 ng/ml) or a combination of both.
cytokine assays
Human tumor necrosis factor-α (Tnfα), interleukin-10 (il-10) and il-1Ra were 
determined by elisa (in-house 4-span elisa for Tnfα 21, Pelikine compact elisa 
(sanquin) for the other cytokines, lower limit of detection 20 pg/ml), interleukin-1β 
(il-1β) was determined by radioimmunoassay (Ria) as described by Drenth et al 
22. The lower limit of detection was 40 pg/ml. Murine cytokines were measured 
using the Bioplex cytokine assays (Bio-Rad, Usa) following the manufacturer’s 
instruction.
ResUlTs 
cytokine induction by N. meningitidis H44/76 lPs and lpxL1 or 
lpxL2 mutant lPs
N. meningitidis H44/76 LPS was a potent inducer of the cytokines TNFα and IL-10 
in human PBMc. in contrast, the lpxL1 and lpxL2 mutant lPs types were 100 – 
1000 times less potent in the induction of these cytokines, inducing only minimal 
cytokine production at concentrations of 10 μg/mL (figure 1). The mutant lPs were 
also minimal inducers of il-1β and il-1Ra (data not shown). 
antagonistic properties of lpxL1 and lpxL2 mutant lPs
similar to meningococcal lPs, E. coli LPS was a potent inducer of TNFα and IL-
10 in human PBMcs. Pre incubation of the PBMcs with lpxL1 or lpxL2 lPs (1 
Figure 1
Tnfα and il-10 production after 
stimulation of human PBMcs for 
24 hours with N. meningitidis 
H44/76 lPs, and the mutant 
lpxL1 and lpxL2 lPs.
Mean values and sD are shown, 
n = 3. ** indicates P < 0.01 for 
the comparison of lpxl1 and 
lpxL2 lPs with N. meningitidis 
H44/76 lPs by two way anoVa. 
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6
μg/mL) completely inhibited TNFα and IL-10 production induced by E. coli lPs. 
This antagonistic effect was present at all concentrations of E. coli lPs tested, 
ranging form 0.1 ng/ml up to 100 ng/ml (figure 2). N. meningitidis H44/76 lPs 
was inhibited to a similar extent by the mutant lPs (not shown). The antagonistic 
effect of lpxL1 and lpxL2 lPs on cytokine induction by 10 ng/ml of E. coli lPs 
was present in concentrations of 10 ng/ml of lpxL1 or lpxL2 or higher. complete 
inhibition was seen at concentrations of 100 ng/ml of lpxL2 lPs and 1 µg/ml 
of lpxL1 lPs (figure 3). in addition, we examined whether pre-incubation was 
necessary for inhibition of lPs-induced cytokines by lpxL1 and lpxL2. We found 
that lPs-induced cytokine production was inhibited by the lpxL-mutants equally 
well when they were preincubated with the PBMcs or simultaneously added with 
the E. coli lPs (figure 4).
finally, we tested whether the observed inhibitory effect on cytokine production 
was dependent on inhibition of lPs-binding to TlR4. figure 5 shows that binding 
of fiTc-labelled E. coli lPs to cHo cells transfected with hcD14 and hTlR4 was 
Figure 2
E.coli induced Tnfα and il-10 
production by human PBMcs in 
the absence or presence of the 
mutant lpxL1 and lpxL2 LPS (1μg/
ml).
LpxL1 and lpxL2 lPs were 
preincubated with the PBMcs for 
30 minutes prior to stimulation with 
E. coli lPs. Mean values and sD 
are shown, n = 3. * indicates P < 
0.05 for the comparison of lpxL1 
and lpxL2 lPs with the control 
(RPMi) by two way anoVaCONTROL lpxL1 LPS lpxL2 LPS
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Figure 3
E. coli (10 ng/ml) induced Tnfα production by human PBMc in 
the presence of different concentrations of lpxL1 and lpxL2 lPs.
LpxL1 and lpxL2 lPs were preincubated with the PBMcs for 30 
minutes prior to stimulation with E. coli lPs. Mean values and 
sD are shown, n = 3. lpxL1 and lpxL2 did not significantly differ 
in their ability to inhibit E. coli induced Tnfα (two-way anoVa)
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completely inhibited by the lpxL1 and lpxL2 mutant lPs. This indicates that the 
antagonistic effect is dependent on TlR4 binding by the lpxL-mutant lPs.
expression of human TlR4 is necessary for lPs antagonism
To test whether the observed antagonistic effect of lpxL1 and lpxL2 lPs was 
dependent on differences in TlR4-mediated signalling, we made use of the 
differences in TlR4 dependent signalling between human and hamster TlR4, 
employing a cHo cell line stably expressing human cD14 and either hamster TlR4 
(3e10) or overexpressing human TlR4 (3e10-TlR4). 
isolated E. coli lPs and  wild-type N. meningitidis H44/76 lPs (not shown) induced 
nf-κB activation in both cell lines. in contrast, lpxL1 and lpxL2 lPs induced a 
similar response to E. coli lPs in the cD14 transfected cHo cells expressing 
hamster TlR4, but when these cHo cells overexpress human TlR4, the nf-κB 
response is blunted (figure 6a). These results indicate that nf-κB activation by the 
lpxL1 and lpxL2 mutant lPs differs between species, and its absence in humans is 
Figure 5
inhibition of binding of fiTc lPs to cHo 3e10-TlR4 by lpxL1 
and lpxL2 lPs.
Representative experiment of 3 performed is shown. FITC-LPS (µg/mL)
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E. coli-induced Tnfα production by human PBMcs in the 
absence (RPMi) or presence of lpxL1 and lpxL2 mutant 
lPs, pre-incubated with the PBMcs for 30 minutes or added 
directly together with the E. coli lPs.
Mean values and sD are shown, n = 2
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6dependent on TlR4. 
antagonistic activity of lpxL1 and lpxL2 lPs was dependent on expression of 
human TlR4, as the lpxl mutants were able to inhibit E. coli lPs-induced nf-κB 
activation in hcD14-transfected cHo cells overexpressing human TlR4 but not in 
hcD14-transfected cHo cells expressing hamster TlR4 (figure 6B). 
Taken together, these results indicate that that lpxL1 and lpxL2 lPs bind hamster 
and human TlR4, inducing a strong nf-κB response by hamster TlR4, but no nf-
κB dependent signaling by human TlR4. in this way, they are proficient to inhibit 
binding of agonist-lPs to human TlR4, antagonizing the effects of agonist-lPs on 
nf-κB dependent cytokine production in humans.  
lpxL1 is not an antagonist in mice, and exacerbates arthritis in a 
murine model of arthritis
Because of the antagonistic nature of the lpxL1 lPs in human cells we investigated 
whether lpxL1 lPs was able to attenuate arthritis in a murine model of collagen 
induced arthritis, similar to previously published results for Bartonella quintana 
lPs 23. However, in contrast to the findings with Bartonella lPs, we found that 
the lpxL1 lPs exacerbated arthritis in DBa mice, as evidenced by higher arthritis 
scores in the mice injected with lpxL1 lPs in comparison with control mice injected 
with saline (figure 7a). as previous studies have shown that agonist E. coli lPs 
also causes exacerbation of arthritis, we investigated whether the lpxL1 lPs is 
an agonist for cytokine production in the DBa mice. experiments with murine 
peritoneal macrophages demonstrated that in mice, the lpxL1 lPs induced a potent 
TNFα, IL-1β and IL-6 response - albeit that lpxL1 lPs was approximately 10 times 
Figure 6
NF-κB dependent CD25 expression on CHO cells stably transfected with human CD14 alone or human 
cD14 and human TlR4.
cells were stimulated with E. coli lPs lpxL1 lPs or lpxL2 LPS at 1 μg/mL for 20 hours (A) or preincubated 
with the lpxL1 and lpxL2 lPs for 30 minutes and they were stimulated with E. coli LPS (1μg/mL) for 20 
hours (B). average and sD are presented of 3 experiments performed. 
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less potent then E. coli lPs - and was not able to inhibit cytokine production by E. 
coli lPs (figure 7B, results for Tnfα are shown). This indicates that in the DBa 
mice, the lpxL1 lPs functions as an agonist for TlR4 - in contrast to the situation in 
humans where lpxL1 lPs is antagonistic. 
DiscUssion 
in the present study, we show that lipid a mutant lPs, derived from genetically 
engineered meningococci expressing penta- or tetra-acylated lPs, have a strongly 
reduced capacity to induce nfκB activation and cytokine production by human 
TlR4. in contrast, they function as lPs-antagonists in humans, by binding TlR4 
and competitively inhibiting cytokine production by agonist lPs. This effect on 
TlR4 transmitted signals is species-specific. Pentaacylated mutant lpxL1 lPs 
exacerbates disease in a murine arthritis model and is an agonist for TlR4 mediated 
cytokine production in murine peritoneal macrophages and hamster cells.
Recently, Teghanemt et al. reported that the meningococcal msbB lPs-mutant, 
structurally equal to the lpxL1 lPs mutant used in the present study, bound MD2 
and subsequently TlR4 in a similar manner as wild type meningococcal lPs but 
was a partial antagonist of TlR4 dependent il-8 production in HeK293 cells 15. 
We expand these findings with our observations that the antagonistic effect is also 
present in human primary cells for a range of pro and anti-inflammatory cytokines, 
that the lpxL2 lPs has a similar antagonistic effect as the lpxL1 lPs and that this 
effect is species-specific, not present in DBa mice or hamster cells. Teghanemt 
et al., proposed that the mechanism behind the antagonistic effect of the msbB 
Figure 7
exacerbation of arthritis in a collagen induced arthritis model in DBa mice by lpxL1 lPs (panel a).
Mean and seM of arthritis scores in 11 mice are shown;  = mice challenged with collagen and 3 
intraperitoneal injections of lpxL1 lPs at day 0, 2 and 5, ο = mice injected with 0.9 % saline solution. Panel 
B shows Tnfα production by murine peritoneal macrophages 24 hours after stimulation with DMeM, lpxL1 
lPs (100 ng/ml), E. coli lPs (10 ng/ml) or a combination of lpxL1 lPs (100 ng/ml) and E. coli lPs (10 
ng/ml). Representative experiment of 2 performed is shown. * indicates P < 0.05 by Mann Whitney test
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6lPs was an alteration of the interaction of the MD2-lPs complex with the TlR4 
receptor 15. for E. coli msbB lPs a similar mechanism was suggested by coats 
et al, who found that MD-2 and TlR4 were the only components of the receptor 
complex necessary to mediate msbB lPs antagonism of TlR4 dependent signalling 
by wt E .coli lPs 11. interestingly, the cHo cells we used in the present study 
only overexpress human cD14 and TlR4, whereas MD-2 is not overexpressed, 
although it may be present endogenously 24. Thus, the antagonistic property of 
the lpxL1 and lpxL2 lPs mutants in the cHo cells overexpressing human TlR4 is 
independent of human MD-2. This suggests that the TlR4 molecule itself is central 
to the antagonistic effect of the lpxL1 and lpxL2 lPs. 
an important feature of lPs molecules that exhibit antagonistic properties is that 
this effect is species-specific. for instance, R. sphaeroides lPs and lipid iVa 
are agonists for cytokine production in hamster cells 25, whereas in mouse, R. 
sphaeroides lPs is an antagonist and lipid iVa is an lPs mimetic 9. in the present 
study we found that the lpxL1 and lpxL2 lPs are antagonists in humans, are lPs-
mimetics in cHo cells expressing hamster TlR4 but are antagonists again in cHo 
cells overexpressing human TlR4. interestingly, in DBa mice, lpxL1 lPs was an 
agonist for cytokine responses, and exacerbated disease in a murine model of 
arthritis. This is a well know effect of agonistic lPs 20,26 and shows that the in vitro 
differences in antagonistic properties between species for these lPs types also 
confer to in vivo functional effects. our results are in agreement with the differential 
signaling of lpxL1 lPs through murine and human TlR4 as reported by steeghs et 
al. 27, which showed that the reduction in activity of lpxL1 as compared to wildtype 
meningococcal lPs is much more pronounced in the human than the mouse 
system.
The antagonistic nature of penta or tetra-acylated lPs has received significant 
attention as potential therapy for human diseases such as septic shock 28,29, 
rheumatoid arthritis 23,30, asthma 31 and inflammatory bowel disease 32. The beneficial 
effects may be caused by inhibition of the interaction of gram-negative bacteria 
with cells of our immune system, but there is increasing evidence that lPs is not 
the only ligand for the TlR4 complex, and it is possible that antagonists for lPs will 
also be antagonists for these other ligands 33. 
in conclusion, N. meningitidis lipid a mutant lipopolysaccharide (lPs) lpxL1 and 
lpxL2 function as lPs antagonists in humans by inhibiting TlR4 dependent cytokine 
production. as such, lpxL1 and lpxL2 mutant lPs might be of therapeutical value in 
TlR4 dependent inflammatory conditions. Differences of human and murine TlR4 
however, preclude the use of mouse models in studies addressed to this item.
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Mannose binding lectin enhances il-1beta and il-10 induction by non-
lipopolysaccharide (lPs) components of Neisseria meningitidis. 7
aBsTRacT
Mannose binding lectin (MBl) is a key molecule in the lectin pathway of complement 
activation, and likely of importance in our innate defence against meningococcal 
infection. We evaluated the role of MBl in cytokine induction by lPs or non-lPs 
components of Neisseria meningitidis, using a meningococcal mutant deficient 
for lPs. Binding experiments showed that MBl exhibited low, but significant 
binding to encapsulated LPS+ meningococci (H44/76) and LPS-deficient (LPS−) 
meningococci (H44/76lpxA). experiments with human mononuclear cells (PBMcs) 
showed that MBL significantly augmented IL-1β production after stimulation with 
LPS+ and LPS− meningococci, in a dose-dependent fashion. In addition, IL-10 
production was enhanced after stimulation with LPS− meningococci. In contrast, 
TNFα, IL-6 and IFNγ productions were unaffected. No effect of MBL was observed 
on cytokine induction by meningococcal lPs. MBl enhanced cytokine production at 
concentrations >107 meningococci. it is concluded that MBl interacts with non-lPs 
components of N. meningitidis and in this way modulates the cytokine response.
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7inTRoDUcTion
Meningococcal disease, caused by the gram-negative diplococcus Neisseria 
meningitidis, is an important cause of mortality and morbidity, particularly in children. 
The clinical course of the disease ranges from meningitis with a relatively benign 
clinical picture and a mortality rate of less then 5% to fulminant meningococcal 
sepsis with a rapidly deteriorating clinical condition and a mortality rate ranging 
from 20 to 50% 1.
Disease severity and mortality in meningococcal disease are correlated with high 
plasma concentrations of the pro-inflammatory cytokines TNFα and IL-1β, which 
induce shock and disseminated intravascular coagulation 2,3. However, cytokines 
play a complex dual role in the pathophysiology of invasive meningococcal disease, 
as it also has been shown that a low production capacity for TNFα combined with a 
high production capacity for the anti-inflammatory cytokine il-10 or poor regulation 
of the il-1 system constitute a risk factor for invasive disease 4,5. Meningococcal 
lipopolysaccharide (lPs) is generally considered to be the main cytokine-inducing 
element 6. Using lPs-deficient mutant N. meningitidis we and others have shown 
however, that non-lPs components of the meningococcus can also induce cytokine 
production in human monocytes or macrophages 7-9.
Mannose binding lectin (MBl) is a pattern-recognition molecule present in serum 
that is involved in the innate immune defence by activation of complement, 
promotion of opsonophagocytosis and modulation of inflammatory mediators 10. 
serum concentrations of MBl are determined by structural mutations in the exon 
1 region and polymorphism of the promoter region of the MBl-gene (caucasian 
median value: 1600 ng/ml) 11,12. Homozygousity for any of the 3 structural mutations 
in the exon 1 region reduces serum levels of MBl to values <100 ng/ml, whereas 
heterozygousity for these mutations also profoundly reduces MBl concentrations 
to levels <400 ng/ml. The presence of promoter polymorphisms contributes to the 
wide range of MBl concentrations as observed in the general population. in addition, 
MBl is an acute phase protein and during inflammation levels can increase some 
three-fold 13. Recent evidence suggests that MBl plays a role in the pathogenesis 
of meningococcal disease. MBl can bind meningococci, activate complement and 
increase killing of these organisms 14,15. in addition, genetic deficiency for MBl has 
been shown to increase susceptibility to meningococcal infection, particularly in 
children 16-18. However, the exact pathophysiological role of MBl in meningococcal 
disease is incompletely understood.
MBl has been reported to influence also the cytokine network after stimulation 
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with various microorganisms 19-21. Knowing the crucial role of the cytokine network 
in meningococcal disease, the principal aim of the present study was to assess 
the role of MBl in cytokine induction by lPs and by non-lPs components of N. 
meningitidis.
MaTeRials anD MeTHoDs
Meningococcal strains, lipopolysaccharide and mannose binding 
lectin
The wild-type encapsulated serogroup B N. meningitidis H44/76 strain (indicated 
as lPs+N. meningitidis) was isolated from a patient with invasive meningococcal 
disease 22. The meningococcal strain H44/76lpxA (indicated as LPS−N. meningitidis) 
is a viable isogenic mutant completely devoid of lPs in the outer membrane. 
absence of lPs in this strain was confirmed as described previously 23. absence 
of lPs-activity in the lpxA batch-suspension was confirmed by non-reactivity 
in the limulus amebocyte lysate assay. The major outer membrane proteins of 
the LPS− meningococcus are expressed in similar amounts as compared to the 
lPs+N. meningitidis. However, decreased amounts of the cell surface-exposed 
lipoproteins LbpB and TbpB are seen. The outer membrane phospholipids in LPS− 
meningococci consist of shorter chains and more phospholipids with saturated fatty 
acids are present 24,25. Heat killed (1 h, 56 °c) bacteria washed once in phosphate 
buffered saline (PBs) were used for stimulation experiments and binding studies. 
encapsulated N. meningitidis B1940 wild-type and the isogenic mutant cpsD− 
which has a truncated, non-sialylated lPs, kindly provided by Dr. Matthias frosch 
(University of Würzburg, germany), were used as negative and positive MBl-
binding controls in the dot blotting experiments.
Meningococcal H44/76 lPs was isolated and purified by the phenol/water extraction 
method as described by Westphal and Jann 26. after extraction, lPs was treated 
with proteinase K (sigma–aldrich co), Dna-ase and Rna-ase (Roche diagnostics) 
for additional purification. Protein contamination of the lPs-suspension after 
treatment was less than 1.0%, nucleic acid contamination was 4.4%. The amount 
of H44/76 lPs in the batch-suspension was quantified by assaying for 2-keto-3-
deoxyoctanate (KDo) 27. The amount of lPs in lPs+N. meningitidis H44/76 was 
determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (sDs-
Page) and assay for KDo 28. in the stimulation experiments, N. meningitidis H44/76 
lPs was used in concentrations approximately equivalent to the amount present in 
lPs+ H44/76 meningococci.
Mannose binding lectin (MBl) was isolated from human plasma (donated by c. 
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7Dash, Blood products laboratory, elstree, United Kingdom) by a modification of 
the method of Kilpatrick, as described previously 29,30. The concentration of MBl 
was determined by elisa, and purity was verified by non-reducing sDs-Page. 
MBl prepared in this manner is known to be non-covalently associated with MBl-
associated serine protease (MasP).
Binding of MBl to N. meningitidis H44/76 and lpxA
Binding of MBl to bacteria was determined by dot blotting technique. Meningococci 
(10 μL of 2 × 108/ml in PBs) were spotted onto a prewetted Hybond-P membrane 
(amershamPharmacia Biotech, amersham, UK). Membranes were blocked for 
30 min with Pierce superBlock (Perbio science, Tattenhall, UK) before 60 min of 
incubation steps with 1.5 μg/mL MBL, then 1 μg/mL anti-MBL (clone 131-1, Statens 
serum institut, copenhagen, Denmark) and finally a 1/1000 dilution of horse-radish 
peroxidase conjugated goat anti-mouse immunoglobulin (sigma, Poole, UK) before 
chemiluminiscent detection with ecl reagents (amershamPharmacia Biotech). all 
dilutions were in Tris-buffered saline containing 0.002% v/v Tween-20 (TBs-Tw). 
Between incubations, the membrane was washed 4 times in TBs-Tw.
stimulation of human peripheral blood mononuclear cells 
(PBMcs)
Blood for the isolation of PBMcs was drawn in 10 ml eDTa anti-coagulated tubes 
(Vacutainer system, Beckton Dickinson, Rutherford, nJ) from healthy human 
volunteers. PBMcs were isolated by density gradient centrifugation over ficoll-
Hypaque (Pharmacia Biotech aB, Upssala, sweden). The cells from the interphase 
were aspirated, washed 3 times in sterile, endotoxin-free PBs and resuspended 
in culture medium RPMi 1640 (Dutch modification, flow labs, irvine, scotland) 
supplemented with l-glutamine (2 mM), pyruvate (1 mM) and gentamycin (50 mg/
mL). 0.5 × 106 PBMCs per well were incubated with the various stimuli in 200 μL 
96-well plates at 37 °c and 5% co2 for 24 h. Before incubation with the PBMcs, 
MBl was pre-incubated with the various stimuli for 2 h at 37 °c and 5% co2. as no 
serum is added to the cell-culture in this way, no exogenous source of complement 
is present. no c3 was found in the PBMc culture system in a blank sample and 
after stimulation of the PBMc with lPs- n. meningitidis in the presence or absence 
of MBL. The supernatant was obtained by centrifugation and stored at −20 °C until 
required for the cytokine assays.
cytokine assays
Levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNFα) were determined 
by radioimmunoassay as described by Drenth et al. 31. The lower limit of detection 
was 80 pg/mL for both cytokines. Levels of interleukin-10 (IL-10), interferon-γ 
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(IFNγ) and interleukin-6 (IL-6) were determined by ELISA (Pelekine Compact, 
central laboratory of the netherlands Red cross, amsterdam). The lower limit of 
detection was 8 pg/ml.
statistics
Data were analysed using the non-parametric Mann–Whitney U test for unpaired 
data, and by one-way anoVa when indicated. P < 0.05 was considered significant.
ResUlTs
MBL-binding LPS+ and LPS− meningococci
Dot blotting experiments (figure 1) showed that both LPS+ (B) and LPS− (D) 
meningococci were able to bind MBl. Binding of these two strains was at a lower 
level than to the B1940cpsD− mutant (C), but substantially more than to the B1940 
strain (a).
cytokine induction by MBl
Purified MBL did not induce IL-1 and TNFα production in concentrations of MBL 
ranging from 0.75 to 2500 ng/mL. IL-10, IFNγ and IL-6 inductions by purified MBL 
were tested at a single concentration (2500 ng/ml), but again we observed no 
effect on the production of any of these cytokines (data not shown).
The role of MBl in cytokine induction by lPs and non-lPs 
components of N. meningitidis
in figure 2, IL-1β, IL-10, TNFα and IFNγ production after stimulation with both 
meningococcal strains or meningococcal lPs in the absence or presence of MBl (2500 
ng/mL) is shown. IL-1β and IL-10 production after stimulation with LPS−N. meningitidis 
was significantly enhanced by MBL. MBL also significantly enhanced IL-1β production 
after stimulation with wild-type LPS+ meningococci. In contrast to IL-1β and IL-10, MBL 
did not affect TNFα and IFNγ after stimulation with LPS+ or LPS− meningococci. The 
A B
DC
Figure 1. 
Binding of MBl to the meningococcal strains. 
Blotting membrane showing binding of MBl (1500 ng/ml) 
to 2 × 108 of H44/76 lPs+ meningococci (quadrant B), 
lPs− mutant meningococci (quadrant D), N. meningitidis 
B1940 (quadrant a, negative control) and N. meningitidis 
B1940cpsD− (quadrant c, positive control). 
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7production of il-6 was also not affected by MBl (data not shown). furthermore, MBl 
had no effect on the cytokine production induced by meningococcal lPs. To exclude the 
possibility that the enhancing effect of MBl on cytokine induction could be attributed to 
a non-specific protein effect, the effect of human serum albumin (HSA) at 2500 ng/mL 
on the cytokines studied was determined: no effect of Hsa could be observed (data not 
shown). 
Figure 2. 
effect of MBl on cytokine production by lPs and non-lPs of N. meningitidis. 
Production of TNFα, IL-1β, IFNγ and IL-10 after stimulation of human PBMCs in the absence (white bars) 
or presence (hatched bars) of MBL (2500 ng/mL) with wild-type LPS+N. meningitidis (6 × 108/mL), LPS−N. 
meningitidis (6 × 108/ml) and n. meningitidis lPs (600 ng/ml). MBl was pre-incubated with the various 
stimuli for 2 h. Median values ± iQR of 15 separate experiments in different control subjects are presented 
for both bacterial strains, n = 5 for meningococcal lPs. 
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Figure 3. 
MBL enhances non-LPS-induced IL-1β production. 
Dose–effect relationship for MBL in concentrations ranging from 0.75 ng/mL to 2500 ng/mL on IL-1β 
production after stimulation with wild-type LPS+N. meningitidis (6 × 108/mL), LPS−N. meningitidis (6 × 108/
ml) and n. meningitidis lPs (600 ng/ml). MBl was pre-incubated with the various stimuli for 2 h. Mean 
relative change (in %) of IL-1β as compared to control production ± SEM of 10 separate experiments in 
different control subjects is presented for both meningococcal strains, n = 5 for meningococcal lPs. P < 
0.01 for LPS+N. meningitidis and P < 0.001 for LPS−N. meningitidis (one-way ANOVA). 
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To determine the dose–effect relationship for MBL and IL-1β production, PBMCs were 
stimulated with lPs+ and lPs− meningococci and purified meningococcal LPS in 
the presence of increasing concentrations of MBl (range: 0.75 ng/ml–2500 ng/ml). 
figure 3 shows that IL-1β induction by LPS+N. meningitidis as well as by lPs−N. 
meningitidis was significantly enhanced by MBl (P < 0.01 for lPs+N. meningitidis 
and P < 0.001 for lPs−N. meningitidis (one-way anoVa)), in a dose-dependent 
fashion. MBL exerted its greatest effect on IL-1β production after stimulation with 
lPs− meningococci. an enhancement of 84% ± 24.6% (mean ± sD) was found 
with lPs+ meningococci when MBl was present (2500 ng/ml) which increased to 
298% ± 75% with lPs− meningococci at the same MBl concentration. no effect of 
MBl could be observed on cytokine production after stimulation with isolated lPs 
(P = 0.42). TNFα production was not affected at any of the MBL concentrations 
tested (data not shown).
The enhancing effect of MBl on cytokine production was also dependent on 
the quantity of bacteria used for stimulation. figure 4 shows IL-1β and IL-10 
production in the absence or presence of MBl (2500 ng/ml) after stimulation with 
6×106 to 6×108 LPS− meningococci/mL: MBL enhanced cytokine production at 
concentrations > 107 meningococci. However, at lower concentrations no enhancing 
effect occurred. For IL-1β, a similar pattern was present in experiments using LPS+ 
wild-type meningococci, no significant effect of lPs+N. meningitidis was seen on 
il-10 production. 
DiscUssion
The principal findings of the present study are that MBL augmented IL-1β and IL-10 
production by human PBMcs induced by non-lPs components of meningococci. in 
Figure 4.
Effect of MBL on IL-1β at 
different concentrations of 
LPS−N. meningitidis. 
Dose–effect relationship 
for LPS−N. meningitidis in 
concentrations ranging from 
6 × 106 to 6 × 108 bacteria/
mL on IL-1β and IL-10 
production in the absence 
(open circles) or presence 
(closed circles) of MBl 
(2500 ng/ml.). MBl was pre-
incubated with the stimulus 
for 2 h. Median values ± iQR 
of 5 separate experiments in 
different control subjects are 
presented, *P < 0.05. 
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7contrast, TNFα, IL-6 and IFNγ production was unaffected, suggesting a differential 
role of MBL in the signalling pathways for IL-1β and IL-10 on one hand, and TNFα, 
IL-6 and IFNγ on the other. In addition, we found that the LPS+ as well as the LPS− 
meningococci were able to bind MBl to a similar extent.
MBl reportedly binds to repeating sugar units present on the cell surface of various 
human pathogens 32. However, as assessed by flow cytometry, MBl binds poorly 
to intact wild-type serogroup B N. meningitidis probably because of the extensive 
sialylation of the capsule and lPs 33,34. We have previously noted that flow cytometry 
may not identify all of the physiologically relevant MBl-binding to a microorganism 
14. Therefore, in the present study we improved the sensitivity of the detection of 
MBl-binding by using dot blotting of whole organisms. in this way, we showed 
that binding of MBl does occur to the serogroup B H44/76 lPs+ meningococci 
and the LPS− meningococci. Interestingly, this low level of binding is sufficient 
for the modulation of cytokine production 30, as IL-1β production was augmented 
by MBL after stimulation with the LPS+ and LPS− strains. In addition, the finding 
that MBL binds LPS+ and LPS− meningococci to a similar extent suggests that 
MBl does not bind to lPs but to other structures present on the outer membrane. 
This is supported by the findings of estabrook et al. who found that MBl binds 
to outer membrane proteins of the meningococcus and not to lPs 35. further, we 
confirmed our previous finding that meningococcal mutants having a truncated lPs 
bound more MBl than organisms having an untruncated lPs. The B1940 parent 
strain, which was used as a negative control, did not bind significant amounts of 
MBl. This indicates that in both the strains belonging to serogroup B (B1940 and 
H44/76), differences in MBl-binding are present. Possibly, differences in sialylation 
of the lPs or differences in outer membrane protein expression account for this 
difference.
although flow cytometry proved to be insufficiently sensitive to detect MBl-
binding to H44/76 meningococci14, it has been shown that MBl does not appear to 
aggregate bacteria on its own. This is supported by a viable counting methodology 
which shows no effect of MBl on bacterial numbers, even when MBl-binding is 
high, such as to the B1940cpsD− strain (D.L. Jack, unpublished data).
We previously found that purified MBl added to MBl-deficient whole blood modified 
the production of TNFα, IL-1β and IL-6 in a dose-dependent manner 30. in the current 
study, we investigated whether MBl is directly involved in the cytokine response 
by PBMc to N. meningitidis by excluding complement and other serum proteins. 
MBL enhanced IL-1β production but did not influence IL-6, TNFα or IFNγ. Our 
results suggest that MBl has a direct effect on PBMc by highly selective cytokine 
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induction. When compared with our previous results, it appears that other serum 
proteins also have an effect on cytokine induction by MBl, which is particularly 
noticeable for il-6.
We found that MBL had an enhancing effect on IL-1β and IL-10 production only 
at relatively high bacterial concentrations (>107 bacteria/ml). However, during 
meningococcal infection, local concentrations of bacteria at the site of entry are 
probably within this range. in addition, the number of bacteria in the bloodstream or 
in cerebrospinal fluid during severe invasive disease can exceed 108 bacteria/ml 
36-38. Therefore, the finding in this laboratory study may be clinically relevant.
serum concentrations of MBl in individuals with a normal wild-type MBl genotype 
range from 1000 to 5000 ng/ml, which is in range with the highest concentration 
of MBl used in our experiments 12. IL-1β enhancement was observed at MBL 
concentrations. These are levels as seen in individuals heterozygous for a structural 
mutation in exon 1 and suggests that an absence of cytokine modulation by MBl is 
only likely to be seen in individuals completely deficient for MBl.
The ability of meningococcal components other than lPs to induce cytokines has 
recently been established by us and several other groups using the same LPS− 
meningococcal mutant 7,8. We showed that MBl had a more pronounced effect on 
cytokine induction by LPS− meningococci as compared with the LPS+ meningococci 
and that MBl had no effect on cytokines induced by meningococcal lPs. This 
suggests that MBl interacts with the non-lPs components of the meningococci 
to enhance cytokine production. We have recently determined that MBl binds to 
2 outer membrane proteins of the meningococcus, porin B and opacity-associated 
protein but not to lPs. as porin B is a TlR2 ligand, and contributes as a non-lPs 
ligand to cytokine production by PBMc 39, it is tempting to speculate that MBl may 
enhance TlR2 signalling.
MBL had a more pronounced effect on IL-1β and IL-10 induction by LPS− 
meningococci as compared with the lPs+ meningococci. This is unlikely to be 
due to an increased expression of MBl-binding outer membrane proteins such as 
porin and opacity protein a (opa) 25,35, because there is no difference in expression 
of these outer membrane proteins between the different meningococcal strains. 
Because binding of MBl to both meningococcal strains was similar, and no effect 
of MBl on the lPs-induced cytokines was seen, it is more likely that using the 
LPS+ strain enhancement of IL-1β and IL-10 was overshadowed by the relatively 
higher lPs-dependent cytokine production. However, as certain lipoproteins are 
expressed in decreased amounts, and there are differences in composition of the 
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7outer membrane phospholipids, it cannot be ruled out that the difference in MBl-
dependent cytokine production between the strains is dependent on differences in 
outer membrane composition.
Whereas IL-1β and IL-10 productions were enhanced by MBL, no effect was seen on 
the TNFα and IL-6 production. Thus, MBL has a differential effect on the signalling 
pathways of IL-1β and IL-10 on one hand, and TNFα and IL-6 on the other. Recently, 
it has been found that LPS− meningococci use other cellular receptors than 
meningococcal lPs: lPs can employ toll-like receptor (TlR) 4 to induce cytokines, 
whereas LPS− meningococci use pathways independent of TLR4, such as TLR2 
28,40. Various studies showed that the engagement of different cellular receptors 
results in differential production of cytokines 41-43. The differential modulation of 
cytokine production by MBl, therefore, is likely to be caused by engagement of 
cellular receptors other than those for LPS, which favour the production of IL-1β 
and il-10. The observation that MBl upregulates il-10 induction by non-lPs of the 
meningococcus indicates that, interaction of MBl with non-lPs components also 
contributes to an anti-inflammatory response 44.
In contrast to IL-1β, IL-10, TNFα and IL-6, which are monocyte-produced cytokines, 
IFNγ is a primarily T-cell- and NK-cell-derived cytokine. The lack of effect of MBL 
on IFNγ production might imply that MBL interacts predominantly with monocytes 
to augment monocyte-produced cytokines.
in meningococcal disease, a poor outcome is correlated with high plasma levels 
of pro-inflammatory cytokines 3,45. For IL-1β in particular, its presence in plasma 
of a patient predicts a fulminant course of the disease 3. on the other hand, il-
10 is also upregulated in meningococcal disease and has been suggested to be 
the most important anti-inflammatory cytokine, implicated in down-regulation of 
monocyte responses to lPs 3 46. Because MBl enhances the production of both il-
1β and IL-10, we suggest that these in vitro findings are also of importance in the 
pathogenesis of meningococcal sepsis. However, the ultimate effect of MBl on the 
balance between pro- and anti-inflammatory cytokines in meningococcal disease 
remains elusive.
in conclusion, this study shows that MBl engages with non-lPs components 
of N. meningitidis to enhance the production of the cytokines IL-1β and IL-
10 by human PBMcs, in addition to its effects on complement activation and 
opsonophagocytosis. 
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Inhibition of C5a-induced inflammation with preserved C 5b-9-mediated 
bactericidal activity in a human whole blood model of meningococcal 
sepsis.
aBsTRacT
The complement system plays an important role in the initial defense against 
Neisseria meningitidis. in contrast, uncontrolled activation in meningococcal sepsis 
contributes to the development of tissue damage and shock. in a novel human 
whole blood model of meningococcal sepsis, we studied the effect of complement 
inhibition on inflammation and bacterial killing. Monoclonal antibodies (mabs) 
blocking lectin and alternative pathways inhibited complement activation by N. 
meningitidis and oxidative burst induced in granulocytes and monocytes. oxidative 
burst was critically dependent on CD11b/CD18 (CR3) expression but not on Fcγ-
receptors. specific inhibition of c5a using mab 137-26 binding the c5a moiety of 
c5 before cleavage prohibited cR3 up-regulation, phagocytosis, and oxidative 
burst but had no effect on c5b-9 (Tcc) formation, lysis, and bacterial killing. an 
mab-blocking cleavage of c5, preventing c5a and Tcc formation, showed the 
same effect on cR3, phagocytosis, and oxidative burst as the anti-c5a mab but 
additionally inhibited Tcc formation, lysis, and bacterial killing, consistent with 
a c5b-9-dependent killing mechanism. in conclusion, the anti-c5a mab 137-26 
inhibits the potentially harmful effects of N. meningitidis-induced c5a formation 
while preserving complement-mediated bacterial killing. We suggest that this may 
be an attractive approach for the treatment of meningococcal sepsis. 
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8inTRoDUcTion
The gram-negative bacterium Neisseria meningitidis is an important human pathogen 
worldwide. it can cause meningitis or fulminant meningococcal sepsis (fMs); the 
latter is an overwhelming and often lethal condition that may lead to death within 24 
hours. The pathogenic mechanism leading to fMs is a breakdown of homeostasis by a 
massive activation of diverse inflammatory systems such as the cytokine network and 
plasma cascades such as the complement, coagulation, fibrinolytic, and kinin/kallikreinin 
systems 1,2. 
The importance of the complement system in meningococcal disease is emphasized 
by several observations. Complement deficiencies are defined risk factors for 
meningococcal infections, indicating that complement is crucial in the initial defense 
against this bacterium 3-5. on the other hand, during fMs, disease severity, tissue 
damage, and outcome are closely related to the degree of complement activation 6,7. 
Thus, with respect to the pathogenesis of meningococcal disease, the complement 
system has been aptly named a double-edged sword 8. 
complement is activated on the surfaces of meningococci by one or more of the 3 initial 
complement-activating pathways—classical, lectin, and alternative. after the activation 
of complement factor-3 (c3) by any of these 3 pathways, a c5 convertase (c4b2a3b 
through the classical and lectin pathways or c3bBbc3b through the alternative pathway) 
is formed, and the pivotal c5 molecule is cleaved into c5a and c5b. c5b is the initial 
molecule in the formation of the terminal c5b-9 complement complex (Tcc). Membrane-
associated Tcc, also designated the c5b-9 membrane attack complex (Mac), plays a 
key role in lysis of the bacterium, whereas the fluid-phase SC5b-9 is lytically inactive 
after binding to vitronectin and clusterin. c5a is an important anaphylatoxin that has 
a wide range of proinflammatory effects, including endothelium activation, vascular 
permeability induction, histamine release, coagulation system activation, chemotaxis, 
cytokine modulation, cR3 up-regulation, and oxidative burst induction 9-11. a schematic 
overview of the complement system is shown in figure 1.
in systemic meningococcal disease, there is a continuous search for a treatment 
modality that abrogates the deleterious inflammatory response. Unfortunately, to 
date no effective regimen has been found. Modulation of the complement system may 
be an attractive approach in the treatment of fMs or other inflammatory diseases 
12,13. a main challenge of reducing disease severity by inhibiting complement in fMs 
is to preserve the beneficial bactericidal effect of complement while attenuating the 
detrimental systemic inflammatory effects, thus blunting one edge of the double-
edged sword while sharpening the other. 
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The aim of the present study was to identify such a strategy. for this purpose we 
developed a human whole blood model of meningococcal sepsis based on a newly 
described method 11 to determine the effect of inhibiting N. meningitidis-induced 
complement activation on bactericidal activity and the inflammatory response. 
MaTeRials anD MeTHoDs
equipment and reagents 
all materials used in the stimulation experiments were endotoxin free. Polypropylene 
tubes were either nUnc cryotubes (nalgene nUnc, Roskilde, Denmark) or falcon 
(Becton Dickinson, franklin lakes, nJ) tubes. Phosphate-buffered saline (PBs) 
was produced in the laboratory, Dulbecco medium was obtained from invitrogen 
(Paisley, scotland), and lepirudin (Refludan) was from Hoechst (frankfurt am Main, 
germany). flow cytometry was performed with facscalibur (Becton Dickinson, san 
Jose, ca) and with an epics Xl (coulter, Hialeah, fl) apparatus. MRX microplate 
reader (Dynex Technologies, Denkendorf, germany) was used to determine optical 
density (oD). 
inhibitory antibodies 
Mouse immunoglobulin g1 (igg1) mabs to human c2 (clone 175-26), factor D 
Figure 1. 
schematic overview of the complement system. 
Boxes indicate specific complement activation products measured by enzyme-linked immunosorbent assay 
(elisa) and their relation to specific complement activation pathways. c1rs-c1inh complexes reflect 
classical pathway activation, c4bc reflects both classical and lectin pathway activation, and c3bBbP 
reflects alternative pathway activation. c3bc and terminal complement complex (Tcc) are activation 
products of the final common and terminal pathways. MBl indicates mannose-binding lectin; MasP, MBl-
associated serine protease.
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8(clone 166-32), c5 (clone 137-76), c5a (clone 137-26), and the isotype-matched 
control (clone g3-519, anti-HiV1 gp 120) were produced and purified under 
identical conditions in the laboratory of one of the coauthors (M.f.) 14. The anti-c5 
antibody 137-76 binds c5 and prevents its cleavage, blocking the formation of c5a 
and that of c5b-9 15. anti-c5a 137-26 blocks free c5a directly and preneutralizes its 
biologic effects by binding to the c5a moiety on native c5 without interfering with 
c5 cleavage. The anti-c5a antibody 137-26 is highly human specific, and no cross-
reactivity has been observed with nonprimate species 16.
Purified mouse igg1 mab to human cD11b (clone icRf 44) was obtained from 
serotec (oxford, United Kingdom). Mouse mab (f(ab’)2) to human CD16/FcγRIII 
(clone 3g8) recognizes both allelic forms of cD16 and blocks the binding of immune-
complexed igg to cD16. Mouse mab (f(ab’)2) to human CD32/FcγRII (clone 7.3) 
reacts with the domain 2 epitope of all cD32 isoforms and blocks igg immune-
complexed binding. Mouse mab (f(ab’)2) to human CD64/FcγRI (clone 10.1) 
recognizes the CD64 molecule of 72 kDa from gene FcγRIA and blocks binding of 
FcγRIA to IgG opsonized cells. All were obtained from ancell corp (Bayport, Mn). 
Purified mouse igg1 mab to human mannose-binding lectin (MBl) (clone HYB131-
01), which reacts with human MBl both in its polymeric conformation and as a single 
subunit, was obtained from the antibodyshop (copenhagen, Denmark) and was 
documented by the manufacturer to block MBl function. all antibodies were used 
in concentrations ranging from 6.25 to 25 µg/ml because preliminary experiments 
showed maximum inhibition in this concentration range, except for the anti-cD11b 
and anti-MBl antibodies, which had to be used in concentrations up to 50 µg/ml 
(anti-cD11b) or 100 µg/ml (anti-MBl) to obtain maximum inhibition. 
Bacterial strains 
N. meningitidis H44/76 is an isolate of a patient with invasive meningococcal 
disease 17. H44/76 is the production strain of the norwegian group B oMV 
vaccine and an international reference strain. it has been serologically classified 
as B:15:P1.7,16, immunotype l3,7,9. N. meningitidis was grown overnight on 
Kellog medium and resuspended in Hanks balanced salt solution (HBss) (gibco 
invitrogen). Heat inactivation occurred at 60°c for 40 minutes. Escherichia coli 
and fluorescein isothiocyanate (fiTc)-labeled, opsonized E. coli strain le 392 
(american Type culture collection 33572) were obtained from orpegen (Pharma, 
Heidelberg, germany) and were used as controls. The concentration of bacteria 
was determined by measuring oD at 630 nm. The variant H44/76-1, more strongly 
expressing the opc protein, was used in the serum-bactericidal activity and whole 
blood bactericidal activity assays. 
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N. meningitidis was fiTc labeled as described previously 18. in brief, 2 x 109 
meningococci/ml was incubated with 0.16 mg/ml fiTc (isomer 1, 90% high-
performance liquid chromatography [HPlc]; sigma chemical, st louis, Mo) for 
30 minutes at 37°c. Bacteria were washed 4 times and resuspended in PBs. The 
concentration of bacteria after washing was determined by measuring oD at 630 
nm. 
for the experiments using live meningococci, bacteria were grown overnight on 
brain-heart infusion (BHi) agar, reseeded on BHi agar plates, grown for 4 hours 
at 37°c in 5% co2 into mid-log-phase, and harvested in HBss with 0.1% bovine 
serum albumin (Bsa). 
Donors 
seven healthy donors were used throughout the experiments. concentration of 
specific antibodies in the sera of the controls against N. meningitidis H44/76 was 
determined by flow cytometry, as described previously 19. in brief, 5 µl of 109 N. 
meningitidis/ml was incubated with 50 µl of dilutions of serum for 1 hour at room 
temperature, washed twice, and developed with fiTc-labeled goat antihuman igg 
(cappel; organon Teknika, Turnhout, Belgium) for 1 hour followed by one washing. 
a 2-fold dilution series of reference plasma was used for the standard curve. for 
the serum bactericidal assay and the whole blood bactericidal activity assay, 2 
separate donors were used with known high bactericidal titers to N. meningitidis 
in the serum bactericidal assay and a high concentration of antibodies after 
vaccination. informed consent was obtained from all donors before the experiments 
were performed, and the human experimentation guidelines of the local ethics 
committee of Rikshospitalet University Hospital were followed in the conduct of the 
research. 
Whole blood model of inflammation 
a recently developed whole blood model to study the role of complement in 
E. coli-induced inflammation was modified for N. meningitides 11. The model is 
based on anticoagulation with lepirudin, a recombinant hirudin, which is a highly 
specific thrombin inhibitor not influencing complement activation. Whole blood was 
collected in polypropylene tubes containing lepirudin (50 µg/ml). Whole blood was 
preincubated with PBs or antibody for 4 minutes at 37°c in a water bath. for cR3 
(cD11b/cD18) expression, phagocytosis, and oxidative burst, incubation with the 
stimulants was for 10 minutes at 37°c. after incubation, samples were processed 
immediately for flow cytometry. for the detection of complement activation, samples 
were incubated for 1 hour at 37°c, and activation was stopped by adding 20 mM 
(final concentration) ethylenediaminetetraacetic acid (eDTa). 
122
8oxidative burst, phagocytosis, and cR3 (cD11b/cD18) 
expression
oxidative burst and phagocytosis were measured using commercially available 
Burst-test and Phago-test kits (orpegen Pharma, Heidelberg, germany). fiTc-
labeled meningococci were used in the phagocytosis assay. Using a forward/side 
scatter (fsc/ssc) dot plot, granulocytes and monocytes were analyzed separately 
with regard to median fluorescence intensity (Mfi). cR3 expression was measured 
after incubation with inhibitors and stimulants after cells were fixed with 0.5% (vol/
vol) paraformaldehyde. cells were stained with anti-cD-14 fiTc (Becton Dickinson, 
san Jose, ca) to distinguish monocytes from granulocytes, the nuclear dye lDs-
751 (fl-3) (Molecular Probes, eugene, oR), anti-cD11b-Pe, or isotype control  
(γ2a). 
complement activation enzyme immunoassays 
activation of the classical complement pathway was determined as described 
previously 20, using the monoclonal antibody Kok-12 specific to a neoepitope exposed 
only when the c1 inhibitor (c1inh) is in complex with its substrates. This antibody 
was a kind gift from Prof Dr c. e. Hack (amsterdam, the netherlands). activation 
of the alternative pathway was detected by quantifying the alternative convertase 
c3bBbP, as was recently described in detail 11. activation of the classical and lectin 
pathways was determined by an assay using a mab specific for a neoepitope 
exposed in activated c4 detecting c4b and c4c (c4bc) 21. The antibody was a kind 
gift from Prof Dr c. e. Hack. activation of the final common pathway was quantified 
using the monoclonal antibody bH6 specific for a neoepitope expressed in c3b, 
ic3b, and c3c (c3bc) as described previously 22. activation of the terminal pathway 
was quantified using the monoclonal antibody ae11 specific for c9 incorporated in 
the fluid-phase sc5b-9 complex (Tcc), as described previously 23. an overview of 
these complement-activation markers can be seen in figure 1
lysis of sensitized sRBcs in human whole blood 
lytic activity of the terminal complement complex in human whole blood was 
established using a modified classical pathway hemolytic assay. sheep red blood 
cells (sRBcs) (hemolytic system; Virion/serion, Würtzburg, germany) were 
incubated at 37°c for 30 minutes, spun down at 1400g, and resuspended to a 5% 
solution in sterile veronal buffered saline (bioMerieux sa, nancy l’Étoile, france) 
supplemented with 0.01% Bsa (sigma chemical). sRBcs (20 µl) were incubated 
in the whole blood (120 µl) samples for 20 minutes at 37°c in a waterbath. Then 20 
mM eDTa was added to stop ongoing complement activation, and the samples were 
spun down at 1400g. supernatants were collected and read at 405 nm. 
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serum bactericidal activity 
The effect of the anti-c5 137-76 and anti-c5a 137-26 mabs on serum bactericidal 
activity was tested using an agar overlay method, as described previously 24,25. in 
brief, human complement, as plasma, was used at a final concentration of 25%. 
a 2-fold dilution series, in HBss with 0.1% Bsa of the sera to be examined, 
were inoculated with approximately 100 colony-forming units (cfUs) per well of 
logarithmic phase-growth meningococci. This mixture was incubated for 60 minutes 
at 37°c in air; after that agar was added, and plates were incubated overni at 37°c 
in 5% co2. The number of cfUs was counted with the use of a magnifying glass. 
log2 titer represents the highest dilution of sera or the lowest antibody concentration 
at which more than 50% of the inoculum was killed. 
Whole blood bactericidal activity 
N. meningitidis H44/76, grown overnight on BHi agar, was subcultured and grown 
into log-phase for 4 hours. approximately 5000 cfUs were added to 1.1 ml 
lepirudin-anticoagulated whole blood samples preincubated for 5 minutes with PBs 
or antibody. immediately after inoculation (t = 0) and after certain time periods, 100 
µl whole blood was seeded on microbiologic Petri dishes containing blood agar and 
incubated for 24 hours at 37°c and 5% co2. Bacterial growth was expressed as 
cfU/100 µl whole blood added. Blood was mixed thoroughly before each sampling 
on a whirl mixer. 
statistics 
The nonparametric Mann-Whitney U test for unpaired data was used to analyze 
comparisons for statistical significant differences. P values less than .05 were 
considered statistically significant. 
ResUlTs
complement activation by N. meningitidis in human whole blood 
To determine the relative contributions of the classical, alternative, and lectin 
pathway on complement activation by N. meningitidis, monoclonal antibodies 
blocking c2 (classical and lectin pathways), MBl (lectin pathway), and factor D 
(alternative pathway) were tested for their ability to inhibit the formation of specific 
complement activation products in lepirudin-anticoagulated human whole blood 
incubated with heat-inactivated bacteria for 1 hour. c1rs-c1inh complexes (classical 
pathway), c4bc (classical and lectin pathway), and c3bBbP (alternative pathway) 
were used as markers of initial pathway activation; Tcc was used as a marker of 
total complement activation (figure 1)
N. meningitidis (1 x 108/ml) induced some classical pathway activation, seen as 
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8a modest, but significant, increase in c1rs-c1inh complexes. as expected, no 
effect of any of the antibodies on c1rs-c1inh could be observed (figure 2a). a 
marked and significant increase in c4bc formation was seen after stimulation with 
N. meningitidis. anti-c2 had no effect; however, anti-MBl completely inhibited c4bc 
formation (figure 2B). noticeable alternative pathway activation was also seen after 
stimulation with meningococci, and anti-factor D inhibited all this alternative pathway 
activation (figure 2c)  N. meningitidis induced a marked increase in fluid-phase 
Tcc, which was completely abolished by anti-factor D, markedly reduced by anti-
MBl (75% reduction), and modestly but not significantly reduced by anti-c2 (figure 
2D) There was no relation between antibody titers against N. meningitidis H44/76 in 
the donors used for these experiments and the degree of complement activation or 
inhibition. Taken together, these data support mainly lectin and alternative pathway-
Figure 2. 
complement activation by N. meningitidis. 
lepirudin-anticoagulated human whole blood was incubated with 1 x 108 heat-inactivated N. meningitidis 
H44/76 for 1 hour at 37°c in the presence or absence of the following complement-inhibiting mabs: anti-
c2 (25 µg/ml), anti-MBl (100 µg/ml), and anti-factor D (25 µg/ml). c1rs-c1inh complexes (classical 
pathway; panel a), c4bc (classical and lectin pathways; panel B), and c3bBbP (alternative pathway; 
panel c) were used as markers of initial pathway activation, and fluid-phase terminal complement complex 
(Tcc) was measured as an indicator of total complement activation (D). Minor spontaneous formation 
of all complement-activation products occurred in unstimulated blood (hatched columns). Meningococci 
(1 x 108) induced a minor increase of c1rs-c1inh complex formation but significant c4bc, c3bBbP, and 
Tcc formation (second columns). anti-c2 had no statistically significant effect on any of the activation 
products, whereas anti-MBl completely inhibited c4bc formation, and anti-factor D completely inhibited 
alternative pathway activation. The increase in Tcc was completely abolished by anti-factor D and was 
markedly reduced by anti-MBl. Median ± iQRs of 4 separately performed experiments are presented. *P < 
.05 compared with N meningitidis-stimulated sample (second columns).
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Figure 3. 
comparison of live and heat-
inactivated bacteria.
a dose-dependent increase 
of granulocyte cR3 (cD11b/
cD18) expression and oxidative 
burst was observed in lepirudin-
anticoagulated human whole blood 
after stimulation for 10 minutes at 
37°c. Results for live log-phase 
and heat-inactivated meningococci 
were similar. Mfi indicates median 
fluorescence intensity; B, baseline 
(unstimulated sample) at time 
of incubation (t = 0) and after 10 
minutes (t = 10). The experiment 
was repeated once with virtually 
identical results.
Figure 4. 
effect of complement inhibition on 
oxidative burst.
N. meningitidis H44/76-induced 
granulocyte and monocyte 
oxidative burst was measured in 
whole human blood after a 10-
minute incubation with 2 x 108 
meningococci/ml in the presence 
or absence of complement 
inhibitory mabs. antibody 
concentrations ranged from 6.25 
to 25 µg/ml for anti-c2 and anti-D 
and from 25 to 100 µg/ml for anti-
MBl and the isotype control. note 
that combining anti-factor D with 
anti-MBl or anti-c2 enhanced 
the inhibitory effect. B indicates 
baseline (unstimulated sample) 
incubated for 10 minutes (t = 
10). Median values of 4 separate 
experiments are presented
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8dependent mechanisms of complement activation by N. meningitidis H44/76 in this 
whole blood assay.
cR3 up-regulation and induction of oxidative burst by live and 
heat-inactivated meningococci 
To validate the use of heat-inactivated meningococci in the inflammatory response 
experiments, live log-phase N. meningitidis H44/76 and heat-inactivated N. 
meningitidis H44/76 were compared with respect to cR3 (cD11b/cD18) expression 
and oxidative burst. a dose-dependent increase in granulocyte cR3 and oxidative 
burst was observed, with no difference between live and heat-inactivated bacteria 
(figure 3). Results in monocytes showed a similar pattern to those seen in 
granulocytes. Based on these results the following experiments were performed 
with heat-inactivated meningococci. 
effect of initial complement pathway inhibition on oxidative burst 
N. meningitidis-induced oxidative burst in human whole blood was essentially 
dependent on complement activation because mabs blocking the initial complement 
Figure 5.
effect of anti-c5 and anti-c5a on granulocyte responses.
N. meningitidis H44/76-induced cR3 (cD11b/cD18) expression, phagocytosis of fiTc-labeled 
meningococci, and oxidative burst by N. meningitidis were measured in whole human blood after a 10-
minute incubation with 2 x 108 meningococci/ml in the presence or absence of the mabs anti-c5 (clone 
137-76, preventing c5 cleavage), anti-c5a (clone 137-26), and an isotype control (6.25-50 µg/ml). anti-
c5 and anti-c5a markedly, and to the same extent, inhibited N. meningitidis-induced granulocyte cR3 
up-regulation, phagocytosis, and oxidative burst. B indicates baseline (unstimulated sample) at time of 
incubation (t = 0) or after 10 minutes of incubation at 37°c (t = 10). Results from 1 of 3 representative 
experiments are shown.
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pathways markedly inhibited oxidative burst in granulocytes figure 4 left panel) 
and monocytes figure 4 right panel). anti-c2 and anti-factor D partially reduced 
the granulocyte oxidative burst, whereas the monocyte oxidative burst was only 
marginally affected. However, when anti-c2 and anti-factor D were combined, the 
granulocyte oxidative burst was completely abolished and the monocyte oxidative 
burst was markedly reduced. finally, anti-MBl alone markedly inhibited oxidative 
burst in both cell types, an effect that was further enhanced when anti-MBl and 
anti-factor D were combined. These data indicate that oxidative burst induced by 
the meningococcus in whole blood is dependent on complement activation through 
the lectin and alternative pathways. 
effect of inhibiting c5 and c5a on cR3 expression, phagocytosis, 
and oxidative burst 
The effect of inhibiting c5 and c5a on N. meningitidis-induced cR3 expression, 
phagocytosis of fiTc-labeled meningococci, and oxidative burst by N. meningitidis 
in granulocytes and monocytes was examined in human whole blood using anti-
c5 and anti-c5a mabs. Both antibodies efficiently abolished, in a dose-dependent 
fashion, cR3 up-regulation, phagocytosis, and oxidative burst in granulocytes, 
whereas the isotype control antibody had no effect (figure 5) Monocyte cR3 
expression, phagocytosis, and oxidative burst were also inhibited by the anti-
c5 and anti-c5a antibodies, though this inhibition was less pronounced than 
in granulocytes. The data suggest that the inflammatory responses observed, 
particularly in granulocytes, were largely dependent on c5 activation, and the 
Figure 6. 
Effect of CR3 and FcγR inhibition on 
granulocyte oxidative burst.
The anti-cD11b-blocking antibody 
icRf44 (6.25-50 µg/ml) completely 
inhibited oxidative burst by N. 
meningitidis H44/76 (2 x 108/ml, 10-
minute incubation) (left panel). in 
contrast, blocking of FcγR using anti-
CD16 (FcγRIII), anti-CD32 (FcγRII), 
and anti-CD64 (FcγRI) (6.25-50 µg/mL) 
had no effect (right panel). anti-c5a 
(clone 137-26) was included in both 
experiments for comparison. B indicates 
baseline (unstimulated sample) after a 
10-minute incubation (t = 10). Results 
from 1 of 3 representative experiments 
are shown.
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8observation that both antibodies were equally efficient indicates that the response 
was mediated by c5a and not by Tcc (c5b-9). 
Effect of inhibition of CR3 and Fcγ receptors on the oxidative 
burst 
The substantial complement-dependent increase in the expression of cR3 led us to 
investigate the relative roles of CR3 and Fcγ receptor (FcγR) in the oxidative burst 
induced by N. meningitidis. inhibition of cR3 using a mab blocking cD11b showed 
that oxidative burst in granulocytes (figure 6) left panel) was critically dependent on 
cR3 because anti-cD11b inhibited oxidative burst to baseline values. in contrast, 
f(ab’)2 antibodies blocking the interaction of FcγRI, FcγRII, and FcγRIII (CD64, 
cD32, and cD16, respectively) with their ligands had no effect on granulocyte 
oxidative burst (figure 6 right panel). Results obtained for monocyte oxidative burst 
showed a similar pattern. 
effect of inhibiting c5 and c5a on red cell lysis and bactericidal 
activity 
The effect of the anti-c5 and anti-c5a antibodies on the formation of fluid-phase c3 
activation products (c3bc) and Tcc in human whole blood was first investigated. 
as expected, neither of the antibodies had any effect on initial complement pathway 
activation because c3bc formation was unaffected (figure 7 left panel). Blocking c5 
activation by anti-c5 137-76 completely abrogated the formation of Tcc, whereas 
anti-c5a 137-26 and the isotype control had no effect on Tcc formation (figure 7  
right panel). 
Figure 7. 
effect of anti-c5 and anti-c5a on N. meningitidis-induced complement activation.
generation of c3bc (left panel) and Tcc (right panel) in lepirudin-anticoagulated human whole blood after 
incubation for 1 hour at 37°c with 1 x 108 heat-inactivated N meningitidis H44/76 in the presence of anti-
c5 (clone 137-76, 50 µg/ml), anti-c5a (clone 137-26, 50 µg/ml), or isotype control antibody (50 µg/ml). 
formation of Tcc was completely blocked by anti-c5 but unaffected by anti-c5a. Median ± iQRs of 4 
separate experiments are presented. *P < .05 compared with isotype control.
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The ability of the anti-c5 mabs to interfere with the formation of a functional lytic 
c5b-9 Mac was investigated using an adapted cH-50 hemolytic assay to study 
complement-lytic activity of human whole blood on sensitized sRBcs. anti-c5 137-
76 inhibited the lysis of sRBcs in whole blood by 89% (interquartile range [iQR], 
96%-73%), whereas anti-c5a 137-26 had no effect. furthermore, in a standard 
test for serum bactericidal activity (sBa), anti-c5 137-76 completely inhibited 
sBa of human sera and isolated anti-meningococcal antibody supplemented with 
exogenous complement, whereas anti-c5a 137-26 and the isotype control antibody 
showed no effect (Table 1). 
finally, live N. meningitidis H44/76 was incubated in human whole blood. samples 
from the same 2 control subjects used in the sBa measurements were used. after 
5 minutes of incubation no growth of meningococci was seen (figure 8). anti-c5a 
137-26 and the isotype control antibody had no effect on the bactericidal activity. 
inhibition with anti-c5 137-76, however, completely abrogated the ability of human 
whole blood to eliminate meningococci. Here, bacterial counts after shorter 
periods of incubation remained equivalent to amounts at the start of incubation, 
Bactericidal 
activity
no
antibody
isotype control anti-c5a (137-
26)
anti-c5 (137-76)
l,3,7,9 (positive 
control)
14 15 15 < 8
l8 (negative 
control)
< 8 < 8 < 8 < 8
subject 1 6 5 5 < 1
subject 2 7 8 7 < 1
Bactericidal activity (agar overlay method) of serum of the two control subjects and of anti-lPs l3,7,9 
igg2a antibody (positive control) and anti-lPs l8 igg1 antibody (negative control) expressed as log2 titre 
of the last reciprocal serum dilution at which more than 50 % of the inoculum was killed. Both control 
subjects showed excellent serum bactericidal activity against N. meningitidis H44/76-1. anti-c5 completely 
inhibited all bactericidal activity, whereas anti-c5a and isotype control had no effect.
Figure 8. 
effect of anti-c5 and anti-c5a on bacterial 
killing in whole blood.
Bacterial counts on blood-agar plates 24 
hours after seeding 100 µl whole blood 
incubated for different time intervals with 
live log-phase N. meningitidis H44/76 in the 
absence or presence of anti-c5 (clone 137-
76), anti-c5a (clone 137-26), and isotype 
control antibody. Median results of duplicate 
experiments with 2 different donors are 
presented.
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8whereas after 60 minutes bacterial counts had increased almost 2-fold, indicating 
active bacterial growth in these samples (figure 8). These data indicate that the 
elimination of serogroup B N. meningitidis from this human whole blood model at 
the concentration tested is dependent on the lytic c5b-9 pathway of complement 
and that this pathway is kept functionally open in the presence of the anti-c5a mab 
137-26. 
DiscUssion
N. meningitidis is exclusively a human pathogen, and no animal model accurately 
simulating fulminant meningococcal sepsis is available. This mandates the use 
of an in vitro experimental system approaching as closely as possible the in vivo 
situation. Recently, an in vitro whole human blood model was developed to study 
the role of complement in E coli-induced inflammatory processes 11. The principle of 
this model is to keep all ambient inflammatory systems intact to be activated, and to 
mutually interact, but still avoid coagulation. Because most anticoagulants such as 
eDTa, citrate, and heparin interact with critical steps in the inflammatory network, 
the model uses the highly specific thrombin inhibitor lepirudin, a recombinant hirudin 
analog, as anticoagulant. in the present study the model was used to evaluate 
the in vitro inflammatory responses to N. meningitidis. The main limitations of the 
model with regard to the in vivo situation are the absence of a vascular endothelium 
and the effect of lepirudin on thrombin. Thrombin is known to be an inflammatory 
mediator 26, and hirudin-based peptides were found to inhibit thrombin-induced 
inflammatory effects on endothelial cells 27. However, because whole blood models 
need anticoagulation, it is impossible to circumvent this problem completely. We 
suggest that lepirudin is the best alternative in complement activation studies 
because its effect is limited to thrombin inhibition, the final step of coagulation. 
Hirudin was found to be superior in studying platelet and monocyte activation in 
whole blood, and it did not modulate complement activation, interleukin-8 (il-8) 
release, or tissue-factor expression, supporting lepirudin as the anticoagulant of 
choice for this model 28,29. 
for safety reasons heat-inactivated bacteria were used whenever possible. Because 
heat inactivation may influence the antigen exposure on bacteria, the interaction 
with the immune system may be altered 18,30. Therefore, we compared live and heat-
inactivated bacteria with respect to inflammatory responses of importance for this 
study and showed that they elicited virtually identical responses. This validates the 
use of heat-inactivated N. meningitidis to investigate the inflammatory response 
induced by these microorganisms. 
in the whole blood model, a relatively high bacterial concentration (2 x 108) was 
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used for the induction of cR3 up-regulation and oxidative burst. The central 
mechanism in the pathogenesis of fulminant meningococcal septic shock (fMs) 
is an unimpeded—and unmatched by any other infectious organism—outgrowth of 
meningococci within the bloodstream. Bacterial concentrations in blood during fMs 
can exceed 108 bacteria/ml,31-33 and these high bacterial loads are seen only in the 
most severe cases 34. The concentrations we used in the in vitro model resemble 
the concentration of meningococci seen in the bloodstream during severe fMs and 
reflect the levels of bacteremia that induce the deleterious systemic inflammatory 
response. The number of bacteria used in the serum and whole blood bactericidal 
assays (2.5 x 102) was much lower than the amount used to study cR3 up-regulation 
and oxidative burst. after invasion in the bloodstream by N. meningitidis, the 
first line of defense is formed by complement-mediated, c5b-9-dependent direct 
bacterial lysis. Thus, this line of defense is engaged already at low concentrations 
of bacteria. When this defense fails, meningococci will multiply unimpeded, 
reaching concentrations (107-108 bacteria/ml) at which massive activation of the 
complement system causes tissue damage by granulocyte activation. for these 
reasons, we studied killing at relatively low concentrations, whereas the harmful 
effect of complement activation was studied at high concentrations of bacteria. 
The aim of the present study was to evaluate with this model an anticomplement 
strategy that inhibits complement-mediated harmful processes and leaves 
bactericidal activity intact as a possible treatment option for meningococcal disease. 
it was shown that mabs blocking the lectin pathway and alternative pathway, alone 
or in combination, inhibited complement activation by N. meningitidis. in addition, it 
was found that blocking complement activation in this way abolished the oxidative 
burst in granulocytes and attenuated it in monocytes. The oxidative burst was 
dependent on CR3 (CD11b/CD18) expression, whereas the inhibition of Fcγ-
receptors had no effect on oxidative burst, as previously demonstrated for E coli.11 
The mab 137-76, which blocks the cleavage of c5, averted cR3 up-regulation 
and inhibited phagocytosis and associated oxidative burst, but also inhibited the 
formation of Tcc and bactericidal activity. However, the inhibition of c5a by the 
mab 137-26, which binds both free c5a and the c5a moiety of native c5 without 
interfering with the cleavage of c5,16 had the same inhibitory effect on cR3 up-
regulation, phagocytosis, and oxidative burst, but it preserved Tcc formation and 
bactericidal activity. 
Theoretically, the inflammatory response induced by c5 activation could be 
attributed to the potent anaphylatoxin c5a or to the c5b-9 complex given that the 
latter has been shown not only to be a lytic, bactericidal structure but is also able 
to induce inflammatory reactions by sublytic attack on nucleated cells 35. However, 
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8the inflammatory responses we observed, as caused by c5 activation, were solely 
mediated by c5a and not by the c5b-9 complex because exactly the same degree 
of inhibition was observed using either the anti-c5 or the anti-c5a antibody. 
The initial pathways of complement activation after stimulation of whole blood by 
N. meningitidis were studied by measuring specific complement activation products 
and by using monoclonal antibodies blocking specific complement components 
essential for each of these pathways. N. meningitidis induced significant increases 
in all activation products, but they were more pronounced for c4bc and c3bBbP 
than for c1rs-c1inh complexes. We found that anti-MBl blocked c4bc formation 
and that anti-factor D blocked c3bBbP formation. Both anti-MBl and anti-factor D 
inhibited Tcc formation by N. meningitidis. This indicates that both the lectin and 
the alternative pathway are involved in complement activation by meningococci. 
The alternative pathway may be activated directly or as an amplification of the lectin 
pathway activation. These results also imply a limited role for the classical pathway 
in complement activation by N. meningitidis, further underscored by the finding that 
the antibody titer against H44/76 meningococci did not correlate with the magnitude 
of classical pathway activation in this assay system. our findings are supported 
by the findings of Bjerre et al 36, who suggested that complement activation by 
neisserial oMVs is largely dependent on the lectin and alternative pathways, and 
by Brandtzaeg et al 8, who found that during meningococcal septic shock, systemic 
complement activation is predominantly dependent on the alternative pathway. The 
latter study was performed before the contribution of the lectin pathway could be 
assessed, and it might be that the alternative pathway activation observed was partly 
the result of amplification from the lectin pathway. The observation that complement 
activation by the meningococcus is mostly lectin- and alternative-pathway-
mediated seemingly contrasts with the increased sBa seen by specific bactericidal 
antibodies. Drogari-apiranthitou et al 37, who also found that complement activation 
and assembly of the c5b-9 (Mac) on the meningococcal surface are for the most 
part independent of classical pathway activation, suggest that it is likely that proper 
Mac insertion mediated by antibody rather than the quantity of Mac formation is of 
importance for efficient bacterial killing 38,39. The observation that anti-c2 inhibited 
complement activation to a lesser extent than anti-MBl may be explained by a direct 
activation of c3 by MBl-associated serine proteases (MasPs), bypassing c2, as 
was suggested recently 40,41, though recent data contrast such a direct activation 
under physiologic conditions42. 
incubation of whole blood with N. meningitidis induces the formation of reactive 
oxygen species such as the superoxide anion and hydrogen peroxide. These 
reactive oxygen species are reported to activate the nuclear transcription factor 
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NFκB and are highly toxic to host tissues 43,44. When microbes intrude the body, 
granulocyte activation and oxidative burst—aimed at eliminating the invading 
agent—occur in a localized area with limited tissue damage. However, if systemic 
activation of the granulocytes occurs, this contributes to the development of organ 
failure, including acute respiratory distress syndrome (aRDs) and irreversible 
septic shock. importantly, we showed that after incubation of whole blood with N. 
meningitidis, the production of reactive oxygen species, as reflected by the oxidative 
burst, is completely dependent on complement activation because it could be fully 
inhibited by blocking complement. Remarkably, anti-MBl alone inhibited oxidative 
burst better than one would expect based on the effects of anti-MBl on complement 
activation. an additional function of MBl, the reported direct effect of this protein on 
opsonophagocytosis, may explain this observation 45. 
The oxidative burst process was dependent on c5a-mediated up-regulation of cR3, 
leading to increased phagocytosis of meningococci and increased oxidative burst, 2 
closely related processes. This expands for N. meningitidis our earlier observation 
that showed c5a and c5aR play essential roles in the E. coli-induced up-regulation 
of cR3, phagocytosis, and oxidative burst 11. The divergent effect of c5a inhibition 
on cR3 expression, phagocytosis, and oxidative burst between granulocytes and 
monocytes, with a relatively decreased effect of c5a inhibition on these processes 
in the monocyte, suggests that alternative mediators are also of importance in the 
regulation of monocyte cR3 expression. 
invasive gram-negative bacteria can be cleared from the blood by c3b- or igg-
dependent phagocytosis or by lysis of the bacterium by the Mac 46. in the present 
study we showed that in whole human blood with strong anti-meningococcal sBa, 
meningococci are rapidly and completely killed. inhibition of c5a, with potent 
inhibitory effects on cR3-mediated phagocytosis, had no effect on Tcc formation, 
sBa, or bactericidal activity in whole blood. of importance, however, the inhibition 
of c5 completely prevented Tcc formation and the killing of meningococci. This 
implies that in the presence of a functional Mac, meningococci are rapidly killed, 
whereas in the absence of the Mac unimpeded growth occurs. Thus, the Mac is 
the main determinant of meningococcal killing in this human whole blood assay 
using a low inoculum of bacteria. Theoretically, the inhibition of phagocytosis by 
the anti-c5a antibody at high intravascular bacterial concentrations could be 
deleterious because this is also a primary host defense mechanism. However, if 
the anti-c5a antibody were used in the treatment of patients with fMs, the situation 
would differ from the one studied in our in vitro whole blood model. first, the 
mainstay of treatment of meningococcal infection is bactericidal antibiotic therapy, 
which kills the meningococci rapidly. second, the main clearance mechanisms of 
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8gram-negative bacteria from the circulation in mammals are Kupffer cells in the liver 
and, to a lesser extent, spleen macrophages 47,48. The class a scavenger receptor 
of the macrophages has been implicated as a major receptor for phagocytosis 
of meningococci 49. granulocytes appear to play a minor role in the intravascular 
clearance of meningococci 47, and the phagocytosis of meningococci by 
granulocytes intravascularly is a pathologic condition that presumably occurs only 
at high concentrations of bacteria because it is associated with fatal meningococcal 
septic shock 50. Therefore, the inhibition of systemic phagocytosis-related oxidative 
burst is likely to be advantageous in clinically severe sepsis. 
in meningococcal disease, excessive activation of the complement system is closely 
related to disease severity and patient death, implicating a possible beneficial 
effect of complement inhibition on disease severity in fMs 6,7. in contrast to other 
mediators in fMs such as proinflammatory cytokines that immediately decline 
after the initiation of effective antibiotic therapy 51-53, complement activation is 
sustained and reaches a maximum at 12 to 15 hours after the initiation of treatment 
8,34. attempts to influence disease severity by modulating complement activation 
therefore have an increased time span for possible therapeutic intervention. 
By preference, adjunctive treatment for fMs should be aimed at inhibiting the 
negative effects of inflammatory substances without decreasing the capacity of 
the immune system to eliminate the infectious organism. in addition, primary 
mediators that induce secondary inflammatory reactions, enhancing the systemic 
breakdown of homeostasis, are particularly important candidates for intervention. 
inhibition of c5a is a treatment modality that could perform such a task. Previous 
studies have shown that neutralizing the effect of c5a, either by antibodies or by 
receptor antagonists, has beneficial effects on survival in a range of animal models 
of gram-negative septic shock 54-57. These favorable effects may be explained by 
the preservation of neutrophil function, attenuation of cR3 expression, and reduced 
production of reactive oxygen species, as we show for N. meningitidis in the present 
study. in addition, other secondary c5a-mediated effects that may contribute to 
the degree of septic shock might be attenuated, such as the release of histamine, 
chemotactic proteins, and proinflammatory cytokines leading to vasodilation 
and capillary leakage 9,10,58 and to direct effects on coagulation and fibrinolysis 
57. in conclusion, the present study supports a beneficial effect of complement 
modulation on potentially harmful systemic inflammatory responses such as cR3 
expression and oxidative burst induced by N. meningitidis. This was achieved by 
selective inhibition of c5a with preserved bactericidal activity using the anti-c5a 
mab 137-26. We suggest this is an attractive approach to the arduous treatment of 
meningococcal septic shock.
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Deficient alternative complement pathway activation due to factor D 
deficiency by two novel mutations in the Complement Factor D gene
in a family with meningococcal infections. 9
aBsTRacT
The complement system is an essential element in our innate defense against 
infections with Neisseria meningitidis. We describe 2 cases of meningococcal septic 
shock, 1 of them fatal, in 2 children of a Turkish family. in the surviving patient, 
alternative pathway activation was absent and factor D plasma concentrations 
were undetectable. concentrations of mannose-binding lectin (MBl), c1q, c4 and 
c3, factor B, properdin, factor H, and factor i were normal. Mutation analysis of 
the factor D gene revealed a T638 > g (Val213 > gly) and a T640 > c (cys214 
> arg) mutation in the genomic Dna from the patient, both in homozygous form. 
The consanguineous parents and an unaffected sister had these mutations in 
heterozygous form. in vitro incubation of factor-D–deficient plasma of the boy with 
serogroup B N. meningitidis showed normal MBl-mediated complement activation 
but no formation of the alternative pathway c3-convertase c3bBbP, and severely 
decreased c3bc formation and terminal complement activation. The defect was 
restored after supplementation with factor D. in conclusion, this is the second 
report of a factor D gene mutation leading to factor D deficiency in a family with 
meningococcal disease. This deficiency abolishes alternative-pathway dependent 
complement activation by N. meningitidis, and leads to an increased susceptibility 
to invasive meningococcal disease.
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9inTRoDUcTion
as stated in 1969 by goldschneider et al 1,2 and confirmed by large scale vaccination 
campaigns at the start of this century 3,4, specific antibodies offer complete protection 
against invasive meningococcal disease. Without antibodies, the primary humoral 
defense against Neisseria meningitidis invasion relies solely on the complement 
system. 
complement activation contributes to the clearance of meningococci by c3b and 
the membrane attack complex (Mac). c3b(i), fixed to meningococci, opsonizes the 
bacterium. in addition, c3b-coated bacterial particles are shuttled to and cleared 
by the reticuloendothelial system in liver and spleen by binding to complement 
receptor type 1 (cR1; cD35) on erythrocytes 5,6. Mac induces bacteriolysis through 
insertion in the meningococcal outermembrane of a macromolecular complex 
composed of the terminal complement components c5b, c6, c7, c8, and 1 or more 
c9 molecules, which become activated in a relay race fashion after adherence 
of c3b. Deficiency of 1 of the terminal complement factors leads to inadequate 
Mac formation and a 1000-fold increased risk for meningococcal infections 7,8. 
interestingly, most of these infections are caused by relatively rare serogroups 
and run a mild course 9-11. in cases of insufficient proximal complement activation, 
not only Mac formation but also c3b-mediated clearance is missing. in these 
cases, the defense against meningococci is more seriously affected and a more 
severe course may be expected. However, extensive complement activation in 
meningococcal infections also has deleterious effects to the host by the generation 
of excess amounts of anaphylatoxin c3a and c5a 12, which are known to induce the 
generation of reactive oxygen species by phagocytes 13, up-regulate production of 
proinflammatory cytokines 14, increase disseminated intravascular coagulation 15, 
and aggravate cardiodepression 16. 
initial complement activation, aimed to activate c3 and to bind c3b(i) to a microbial 
or cellular surface, can be started by the classical pathway, the mannose-binding 
lectin (MBl) pathway, or the alternative pathway. engagement of the classical 
pathway requires specific antibodies or c-reactive protein (cRP) attached 
to the bacterium for binding and activation of c1qrs. in the very early stage of 
meningococcal disease, specific antibodies and cRP are still absent 17,18. Therefore, 
only the lectin and the alternative pathway will play a role at this stage. The relative 
contribution of these pathways is still a subject of study 19,20. as we recently showed 
in vitro, maximal complement activation by meningococci requires involvement of 
both pathways 13, with an initiating role for the lectin pathway and an amplifying role 
for the alternative pathway 21. 
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clinically, MBl deficiency is associated with a higher risk for invasive meningococcal 
disease although it runs a less severe course in MBl-deficient patients 22-
24. Deficiency of factor B, the primary alternative pathway initiator, has never 
been found. However, deficiency of properdin (P), the protein that stabilizes the 
alternative pathway c3-convertase c3bBb, is associated with a high risk for severe 
disease 25-27. in 2001, we reported a factor D gene mutation leading to complete 
deficiency of factor D, in a Dutch family with 2 cases of meningococcal disease 28. 
combined with the earlier observation of Hiemstra et al 29, this finding suggests that 
factor D deficiency also predisposes to invasive meningococcal disease. 
in the present study, we describe the clinical course of meningococcal disease 
in 2 children of a Turkish family with a novel factor D gene mutation leading to 
undetectable factor D plasma concentrations. The family had a normal genetic 
makeup for MBl. Therefore, we were able to explore, by additional in vitro 
experiments, the relative importance of the lectin and the alternative pathway in 
complement activation by N. meningitidis.
PaTienTs, MaTeRials anD MeTHoDs
Patient a
a 9-month-old girl was admitted in 1996 to a local hospital because of purpura for 2 
hours and 45 minutes. she had a history of high fever for 6 days, coughing, diarrhea, 
and vomiting. at admission the temperature was 40°c, she was tachypneic, and 
had signs of a poor peripheral circulation and moderate nuchal rigidity. The pulse 
rate was 220 beats per minute and blood pressure was 141/80 mm Hg. laboratory 
examination at admission showed: cRP level, 53 mg/l; leukocyte count, 3.9 x 109/l; 
platelet count, 234 x 109/l; creatinine, 78 µM; arterial pH, 7.19; Pco2, 4.2 mM; 
bicarbonate, 11 mM; and base excess, –15.2 mM. Blood cultures were negative. 
cerebrospinal fluid (csf) examination revealed only mild signs of inflammation: 
leukocytes, 20 x 109/l; glucose, 3.8 mM; and protein, 280 mg/l. csf cultures grew 
N. meningitidis serogroup B:P1:15. The chest x-ray showed an infiltrate in the right 
upper quadrant. shortly after lumbar puncture, generalized seizures occurred and 
treatment was started with phenobarbital, ampicillin, dexamethasone, bicarbonate, 
and paracetamol. Unfortunately, the severity of disease was not sufficiently 
recognized and the patient was admitted to a regular pediatric ward. 
after 1.5 hours, blood pressure fell to 79/52 mm Hg. in spite of 200 ml/kg fluid 
resuscitation during the first 24 hours, blood pressure remained low and complete 
renal failure and thrombopenia (38 x 109/l) developed. no inotropics, ventilatory 
support, or fresh plasma were given. Thirty-six hours after admission, blood 
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9pressure decreased suddenly to 49/29 mm Hg followed by respiratory arrest. 
cardiopulmonary resuscitation was needed and transfer to our Pediatric intensive 
care Unit (PicU) was requested. at arrival, 36 hours after hospital admission, the 
patient had poorly perfused extremities and was persistently hypotensive in spite of 
high dosages of inotropic and vasopressive medication. The electroencephalogram 
was compatible with postresuscitation cerebral damage. The girl died 11 hours later 
because of refractory shock. autopsy was not allowed. 
Patient B
four years later, the 13-month-old brother of patient a was admitted to the same 
local hospital because of sudden onset of fever and a petechial rash. at the age 
of 4 months he had been hospitalized for a respiratory syncytial virus infection 
complicated by bacterial superinfection. later, he suffered several times from 
recurrent upper or lower respiratory tract infections that required frequent antibiotic 
treatment. now, at admission, he was covered with small purpuric lesions, had 
decreased capillary refill, and no signs of meningismus. His body temperature was 
39.7°c, pulse rate 180 beats per minute and a respiration rate of 36 breaths per 
minute. laboratory results showed: cRP level, 119 mg/l; leukocyte count, 10.9 x 
109/l; platelet count, 324 x 109/l; creatinine, 52 µM, activated partial thromboplastin 
time (aPTT), 46 seconds (normal, 25-35 seconds); and plasma D-dimers, 1.35 
mg/l (normal, < 0.5 mg/l). The chest X-ray was normal. Blood cultures grew N. 
meningitidis B.1.P1-4. 
Directly after admission, treatment was started with ceftriaxone, dexamethasone, 
and fluid challenges (2 x 23 ml/kg 0.9% nacl). after consultation with our PicU 
staff by telephone, 4 hours later, dobutamine (5 µg/kg/min) and 15 ml/kg fresh-
frozen plasma (ffP) was given. in the first 18 hours, the situation remained stable. 
laboratory analysis after 18 hours showed creatinine at 45 µM, a leukocyte count 
of 40.6 x 109/l, a normal platelet count, and signs of compensated disseminated 
intravascular coagulation (aPTT, 41 seconds; fibrinogen, 7.9 g/l; and D-dimers, 
4.47 mg/l). During the following day he received another 2 x 15 ml ffP. Recovery 
was uneventful. Two weeks after admission he was discharged in good condition. 
Because the boy was the second patient with severe meningococcal disease in the 
same family and his parents appeared to be consanguineous, further immunologic 
analysis was performed. The concentrations of immunoglobulin classes and 
subclasses were normal, as were the antibodies against polysaccharide capsule of 
Streptococcus pneumoniae serogroup 3, 4, and 9 and Haemophilus influenza type 
B. analysis of the complement pathway showed normal concentrations of MBl, 
c1q, c4, and c3, but a complete absence of alternative pathway activation in the 
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alternative pathway hemolytic activity 50 (aP50) test (aP50 < 5%; normal, 75%-
125%). factor B level was 84 iU/ml (normal, 49-129 iU/l). factor H level was 0.31 
g/l (normal, 0.2-0.6 mg/l). Properdin as well as factor i, determined qualitatively, 
were present. However, factor D was undetectable at less than 0.03 mg/l (normal, 
1.0-2.0 mg/l). Because of this deficiency the boy was put on antibiotic prophylaxis 
(1 x 100 mg clarythromycin daily) and was vaccinated with the conjugated N. 
meningitidis serogroup c vaccine and the unconjugated serogroup a plus c 
vaccine. With informed consent of his parents, the patient’s factor D gene defect 
was analyzed and additional in vitro complement activation tests were performed. 
informed consent statement
studies were conducted in accordance with the local guidelines for human 
experiments (commissie Mensgebonden onderzoek regio arnhem-nijmegen, 
Radboud University nijmegen Medical centre). informed consent (according to the 
Declaration of Helsinki) was obtained from the patient, his mother, and the healthy 
controls prior to performing the experiments. 
factor D protein determination and factor D gene sequencing
The activity and the protein concentration of factor D were measured as described 
  Primer  
complement factor D
cfD-ex1-fw  5’-gagTcTggcaggaggTaacccagTc-3’  
cfD-ex1-rev  5’-gcgTTcagagccTTccaTTagTgag-3’  
cfD-ex2-fw  5’-gagagcTgggaTcccgTcaggcagc-3’  
cfD-ex2-rev  5’-gagTccgcggTcggTgccagccgacTc-3’  
cfD-ex3-fw  5’-gagTcggcTggcaccgaccgcggacTc-3’  
cfD-ex3-rev  5’-caTgcagcaggagaggTcgaggcTgg-3’  
cfD-ex4-fw  5’-cTccccgagccTagcggcaTTcTcc-3’  
cfD-ex4-rev  5’-TcaTgcTccgcccaTcTTccagTTc-3’  
cfD-ex5-fw  5’-acTagTgaagaccaaaTTaacacgg-3’  
cfD-ex5-rev  5’-gcaggagTggaTgacTTcaTTgcTcg-3’  
MBl    
MBl-l-fw  5’-TTagcacTcTgccagggccaacg-3’  
MBl-l-rev  5’-cccaTcTTTgTaTcTgggcagcTga-3’  
MBl-X-fw  5’-TcTTTggaTcaccaaaagcTTTcagcTc-3’  
MBl-X-rev  5’-gaggggTTcaTcTgTgccTagac-3’  
MBl-aBcD-fw  5’-agTTTTcTcacaccaaggTg-3’  
MBl-aBcD-rev  5’-aTccccaggcagTTTccTcTggaag-3’  
 
Table 1. sequence of genomic PcR primers used in this study 
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9previously 28. The factor D gene polymerase chain reaction (PcR) was performed 
with primers annealing to intron sequences close to each exon (Table 1). The PcR 
conditions and the sequence reactions were as described by Hiemstra et al 29.
MBl protein determination and gene analysis
MBl protein was determined in a solid-phase enzyme-linked immunosorbent assay 
(elisa) with mannan coated to a 96-well plate and detection with monoclonal 
antibody (mab) MBl-1 (biotinylated mouse anti–human MBl, immunoglobulin g1 
[igg1], 10 µg/ml; sanquin, amsterdam, the netherlands). Briefly, microtiter plates 
were coated with 100 µg/ml mannan in 0.1 M naHco3 (pH 9.6) overnight at room 
temperature. The microtiter plates were washed 5 times with H2o. Plasma or 
serum samples and MBl standards (standard serum, 1.5 µg/ml MBl) were diluted 
in TTg/ca2+ (20 mM Tris [pH 7.4]/150 mM nacl/0.02% Tween-20/0.2% gelatin/10 
mM cacl2), with 10 U/ml heparin, added to the plates, and incubated by shaking 
at room temperature for 1 hour. after washing, the plates were incubated for 1 
hour with biotinylated MBl-1 in TTg/ca2+, washed with H2o, and incubated by 
shaking at room temperature for 30 minutes with streptavidin poly–horseradish 
peroxidase (HRP) at a ratio of 1:10 000 in TBs/ca2+/2% milk (20 mM Tris [pH 
7.4]/150 mM nacl/10 mM cacl2/2% milk). after washing, the color was developed 
with tetramethyl-3,3’,5,5’-benzidine (TMB)/0.01% H2o2 in 0.1 M na acetate (pH 
5.5), stopped with 2 M H2so4, and measured spectrophotometrically at 405 nm 
(Bioassay Reader sunrise; Tecan, salzburg, austria). 
MBl gene analysis for mutations in exon 1 and polymorphisms in the promoter 
region was performed by sequencing of PcR products obtained with primers 
described in Table 1. The PcR and sequencing conditions were as for factor D. 
complement activation experiments
lepirudin (Refludan; Pharmion, Tiel, the netherlands)–anticoagulated (50 µg/ml 
final concentration) blood from patient B, his mother, and 4 healthy volunteers 
was drawn in polyproplylene tubes on ice (2-4 years after presentation with 
meningococcal sepsis) and centrifuged immediately. The plasma was stored at 
–80°c until further experiments. complement activation was tested by adding heat-
killed serogroup B N meningitidis H44/76. This strain is an isolate of a patient with 
invasive disease and an international reference strain, serologically classified as 
B:15:P1.7,16, immunotype l3,7,9 30. 
for the complement activation experiments, 300 µl plasma was incubated in 
polypropylene 96-well plates (nUnc, Roskilde, Denmark) with 75 µl phosphate-
buffered saline (PBs) or N. meningitidis (final concentration, 1 x 108/ml) suspended 
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in PBs (75 µl) and purified human factor D at 75 µl to a final concentration of 
2 mg/l (QUiDel, san Diego, ca) or murine mab against human factor D (clone 
166-32) at 75 µl in a final concentration of 25 µg/ml (kindly provided by M. fung, 
Tanox, Houston, TX) 31. sample preparation was always on ice, and incubation 
was for 1 hour at 37°c. To stop complement activation after 1 hour, the plates 
were put on ice and 10 mM eDTa was added. Thereafter, samples were stored 
at –80°c until complement analysis. complement factor 1 rs (c1rs)–c1-inhibitor 
(c1rs-c1inh) complexes, c4bc, c3bBbP, c3bc, and soluble terminal complement 
complex (Tcc) was assayed by elisa as described previously in detail 13,32. for 
comparison, plasma of 2 healthy adult controls was incubated in all experiments in 
the same run.
ResUlTs
factor D and MBl values in the patient, his parents, and his sister
Patient B had an undetectable level of factor D protein in his blood; his mother, 
father, and unaffected sister had strongly decreased levels of factor D (Table 2). 
The circulating MBl protein levels of these individuals were also measured to 
exclude increased susceptibility for neisseria infection due to MBl deficiency. all 
members of this family had normal MBl levels, although the father of the patient 
was heterozygous for an arg52 > cys mutation (allele D) (Table 2). 
genetic analysis of the factor D gene in the patient and his family
Mutation analysis of the factor D gene revealed a T638 > g (Val213 > gly) and a 
T640 > c (cys214 > arg) mutation in the genomic Dna from the patient, both in 
apparently homozygous form. Both parents and the unaffected sister had these 
mutations in a heterozygous form. These mutations are in conserved residues, 
close to ser208 in the catalytic center of the enzyme (figure 1). Moreover, the 
cys214 > arg mutation destroys an internal disulfide bond between 2 conserved 
cysteines 33. 
  factor D 
protein, mg/l*  
factor D gene 
mutation  
MBl protein, 
mg/l†
MBl gene‡
Patient B  < 0.03  Homozygous  2.6  HYPa/HYPa  
Mother  0.44  Heterozygous  1.3  HYPa/HYPa  
father  0.14  Heterozygous  1.4  HYPD/HYPa  
sister  0.34  Heterozygous  2.6  HYPa/HYPa  
* normal range, 1.0-2.0 mg/l. 
†normal range, > 0.8 mg/l. 
‡normal, HYPa/HYPa
Table 2. 
Results of family investigations 
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9N. meningitidis–induced complement activation
Upon stimulation with 108/ml N. meningitidis, factor D–deficient plasma of the 
patient produced clearly less c3bc and Tcc compared with healthy individuals (see 
figure 2). Plasma of the heterozygous mother had a c3bc and Tcc production 
approximately similar to that of the healthy controls. addition of a monoclonal 
antibody against factor D inhibited complement activation in the mother and the 
controls, but had no effect on complement activation in the patient. Thus, factor 
D is important for the activation of c3 as well as the activation of the terminal 
Figure 1. 
amino-acid and cDna nucleotide sequence of human complement factor D.
The sequence data are from White et al. 45 and Biesma et al 28. 5’UTR indicates 5’untranslated region; first 
arrow, start of protein synthesis; second arrow, start of circulating protein sequence; asterisks, positions 
of catalytic triad asp114, His66, and ser208; arrowheads, positions of mutations; and 3’UTR, part of 
3’untranslated region. a disulfide bond exists in the wild-type factor D between cys148 and cys214, which 
is indicated in bold on a gray background (gray boxes).
1
Signal peptide 11
amino acids 5’UTR M H S W E R L A V L V
nucleotides GAG TGT CTC AGC CAC AGC GGC TTC ACC ATG CAC AGC TGG GAG CGC CTG GCA GTT CTG GTC
Activation
12 Exon 1 Exon 2 peptide Active factor D 31
amino acids L L G A A A C A A P P R G R I L G G R E
nucleotides CTC CTA GGA GCG GCC GCC TGC GCG GCG CCG CCC CGT GGT CGG ATC CTG GGC GGC AGA GAG
32 51
amino acids A E A H A R P Y M A S V Q L N G A H L C
nucleotides GCC GAG GCG CAC GCG CGG CCC TAC ATG GCG TCG GTG CAG CTG AAC GGC GCG CAC CTG TGC
52 ≠ Exon 2 71
amino acids G G V L V A E Q W V L S A A H C L E D A
nucleotides GGC GGC GTC CTG GTG GCG GAG CAG TGG GTG CTG AGC GCG GCG CAC TGC CTG GAG GAC GCG
72 Exon 3 91
amino acids A D G K V Q V L L G A H S L S Q P E P S
nucleotides GCC GAC GGG AAG GTG CAG GTT CTC CTG GGC GCG CAC TCC CTG TCG CAG CCG GAG CCC TCC
92 111
amino acids K R L Y D V L R A V P H P D S Q P D T I
nucleotides AAG CGC CTG TAC GAC GTG CTC CGC GCA GTG CCC CAC CCG GAC AGC CAG CCC GAC ACC ATC
112 ≠ Exon3 Exon 4 131
amino acids D H D L L L L Q L S E K A T L G P A V R
nucleotides GAC CAC GAC CTC CTG CTG CTA CAG CTG TCG GAG AAG GCC ACA CTG GGC CCT GCT GTG CGC
132 151
amino acids P L P W Q R V D R D V A P G T L C D V A
nucleotides CCC CTG CCC TGG CAG CGC GTG GAC CGC GAC GTG GCA CCG GGA ACT CTC TGC GAC GTG GCC
152 171
amino acids G W G I V N H A G R R P D S L Q H V L L
nucleotides GGC TGG GGC ATA GTC AAC CAC GCG GGC CGC CGC CCG GAC AGC CTG CAG CAC GTG CTC TTG
172 191
amino acids P V L D R A T C N R R T H H D G A I T E
nucleotides CCA GTG CTG GAC CGC GCC ACC TGC AAC CGG CGC ACG CAC CAC GAC GGC GCC ATC ACC GAG
192 Exon 4 Exon 5 ≠ 211
amino acids R L M C A E S N R R D S C K G D S G G P
nucleotides CGC TTG ATG TGC GCG GAG AGC AAT CGC CGG GAC AGC TGC AAG GGT GAC TCC GGG GGC CCG
212 Sites of mutations T638>G, T640>C (Val213>Gly, Cys214>Arg) 231
amino acids L V C G G V L E G V V T S G S R V C G N
nucleotides CTG GTG TGC GGG GGC GTG CTC GAG GGC GTG GTC ACC TCG GGC TCG CGC GTT TGC GGC AAC
232 251
amino acids R K K P G I Y T R V A S Y A A W I D S V
nucleotides CGC AAG AAG CCC GGG ATC TAC ACC CGC GTG GCG AGC TAT GCG GCC TGG ATC GAC AGC GTC
252
amino acids L A stop 3’ UTR
nucleotides CTG GCC TAG GGT GCC GGG GCC TGA AGG TCA GGG TCA CCC AAG CAA CAA AGT CCC GAG CAA
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complement cascade. 
addition of purified human factor D alone in the absence of other stimuli had no 
effect on complement activation in plasma of the controls and in plasma of the 
mother. However, some c3bc and Tcc were induced in the factor D–deficient 
plasma of the patient. factor D supplementation to plasma stimulated with 
meningococci restored c3bc and Tcc activation in the patient’s plasma and that of 
his mother, for the patient even to values higher than that seen in controls. 
Figure 3. 
classical, lectin, and alternative complement pathway activation by N. meningitidis in plasma from the 
patient and his mother.
The formation of c1rs-c1inh complexes (marker of classical pathway activation), c4bc (marker of classical 
or lectin pathway), and c3bBbP (marker of the alternative pathway) in plasma of the homozygous factor 
D–deficient patient (white bars), his heterozygous mother (black bars), and the median (± iQR) of 4 healthy 
controls (dashed bars). The plasma was incubated for 1 hour at 37°c without stimulus or with 108/ml 
meningococci, in the absence or presence of recombinant factor D or anti–factor D, as indicated. The 
experiment was repeated once, yielding virtually identical results (not shown).
Figure 2. 
Proximal and terminal complement pathway activation by N. meningitidis in plasma from the patient and 
his mother.
The formation of c3bc and sTcc, reflecting proximal complement activation and terminal pathway 
activation, respectively, in plasma of the homozygous factor D-deficient patient B (white bars), his 
heterozygous mother (black bars), and the median ± interquartile range (iQR) of 4 healthy controls (dashed 
bars). The plasma was incubated for 1 hour at 37°c without stimulus or with 108/ml meningococci in the 
absence or presence of recombinant factor D or anti–factor D, as indicated. The experiment was repeated 
once, yielding virtually identical results (not shown).
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9next, we assayed complement intermediates indicative for initial pathway 
complement activation. as can be seen in figure 3, meningococci did not induce 
c1rs-c1inh complexes in amounts exceeding that of the baseline. This shows that 
no classical pathway activation occurred. 
However, c4bc, reflecting lectin pathway activation (because classical pathway 
activation was absent), was induced after stimulation with meningococci in 
the patient and his mother, possibly to a higher extent than in the controls. as 
expected, addition of purified human factor D or anti–factor D had no effect on 
c4bc formation. 
finally, after stimulation with meningococci, c3bBbP reflecting alternative 
pathway activation was increased in the mother and the controls but not in the 
factor D–deficient patient. addition of purified factor D to the patient’s plasma, not 
stimulated or stimulated with meningococci, increased the production of c3bBbP in 
the patient to much higher values than in the mother or the controls. anti–factor D 
with meningococcal stimulation abolished c3bBbP in the mother and the controls. 
Taken together, these results indicate that meningococci can induce complement 
activation via the lectin and alternative pathways, and that complement activation by 
meningococci is reduced in factor D deficiency, owing to a defect in the alternative 
pathway
DiscUssion
in the present study, we report 2 patients, one of them with a fatal course, with 
invasive meningococcal serogroup B disease in a family of consanguineous parents. 
The surviving child, a boy of 13 months, had no alternative pathway complement 
activation as measured by the aP50 assay. This was explained by 2 novel 
homozygous mutations in the factor D gene, leading to undetectable factor D protein 
plasma concentrations. Mother, father, and unaffected sister were heterozygous for 
the mutated gene and had a partial factor D protein deficiency. The genetics of the 
deceased sister are not known. in vitro incubation of the factor D–deficient plasma 
of the boy with meningococci showed normal MBl-mediated complement activation 
but no formation of the alternative pathway c3-convertase c3bBbP, and severely 
decreased c3bc formation and terminal complement activation. The defect was 
restored in an overcompensated fashion after supplementation with factor D at a 
physiologic concentration.
factor D is a serine protease that 34, in contrast to most other complement proteins, 
does not require enzymatic cleavage for the expression of its proteolytic activity 
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35. instead, factor D activity is attained by reversible conformational changes 
occurring after contact with its exclusive substrate; that is, factor B attached to c3b 
33,36. factor D catalyzes the cleavage of factor B to Bb. subsequently, the complex 
c3bBb is stabilized by properdin (P) forming the alternative pathway c3-convertase: 
c3bBbP. factor D activity is the rate-limiting step in the formation of c3bBbP. The 
gene for factor D is located on chromosome 19p13.333,37. factor D is produced as 
a preproprotein with a signaling polypeptide of 23 amino acids. The proprotein is 
formed by amino acids 24-253. The mature protein consists of amino acids 26-253. 
The 2 mutations found in the patient lead to 2 amino-acid substitutions: Val213 
> gly and cys214 > arg. Heterozygosity for these missense mutations leads to 
protein concentrations in plasma—assayed by a polyclonal elisa—less than 
50% of the normal concentration. Homozygosity leads to complete absence of the 
protein. Because cys214 in the wild-type protein forms an s-s bond with cys148, 
we presume that the absence of detectable protein is caused by an abnormal 
folding of the peptide with impeded cellular secretion and/or increased instability. 
Pivotal in the cascade of complement activation is cleavage, by the classical 
(c4b2b) or the alternative pathway c3-convertase (c3bBbP), of the -chain of c3, 
which generates c3b. This cleavage results in exposure of an internal thioester 
that enables c3b to bind covalently to hydroxyl or amino groups present on 
(meningococcal) surfaces. Because classical pathway activation on meningococci 
does not occur during meningococcal septic shock, as there is no antibody or cRP 
yet 17,18, the c3-convertase required for c3b generation will be delivered by the lectin 
pathway or by the alternative pathway. as reported, MBl binds to outer-membrane 
proteins of serogroup B meningococci 38. The MBl-associated serine protease 
MasP2 subsequently cleaves c4 and c2, which will bind to the surface as c4b 
and c2a and form the classical/lectin pathway c3-convertase c4b2a 39. factor D 
induces the formation of the alternative pathway c3-convertase c3bBbP. alternative 
route activation is under tight control by various membrane-bound regulatory 
proteins on human cells and by fluid-phase regulatory proteins such as factor i, 
factor H, and c4 binding protein (c4BP). factor i degrades c3b in the presence 
of the cofactor molecules c4BP or factor H 40,41. factor H also accelerates the 
dissociation of Bb from active c3bBb. Both the classical/lectin- and the alternative 
pathway c3-convertase function, in the presence of an additional c3b molecule, as 
c5-convertase. cleaving of c5 is the initiating step of Mac formation. 
We recently described a whole blood in vitro system for the evaluation of 
complement activation by meningococci 13,32. in the present study, this model was 
slightly modified by the use of plasma instead of whole blood. Using this model, 
we found that the factor D–deficient patient had severely reduced c3 activation 
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9(measured as c3bc) and terminal complement activation (measured as Tcc). 
analysis of the intermediates showed no classical route activity (no c1rs-c1inh), 
confirming previous results sprong, 2003 #1800}32,42. Thus, the c4 activation 
(measured as c4bc) that occurred in the patient’s plasma was mediated solely 
by the lectin pathway. notably, as can be seen in the factor-D–deficient serum of 
the patient and in the experiments with anti–factor D, MBl-induced c4 activation 
induces only minimal amounts of c3bc and Tcc when the alternative pathway 
activation is switched off. Thus, the alternative route functions as an amplification 
mechanism for MBl-initiated complement activation by meningococci. 
interestingly, supplementation of factor D to the factor D–deficient plasma of the 
patient, in the absence of another stimulus, induced some spontaneous alternative 
route activation (c3bBbP) with c3b formation (c3bc) and terminal complement 
activation (Tcc). furthermore, in the presence of meningococci, supplementation 
with factor D gave more complement activation in comparison with the mother and 
the controls. This may be explained by a greater intrinsic activity of the purified 
factor D. However, it may also reflect a lower concentration of factor H, factor i, 
or another regulatory protein in the plasma of the factor D–deficient patient. in our 
patient, factor H was 0.31 g/l, a normal value, and factor i was present, rendering 
it unlikely that a lower amount or deficiency of these proteins explains these 
findings. 
clinically, invasive meningococcal disease presents with varying severity. one 
side of the spectrum is formed by benign meningococcemia and meningitis, both 
characterized by a moderate outgrowth of meningococci in the bloodstream. on the 
opposite side fulminant meningococcal septic shock (Mss) is found, characterized 
by the rapidly overwhelming intravascular outgrowth of meningococci, high 
concentrations of endotoxin and massive induction of proinflammatory mediators 43. 
in case of complement deficiency, the outgrowth of meningococci in the bloodstream 
is not inhibited and high concentrations of bacteria may develop with massive 
release of proinflammatory mediators, until start of antibiotic treatment. However, as 
soon as meningococcal proliferation is stopped by the timely start of antibiotics, the 
generation of lower amounts of anaphylatoxins may be beneficial. Therefore, the 
ultimate outcome of meningococcal disease in a complement-deficient individual 
is determined by the interplay between virulence of the bacterium, the initial host 
response, and early recognition with timely start of adequate therapy. Reportedly, 
deficiency of terminal complement factors or MBl is found in patients with mild 
disease, while properdin deficiency leads to severe disease. This underscores the 
indispensability of an intact alternative pathway. We have not been able to analyze 
the complement status in patient a but suspect that she also was factor D deficient. 
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Her fatal outcome may be explained by this defect and by the failure to recognize 
the severity of disease in time with installation of appropriate antishock therapy. 
Treatment in patient B was guided by an intensive care physician experienced in 
the treatment of Mss. interestingly, this patient received as a part of the initial 
treatment, before factor D deficiency was known, ffP that contained factor D 
as well as the alternative pathway regulatory proteins in balanced amounts. The 
question whether the infusion of ffP has contributed to the favorable outcome—
next to early antibiotic treatment and adequate resuscitation—requires further 
investigation 44.
in conclusion, we describe in a Turkish patient of consanguineous parents, 2 novel 
homozygous mutations of the factor D gene leading to the complete absence of 
detectable factor D protein in plasma. This deficiency leads to reduced alternative-
pathway–dependent complement activation by meningococci, and explains the 
increased susceptibility to invasive meningococcal disease.
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Mannose-binding lectin is a critical factor in systemic complement 
activation during meningococcal septic shock 10
aBsTRacT
systemic activation of complement during meningococcal disease is associated 
with severe disease and poor outcome. The exact mechanism of activation of 
complement is unknown, but important for future therapies aimed at modulating 
the complement system in this disease. We studied complement activation in 22 
patients, eighteen with meningococcal septic shock and four with meningococcal 
disease without shock. Two of the shock patients were MBl-deficient: one 
patient was homozygous and one patient was compound heterozygous for exon 
1 mutations in the gene for MBl. These MBl-deficient patients had relatively 
low disease severity and mild disseminated intravascular coagulation (Dic). at 
admission, the MBl-deficient patients had much lower circulating values of c3bc 
(indicating common pathway activation) and Tcc (terminal pathway) than MBl-
sufficient patients that presented with meningococcal septic shock. c4bc (classical 
or lectin pathway) and c3bBbP (alternative pathway) were also decreased in the 
MBl-deficient patients. systemic activation of complement excellently correlated 
with disease severity and parameters of Dic. Testing of convalescent blood of one 
of the MBl-deficient patients in a model of meningococcal sepsis showed absent 
lectin pathway activation leading to a reduced activation of complement. This 
indicates that MBl is critical for the systemic activation of complement seen during 
meningococcal septic shock.
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10
inTRoDUcTion 
Meningococcal septic shock (Mss) is a lethal disease that can slay previously 
completely healthy children within 24 hours 1. The complement system plays 
a complex dual role in the pathogenesis of meningococcal septic shock. it is 
essential for the early defence against Neisseria meningitidis 2,3. on the other hand, 
extensive systemic complement activation is associated with severe disease and 
poor outcome 4,5. 
complement is activated on the surfaces of meningococci or meningococcal outer 
membrane blebs by one or more of the three initial complement-activating pathways 
- the classical-, the lectin- and the alternative pathway. antibody, c-reactive protein 
and complement factor (c) c1q mediate classical pathway activation. Mannose-
binding lectin (MBl) is the central molecule in the lectin pathway of complement 
activation. MBl binds to meningococci 6 and, as was recently shown by us, MBl is 
crucial for the activation of complement in a whole blood model of meningococcal 
sepsis 7. Deficiency for MBl (i.e. undetectable plasma levels) occurs when a person 
is homozygous (or compound heterozygous) for any of the three structural mutations 
in exon 1 of the MBl-gene; heterozygousity for these mutations leads to reduced 
plasma MBl concentrations. MBl deficiency is relatively frequent, and is linked to 
increased susceptibility to certain infectious diseases8,9, although its exact role is 
still subject to debate. The alternative pathway is activated on bacterial surfaces 
both by pattern recognition and imbalanced regulatory control, but is particularly 
important for amplification of complement activation after initiation by the classical 
or lectin pathway.
after engagement of any of the three initial pathways, the activation converges 
at the level of c3 and subsequently c5 is activated, leading to the formation of 
the terminal c5b-c9 complement complex (also called Tcc) and the anaphylatoxin 
c5a. Membrane associated c5b-c9 or membrane attack complex (Mac) is critically 
important in neisserial killing, whereas c5a is a powerful pro-inflammatory mediator 
and harmful to the host during septic shock 10. The mechanism of complement 
activation as well as the exact role of systemic complement activation in the 
pathogenesis of tissue damage during Mss is still subject to debate.
We studied complement activation, cytokine production and disease severity in 22 
patients with invasive meningcoccal disease. Two of these patients were deficient 
for MBl, the central molecule in the lectin pathway of complement activation.
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MeTHoDs
from 2001 until 2006, 25 children with meningococcal disease were admitted to 
our the PicU of the Radboud University nijmegen Medical centre. The PicU of 
the Radboud University nijmegen Medical centre receives patients either as direct 
admissions from the emergency department or after referral by other hospitals. from 
22 patients material was available for analysis. informed consent was given for each 
patient from the parents, and the study was approved by the local ethics committee 
and performed according to local guidelines. Diagnosis of meningococcal disease 
was made based on positive culture or gram-stain of blood, cerebrospinal fluid or 
skin biopsy (82%) or typical presentation (18%). all isolated meningococci were 
serogroup B (the study was started after the national vaccination campaign against 
group c meningococci). 18 patients presented with septic shock (shock group), and 
4 patients had no shock (1 had meningoccal bacteraemia and 3 had meningocccal 
meningitis). shock was defined according to the consensus conference Definitions 
for sepsis and organ Dysfunction in Pediatrics 11. all patients received prompt 
antibiotic therapy (ceftriaxone i.v.) and dexamethasone during the first 3 days of 
admission. fresh frozen Plasma (ffP) was given to 14 patients with septic shock 
and signs of Dic. one of the two MBl-deficient patients (MBl-P1) received no 
ffP whereas the other MBl-deficient patient (MBl-P2) received ffP before 
admission to our PicU. among the patients without MBl-deficiency, three received 
recombinant tissue plasminogen activator (rTPa) as adjunctive treatment. PRisM 
score was calculated retrospectively by one of the researchers (Ts)12,13. 
for determination of complement activation, eDTa-anticoagulated blood was 
sampled at admission to PicU and at t = 2, t = 8, t = 24 and t = 48 hours after 
admission. Heparin-anticoagulated blood was obtained for determination of cytokine 
concentrations. samples were immediately put on ice, centrifuged for 15 min at 
2800 x g, and frozen at -80°c until analysis in batch. 
one of the MBl-deficient patients (MBl-P1) and an age and disease matched 
control that had had meningococcal meningitis were invited, more than 1 year 
after their episode of meningococcal disease, for an additional in vitro whole 
blood stimulation experiment 7. in brief, lepirudin anticoagulated whole blood was 
incubated for 1 hour with 108 / ml serogroup B Neisseria meningitidis at 37°c, 
whereafter 25 mM eDTa was added, put on ice, centrifuged and frozen at -80°c 
until assay for the complement intermediates. Patient (MBl-P2) and his parents did 
not give permission to draw blood for additional experiments after convalescence 
due to extreme fear for venapuncture in this patient.
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complement activation products were measured by enzyme-linked immunosorbent 
assay (elisa) as described previously in detail. c1rs-c1inh complexes (classical 
pathway) 14, c4bc (classical and lectin pathway) 15, and c3bBbP (alternative 
pathway) 16 were used as markers of initial pathway activation, c3bc 17 and 
terminal complement complexes (Tcc) 18 indicate final common pathway or total 
complement activation.  cytokines (Tnfα, il-1β and il-10) were determined 
using commercially available Bio-Plex protein array system (Bio-Rad laboratories, 
inc.) 19. MBl plasma concentration was measured by elisa (antibodyshop, 
copenhagen, Denmark). MBl-genotype was determined using restriction fragment 
length polymorphism (RflP) analysis for the structural mutations in exon 1 of the 
MBl-gene 20,21.
ResUlTs
eighteen patients presented with shock: one patient (MBl-P1) was identified 
homozygous for a point mutation in codon 54 of exon 1 of the MBl-gene, and had 
undetectable plasma concentrations of MBl at admission. a second patient (MBl-
P2) was compound heterozygous for mutations in codon 52 and 54 of exon 1, and 
due to the infusion of ffPs before admission the patient had a plasma concentration 
of MBl of 840 ng/ml at admission. 7 patients were heterozygous (a/o) for a mutation 
in exon 1 of the MBl-gene and had MBl-plasma concentrations at admission of 
median 360, (range 30 - 680 ng/ml). 9 patients had a normal genotype (a/a) (MBl-
plasma concentrations at admission median 1750, range 1110 - 9000 ng/ml). 4 
patients presented without shock: two had a normal MBl-genotype and two were 
heterozygous for an exon 1 mutation in the MBl gene (MBl-plasma concentrations 
at admission median 2351, range 266 - 4350). 
The a/a and a/o patients with shock suffered from more fulminant and severe 
disease, reflected by a higher mortality or more sequelae, a shorter time from 
disease onset to admission and a higher PRisM score in comparison with the 
patients without shock. in addition, plasma concentrations of the cytokines Tnfα, 
il-1β and il-10 in these shock patients was also increased compared to the no 
shock patients. characteristics of the patients MBl-P1 and MBl-P2 (o/o) with 
shock were in range with that of the other shock patients, although they had a 
relatively low disease severity and mild Dic (Table 1).
in the a/a and a/o patients with shock considerably higher plasma concentrations 
of c3bc (reflecting systemic common pathway activation) and Tcc (reflecting 
systemic terminal pathway activation) were seen at admission than in the in the 
o/o patients and the patients without shock (figure 1). c4bc (reflecting classical 
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or lectin pathway activation) was higher in the a/a and a/o patients with shock 
compared to o/o patients. no differences in activation of the classical pathway 
(c1rs-c1inh complexes) were seen for these patients (data not shown). c3bBbP 
(reflecting alternative pathway activation) was highest in the a/a ‘shock’ patients, 
followed by the a/o patients and lowest in patients MBl-P1 and MBl-P2 (o/o) and 
the patients without shock. Taken together, these results indicate that MBl is of 
vital importance for the systemic activation of the complement system seen during 
meningococcal septic shock. 
Time-course analysis showed that increased values of complement activation 
products could be found until 8 hours after admission in the shock patients, hereafter 
decreasing to values comparable to that in patients without shock (not shown). 
sHocK and 
a/a (n=9)
sHocK and 
a/o  (n=7)
sHocK and 
o/o (n=2)
no sHocK
(n = 4)
Male / female 5/4 3/4 1/1 3/1
age (years) 1.1
(0.5 - 7.3)
3.5 
(0.6 - 5.6)
5.5 - 3.6 1.8 
(0.6 - 4.7)
sequelae 6/9 3/7 0/2 0/4
Mortality 0/9 2/7 0/2 0/2
Time (hours) 12 
(9 - 17)**
16 
(12 - 17)**
14 - 20 38 
(23 - 96)
PRisM 13 
(5 - 23)**
17 
(7 - 35)**
6 - 10 3 
(0 - 5)
MaP1 69 
(55 - 87)
50 
(30 - 93)
67 - 77 84
(64 - 93)
lactate1 3.3 
(2 - 7.4)*, #
6.1
(4 - 12)**
2.8 - 3.3 1.9 
(0.7 - 2.4)
Platelet nadir 31 
(13 - 205)**
42 
(10 - 129)**
198 - 73 259 
(233 - 291)
fibrinogen1 1790 
(490 - 3760)*
1770 
(330 -4500)*
2370 - 3620 3220 
(2790 - 6420)
Tnf1 40 
(8 - 93)*
17 
(8 - 125)*
15 – 38 8 (8 - 8)
il-11 39 
(8 – 515)
42 
(32 – 304)
59 – 8 16.5 
(8 – 58)
il-101 5566 
(956 - 30732)**
2087 
(886 - 13571)*
3771 - 734 168 
(14 - 1140)
cRP1 91 
(27 - 108)*
93 
(37 - 121)*
57 - 64 178 
(99 - 307)
Table 1. Disease characteristics for the different patient groups
a/a = MBl-WT, a/o = heterozygous exon 1 mutation, o/o = homozygous exon 1 mutation. shown are 
medians and ranges. P values are by χ2 or Mann-Whitney test when appropriate. * = P < .05 for the 
comparison with the no sHocK group, ** = P < .01  for the comparison with the no sHocK group, # = P 
< .05 for the comparison with the sHocK and exon 1 heterozygous group. Time indicates time from onset 
of symptoms to admission to the referring hospital. PRisM = pediatric risk of mortality. MaP = mean arterial 
pressure. Platelet nadir indicates the lowest value of platelets obtained in the first 48 hours after admission. 
1 indicates values obtained at PicU admission.
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complement activation correlated significantly with disease severity R (spearman) 
= 0.79, P < 0.0001 for the correlation between Tcc and Paediatric Risk of Mortality 
(PRisM)). in addition, high plasma D-dimer concentration at admission and low 
platelet nadir (i.e., the lowest value in the first 48 hours after admission) 22 - reflecting 
Dic - significantly correlated with plasma concentration of Tcc (R (spearman) = 
0.80, P < 0.0001 for D-dimers, and R (spearman) = -0.88. P < 0.0001 for platelet 
nadir).  
Figure 1. 
complement activation products at admission to PicU in patients with meningococcal disease
a/a = MBl-WT, a/o = heterozygous exon 1 mutation, o/o = homozygous exon 1 mutation. c4bc reflects 
classical or lectin pathway activation, c3bBbP reflects alternative pathway activation, c3bc and Tcc 
reflect total complement activation. lines indicate medians, differences between groups were tested for 
significance using Mann-Whitney test. 
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Figure 2. complement activation in a whole 
blood model of meningococcal sepsis 
lepirudin anti-coagulated whole blood from 
the patient deficient for MBl (white bars) 
and an age and disease matched MBl-
sufficient control (grey bars) was stimulated 
with 108 / ml serogroup B meningococci for 
1 hour. left Y-axis is aU/ml for c1rs/c1inh, 
c4bc, c3bBbP, c3bc, right Y axis is aU/ml 
for Tcc. 
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additional in vitro experiments with convalescent blood from one of the MBl-
deficient patients (MBl-P1) and an age matched control that had experienced 
meningococcal meningitis were performed. patient MBl-P1 had normal classical and 
alternative pathway haemolytic activity. in a whole blood model of meningococcal 
sepsis, significant c4bc and c3bBbP activation was seen in the control patient, 
whereas no lectin pathway activation and markedly reduced alternative pathway 
activation was found in the MBl-deficient patient (figure 2). similarly, substantial 
total complement activation, reflected by formation of c3bc and Tcc, was found in 
the control patient, but was largely abolished in the MBl-deficient patient (figure 
2). 
DiscUssion
This is the first report describing complement activation during meningococcal 
septic shock in relation to genotype for MBl. in the a/a and a/o patients with 
meningococcal septic shock substantially higher plasma concentrations of the 
complement activation products c3bc, Tcc, c4bc and c3bBbP were seen than 
in the in the MBl0deficient (o/o) patients and the patients without shock. This 
indicates that there is an important role for MBl in the systemic activation of 
complement during meningococcal septic shock. 
The mechanism of complement activation during meningococcal septic shock has 
been debated, and classical- as well as alternative pathway-dependent routes of 
activation have been proposed 5,23. However, these studies were performed before 
the contribution of the lectin pathway could be assessed. We previously found that 
complement activation in a whole blood model of meningococcal sepsis is inhibited 
by anti-MBl antibodies, indicating that in whole blood complement activation by 
meningococci is, at least in part, dependent on MBl 7. The present in vivo results 
are support the previous in vitro findings. in addition, by using convalescent blood 
samples of one of the patients homozygous for a mutation in exon 1 of the MBl 
gene, we confirmed in vitro that MBl-deficiency leads to the absence of lectin 
pathway activation and decreased common pathway activation, in comparison to 
an MBl-sufficient control patient.
one of the MBl-deficient patients (MBl-P2) had a plasma concentration of MBl at 
admission similar to that of heterozygous patients, consistent with the transfusion 
of large amounts of ffP before admission. We have observed this phenomenon 
also in other patients that were given ffP and were heterozygous for an exon 1 
mutation. for instance, MBl plasma concentration at admission of 495 ng/ml in 
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one patient increased to 2160 ng/ml after ffP transfusion and decreased again 
to 1135 (48 hours after admission) and 915 ng/ml (144 hours after admission). 
in addition, this phenomenon was also observed in MBl-deficient patients given 
ffPs after cardiac surgery 24. interestingly, the infusion of ffP in patient MBl-P2 
did not lead to measurable complement activation. We suggest that this might be 
due to lack of complement activation during the disease course before ffP was 
given, combined with a rapid clearance of meningococci and complement activation 
intermediates after start of treatment.
During meningococcal septic shock and in the whole blood model, the alternative 
pathway was considerably activated in MBl-sufficient patients, but reduced in the 
patients with MBl deficiency. This is consistent with the view that the role of the 
alternative pathway lies in amplification of complement activation; in this case 
trough MBl initiated lectin pathway activation7,25.
Heterozygousity for an exon 1 mutation in the MBl gene had a limited effect 
on complement activation during meningcoccal septic shock, although median 
values of c3bc, Tcc and c3bBbP were somewhat lower in this group compared 
to the a/a group. This suggests that MBl-dependent complement activation is 
sufficiently maintained in plasma with reduced MBl levels, as in a/o genotypes, 
but strongly affected when it falls below a certain limit and is lost in o/o plasma 26. 
Three a/o patients had MBl-plasma concentrations below 200 ng/ml; these very 
low concentrations may be related to consumption of MBl during septic shock, 
reflecting binding of MBl to microbes in order to activate complement 27.
The two MBl-deficient patients had a relatively low disease severity and mild 
Dic. This parallels the findings in patients with terminal complement component 
deficiencies 3, and is in line with the study by Hibberd who showed that although 
susceptibility to meningococcal disease was increased by MBl-deficiency, disease 
severity seemed to be reduced 9. in contrast, patients with alternative pathway 
deficiencies (Properdin or factor D) who also have increased susceptibility to 
meningococcal disease, are reported to have a more fulminant disease course 3,28,29. 
apparently, there is a slender balance between susceptibility for meningococcal 
infections and the course of disease. 
crucial for the development of tissue damage and limb-ischemia in meningococcal 
septic shock is the severity of Dic. experimentally, c5a is a potent inducer of 
tissue factor expression, critical in the development of Dic 30-32. We found that the 
MBl-deficient patients had limited signs of Dic, and that the degree of systemic 
complement activation was strongly correlated to Dic-parameters. This suggests 
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that MBl-dependent complement activation, which leads to the formation of c5a, is 
important for development of Dic. 
activation of the cytokine network is considered to be one of the main pathological 
events during meningococcal septic shock 1. The extent of the inflammatory 
cytokine response in the MBl-deficient patients was similar to that of the other 
shock patients. This indicates that the lower disease severity and the absence of 
Dic in the MBl-deficient patient compared to the other patients, was not caused by 
a reduction in cytokine activation.
To date, no adjunctive immunomodulatory treatment is available that is proven to 
influence the course of disease in meningococcal septic shock. Modulation of the 
complement system is postulated to be an attractive approach, based on in vitro 
research and data in animal experiments 7,33,34. new therapies that aim to modulate 
the complement system during meningococcal septic shock should at least also 
inhibit activation of complement via the lectin pathway.  
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PcR-Restriction fragment length Polymorphism method to detect the 
X/Y polymorphism in the promoter site of the mannose-binding lectin gene 11
inTRoDUcTion
Mannose-binding lectin (MBl), a pattern-recognition molecule produced by the 
liver and present in serum, is an important player in the innate immune system. 
MBl acts by binding various carbohydrate structures on microbial surfaces, after 
which it activates the complement system via the lectin pathway. in addition, MBl 
can promote direct opsonophagocytosis of microorganisms and modulate diverse 
inflammatory mediators 1.
Deficiency of MBl was first identified in association with a common defect of 
opsonization in children. additional studies have identified MBl deficiency as a risk 
factor for diverse infectious diseases 1. in addition, MBl deficiency has been found 
to be associated with certain autoimmune diseases 1 and, recently, atherosclerosis 
2. MBl deficiency is caused by mutations in the coding and promoter regions of 
the MBl gene, which have a profound effect on plasma concentrations of the MBl 
protein. 
Three point mutations have been found in the structural region of the MBl gene: at 
codons 54, 52, and 57 in exon 1. These mutations cause allelic variants designated 
B, c, and D, respectively. in addition to these exon 1 mutations, there are three 
major polymorphisms in the promoter region of the MBl gene, which are expressed 
as four haplotypes called HYP, lYP, lXP, and lYQ. The X/Y polymorphism at 
position -221 is important because the X haplotype is highly prevalent (24% in 
caucasian populations 3) and is associated with low circulating MBl concentrations, 
comparable to those of the structural variants B, c, and D 4. Therefore, determination 
of the exon 1 point mutations and the X/Y promoter polymorphism is adequate to 
assess MBl deficiency in a certain individual. 
several methods have been described for the detection of mutations in the structural 
region, such as PcR followed by restriction fragment length polymorphism (RflP) 
analysis 4. This method is simple and gives unambiguous results, but such a 
method has not been published for the detection of the X/Y promoter polymorphism 
mentioned above. Here we describe a PcR-RflP method for the X/Y polymorphism. 
The method fits well with the PcR RflP method we implemented for the detection 
of the three point mutations in exon 1.
MaTeRials, MeTHoDs, ResUlTs anD 
conclUsion
PcR was carried out in a final volume of 50 µl containing 1 µl (30–100 ng) of 
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genomic Dna, 2.5 mM Mgcl2, 50 µM deoxynucleotide triphosphates, 0.4 µM 
upstream primer (5'-gTTTccacTcaTTcTcaTTcccTaag-3'), 0.4 µM downstream 
primer (5'-gaaaacTcagggaaggTTaaTcTcag-3'), and 1 U of ampliTaq gold 
(applied Biosystems) in a buffer containing 100 mM Tris-Hcl (pH 8.3) and 500 mM 
Kcl. 
The PcR was initiated by a 10-min denaturation and enzyme activation step at 95 
°c and completed by a 10-min extension step at 72 °c. The temperature cycles 
were as follows: 35 cycles of 30 s at 95 °c, 30 s at 60 °c, and 45 s at 72 °c. The 
amplification product, with a length of 350 bp, was digested by BsaJi according to 
the manufacturer’s instruction (new england Biolabs inc.). 
The PcR product contained one nonpolymorphic BsaJi restriction site that served 
as an internal control for enzyme digestion, producing two fragments of 242 and 
108 bp. in the Y variant, the 242-bp fragment was cleaved into two fragments of 
166 and 76 bp. Because of the substitution of the base cytosine for guanine at 
position -221 of the MBl gene, this does not occur in the X variant. PcR restriction 
fragments were separated by electrophoresis in 2% Response Research (Biozym) 
agarose gels (fig. 1). 
To assess the validity of the method, we tested a series of 17 different Dna samples 
(partially provided by Prof. Dr. M. Turner, institute of child Health, london, UK) with 
our newly developed PcR-RflP method. Haplotype frequencies were 1 XX, 6 XY, 
and 10 YY. The observed haplotypes were confirmed by a heteroduplex method 
using PcR-amplifiable synthetic Dna 5. 
in conclusion, our newly developed PcR-RflP method for the X/Y promoter 
Figure 1. 
Detection of the X/Y 
polymorphism in the 
promoter site of the 
MBl gene by the PcR-
RflP assay. lane 
M, molecular weight 
marker (50-bp Dna 
ladder; invitrogen) 
with sizes in bp. lane 
1, haplotype X/X; lane 
2, haplotype Y/Y; lane 
3, haplotype X/Y; lane 
4, undigested PcR-
fragment; lane 5, 
negative control.
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polymorphism of the MBl gene works with the previously described PcR-RflP 
method for the three exon 1 variants to detect the mutations in the MBl gene that 
cause MBl deficiency.
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inTRoDUcTion 
sepsis and septic shock are major killers world-wide. antibiotic treatment and early-
goal directed therapy in the intensive care unit are essential elements of care, but 
no adjunctive immuno-modulatory treatment to alter the outcome has proven to be 
effective. The complement system plays a protective role in infectious diseases 
acting locally to kill the microbe, but during sepsis, complement can be activated 
systemically to induce an undesired excessive inflammation with subsequent tissue 
damage. This review discusses the diverse actions of the complement system in 
sepsis, emphasising on the defence against infection and the damage done by 
uncontrolled systemic activation of the complement system. 
THe coMPleMenT sYsTeM
our first line of defence against infections is formed by the innate immune system. 
The innate immune system comprises a plasmatic part in which the complement 
system is most important, and a cellular part that recognises microbes using 
receptors such as the toll-like receptors (TlRs). Because components of the 
complement system circulate in the plasma as inactive enzymes that are ready to 
jump into gear upon activation, it is the only defence against infections that can be 
instantaneously activated when a pathogens enters the body. Thus, it is crucially 
important in fulminating infections since the other defence systems take more 
time to start up. The complement system in infectious diseases is a redundant 
system with diverse functions:  1. recognition of pathogens; 2. elimination of these 
pathogens; 3. signalling danger; 4. removal and repair of apoptotic immune cells 
and damaged tissue and 5. prevention of excessive activation. 
Recognition of pathogens by the complement system is done by the initial pathways 
for complement activation: the classical, lectin and alternative pathways. Both 
classical pathway and lectin pathway use specific proteins designed to recognize 
pathogens for this aim. classical pathway activation requires binding of antibody 
(igg or igM) to a microbial antigen, or binding of pentraxins like c-reactive protein 
(cRP) and pentraxin iii to specific target molecules. By the mechanism of antibody-
antigen mediated classical pathway activation, the complement system is linked 
to the adaptive immune system. The lectin pathway is activated after recognition 
of carbohydrates on the microbial surface by mannose binding lectin, and also 
l-ficolin (or ficolin 2) and H- ficolin (or ficolin 3) 1. The alternative pathway has no 
specific molecule that aids in activation of this route. instead it is started up by 
spontaneous binding of c3 to foreign surfaces in the absence of membrane-bound 
complement inhibitors. all human cells posses these inhibitors while the surface of 
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most pathogens lacks these proteins. in this way, it is possible for the alternative 
pathway to discriminate between self and non-self. of note, the alternative 
pathway is also particularly important for amplification of complement activation 
after deposition of c3 on a pathogen by any of the other two initial pathways of 
complement activation 2.
elimination of pathogens occurs after cleavage and activation of c3 to c3b and c5 
to c5b, key molecules of the complement system. Most pathogens are eliminated 
by opsonisation with c3b that promotes phagocytosis. c3b bound to a pathogen 
can be recognised by complement receptors on phagocytic cells in the blood, liver 
and spleen, and after recognition, phagocytosis can occur. This mechanism is 
especially important for gram-positive encapsulated bacteria which have a thick 
cell wall. Thus, deficiency of c3 is associated with serious bacterial infections. 
gram-negative bacteria, which have an outer membrane and a thin cell wall, can 
be killed directly by the lytic effect of the membrane attack complex (Mac). The 
Mac is a macromolecule composed of c5b, c6, c7, c8 and multiple c9 molecules. 
The Mac penetrates the bacterial cell membrane, punches a hole, and after this 
lysis of the bacterium will occur. This mechanism of bacterial complement lysis is 
principally important for killing of neisserial species.  
cleavage and activation of c3 and c5 occurs by so-called convertases. The 
classical pathway c3 convertase - c4b2a  - is generated when c1q is bound by 
antibody-antigen complexes and activates c1rs. subsequently, c1rs can activate 
and cleave both c4 and c2. The lectin pathway forms the same c3 convertase, 
and here c4 and c2 are activated when binding of MBl to pathogens triggers the 
MBl-associated serine proteases (MasPs). The alternative pathway has another 
c3 convertase, called c3bBbP. This enzyme is formed after binding of factor B to 
c3b, cleavage of factor B by factor D and stabilisation of this complex by factor P. 
The c5 convertases (c4b2a3b for classical and lectin pathway and c3b3bBbP for 
the alternative pathway) are formed when a second c3b-molecule binds covalently 
to the c3 convertases. 
The complement system signals danger by the actions of the anaphylatoxins: c4a, 
c3a and c5a. These are small peptide remnants that arise after cleavage of c4, 
c3 and c5. in particular c5a has been shown to be a potent pro-inflammatory 
mediator, whereas c3a has diverse effects also acting anti-inflammatory and 
possibly bactericidal 3,4. Various immune competent cells like granulocytes and 
mast cells possess receptors for these anaphylatoxins. The anaphylatoxins exert 
their actions by ligation of these receptors. in this way, the complement system is 
also linked to the cellular part of the innate immune system. The specific actions of 
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c5a are discussed below. 
Unwanted or excessive activation of the complement system may cause damage 
to the host. Therefore, the body is equipped with complement-regulatory proteins. 
The most important are c1 inhibitor that prevents excessive activation of the 
classical and lectin pathways 5, c4-binding protein that prevents formation of 
c4b2a, and factor H and i that prevent alternative pathway activation. in addition, 
host cell-membranes are protected by membrane-bound regulators: complement 
Receptor 1 (cR1), membrane cofactor protein (McP) and decay accelerating factor 
(Daf). These membrane proteins prevent blood and endothelial cells against c3b 
formation. in addition, cD59 is present on most cells to protect against insertion of 
the lytic c5b-9 (Mac) complex. The anaphylatoxins are rapidly inactivated by the 
carboxypeptidases when they are released in the systemic circulation. figure 1 
shows a simplified overview of the complement system.
Defence 
Because the complement system is crucially important for the elimination of certain 
pathogens, inherited or acquired deficiency for a complement protein will predispose 
to bacterial infection or sepsis. 
in animal studies, it has been shown for nearly all complement components - i.e. 
c1, c2, c3, c4, c5, factor B and factor D - that deficiency leads to either increased 
susceptibility to infection and/or increased virulence of bacteria 6-9.  
in humans, deficiency for c1q, c4 and c2, the proximal components of the classical 
Figure 1.  
a simplified overview of the complement system.
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and lectin pathway, is associated with infections by encapsulated bacteria such 
as S. pneumonia and N. meningitidis. in addition, patients with classical pathway 
deficiencies are especially prone to developing auto-immune diseases such as 
systemic lupus erythematosus (sle). common pathway deficiency (c3) leads to 
a severe immune deficiency and predisposes to infections with a wide range of 
gram-positive, gram-negative and other infections. Patients with deficiencies for 
the alternative pathway and the terminal complement components c6-c9 are at 
risk particularly for infections with Neisseria meningitidis. Because complement 
deficiencies are rare, with prevalences reported to be < 0.1 % 10, they may be of 
minor importance in daily clinical practice. Yet, they underscore the importance of 
complement in defence against infections. 
Deficiency for MBl, the initiating molecule of the lectin pathway of complement is 
much more common, with approximately 5-10 % of the population being completely 
deficient for this protein and over 35 % partially deficient 11. MBl deficiency is 
reported to be associated with pneumococcal and meningococcal infection 12,13 
but overall, a only relatively small amount of these infections can be explained 
by MBl-deficiency. Because of the redundancy of the immune system, MBl-
deficiency is probably more important in situations where the immune response 
is compromised by other mechanisms such as in young children 14, chemotherapy 
induced neutropenia 15, other immune deficiencies 16, or in critically ill patients (see 
below). 
a number of observations have highlighted the consequences of MBl-deficiency 
in patients with sepsis admitted to the icU. first, it appears that patients with 
sepsis admitted to the icU have a higher incidence of MBl-deficiency than normal 
controls or patients with the systemic inflammatory response syndrome (siRs) in 
the absence of infection 17-19. This indicates that MBl-deficiency predisposes to 
serious infections needing intensive care treatment. likewise, MBl-deficiency is 
also linked to a higher number of infectious complications in patients with cancer 
following major surgery (20,21. second, recently it was found that low MBl-plasma 
concentrations predispose to pour outcome in sepsis and septic shock, although 
this effect was only evident in patients with a normal MBl-genotype 22. in addition, 
in pediatric patients with sepsis admitted to the icU, low MBl plasma levels were 
associated with more severe disease in patients with sepsis 19. Thus, MBl-deficiency 
may be associated with a poor outcome in patients with sepsis admitted to the icU. 
interestingly, this may also be the case for patients without infection admitted to 
the icU; as it was recently found in a trial assessing the effect of intensive insulin 
treatment on a surgical icU unit, that low MBl plasma concentration in the control 
group, but not in the patients with intensive insulin treatment was linked to mortality 
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23. Possibly this is related to the development of more infectious complications in the 
patients with low MBl plasma concentrations. in sum, in critically ill patients, there 
is mounting evidence that MBl-deficiency predisposes to infectious complications 
and is associated with an increased risk for fatal outcome 24. 
The role of complement in the defence against infections is indisputable; without it 
we would succomb to infectious diseases. The complement system is designed to 
function locally - on the pathogen at the site of infection - in a highly controlled way. 
in conditions when the control fails, systemic and insufficiently controlled activation 
of the complement system can be harmful and disrupt homeostasis; this is the case 
in sepsis and septic shock. Therefore, the complement system has been termed 
a ‘double-edged sword’ in the pathogenesis of sepsis. in the next paragraph, the 
implications of excessive systemic activation of the complement system in the 
pathogenesis of sepsis will be discussed. 
DaMage 
The first study that documented increased complement activation in sepsis in 
humans was performed over 30 years ago 25. Two years later, the same group 
showed that the alternative pathway was important for this activation 26. in these 
studies, complement activation was seen in patients with septic shock, but not 
in patients with uncomplicated bacteraemia. it was concluded that complement 
activation in concert with activation of other mediators could play a critical role in 
the pathogenesis of shock. subsequent studies showed that increased activation of 
complement was associated with a poor outcome 27-29, development of shock 30 and 
the adult respiratory distress syndrome 31.
in the above studies evidence was found for classical and alternative pathway 
dependent mechanisms of complement activation during sepsis. it should be noted 
however that activation of the lectin pathway (only discoverded in the 1990ies) 
of complement was indistinguishable from classical pathway activation in these 
studies. Recent evidence from in-vitro and animal models also points to lectin-
pathway dependent complement activation during sepsis 32,33. 
it is likely that the pathogen itself is responsible for the systemic activation seen 
during septic shock; it has been shown that in-vitro in whole blood substantial 
complement activation is seen after stimulation with different bacteria 32,34, at 
concentrations relevant for the situation during septic shock. However, several 
other mechanisms can also contribute to activation of complement. first, thrombin 
and fibrin can also activate complement 35 and both proteins are formed in 
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abundance during disseminated intravascular coagulation (Dic) seen during septic 
shock. second, during septic shock, ischaemia-reperfusion (i-R) injury occurs, and 
activation of complement is an important pathogenic event in i-R 36. 
excessive activation of the complement system with formation of the anaphylatoxins 
is deleterious to the host. c5a is the best studied anaphylatoxin in sepsis, and a large 
body of data from animal models indicates that uncontrolled, systemic activation of 
c5a during sepsis is harmful. Blockade of c5a activity with monoclonal inhibitory 
antibodies against c5a or c5 in cecal ligation and puncture (clP)-induced shock 
in rats has a protective effect 37,38, and attenuates the development of multi-organ 
failure 39. in addition, lung injury in mice induced by administration of cobra venom 
factor, an activator of complement, is mediated by c5a 40. in primates receiving with 
a lethal dose of E. coli, anti-c5a protects against early mortality, and inhibits the 
development of the adult respiratory distress syndrome and shock 41. Thus, c5a 
plays a critical role in the development of organ failure during sepsis. 
in the human sepsis and septic shock, c5a has been studied and relates to disease 
severity. c5a is high in sepsis and septic shock 42,43, normalizes when the patient 
recovers, and remains high when patients fail to respond to treatment 43,44. in 
addition, soluble terminal complement complexes (sTcc or sc5b-9),  that indicate 
c5a generation, are also increased in patients with septic shock, and correlate with 
mortality 28,44. 
Because of the important role of c5a in the pathofysiology of sepsis, numerous 
studies have adressed the mechanism by which c5a can induce damage. it is now 
evident that during sepsis c5a exerts various separate but intertwined activities. 
first, c5a induces the synthesis of other mediators such as the cytokines and 
activates the coagulation cascade, which are both crucial factors in the development 
of organ damage during sepsis 45,46. second, granulocytes and endothelial cells 
are activated excessively, leading to upregulation of pro-inflammatory molecules, 
adhesion of granulocytes to endothelium, release of oxygen radicals and activation 
of coagulation 32,34,47,48. Third, c5a has a direct effect on vasopermeability and 
vasodilatation 49 and can induce cardiac dysfunction 50, events that are thought to be 
highly important in the development of shock. finally, c5a impairs the bactericidal 
activity of neutrophils 37,51 which may counteract the host defence against infections. 
it is likely that these activities in concert are responsible for the harmful effect of 
c5a activation during sepsis (figure 2). 
The role of the other anaphylatoxins and the Mac in human sepsis is less clear. 
c3a has bactericidal activities 4, but in contrast to c5a it is thought to have an 
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anti-inflammatory role during sepsis 3. The Mac is possibly related to lytic damage 
during sepsis 52. in addition, the Mac and c3b aid in the induction of apaoptosis 
and the removal of apoptotic cells during inflammatory reactions 53,54. 
Thus, uncontrolled systemic activation of the complement sytem plays an important 
role in the development of damage during sepsis, and it is likely that most of these 
effects are mediated by the anaphylatoxin c5a.  
THeRaPY
Because of the evidence from animal models that inhibition of complement 
activation might be helpful and the observations in humans that excessive 
complement activation during sepsis is associated with severe disease and fatal 
outcome, modulation of complement activation during sepsis has been attempted 
in humans. 
c1 inhibitor inhibits complement activation by classical and lectin pathway and 
additionally impedes activation of the contact and kinin systems 5,55 has been 
evaluated in a small randomized controlled trial. in this trial involving 40 patients 
with sepsis, treatment with c1 inhibitor had a beneficial effect on renal function 
and effectively inhibited activation of classical pathway, the contact system and 
granulocytes 56,57. However, no effect on outcome was observed. in addition, two 
case reports showed a possible beneficial effect of c1 inhibitor in patients with 
sepsis and streptococcal toxic shock syndrome 58,59. it must be noted however that 
the classical and lectin pathways are not the only pathways activated during sepsis, 
and that c1 inhibitor administration in primates suffering from lethal E. coli sepsis 
Figure 2
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had only a limited effect on terminal pathway activation 60. 
one important problem of complement-inhibitory therapies aimed at inhibiting 
initial pathway (i.e. clasical, lectin or alternative) activation is that they also have 
a disadvantageous effect on the host defence. This might be of less importance in 
the early phase of the disease, when patients are treated with antibiotics and they 
have an excessive inflammatory response, but can be expected to be harmful later 
on in the course of their intensive care treatment when multiple organ failure may 
develop and infectious complications lie in ambush. Therefore, it would be more 
attractive to inhibit the effects of excessive complement activation without impairing 
elimination of bacteria, i.e. leaving intact the generation of c3b and the terminal 
c5b-9 complex. in the light of the crucial role c5a plays in the pathogenesis 
of sepsis and septic shock, selective inhibition of c5a or the c5a receptor is a 
promising option. By selective inhibition of c5a most of the damaging effects of 
complement activation can be prevented without significantly impairing the host 
defence systems 32,61. interestingly, in a large randomised placebo controlled trial 
studying the effect of the c5-inhibitor pexelizumab on mortality and myocardial 
infarction after caBg, the incidence of septicaemia was even significantly reduced, 
although there were more cases of pneumonia 62.
although inhibition of c5a may be an attractive approach to diminish the devastating 
effects of septic shock, it should be noted that the pathogenesis of sepsis and 
septic shock is complex and involves multiple mediators at multiple time points. 
Thus, therapies aimed at modulating the course of sepsis would most likely require 
a multi-target approach and should attack mediators upstream in the inflammatory 
reaction, of which c5a indeed is one of the candidates.  
sUMMaRY anD conclUsions
The complement system is aimed to recognise pathogens and eliminate them. 
in addition, it provides dangers signals. complement is essential in the defence 
against certain infections, complement deficiency, of which MBl is the most 
frequent, predisposes to serious infections. on the other hand, during sepsis and 
septic shock, excessive systemic activation of complement contributes to the 
development of shock and organ failure. The anaphylatoxin c5a plays a key role in 
the pathogenesis of sepsis. future therapies aimed at modulating the complement 
system should target this molecule or its receptor.
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Vascular endothelial growth factor is increased during the first 
48 hours of human septic shock and correlates with vascular 
permeability. 13
aBsTRacT
Meningococcal septic shock is an important cause of morbidity and mortality in 
children and young adults worldwide and is the prototypical gram-negative septic 
shock. one of the key factors in the development of shock is increased microvascular 
permeability. Vascular endothelial growth factor (Vegf) is a central factor in 
angiogenesis and is an important mediator of vascular permeability. Thirteen patients 
with meningococcal infection (eight presenting with shock) were investigated in the 
early phase of invasive meningococcal disease. cytokines, complement activation, 
and Vegf plasma concentrations were measured during the first 48 h on the 
pediatric intensive care unit. increased cytokine concentrations and activation of the 
complement system were observed. Vegf plasma concentrations were increased 
(median 193 pg/ml, range 71-1082) and were highest in the presence of shock 
(208 pg/ml, 169-1082) compared with patients presenting without shock (92 pg/
ml range 71-299). Vegf concentration at admission correlated with the severity 
of disease (pediatric risk of mortality score, R = 0.90 [spearman], P = 0.0001) and 
the amount of fluids administered within the first 24 h (R = 0.90, P < 0.0001). in all 
patients, a decrease in Vegf was associated with a decrease in fluid intake during 
t = 24 to 48 h. The results suggest that apart from correlation with IL-1β, -10, -12, 
and complement activation, microvascular permeability in sepsis is also closely 
linked to the plasma concentration of Vegf. The role of Vegf in sepsis-associated 
increased microvascular permeability needs further exploration and may represent 
a new therapeutic target.
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inTRoDUcTion
fulminant meningococcal sepsis is an important cause of childhood morbidity 
and mortality. The development of shock in meningococcal disease is caused 
by the activation of a range of mediators belonging to the cytokine system, and 
the coagulation and complement cascade. activation of these mediators leads 
to increased microvascular permeability, vasoplegia, disseminated intravascular 
coagulation, and myocardial depression. Ultimately, this results in impaired tissue 
oxygenation, a critical factor in the development of multiple organ failure and 
limb ischemia 1. excessive activation of the complement system in children with 
meningococcal shock was found to be related to outcome, severity of disease, and 
extent of capillary leakage 2, and the inflammation-induced loss of endothelial and 
basement membrane glycosaminoglycans during meningococcal sepsis may be 
causally correlated to the increase in permeability to proteins 3. in contrast to its 
clinical importance, the pathophysiology of increased microvascular permeability 
in human septic shock is only sparsely studied and is not a therapeutic target in 
today’s treatment.
Vascular endothelial growth factor (Vegf), first described in 1983 by senger et 
al. as a secretory protein from hepatocarcinoma cells that increased extravasation 
of dye in the skin of guinea pigs, is a dimeric 46-kD endothelium-specific 
multifunctional cytokine that plays a pivotal role in microvascular permeability and 
angiogenesis 4 5. Vegf is synthesized and released by vascular smooth muscle 
cells, lung epithelium, platelets, leukocytes, and macrophages 6. Vegf is a key 
molecule in the control of vascular permeability as it is 20,000 times more potent in 
the induction of vascular permeability than histamine 7.
Vegf expression is influenced by cytokines and nitric oxide 8, and is found to 
be upregulated in a variety of pathologic conditions such as wound healing, 
myocardial ischemia, tumor growth, and endotoxemia 9. Recently, increased Vegf 
concentrations were described in patients with sepsis, but no correlation with a 
decline in serum albumin (as measure of vascular permeability) was found 10. Up 
to now, Vegf concentrations have not been measured in meningococcal sepsis, 
known for its profound effects on vascular permeability.
in view of the key role played by Vegf in regulating microvascular permeability, 
we measured Vegf concentrations in 13 children with invasive meningococcal 
infections, and correlated Vegf concentration with fluid balance as a measure of 
systemic vascular permeability.
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MaTeRials anD MeTHoDs
after approval of the local ethics committee and with informed consent of their 
parents, 13 previously healthy children (seven boys) with invasive meningococcal 
disease admitted to our pediatric intensive care unit (PicU) between september 2002 
and January 2004 were included. Diagnosis was made based on positive culture 
of blood, cerebrospinal fluid, or skin biopsy, or typical presentation. eight patients 
presented with septic shock, defined as hemodynamic instability irresponsive to fluid 
resuscitation and requiring sustained (>12 h) vasopressive support [dopamine and 
(nor)epinephrine; shock group]. one of these patients died 3.5 h after admission. 
five patients presented without shock, four of them had meningitis, and one was 
identified as meningococcal bacteremia with purpura but without hemodynamic 
complications (no shock group). all five of these patients recovered completely. 
Time of disease onset was determined by taking a detailed disease history of the 
parents and noting the first symptom that appeared, e.g., malaise or fever. Disease 
severity was determined by the pediatric risk of mortality score (PRisM) based on 
the worst value of parameters during the first 24 h 11. Hemodynamic parameters, 
net fluid amount (the amount of fluids administrated within the first 24 h minus 
diuresis), and tumor necrosis factor-α (TNFa), and interleukin 1β (IL-1β), -10, and 
-12 were determined using a commercially available Bio-Plex protein array system 
(Bio-Rad laboratories, Hercules, ca) with lower limits of detection of 8 to 16 pg/
ml. complement activation was measured by an enzyme-linked immunoabsorbant 
assay (elisa) specific for soluble c5b-9 (soluble terminal complement complex, 
sTcc) as described previously 12. Vegf was measured in eDTa plasma 0, 2, 8, 12, 
24, and 48 h after admission to PicU by a commercially available elisa (Duoset 
elisa development system; R&D systems, Minneapolis, Mn) with a lower limit of 
detection of 16 pg/ml. also, Vegf levels were measured in 12 healthy controls 
(aged 23.1 ± 0.9 years).
statistics
Differences between groups were analyzed using a two-sided nonparametric 
Mann-Whitney test. linear regression was calculated using spearman’s correlation 
coefficient. Time-dependent changes were analyzed by analysis of variance 
(anoVa) with repeated measures. a P value <0.05 was considered significant. 
statistical analyses were performed with graphPad Prism version 3.00 software 
(graphPad, san Diego, ca).
ResUlTs
Baseline characteristics of the patients are illustrated in Table 1. The shock patients 
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tended to be younger, but this difference was not significant. Time from onset of 
disease to admission was significantly shorter in the shock group, demonstrating a 
more fulminant course of disease. The patients in shock had a significantly higher 
disease severity score and a higher net fluid intake, indicating that a higher volume of 
fluids was necessary for resuscitation. MaP and heart rate did not differ significantly 
between the shock and no shock groups, reflecting adequate resuscitation of the 
shock patients before PicU admission. The inflammatory parameter cRP was lower 
in the shock group, whereas all proinflammatory cytokines were significantly higher. 
Taken together, these data show that our patients with meningococcal septic shock 
had a more rapidly progressing and severe systemic disease than patients without 
shock.
PRisM = pediatric risk of mortality score, MaP = mean arterial pressure, bpm = beats per minute, net fluid 
amount is the amount of fluids administrated within the first 24 hours minus diuresis (in ml/kg body weight), 
cRP = c-reactive protein. statistics by Mann-Whitney test, P < 0.05 is considered significant. n.d. means 
not determined.
‘no shock’ group ‘shock’group P
n 5 8 n.d.
age (years) 4.7 (0.6 - 5.6) 2.7 (0.6 - 5.5) 0.354
Time from disease 
onset to icU 
admission
28 (19 - 100) 16.5 (13 - 21.5) 0.003
PRisM ii 5 (0 - 10) 14 (6 - 35) 0.011
RR (MaP) 80 ( 40 - 88) 73 (54 - 87) 0.724
Heart rate (bpm) 145 (92 - 163) 162 (147 - 210) 0.065
net fluid amount 
(ml/kg)
32 (0 - 80) 117 (55 - 484) 0.006
cRP (mg/l) 147 (99 - 307) 82 (37 - 118) 0.008
inotrope/
vasopressor therapy
2/5 (Dobu) 8/8 n.d.
Mortality 0/5 1/8 n.d.
sequelae 0/5 1/7 (amputation) n.d.
Table 1. 
Patient characteristics at admission
Figure 1. 
Vegf concentration (pg/ml, elisa) in the plasma 
of eight patients presenting with meningococcal 
septic shock (shock), five patients with 
meningococcal meningitis (n = 4) or bacteremia 
(n = 1) without shock (no shock), and 12 healthy 
control subjects (controls). The horizontal line 
represents the median value of the group. †Patient 
who died. significance was tested by two-sided 
Mann-Whitney test.
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at presentation, patients with meningococcal septic shock had significantly higher 
Vegf plasma concentrations (median 208 pg/ml, range 169-1082) than the no 
shock patients (median 92 pg/ml, range 71-299, P = 0.03) or controls (median 
39 pg/ml, range 25-55, P < 0.001; figure 1). The patient with the highest Vegf 
concentration in the no shock group was the bacteremic patient who required no 
vasopressor support. During the first 48 h, Vegf levels decreased in the patients 
PRisM = pediatric risk of mortality score, MaP = mean arterial pressure, net fluid amount is the amount 
of fluids administrated within the first 24 hours minus diuresis (in ml/kg body weight), cRP = c-reactive 
protein, il-1β = interleukin 1β. 
R (spearman) P-value
PRisM 0.90 0.0001
net fluid amount 0.90 0.0001
Heart rate 0.75 0.0031
Mean arterial pressure (MaP) -0.33 0.27
cRP -0.57 0.05
il-1β 0.82 0.0017
leucocytes -0.49 0.1
Platelets -0.90 <0.0001
Table 2.
spearman correlation coefficient for Vegf (for all patients).
Figure 3.
Plasma concentration of Vegf (pg/ml, elisa) in patients 
with meningococcal disease presenting with shock (•) 
or without shock ([white circle]) correlated with net fluid 
balance (R = 0.90, P < 0.0001). Data was analyzed without 
one outlier in the shock group, indicated by the arrow. net 
fluid amount is the amount of fluids administrated within 
the first 24 h minus diuresis (in ml/kg body weight). 
Figure 2.
Plasma concentration of Vegf (pg/ml, elisa) in patients 
with meningococcal disease presenting with shock or 
without shock from admission at PicU to 48 h after 
admission. Median and upper quartile are presented, n 
= 8 for the shock group at T = 0 and T = 2, and n = 6 
for the shock group at subsequent time points. n = 5 for 
the patients without shock. The dotted line represents the 
upper limit of Vegf concentration of the control subjects. 
During the first 48 h, there was a significant decrease of 
Vegf in the shock patients (anoVa repeated measures, 
P = 0.03), whereas the Vegf concentration in the no 
shock group remained unchanged.
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with shock (P = 0.03 with repeated-measures anoVa), and remained unchanged 
in the patients without shock (figure 2). as shown in Table 2, Vegf correlated well 
with the severity of disease expressed by the PRisM score, the activation of the 
cytokine network expressed by the IL-1β concentration, and the net amount of fluid 
administered within the first 24 h (figure 3). as indicated in figure 3, one outlier 
was excluded from the correlation analysis; however, with inclusion of this patient, 
the correlation remains significant (R = 0.79, P = 0.003). Table 3 illustrates that 
IL-1β, -10, and -12 and complement activation also correlated with fluid balance. 
The time-dependent decrease in Vegf in shock patients was associated with a 
significant decrease in fluid intake in all patients during the first 48 h (P = 0.03), 
however, the number of patients was too small to find a significant correlation 
between the decrease in Vegf and the decrease in positive fluid balance.
finally, we found that leukocyte count was not correlated with Vegf concentrations 
(R = -0.49, P = 0.1), but a significant negative correlation was found for platelets (R 
= -0.90, P < 0.0001; see Table 2).
DiscUssion
in vitro as well as in vivo in animals, Vegf is shown to be an important mediator of 
vascular permeability. serum Vegf levels were recently found elevated in human 
sepsis, but no correlation with capillary leakage was found 10. in the present study, 
we confirmed previous results concerning the activation of cytokine network and 
the complement system during meningococcal sepsis, but more importantly, we 
observed that the early phase of meningococcal septic shock is associated with 
increased concentrations of Vegf. ils, complement activation, and Vegf levels 
all correlated with the net amount of fluid intake in these patients, indicating that 
in concert with various cytokines and complement, Vegf may mediate vascular 
permeability during sepsis. Moreover, cytokines, complement, and Vegf interact 
with each other in their permeability increasing effect 13,14.
admission Value 
median, [range] (pg/ml)
R (spearman) P-value
Tnfα 39 [8-726] 0.56 0.06
il-1β 58 [8-304] 0.81 0.001
il-10 5710 [14-13571] 0.91 <0.0001
il-12 71 [8-3771] 0.91 <0.0001
Tcc 2.8 [0.9-8.0] 0.71 0.01
Table 3. 
spearman correlation coefficient of cytokines and complement activation products with net 
fluid amount (for all patients). 
net fluid amount is the amount of fluids administrated within the first 24 hours minus diuresis (in ml/kg 
body weight).
201
The high Vegf concentrations at presentation, its decline during the first 48 h in 
shock patients, and the correlation with the proinflammatory cytokine IL-1β suggest 
that the early Vegf peak is induced by cytokines or directly by the meningococcal 
components itself. in accordance, it has been demonstrated that proinflammatory 
cytokines account for Vegf release from various tissues 8, whereas the effect 
on Vegf receptor density is unclear as up- 15 and down-regulation 16 have been 
reported. The source of Vegf is not clear. it is likely that activated leukocytes and 
thrombocytes are sequestered, and that these are the ones that release Vegf. 
in accordance, we found a negative correlation of Vegf concentrations with the 
platelet count. This can indicate that activated platelets are the source of Vegf. 
However, another possibility is that activated endothelial cells are responsible for 
the release of Vegf, as well as for the binding of the platelets.
in patients with bacterial meningitis, circulating Vegf concentrations were normal, 
but the Vegf concentrations were elevated in cerebrospinal fluid, indicating 
intrathecal production 17. cryptococcal meningitis induced elevated Vegf 
concentrations in cerebrospinal fluid and plasma 18. in acute respiratory distress 
syndrome (aRDs), another form of inflammatory-mediated tissue damage, it was 
found that plasma Vegf concentrations were elevated and that peripheral blood 
mononuclear cells of these patients produced more Vegf in vitro than cells from the 
control group 19. also, plasma of these patients increased endothelial permeability 
in vitro, an effect that could be inhibited by the addition of a soluble Vegf inhibitor. 
These studies indicate that Vegf is a potent inducer of inflammation-associated 
capillary leakage in critically ill patients. in accordance with our study, Van der flier 
et al. 10 recently reported elevated circulating Vegf concentrations in severe septic 
patients. Because of the clinical entity of meningococcal disease, our patients 
represent a more homogeneous group of patients with sepsis, and the time from 
disease onset of meningococcal sepsis is more precise compared with sepsis from 
other causes. also, meningococcal sepsis is especially known for its severe effect 
on capillary leakage. These factors may explain that a correlation of elevated Vegf 
levels with vascular permeability was found in our study, in contrast to the study of 
Van der flier et al. 10.
angiogenesis is a key component of the repair mechanisms triggered by tissue 
injury. The cellular expression of Vegf may be important for tissue repair during 
hypoxia, trauma, burns, and inflammatory diseases such as aRDs. in this context, 
Vegf may in fact be induced by the disease to promote tissue repair. in burn and 
trauma patients, markedly enhanced levels of serum Vegf are present 2 to 3 
weeks after trauma or burn injury 20,21. furthermore, the subgroup of patients with 
uncomplicated healing showed significantly higher increases of serum Vegf than 
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the subgroup who developed severe complications during the post-traumatic course, 
such as sepsis, aRDs, or multiple organ failure 20. Because occurrence of severe 
complications during the post-traumatic period was associated with lower levels 
of serum Vegf, one might argue that Vegf is necessary rather than deleterious. 
it is of evident importance to notice that the Vegf-mediated repair mechanisms 
(angiogenesis) appear to coincide with the Vegf peak 2 to 3 weeks after the insult. 
in contrast, it is possible that early during sepsis, Vegf mediates an increase in 
vascular permeability, explaining the correlation with a positive fluid balance we 
found in this study. These apparent contradictory effects may be explained by the 
absence or presence of angiopoietin-1. like Vegf, angiopoietin-1 is important 
during vascular development, but acts reciprocally as an antipermeability factor. 
Vegf alone causes an increase in vascular permeability, whereas simultaneous 
transgenic overexpression or administration of angiopoietin-1 22,23 normalized this 
effect. combining these results, it is tempting to speculate that the early Vegf-
induced increase in vascular permeability may be deleterious, whereas the later 
peak is favorable in the healing process.
Therapeutic opportunities
During gram-negative septic shock, at least three pathophysiologic processes 
occur: increased capillary leakage, disseminated intravascular coagulation, and 
myocardial depression contribute to the development of shock and multiple organ 
failure. although an increased microvascular permeability is frequently encountered 
and is an important cause of multiple organ failure in patients with sepsis, it is 
only sparsely studied in humans. at present, there is no therapy available directed 
specifically against the sepsis-induced increase in microvascular permeability. 
agents successfully used in animal models are not effective or are not applicable 
in humans 24-27.
Recently, an anti-Vegf antibody became available for human use 28. administration 
of the anti-Vegf antibody bevacizumab in patients with metastatic renal cancer 
was associated with only mild asymptomatic side effects. The recent findings 
that inflammation-mediated capillary leakage is associated with elevated Vegf 
concentrations is of particular interest as Vegf may be considered as a new 
therapeutic target for the treatment with anti-Vegf antibodies. However, blocking 
Vegf during critical illness might devoid patients from the positive effects of 
Vegf during the chronic phase. Because mainly the later peak of Vegf seems 
to be beneficial, blocking Vegf in the early phase of sepsis could be considered. 
However, before this hypothesis can be tested, more research to obtain Koch’s 
postulates regarding disease causation is needed.
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in conclusion, we found that the positive fluid balance of patients in meningococcal 
septic shock correlates with increased plasma concentrations of Vegf. further 
efforts should be made to confirm that Vegf mediates vascular permeability in 
meningococcal septic shock and other types of human sepsis and to establish 
whether modulation of Vegf release may be beneficial in the treatment of 
inflammation-induced capillary leakage.
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Macrophage migration inhibitory factor (Mif) in meningococcal 
septic shock and experimental human endotoxemia. 14
aBsTRacT
Macrophage migration inhibitory factor (Mif) is a mediator of innate immunity and 
important in the pathogenesis of septic shock. lipopolysaccharide (lPs) and tumor 
necrosis factor (TNF)α are reported to be inducers of MIF. We studied MIF and 
cytokines in vivo in patients with meningococcal disease, in human experimental 
endotoxemia, and in whole blood cultures using a newly developed sensitive and 
specific enzyme-linked immunosorbent assay. Twenty patients with meningococcal 
disease were investigated. for the human endotoxemia model, 8 healthy 
volunteers were intravenously injected with 2 ng/kg escherichia coli lPs. Whole 
blood from healthy volunteers was incubated with lPs or heat-killed meningococci. 
Macrophage migration inhibitory factor concentration in blood was increased 
during meningococcal disease and highest in the patients presenting with shock 
compared with patients without shock. Plasma concentration of Mif correlated with 
disease severity, the presence of shock and with the cytokines interleukin (IL) 1β, 
IL-10, IL-12, and vascular endothelial growth factor, but not with TNF-α. MIF was 
not detected in blood in experimental endotoxemia, nor after stimulation of whole 
blood with LPS or meningococci, although high levels of TNF-α were seen in both 
models. in conclusion, Mif is increased in patients with meningococcal disease and 
highest in the presence of shock. Macrophage migration inhibitory factor cannot be 
detected in a human endotoxemia model and is not produced by whole blood cells 
incubated with lPs or meningococci.
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inTRoDUcTion
Macrophage migration inhibitory factor (Mif), discovered more than 40 years ago 
1,2, has recently emerged as a major mediator of the inflammatory response. in in 
vitro and animal models, Mif is induced by bacterial components such as endotoxin 
[lipopolysaccharide (lPs)] 3,4 and proinflammatory cytokines such as tumor necrosis 
factor-α (TNF-α) and interferon-γ (IFN-γ) 3, and is expressed in macrophages, T 
cells, cells in the anterior pituitary gland, and other tissues throughout the body 5. 
once released, Mif regulates the inflammatory response by modulating apoptosis 
6, influencing the carbohydrate metabolism 7, activating macrophages and T cells 
8,9, and by counteracting the anti-inflammatory actions of glucocorticoids on immune 
cells 8. in addition, Mif has recently been shown to modulate the expression of Toll-
like receptor 4, an integral part of the lPs receptor complex 10.
Because of its important immunoregulatory function, Mif has been extensively 
studied in murine models of sepsis, and it was shown that targeted disruption of the 
MIF gene or neutralization of Mif by anti-Mif antibodies (abs) results in increased 
survival in these models 11-13. This suggests that Mif is a player in the pathogenesis 
of septic shock, together with the cytokine network and the complement, coagulation, 
fibrinolytic and kinin/kallikrein systems.
Meningococcal disease is caused by bloodstream invasion of the gram-negative 
pathogen Neisseria meningitidis and presents as meningococcal meningitis 
or bacteremia, with a relatively benign clinical picture and low mortality, or as 
meningococcal septic shock, an overwhelming septic shock syndrome with a high 
morbidity and mortality 14. Because it strikes mostly previously healthy children and 
the time from start of symptoms to clinically overt disease is usually short, it has 
been termed the prototypical gram-negative sepsis, and functions as an excellent 
model for studying sepsis. in the human situation, increased plasma concentrations 
of Mif have been found in intensive care unit (icU) patients with diverse types 
of gram-negative, gram-positive, or polymicrobial sepsis 13,15-18. However, Mif in 
meningococcal disease and the interplay between endotoxin (lPs), cytokines, 
and Mif in the human situation has not been studied. Therefore, we used a newly 
developed specific and sensitive enzyme-linked immunosorbent assay (elisa) 
method to determine the plasma concentrations of Mif and the relation of Mif to 
cytokine production in meningococcal disease, in experimental human endotoxemia, 
and ex vivo in whole blood incubated with lPs or meningococci.
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PaTienTs anD MeTHoDs
ethics
all studies were performed with approval of the local ethics committee, and informed 
consent was obtained for all patients and volunteers.
Meningococcal disease
Patients admitted to our pediatric intensive care unit (PicU) between september 
2002 and January 2006 with invasive meningococcal disease were included; 
diagnosis was made based on positive culture of blood, cerebrospinal fluid or skin 
biopsy, or typical presentation. Patients were admitted after first being treated in 
a secondary care hospital (n = 17; delay between presentation on PicU and first 
admission, 3.4 h; range, 1.8-6 h) or referred directly to our hospital (n = 3). septic 
shock was defined as hemodynamic instability irresponsive to fluid resuscitation and 
requiring sustained (>12 h) vasopressive support [dopamine or (nor-)epinephrine]. 
Two patients died, both within 8 h after admission. all patients received antibiotic 
therapy (ceftriaxone, i.v.) and i.v. fluids at first admission and 4 × 0.15 mg/kg 
dexamethasone during the first 3 days of admission. eDTa-anticoagulated blood 
was sampled serially at admission to PicU (t = 0) and at t = 2, t = 8, t = 24 and t = 
48 h after admission when possible. Heparin-anticoagulated blood was obtained at 
admission (t = 0) for determination of cytokines in all 20 patients. Data on vascular 
endothelial growth factor (Vegf) were obtained for 13 patients.
Human endotoxemia
fourteen healthy adult human volunteers aged 18 to 25 years (7 men) and checked 
by routine medical examination, laboratory testing, and electrocardiography 
participated in the study. During the experiment, vital signs were continuously 
monitored. all subjects received i.v. infusion of glucose/saline solution (2.5% 
glucose, 0.45% nacl, 75 ml/h). at t = 0 h, a bolus of 2 ng/kg body weight 
Escherichia coli 0113 lPs (batch o:113, United states Pharmacopia convention, 
Rockville, Md) was injected intravenously in 1 to 2 min in 8 of the subjects 
(endotoxin group); 6 subjects received an infusion of 10 ml of physiological saline 
(0.9% nacl, control group). eDTa-anticoagulated blood for determination of Mif 
and Vegf concentration and heparin anticoagulated blood for cytokines were 
obtained just before infusion and serially thereafter at regular time intervals up to 
22 h after infusion of lPs. Blood was centrifuged at 2800g for 15 min and stored 
at -80°c until analysis of the parameters in 1 batch. Baseline Mif values of these 
subjects were used as control for comparison with the Mif concentration in patients 
with meningococcal disease.
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Whole blood model of sepsis
Heparin-anticoagulated whole blood was collected by venapuncture from 8 healthy 
adult volunteers and incubated for 20 h at 37°c in sterile, endotoxin-free cryotubes 
(nUnc, Roskilde, Denmark) with one of the following substances: e. coli B55:05 
lPs (sigma chemical co, st louis, Mo), N. meningitidis H44/76 [an international 
reference strain isolated from a case of meningococcal disease 19 heat-killed (HK) 
for 1 h at 56°c before use], and N. meningitidis H44/76 lPs (isolated and purified 
from strain H44/76 by phenol extraction 20. Both N. meningitidis H44/76 and the 
neisserial lPs were a kind gift from Dr. Peter van der ley (netherlands Vaccine 
institute, Bilthoven, the netherlands).
Measurements
an elisa for human Mif (hMif) was developed by our group according to the 
4-span approach, described in detail by grebenschikov et al. 21,22. antibodies 
were raised in chicken and rabbits using rhMif as an immunogen. The sandwich 
structure used includes 4 different abs, a coating ab (duck anti-chicken) a capture 
ab (chicken anti-hMif), a trapping ab (rabbit anti-hMif), and finally, a detection ab 
(HRP-labeled goat antirabbit). The procedure started with treating the microtiter 
plates with coating ab overnight at 4°c. The next step was the incubation with 
capture ab for 2 h at 37°c. incubation with patient samples, references, and 
standards was performed at 4°c overnight. Hereafter, trapping and detection abs 
were sequentially incubated for 2 h at room temperature. Plates were developed 
with substrate solution in the dark for 30 min at room temperature, color reaction 
was stopped with H2so4, and optical density was measured at 492 nm within 30 
min. in each run, interassay variability and performance were checked using a 
reference preparation (23). The analytical sensitivity for hMif is 39 pg/ml. Precision 
profiling showed a coefficient of variation (cV) of 20% at 45 pg/ml (i.e., functional 
level) decreasing to 7% at higher concentrations. for estimation of the accuracy 
of the method, a lyophilized reference preparation (marked 140799) is used. The 
mean hMif concentration in this preparation was 20.7 ng/ml, whereas the within-
run cV and between-run cV amounted to 6% (n = 8) and 12% (n = 11, over a 
period of 13 months), respectively.
Interleukin (IL) 1β, IL-8, IL-12, IL-10, TNF-α, and interferon-γ (IFN-γ) were measured 
using commercially available Bio-Plex protein array system (Bio-Rad laboratories, 
inc, Hercules, calif) 23. Lower limits of detection were 8 pg/mL for IL-1β, IL-8, IL-
12, IL-10, and TNF-α, and 32 pg/mL for IFN-γ. Vascular endothelial growth factor 
was measured using a commercially available elisa (Duoset elisa development 
system; R&D systems, Minneapolis, Minn) with a lower limit of detection of 16 pg/
ml.
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statistics
Differences were tested for statistical significance by 2-sided Mann-Whitney test. 
correlation was calculated by spearman rank test. graphPad PRisM version 3.00 
software was used for the calculations. P < 0.05 was considered significant.
ResUlTs
Mif and cytokines in patients with meningococcal disease
Patients were divided in 2 groups: patients with meningococcal septic shock (n = 12) 
and patients without shock (in this group, 6 patients presented with meningitis and 
2 patients with meningococcal bacteremia), illustrated in Table 1. The shock group 
experienced a more fulminant and severe disease, reflected by a higher mortality 
and more sequelae, a shorter time from disease onset to icU admission, and a 
higher PRisM score 24,25. The presence of shock is demonstrated by the sustained 
requirement for vasopressors, the higher heart rate, and the higher amount of i.v. 
fluids needed during resuscitation in the first 24 h. Plasma concentrations of the 
cytokines IL-1β, IL-12, IL-10, VEGF, and TNF-α were significantly higher in the 
shock group compared with the patients without shock. There was no significant 
difference for IL-8 and IFN-γ.
Table 1.
characteristics of patients presenting with or without shock during meningococcal disease. 
no shock shock P
n 8 12
Male/female 4/4 6/6
age (years) 3.1 (0.6 - 5.6) 2.6 (0.6 - 5.5) .671
Mortality 0/8 2/8
sequelae 0/8 2/8
culture positive 5 (62.5%) 10 (83%)
Time from disease onset 
to icU admission (h)
26.5 (16 - 100) 16.5 (12.5 - 21.5) .028
PRisM 5 (0 - 13) 16.5 (6 - 35) .003
MaP (mmHg) 78 ( 40 - 93) 68 (30 - 93) .724
HR (bpm) 142 (92 - 188) 162 (147 - 226) .031
net fluid Therapy (ml/kg) 57.5 (0 - 212) 131 (55 - 484) .01 
il-1β (ng/ml) 0.017 (0.008 – 0.175) 0.04 (0.008 – 0.125) .017
il-12 (ng/ml) 0.008 (0.008 – 0.087) 0.112 (0.008 – 0.365) .009
il-10 (ng/ml) 0.634 (0.014 – 21.97) 4.109 (0.89 – 30.73) .010
Vegf (ng/ml) 0.091 (0.071 – 0.299) 0.208 (0.169 – 1.082) .03
Tnfα (ng/ml) 0.008 (0.008 – 0.093) 0.040 (0.008 – 0.125) .012
il-8 (ng/ml) 0.017 (0.008 – 0.175) 4.23 (0.008 – 3.20) .080
ifnγ (ng/ml) 0.100 (0.032 – 2.684) 0.270 (0.106 – 1.423) .211
Where appropriate, median and range is presented. Differences were tested for significance using 
Mann-Whithney test. culture positive = culture of blood, cerebrospinal fluid or skin biopsy positive for n. 
meningitidis PRisM = Pediatric Risk of Mortality, MaP = mean arterial pressure, HR = heart rate, bpm = 
beats per minute. net fluid therapy indicates the amount of fluids infused during resuscitation and in the 
first 24 hours subtracted with diuresis. cytokines were measured at admission.
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Patients with meningococcal disease had increased plasma concentrations of 
Mif at admission to the PicU (median, 70.2 ng/ml; range, 6.2-347 ng/ml) in 
comparison to healthy adult controls. Macrophage migration inhibitory factor plasma 
concentration was higher at admission (P = 0.02) and 2 h after admission (P = 0.08) 
in the patients with shock as compared with the patients without shock, but there 
was a very large variation in Mif concentration in this group (figure 1). Mif plasma 
concentration in the shock group decreased within 8 h to concentrations similar to 
those seen in the patients without shock. in the ensuing 24 to 48 h, Mif plasma 
concentration remained higher than seen in normal controls for both the shock and 
no-shock groups (figure 2).
Macrophage migration inhibitory factor at admission significantly correlated 
with disease severity in all patients with meningococcal disease (as defined by 
PRisM score) and the presence of shock (heart rate and the amount of fluids 
needed for resuscitation) (Table 2). Macrophage migration inhibitory factor plasma 
concentration at admission significantly correlated with plasma concentrations of 
IL-1β, IL-10, IL-12, and VEGF at admission. No significant correlation was observed 
between MIF and IL-8, TNF-α, or IFN-γ (Table 3).
Figure 1.
Mif at admission in meningococcal disease.
Macrophage migration inhibitory factor plasma 
concentration at admission in patients with 
meningococcal disease presenting with shock 
(shock, n =12), without shock (no shock, n = 8), 
and healthy control subjects (n = 14). Differences 
were tested for significance using Mann-Whitney 
test. † indicates the patients that died.  
Figure 2.
Time-course of Mif in meningococcal disease.
Macrophage migration inhibitory factor plasma 
concentration from admission to 48 h after 
admission in patients with meningococcal disease 
presenting with shock (dashed boxes) or without 
shock (white boxes). Box-whisker plots indicate 
medians, 25 and 75 percentiles, and ranges.  
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cytokines and Mif in experimental human endotoxemia and in a 
whole blood in vitro model of sepsis
To define more closely the pathophysiological mechanism leading to production 
of Mif during meningococcal sepsis, we studied Mif in experimental human 
endotoxemia and in an in vitro whole blood model of sepsis.
infusion of 2 ng/kg E. coli lPs in healthy volunteers induced significant clinical 
symptoms such as nausea, pyrexia, increased heart rate, and a drop in blood 
pressure. LPS infusion did not affect MIF plasma concentrations. In contrast, TNF-α 
peaked 1.5 h after lPs infusion, and a small increase in plasma concentrations of 
IL-1β and IL-10 was seen 2 to 3 h after infusion (figure 3).
incubation of human whole blood with E. coli lPs, lPs isolated from N. meningitidis, 
or N. meningitidis HK bacteria did not induce Mif production, whereas increased 
concentrations of TNF-α were found (figure 4). lower concentrations of lPs or 
bacteria (up to 1 ng/ml or 105 bacteria) did also not induce Mif production (data 
not shown). Mif in control samples of unstimulated heparinized plasma differed 
from that in eDTa plasma (62 vs. 10 ng/ml, P < 0.001).
Table 3.
correlation of Mif plasma concentration at admission with plasma concentration of cytokines 
and Vegf at admission  
R (spearman) P
il-1β 0.53 .016
il-12 0.56 .010
il-10 0.59 .006
Vegf 0.73 .005
Tnfα 0.375 .103
il-8 0.21 .370
ifnγ 0.17 .482
Table 2. 
correlation of Mif plasma concentration at admission with disease severity and markers of 
shock  
R (spearman) P
PRisM 0.62 .004
MaP - 0.22 .34
HR (bpm) 0.74 < .001
net fluid therapy 0.69 < .001
correlation of Mif plasma concentration at admission with disease severity and markers of shock. PRisM 
= Pediatric Risk of Mortality, MaP = mean arterial pressure, HR = heart rate, bpm = beats per minute. net 
fluid therapy indicates the amount of fluids infused during resuscitation and in the first 24 hours subtracted 
with diuresis.
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Figure 4. 
MIF and TNF-α in an in vitro whole blood model of sepsis. 
Macrophage migration inhibitory factor and TNF-α concentration after incubation of whole blood with 1 µg/
ml of e. coli lPs, 1 µg/ml or N. meningitidis (N. men) lPs, N. meningitidis bacteria (1 × 109/ml), or PBs 
(control) for 20 h. n = 8 for hMIF, n = 7 for TNF-α. Medians and upper quartiles are presented. ***P < 0.001 
for the comparison between sample and control.  
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Figure 3. 
Mif and cytokines in experimental human endotoxaemia.
Macrophage migration inhibitory factor, TNF-α, IL-1β, and IL-10 plasma concentration at baseline (T = 0) 
and at subsequent time points up to 22 h after i.v. injection of a bolus of 2 ng/kg E. coli lPs (endotoxin 
group, n = 8, open squares, pyramids or circles) or healthy volunteers with saline (control group, n = 6, 
closed circles, only shown for MIF, TNF-α, IL-1β, and IL-10 were below the lower limit of detection in the 
control group). Median values ± interquartile range are presented.  
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DiscUssion
in the present study, we showed that Mif was increased in patients with 
meningococcal disease. The highest plasma concentrations of Mif were seen in 
the patients with shock. not withstanding the very high cytokine levels reached, 
Mif was not detected in blood after infusion of endotoxin in humans-neither is Mif 
induced by incubation of whole blood with lPs or N. meningitidis HK bacteria.
in the patients with meningococcal disease described in this study, plasma 
concentrations of Mif at admission to PicU were increased up to 20-fold in 
comparison with the control subjects, which is in line with earlier studies in adults 
with mixed types of sepsis or siRs 13,15-17. Macrophage migration inhibitory factor 
remained increased in the patients with meningococcal disease up to 48 h after 
admission, which corresponds to the results obtained by gando et al. 16. although 
the control group was older than the patients studied, we believe these conclusions 
can be drawn because in a previous study, no effect of age on Mif plasma 
concentration was found, and Mif levels in our control group are even higher as 
reported in a control group for a study of Mif in children with malaria 26,27.
in patients with meningococcal septic shock, Mif plasma concentration was higher 
during the first 2 h after admission compared with the patients without shock and 
was correlated with several parameters of shock. This observation suggests that 
Mif plays a role in the development of shock in patients with sepsis, which must be 
mediated in concert with other pathological events because infusion of recombinant 
Mif into mice alone did not induce lethality by itself but rather potentiates the 
effect of endotoxemia or sepsis 11. a well-known mechanism that contributes to 
fluid-refractory septic shock is relative adrenal insufficiency, a situation wherein 
the adrenal glands synthesize less endogenous glucocorticoids than is needed in 
the stress situation of sepsis 17,28. This relative deficiency of glucocorticoids can 
lead to vasopressor hyporesponsiveness 29. Because Mif antagonizes the effects 
of endogenous glucocorticoids, it seems possible that this overriding effect of Mif 
on glucocorticoid action 5 exacerbates the relative adrenal insufficiency observed 
in patients with septic shock. indeed, in a previous study, the increase in cortisol 
production is matched by the increase in Mif production in patients with sepsis. 
in this way, Mif is able to antagonize the effect of endogenous glucocorticoids 17. 
another mechanism by which Mif can contribute to the development of shock is 
by modulation of Vegf production. We recently reported that Vegf is a mediator 
of increased vascular permeability in meningococcal disease 30. in the present 
study, Mif plasma concentration at admission was strongly correlated with Vegf, 
suggesting a link between Vegf and Mif in the development of shock. indeed, 
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preclinical studies have shown that Mif induces Vegf production in tumor cell 
lines, and that Mif and Vegf plasma concentrations are correlated in patients with 
cancer 31,32.
after admission, the increased concentration of Mif in the shock patients rapidly 
declines to concentrations that are also seen in less severely ill patients. in one of 
the fatalities, Mif declined between 0 and 2 h after admission (164 -> 115 ng/ml). 
in the other patient that died, Mif increased in the first 2 h after admission (172 -> 
302 ng/ml). The quick decline in Mif plasma concentrations in the patients with 
shock can reflect the normal clearance of Mif from the circulation after successful 
antimicrobial therapy. alternatively, this decline can possibly also be accounted 
for by the administration of corticosteroids in our patients because it was recently 
discovered that corticosteroids normalize leukocyte production of Mif during human 
sepsis 33, and in a murine cecal ligation and puncture model of sepsis, administration 
of dexamethasone led to a decrease in Mif plasma concentration 34. after 8 h, Mif 
plasma concentration in the patients with septic shock is comparable with that in 
the patients without shock. Because none of the patients without shock died or had 
severe sequelae, it can be questioned whether this relatively small increase of Mif 
found more than 8 h after admission in the shock group is of importance for the 
clinical outcome in meningococcal disease.
To define more closely the pathophysiological mechanism leading to production of 
Mif during sepsis, we studied Mif during experimental human endotoxemia and in 
whole blood. in the first in vivo model, E. coli lPs, a component of gram-negative 
bacteria and important in the pathogenesis of septic shock, is infused as a bolus. 
it is a widely accepted model to study acute inflammatory responses during gram-
negative sepsis 35-38. Reportedly, Mif is induced by lPs and the proinflammatory 
cytokines TNF-α and IFN-γ 3,4,8. in the human endotoxemia model, however, we 
found no Mif induction up to 22 h after lPs infusion, although high peak plasma 
concentrations of TNF-α did occur 1.5 h after infusion. Correlation of MIF to 
cytokines found in meningococcal disease showed that Mif did not correlate with 
TNF-α, whereas MIF positively correlated with IL-1β, IL-10, and IL-12. These data 
suggest that LPS or TNF-α are not main driving forces for MIF induction during 
gram-negative sepsis. support for this is found in the observation that Mif is also 
increased in nonseptic inflammatory diseases and after stimulation with gram-
positive bacteria 39-41. Possibly, other cytokines such as IL-1β or other inflammatory 
compounds such as c5a are responsible for the induction of Mif 42 or may be 
necessary in concert with LPS or TNF-α to induce MIF. In addition, components 
of gram-negative bacteria other than lPs can be responsible for the induction 
of Mif because it has been shown that an inflammatory cytokine response and 
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complement activation by meningococci can occur also in the absence of lPs 20,43.
in human whole blood cultures, we attempted to induce Mif by incubation with lPs 
or HK meningococci, as was recently published for isolated mononuclear cells 33. 
at concentrations of lPs or meningococci ranging from 1 ng lPs/ml to 1 µg lPs/
ml or 106 meningococci per milliliter to 109 meningococci per milliliter, and in the 
presence of high levels of TNF-α, no MIF production was seen in whole blood. 
The concentrations of lPs and meningococci in the whole blood experiments 
were chosen to match the situation during meningococcal sepsis. Previously, it 
has been found that during meningococcal septic shock, plasma concentrations 
of bacteria are median 2 × 107/ml. Highest concentrations of bacteria found were 
5.4 × 108, with maximal concentrations of lPs up to 215 ng/ml 44-46. Thus, the 
concentrations we used in the experiments are clinically relevant. in heparinized 
human whole blood, high background levels of Mif were observed, higher than in 
eDTa-anticoagulated samples. it is uncertain whether this is an effect of the elisa 
method used or that it signifies Mif release by human blood cells independently 
of a stimulus. it is likely that Mif is produced in other tissues such as the liver, the 
spleen, and the kidney by resident macrophages and by other tissues such as the 
heart 47 and, more specifically for Mif, the anterior pituitary gland 5.
in conclusion, Mif concentration in blood was increased in patients with 
meningococcal disease, where it may play a role in the development of shock, acting 
in concert with other cytokines. Macrophage migration inhibitory factor plasma 
concentration did not correlate with TNF-α. No MIF production was observed in 
experimental human endotoxemia. in addition, Mif was not produced by human 
whole blood cultures after challenge with lPs or meningococci. Therefore, it can 
be questioned whether MIF in human sepsis is induced by LPS or TNF-α in the 
blood compartment.
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PTX3 and c-reactive protein in severe meningococcal disease 15
aBsTRacT
The long pentraxin PTX3 is an important element of the innate immune system and 
has potential as a diagnostic tool in inflammatory conditions. We studied PTX3 in 
patients admitted to an icU with severe meningococcal disease and compared it 
with the short pentraxin cRP.  
26 patients with meningococcal disease were studied, 17 patients presented with 
meningococcal septic shock (shock group) and 9 patients with meningococcal 
meningitis or bacteraemia (no shock group). PTX3 and cRP were measured by 
elisa. 
High plasma concentrations of PTX3 (median 579 µg/l) were seen at admission 
in patients with meningococcal disease. concentrations were significantly higher 
in patients with shock compared to patients without shock (median 801 µg/l and 
median 256 µg/l, P = .006, respectively). in contrast, cRP at admission was 
lower in the shock group as compared to the no shock group (median 58 mg/l and 
median 165 mg/l, P = .008, respectively). High PTX3 and low cRP concentration 
at admission discriminated between presence and absence of shock (area under 
the Roc curve 0.85, P = .007 for PTX3 and 0.84 P = 0.01 for cRP). PTX3 did not 
correlate with disease severity (PRisM) and days spent in icU. PTX3 at admission 
and PTX3 peak concentration both showed a negative correlation with plasma 
fibrinogen concentrations. cRP concentration at admission correlated negatively 
with disease severity. 
in conclusion, PTX3 was an early indicator of shock in patients with severe 
meningococcal disease that followed a pattern of induction distinct from cRP. 
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inTRoDUcTion
Meningococcal disease is an important cause of morbidity and mortality world-wide. 
invasive meningococcal disease occurs when a pathogenic strain of Neisseria 
meningitidis penetrates the nasopharyngeal mucosa and invades the bloodstream. 
When outgrowth in the bloodstream is restricted, meningococci seeded into the 
subarachnoideal space will proliferate within that compartment and meningococcal 
meningitis develops, with a localized inflammatory response and a mild clinical 
course. in contrast, meningococcal septic shock has a fulminant course and 
is characterized by a seemingly unimpeded outgrowth of meningococci in the 
bloodstream causing a massive systemic activation of a range of inflammatory 
systems, such as the cytokine network and the coagulation and complement 
cascades 1-3. 
Pentraxins such as c-reactive protein (cRP), serum amyloid P (saP) and pentraxin 
3 (PTX3) are acute-phase reactants which play major roles as soluble innate 
immune pattern recognition receptors in defence against microbes and clearance of 
apoptotic or necrotic cells 4. The long pentraxin PTX3 is structurally related to cRP 
and saP. Whereas cRP and saP are made by the liver in response to inflammatory 
mediators such as interleukin-6 (il-6) 5-8, PTX3 is induced by microbial components 
and by Tnf and il-1 in a variety of cell types, most prominently endothelial cells 
and mononuclear phagocytes 9-13. PTX3 is elevated in a variety of viral, bacterial 
and inflammatory diseases 14-16.
in daily practice, plasma concentrations of the short pentraxin cRP are often 
used to discern severe bacterial infections from diseases with a milder course. in 
addition, multiple other prognostic markers have been studied in the past to aid 
diagnosis and treatment of severe meningococcal disease, including leukocyte 
count, endotoxin (lPs), Tnf-alpha and pro-calcitonin. although some of these 
markers may have value in assessing disease severity, most have low sensitivity or 
specificity 17-20.
Based on the observations that PTX3 is essential in defence against certain 
pathogens and prompted by reported correlations of PTX3 plasma concentration 
with severity of disease 21, we evaluated PTX3 in comparison with the short 
pentraxin cRP in patients admitted to an icU with severe meningococcal disease. 
227
MaTeRials anD MeTHoDs
Patient characteristics
Twenty six patients with meningococcal disease admitted between 1994 and 2004 
to the intensive care unit of the Radboud University nijmegen Medical centre were 
studied : 24 children (median age 3.1y, range 0.6-14y, 13 boys, 11 girls) and 2 adult 
patients (1 male, 25.8y and 1 female, 30.6y). informed consent was obtained for all 
patients, and the studies were conducted according to the guidelines of the local 
ethical committee. 
Diagnosis of meningococcal disease was based on typical clinical picture, in 88 
% of the cases this was microbiologically confirmed. sixteen children presented 
with meningococcal septic shock, defined as haemodynamic instability requiring 
sustained (> 12 hours) vasopressive support in spite of adequate fluid resuscitation. 
four shock patients also had signs of meningitis (defined as > 100 x 103 leukocytes 
/ l in the csf or clear nuchal rigidity on physical examination). eight presented 
without shock, six children had meningitis  and two children presented with neither 
shock nor meningitis (no-shock group). The one female adult patient presented 
with shock and died early in the course of disease, the male adult patient presented 
with meningitis and survived. Patients received standardised treatment consisting 
of early appropriate antibiotics (mostly penicillin or ceftriaxone), fluid resuscitation 
with if necessary inotropes or vasopressors, and mechanical ventilation when 
indicated. in addition, corticosteroids were given to all but 1 patient and - as part 
of a clinical trial -  8 of the patients received whole blood exchange transfusion or 
plasmaferesis. 
The time from onset of disease to admission was defined as the time between the 
first symptom noted (for example fever, malaise or vomiting) and admission to the 
hospital.  Patient data were collected prospectively.  
PTX3 and cRP analysis
eDTa-anticoagulated samples stored at -80°c were used for the analysis. 
admission samples were obtained within 4 hours after admission to the icU and 
were available for 20 children and both adults. Peak concentrations were the 
highest concentrations found during admission. Time course was made by grouping 
the data in different categories (t = 8 were samples obtained between 4 and 12 
hours after admission, t = 24 were samples obtained between 12 and 36 hours 
after admission, t = 48 were samples obtained between 36 and 60 hours after 
admission). in the time-course analysis, only patients of which sequential samples 
were available were included (n=20). 
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PTX3 was measured using an in-house enzyme-linked immunosorbent assay 
(elisa) 14,22. PTX3 concentration is expressed as µg/l and plasma concentrations 
in healthy controls are < 2 µg/l. cRP was measured using a commercially available 
elisa purchased from DaKo, glastrup, Denmark.  .
sTaTisTics
Differences between medians were tested using Mann-Whitney test. fishers exact 
test and spearman correlation test were used as indicated in text or legends. graph 
pad PRisM 4.0 software was used to perform the analyses and to create the Roc 
curves. 
ResUlTs
Patient characteristics
The 26 patients presenting with meningococcal disease were divided into two 
groups: patients that developed shock and patients without shock (Table 1). The 
patients with shock had an unfavourable prognosis: they had higher disease 
severity scores (PRisM, 23,24), spent more days in icU, had more sequelae and 
higher mortality than patients without shock. importantly, patients with shock had 
also more fulminant disease, as reflected by the shorter time from disease onset to 
characteristics of patients presenting with or without shock during meningococcal disease. Where 
appropriate, median and range is presented. Differences were tested for significance using Mann-Whithney 
test and fishers exact test when appropriate. PRisM = Pediatric Risk of Mortality, MaP = mean arterial 
pressure. * PRisM score and MaP value are presented only for the children. ** days in icU and sequelae 
were calculated only for survivors. 1 time from first symptom to admission to referring hospital, 2 time from 
first symptom to admission to the icU of the Radboud University nijmegen Medical centre. sequelae 
observed were amputations, severe scars, prolonged hypocortisism, and concentration disturbances / 
learning disability. 
shock no shock P
n 17 9 n.s.
male / female 9/8 5/4 n.s.
age (y) 3.5 (0.6-30.6) 2.7 (0.6-25.8) n.s.
patients included in 1994 (1), 1995 (2), 
1996 (3), 1997 (2), 
1998 (1), 2002 (3), 
2003 (4), 2004 (1) 
1994 (1), 1995 (2), 
1996 (1), 2002 (4), 
2003 (1)
time to admission1 (h) 13 (9.3-23.5) 23.3 (16-96) .0004
time to admission2 (h) 16.5 (12-27) 25 (18.5-100) .0004
PRisM* 17 (6-35) 3 (0-10) .0004
days in icU (days)** 8 (1-23) 1 (1-4) .001
MaP (mmHg) 68.5 (35-100) 82.5 (40-90) n.s.
fibrinogen (mg/l) 1.6 (0.1-2.8) 4.4 (3.4-6.4) <.0001
sequelae** 10/15 (66%) 0/8 .0027
mortality 2/17 (12%) 0/8 n.s.
Table 1. Patient characteristics
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admission. in addition, time to admission correlated negatively with PRisM scores 
and length of icU stay (spearman R = -0.55, P = .007 and R = -0.51, P = .01, 
respectively).
PTX3 and cRP plasma concentrations in severe meningococcal 
disease
High plasma concentrations of PTX3 were seen at admission: median 579 µg/l 
(range 21 - 2335 µg/l). concentrations were significantly higher in patients with 
shock than in patients without shock (median 801 µg/l, range 95 - 2335 µg/l and 
median 256 µg/l, range 21 - 702 µg/l, P = .006, respectively). Peak concentration 
of PTX3 also showed a clear-cut difference between patients with and without 
shock (median 1036 µg/l, range 139-3480 µg/l and median 473 µg/l, range 37 
- 1310 µg/l, P = .002, respectively). in contrast, cRP at admission was lower in 
the patients with meningococcal septic shock as compared to the patients without 
shock (median 58 mg/l, range 19 - 197 mg/l and median 165 mg/l, range 63 - 327 
mg/l, P = .008, respectively). Peak concentration of cRP in patients with shock 
was equal to that in patients without shock (median 244 mg/l, range 66 - 391 mg/l 
and median 265 mg/l, range 151 - 327 mg/l, P =  .945, respectively). 
Time course of PTX3 and cRP showed a divergent pattern of induction: in patients 
with shock, median PTX3 concentration was highest at admission, whereas cRP 
peaked 48 hours after admission. in patients with meningitis cRP peaked within the 
first 24 hours after admission, reflecting a longer pre-clinical disease period in the 
meningitis patients (figure 1). 
PTX3, cRP and severity of disease  
High PTX3 and low cRP concentration at admission discriminated between 
presence and absence of shock: area under the Roc curve 0.85, P = .007 for 
PTX3 and 0.84 P = 0.01 for cRP (figure 2). PTX3 and cRP did not correlate with 
each other. PTX3 at admission and PTX3 peak concentration did not correlate 
with disease severity (PRisM) and days spent in icU, and correlated negatively 
with time to admission. cRP concentrations at admission however, showed a 
strong negative correlation with parameters of disease severity, and correlated 
positively with time to admission. The cRP peak concentration showed no relation 
to parameters of disease severity or time to admission. interestingly, PTX3 at 
admission and PTX3 peak concentration both correlated negatively with plasma 
fibrinogen concentrations (Table 2).
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PTX3 
admission
PTX3
peak
cRP
admission
cRP
peak
PTX3 peak 0.74 (<.01)
cRP admission -0.24 (.28) -0.31 (.20)
cRP peak 0.33 (.18) 0.33 (.14) 0.42 (.08)
time to admission 1 -0.47 (.03) -0.55 (<.01) 0.58 (<.01) 0.08 (.71)
PRisM 0.30 (.20) 0.40 (.08) -0.73 (<.01) -0.25 (.28)
days in icU 0.27(.27) 0.42 (.05) -0.76 (<.01) -0.08 (.72)
MaP 0.12 (.63) -0.08 (0.74) .24 (0.32) -0.07 (.76)
fibrinogen -0.55 (<.01) -0.66 (<.01) 0.55 (<.01) 0.06 (.58)
Table 2. correlation of PTX3 and cRP
Figure 2. 
Receiver operating charac-teristic 
curve for PTX3 and cRP.
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Figure 1.
Time course of PTX3 and cRP in 
meningococcal disease. 
Dashed bars indicate patients with 
shock, white bars patients without 
shock. Median and upper quartile 
is shown. 
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DiscUssion
This is the first study that has analyzed the pentraxins PTX3 and cRP in the 
various manifestations of meningococcal disease and that has taken into account 
their time course. We found that PTX3 peaks in the first hours after admission to 
the icU and thereby was an early indicator of shock. This pattern greatly differs 
from that of cRP which is low at admission and peaks 48 hours after admission in 
the shock patients. Thus, a high PTX3 and a low cRP at admission discriminates 
between the presence or absence of shock. cRP at admission showed a strong 
negative correlation with disease severity, and was positively correlated with time 
to admission. in contrast, PTX3 at admission did not correlate with parameters of 
disease severity other than shock. 
The difference in the time course of PTX3 and cRP is due to differences in their 
regulation: PTX3 is induced by microbial components and early pro-inflammatory 
cytokines such as Tnf and il-1 in endothelial cells and macrophages 9-12,25,26. 
Therefore, PTX3 is expected to appear early in the course of diseases that are 
characterized by activation of these cells. Reportedly, in patients with myocardial 
infarction PTX3 peaked only 7.5 hours after the primary event 22. cRP, in contrast, 
is induced by the secondary cytokine il-6 and produced in the liver, and has a 
slower time course 27-30. Maximal cRP concentrations in humans experimentally 
challenged with endotoxin, peaked 24 hours after the primary event 31.
in meningococcal disease, a short time from disease onset to admission predicts 
a fulminant course and severe disease 1. in the present study, time to admission 
was lower in patients with shock (13 hours compared to 23.3 hours in patients 
without shock) and correlated negatively with PRisM scores and length of icU stay. 
in addition, cRP at admission was positively correlated with time to admission, 
indicating that patients with a shorter time to admission had lower cRP values. 
Therefore, the correlation we found of low cRP with shock and parameters of 
disease severity is most likely caused by the slow kinetic of cRP, indicating a 
more fulminant course in patients with low cRP plasma concentration at admission 
17,18,32,33. 
High PTX3 plasma concentrations discriminate well between the presence or 
absence of shock. The high plasma concentrations of PTX3 in the shock patients at 
admission possibly reflect higher bacterial loads and the higher concentrations of 
Tnf and il-1 found in the shock patients 34-36. PTX3 did not significantly correlate 
with parameters of disease severity other than shock such as PRisM score and 
days spent in icU. This contrasts with earlier findings in patients with sepsis and 
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septic shock of diverse origin 14. However, the correlation coefficient found in that 
study was moderate and comparable to that found in the present study. it may be 
that the relatively small number of patients in our study or the more homogenous 
study population explains the discrepancy between both studies. Previous studies 
in vitro have found that PTX3 is able to up-regulate tissue factor, a crucial factor 
in the initiation of disseminated intravascular coagulation (Dic) 37,38. our finding 
that PTX3 correlated negatively with fibrinogen (low fibrinogen reflects severe Dic) 
suggests that this link between PTX3 and activation of coagulation is also present 
in vivo. 
The biological roles of PTX3 and cRP are intriguing. Both pentraxins are acute 
phase proteins involved in the direct and complement-mediated clearance of 
bacteria, debris and apoptic cell remnants, created during the primary infectious 
insult or set free throughout the subsequent inflammatory response 4. Whereas cRP 
is known to bind the capsule of pneumococci, preliminary data indicates that PTX3 
binds to meningococci (personal communication, B. Botazzi, unpublished data) 
and the gram-negative outer membrane protein ompa 39. Whether this implies a 
protective role for PTX3 in meningococcal disease should be the subject of further 
research. on the other hand, PTX3 could also be a factor that aggravates Dic or 
have a role as a secondary mediator involved in the direct or complement-mediated 
clearance of damaged cells.
in conclusion, PTX3 is an early indicator of shock in patients with severe 
meningococcal disease that follows a pattern of induction distinct from cRP. High 
PTX3 and low cRP plasma concentrations discriminate between the presence or 
absence of shock. Thus, a high PTX3 level at admission should alert the clinician 
for imminent deterioration and shock. 
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Mannose-binding lectin (MBl) and meningococcal disease, 
a case-parent study 16
aBsTRacT
it is controversial whether mannose-binding lectin (MBl) deficiency constitutes a 
risk factor for meningococcal disease. We conducted an icU based case-parent 
study in 120 survivors of meningococcal disease to investigate the role of MBl 
genotype, MBl plasma concentration and MBl/MasP2-activity in susceptibility to 
and clinical presentation of disease. 
genotype for MBl was assessed using line probe assay. Transmission-disequilibrium 
test was performed for snPs in the MBL2 gene, relative risks for effects of the exon 
1 snPs combined were determined using a log-linear model. 
no transmission disequilibrium was found for the snPs in the MBL2 gene, the 
exon1 snPs combined were also not associated with an increased risk for disease. 
subgroup analysis showed increased risk for meningococcal meningitis associated 
with the exon 1 snPs (RR 3.9, P = 0.03 and RR 3.77, P = 0.2, for heterozygousity 
and homozygousity, respectively). MBl plasma concentrations in meningitis 
patients were significantly lower than in patients with shock or bacteraemia. no 
patients were deficient for MasP2. 
Polymorphisms in the gene for MBl do not predispose for severe meningococcal 
disease. snPs in exon 1 may be a risk factor for meningococcal meningitis. MasP2 
deficiency is no frequent cause of meningococcal disease. 
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inTRoDUcTion
invasive meningococcal disease occurs when a pathogenic strain of Neisseria 
meningitidis penetrates the nasopharyngeal mucosa and invades the bloodstream. 
Restricted outgrowth of meningococci in the bloodstream and seeding into the 
subarachnoideal space leads to compartmentalized proliferation and signs of 
meningitis. Meningococcal septic shock, most often without signs of meningitis, 
develops when meningococci replicate rapidly in the bloodstream with systemic 
activation of the cytokine network, the coagulation and fibrinlolytic cascade and the 
kinin and complement system1.  carriage rate of meningococci in dutch children 
is reported to be up to 26 % 2,3, although a recent study showed a lower prevalence 
of 1.5 % 4. incidence of disease in the netherlands between 1990 and 2002 was 
approximately 0.003 % - 0.004 % / year, dropping to approximately 0.002 % / year 
between 2002 and 2006 after the start of the vaccination campaign against group c 
meningococci.  
Mannose-binding lectin (MBl) is a multimeric protein composed of  5 to 6 trimeric 
units complexed with MBl-associated serine protease-2 (MasP2)5. Binding of the 
MBl-MasP2 complex to Neisseria meningitidis activates complement via the lectin 
pathway 6-8. The magnitude of this process is determined by the quantity of bacteria, 
the MBl concentration and the functionality of MasP2. The MBl concentration is 
influenced by various single nucleotide polymorphisms (snPs) localized in exon 1 
and the promotor region of the MBL2 gene. The snPs in exon 1, situated in codon 
52, 54 and 57 designated D, B and c respectively (the wild-type allele for these 
positions is termed a) lead to impaired twisting of trimeric MBl-units and thereby to 
decreased MBl concentrations. The regulatory polymorphisms in the MBL2 promoter 
and 5’ untranslated region are at position -550, -221 and +4 and designated as l, 
X and Q (the wild type alleles are termed H, Y and P respectively). The 3 exon 
1 snPs and the 3 regulatory polymorphisms are in linkage disequilibrium, with 7 
different common haplotypes reported in caucasian populations: HYPa, lYPa, 
lXPa, lYQa, HYPD, lYPB and lYQc. as the MBl genotype is composed of two of 
these haplotypes, 28 different genotypes may occur 5,9.
insufficient complement activation due to deficiency in complement components is 
a risk factor for invasive meningococcal disease. These complement deficiencies 
are very rare, and thus have low impact on the overall incidence of meningococcal 
disease 10,11. in contrast, MBl deficiency is rather common, with approximately 5 % 
of the population having undetectable MBl-plasma concentrations, and 35 - 40 % 
with low concentrations 12.
241
in 1999, Hibberd et al. reported, based on a case-control study, that polymorphisms 
in exon 1 of the MBL2-gene predispose to meningococcal disease 13. However, 
this study did not evaluate other MBl-genotypes nor MBl-plasma concentrations. 
Two other case-control studies were unable to confirm an association 14,15. This 
controversy is possibly due to differences in patient selection or case-control 
matching. To avoid matching bias we decided to perform a case-parent study that 
uses transmission disequilibrium testing 16, in order to asses whether susceptibility 
to meningococcal disease is related to MBl genotype. in addition, we were the 
first to investigate MBl functional concentration and MBl/MasP2 activity in 120 
clinically well documented survivors of invasive meningococcal disease. This group 
included 12 patients with a positive family history of meningococcal disease.
PaTienTs anD MeTHoDs
ethics
Patients and parents gave full informed consent prior to inclusion in the study. The 
study was approved by the local ethical committee. 
Patients 
The Radboud University nijmegen Medical centre is a tertiary care hospital. 
Between 1990 and 2006, 238 patients with suspected meningococcal disease 
(based on clinical symptoms, purpueric rash and fever) were admitted. Twenty-two 
(9.2 %) of them died. from 179 of the 216 survivors the current address was known. 
These patients and their parents were invited to participate in the study; 59 patients 
did not respond, declined to participate or it was not possible to include the case 
and minimally one parent. Thus, 120 survivors (65 males) participated in the study, 
with 109 fathers and 118 mothers. of 11 patients the father could not be included, 
and of 2 patients the mother. This yielded 107 complete trios. of 115 children, 102 
fathers and 113 mothers also MBl-plasma functional concentrations (MBl-P) and 
MBl/MasP2-activity (MBl-a) were measured. in addition to the patients, 6 affected 
sibs were also included. 
Patients were median 3.4 years old at time of presentation to the icU and 8.6 years 
years upon inclusion in the study. The fathers were aged 41.8 y (range 25.8 - 66.2) 
and the mothers were 39.6 y (range 24.2 - 69.0). Most individuals were caucasian, 
6 patients were of asian origin, 1 patient was of south-american/african origin.
Disease type 
Patient data were collected by retrospective chart analysis when admission 
was before 2002 (n = 102) and by prospective analysis after this date (n = 18). 
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Patients were divided in four groups based on clinical presentation: shock, shock + 
meningitis, bacteremia, or meningitis. shock was defined as sustained hypotension 
despite volume expansion requiring prolonged (> 12 hours) vasopressive support. 
Meningitis was diagnosed when there were > 105 leukocytes/l in csf or nuchal 
rigidity on clinical examination. Meningococcal bacteremia was diagnosed in 
patients having a typical presentation of meningococcal disease (sudden onset of 
fever and a purperic rash) in the absence of shock or meningitis. PRisM scores 
were calculated from data obtained during the first 24 hrs of icU admission 17,18. 
Data on sequelae were obtained from the charts and during the interview at study 
entry. Table 1 shows the characteristics of the patients.
MBl-plasma functional concentration, MBl/MasP2 activity and 
MBl genotype.
MBl-plasma functional concentration was assessed by enzyme-linked 
immunosorbent assay (elisa) using immobilized mannan (Saccharomyces 
cerevisiae (M-7504, sigma)) as ligand and murine monoclonal anti-MBl (HYB 131-
01, statens serum institut) as detection antibody 19. an eDTa-pool from human 
volunteer blood donors was used as a standard, this standard was calibrated on 
the MBl elisa kit (M1990, sanquin, The netherlands). 
MBl/MasP2-activity was assayed as described previously 20. This assay measures 
the complete lectin pathway activity from binding of MBl to activation of c4. in 
brief, 0.1 mg/ml mannan in coatingbuffer (0.05 M carbonate buffer pH=9.5) was 
shock
n = 46
shock + 
Meningitis
n = 12
Bacteraemia
n = 24
Meningitis
n = 38
sex M: 26 (57%)f: 20 (43%)
M: 6 (50%)
f: 6 (50%)
M: 13 (54%)
f: 11 (46%)
M: 20 (53%)
f: 18 (47%)
age (yrs) 2.4 (0.5 - 14.7)* 2.5 (0.1 - 14.0) 3.4 (0.3 - 13.5) 4.8 (0.2 - 22.3)
Proven 45 (98%) 12 (100%) 20 (83%) 32 (84%)
group B 30 (83%) 10 (83%) 12 (81%) 23 (88%)
group c 6 (17%) 2 (17%) 4 (25%) 3 (12%)
PRisM-score 16 (6 - 35)*,# 13 (6 - 26)*,# 5 (0 - 25)* 4 (0 - 14)
MaP (mmHg) 60 (35-90)*,# 60 (42 - 100) # 78 (53-141) 77 (57 - 112)
Days in icU 8 (1-30)*,# 7 (2 - 9)*,# 2 ( 1 - 9) 2 ( 1 - 4 )
sequelae 34 (74%)*,# 5 (42%) 5 (21%) 8 (21%)
Table 1.
Patient characteristics and clinical manifestation of meningococcal disease. 
Medians and ranges (between brackets) are presented or numbers and % (between brackets). PRisM = 
pediatric risk of mortality, MaP= mean arterial pressure, icU = intensive care unit. Proven indicates n. 
meningitidis cultured from blood, csf or skin-biopsy or gram-negative diplococci found in the gram-stain. 
Data on serogroup was available for 36 patients in the shock group, 12 patients in the shock and meningitis 
group, 16 patients in the bacteraemia group and 26 patients in the meningitis group. Differences were 
tested for significance using Mann-Whitney test or χ2-test when appropriate, and corrected for multiple 
testing using Bonferroni correction: P < 0.0083 was considered significant. * indicates significance for 
the comparison with the meningitis group,  # indicates significance for comparison with the bacteraemia 
group.
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incubated overnight at 4 ˚C. Plates were washed 3 times between each subsequent 
step. Blocking occurred with 1 % gelatine solution in TBs, where after eDTa plasma 
samples diluted in binding buffer (20 mM Tris, 1 M nacl, 10 mM cacl2, 0.05% 
Tween, 0.1% gelatine; pH 7.4) were incubated for 1 hour at room temperature (RT). 
Pooled eDTa-plasma from 50 healthy donors was used as standard and set to 
100 %, this plasmapool contains 775 aU/ml functional MBl. next, plates were 
incubated with 1 μg/ml C4 (A-402, Quidell) diluted in GVB-Ca-Mg (3.2 mM Veronal, 
1.8 mM na-Veronal, 146 mM nacl, 2 mM cacl2, 1 mM Mgcl2, 0.1% gelatine, 
pH=7.5 during 50 min at 37℃. Bound C4b  was detected by incubating with rabbit 
anti-human c4 (a0065, Dako) diluted 20.000x in TBs/Tween/ca for 45 min at RT 
and conjugation with alkaline phosphatase labelled goat-anti-rabbit immunoglobulin 
(D487, Dako), 1000x diluted in TBs/Tween/ca for 1 hours at RT. Plates were 
developed using 1 mg/ml p-nitrophenylphosphate (sigma) in diethanolamine buffer 
(1M diethanolamine, 0.5 mM Mgcl2, pH 9.8) for 15 minutes at 37℃, development 
was stopped using 2M naoH, extinction was measured at 405 nm.
MBl-genotyping was done with a line probe assay (inno-liPa MBl2), commercially 
available from innogenetics, gent, Belgium. This assay determines the three snPs 
in exon 1 (D,B and c) and the three common regulatory polymorphisms in the MBl2 
promoter and 5’ untranslated region (l, X and ,Q) of the MBl2-gene. 
statistical analysis
combination of the genotype of the father and mother of complete trios yielded 
the expected genotype frequencies for the offspring. for the individual snPs of 
the MBL2-gene standard transmission disequilibrium testing was performed. for 
calculation of the relative risk for contracting meningococcal disease due to the 
combined effects of exon 1 snPs, we used an extension of the log-linear model as 
developed by gjessing and lie and publicly available HaPlin software ((http://www.
uib.no/smis/gjessing/genetics/software/haplin/) 21. Missing parents were accounted 
for by an expectation - maximisation (eM) algorithm. The effect of heterozygousity 
or homozygousity for YB, Yc or YD was measured relative to the haplotypes Ya 
and Xa. chi-square and Mann-Whitney test were used when appropriate. 
ResUlTs
MBl-plasma functional concentration and MBl/MasP2-activity 
in relation to MBl-genotype. 
MBl functional plasma concentration (MBl-P) and MBl/MasP2-activity MBl/
MasP2-a in the 330 study participants were strongly correlated (spearman R = 
0.92. P < 0.0001). There were no samples with detectable MBl-P but defective 
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MBl/MasP2-a, which indicates that MasP2-deficiency in the absence of MBl-
deficiency did not occur in our study population (figure 1). age at study entry did 
not affect MBl-P or MBl-a levels (spearman correlation for MBl-P and age was R 
0.07, P = 0.48 and for MBl-a and age R 0.05, P = 0.61).   
in the total study population we identified 24 of the reported possible common 28 
genotypes. The genotypes lYQc/lYPa, lYQc/lYPB, lYQc/lYQc/ and lYQc/
HYPD were not found. However, two rare snP combinations were identified in a 
father and child with the genotypes HXPa/lYPD and HYPa/lYPD respectively.
genotypes without exon 1 snPs were the most frequent and had the highest MBl 
plasma concentrations (frequency 54 %, median 2.42 µg/l; range 8.6 - 0.31 µg/l). 
Decreased MBl concentrations occurred in homozygotes for the promoter region 
X polymorphism (frequency 5 %, median 0.86 µg/l; range 2.43 - 0.12 µg/l) and in 
heterozygotes for exon 1 snPs (frequency 42 %, median 0.46 µg/l; range 0.04 - 
2.68 µg/l). interestingly, a D exon 1 snP gave higher MBl plasma concentrations 
than a B or c exon 1 snP. an X-polymorphism on one allele and an exon 1 snP 
on the other allele gave very low MBl-plasma concentrations. Undetectable MBl 
levels were seen in individuals homozygous or compound heterozygous for exon 1 
snPs (frequency 4 %)(figure 2).
MBl genotype in all patients 
Table 2 shows the allele frequencies and the results of the transmission 
disequilibrium test for the 6 different MBL2 polymorphisms in complete trios 
(case, mother and father; n = 107). no significant transmission disequilibrium was 
observed for any of the individual alleles. Transmission disequilibrium at the H/l 
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Figure 1. 
correlation of MBl-plasma functional 
concentration (MBl-P) and MBl/
MasP2 activity (MBl-a)
245
promotor polymorphism approached significance, favouring transmission of the H 
allele. However, the MBl-plasma concentration is mainly determined by exon 1 
polymorphisms either in homozygous or heterozygous form. Using the log-linear 
model (HaPlin analysis) on all 120 patients, with missing parents accounted for by 
the eM algorithm, we tested whether the exon 1 polymorphisms were associated 
with an increased relative risk (RR) for meningococcal disease. We found a small 
increase in RR that was not significant (Table 3). Taken together these calculations 
snP frequency Transmitted (n) Untransmitted (n) P
D 9 % 22 13 0.13
B 11 % 20 26 0.38
c 2 % 5 3 0.48
l 60 % 43 63 0.05
X 22 % 35 43 0.37
Q 20 % 32 42 0.25
Table 2. 
Transmission-disequilibrium test results in the complete trios (n = 107) for the 3 common 
snPs in exon 1 and the 3 regulatory polymorphisms in the promoter regions of the MBl2-
gene.
snP = single nucleotide polymorphism
Figure 2. 
MBl plasma functional concentration (MBl-P) in relation to genotype. Data from all participants are shown 
(n = 330). Bars indicate medians. 
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indicate that in our study population polymorphism in the MBL2 gene did not 
increase susceptibility to meningococcal disease.
MBl in relation to clinical presentation of meningococcal 
disease
MBl-P was significantly lower in meningitis patients than in patients with another 
clinical manifestation (figure 3). accordingly, for meningitis we found more often 
(53%) one or two exon 1 snPs than patients in the other groups, although this was 
not significant (39%; P = 0.13 χ2 test). 
in meningitis patients, the observed frequency of exon 1 snPs was higher than 
expected from the genotype of their parents (53 % observed vs. 43 % expected); 
this was not the case for patients with septic shock (36% observed vs. 34% 
expected) or bacteraemia (29% observed vs. 38% expected). Using the log-linear 
model, we found that for this subgroup, the presence of 1 or 2 exon 1 snPs was 
associated with an increased relative risk for disease (Table 3). This was significant 
in the case of heterozygousity for an exon 1 snP. for homozygous exon 1 snPs 
this was not significant, possibly due to the low number of patients. in the patients 
that had presented with septic shock or meningococcal bacteraemia, the presence 
heterozygous P homozygous P
all patients (n = 120) 1.66 (.91-3.0) 0.10 1.78 (.58-5.3) 0.31
shock n = (46) 1.13 (.43-3.0) 0.82 1.8 (.33-9.9) 0.51
bacteraemia n = (24) 1.07 (.29-4.3) 0.92 0.72 (.55-9.4) 0.80
meningitis n = (38) 3.9 (1.2-13) 0.03 3.77 (.49-29) 0.2
Table 3.
Relative risk for meningococcal disease associated with an exon 1 snP 
Relative risk for disease of haplotypes (+ 95% ci) associated with the D, B and c snPs (YD, YB and 
Yc, respectively) in exon 1 of the MBl2 gene, for all patients combined and for the patient groups 
shock, bacteraemia and meningitis. a reciprocal reference was used, in this case the combination of the 
haplotypes Ya and Xa. The patients that had presented with meningococcal septic shock in combination 
with meningitis could not be included in this analysis because of a too small number. 
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Figure 3. 
MBl plasma functional concentration (MBl-P) 
in relation to disease type. 
s indicates the patients that presented with 
shock, s+M the patients that presented with 
shock in combination with meningitis, B 
indicates patients with bacteraemia and M 
indicates patients with meningitis. P = .13, .19 
and .04 for the comparison of s, s+M and B 
with meningitis, respectively and P = .04 for 
the comparison of s, s+M and B combined 
with meningitis. 
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of an exon 1 polymorphism was not associated with an increased risk for disease. 
This indicates that MBl-deficiency may predispose for meningococcal meningitis, 
but not for other clinical manifestations of meningococcal disease. 
frequency of exon 1 polymorphism in patients with group B meningococci was 
similar to that in patients with group c disease. Patients with group B disease had 
a similar non-significant relative risk for meningococcal disease as the complete 
group of patients (RR for heterozygousity 2.08 (95% ci 0.96-4.54) and RR for 
homozygousity 3.12, 95% ci 0.75-12.8). additionally, the MBl genotype did not 
affect disease susceptibility in patients between 0.5 and 3.0 years (n = 48, RR for 
heterozygousity 1.18 95% ci 0.45-3.07 and RR for homozygousity 1.28, 95% ci 
0.25-6.33). 
MBl genotype in families with meningococcal disease
Twelve families (10%), had a history of an additional first, second or third degree 
relative with meningococcal disease. in 8 families, at least one first degree relative 
had been affected; in 6 families this was a brother or sister, in 1 family this was 
the mother, and in one family both a sister and mother. of these, 3 cases were 
co-primary or secondary. one family had a history of meningococcal disease in a 
second degree relative, 3 families had a history in a third degree relative. frequency 
of exon 1 snPs in patients with a positive family history was similar (heterozygousy 
33 %, homozygousy 0%) to that seen in patients without a positive family history. 
MBl functional plasma concentration in patients with a positive family history was 
median 2.3 µg/l (range 0.15 - 4.50 µg/l). from 8 affected first degree relatives (6 
sibs, 2 mothers) material was also available for genotyping, here frequencies of 
exon 1 snPs were 37.5 % heterozygous and 0 % homozygous. 
DiscUssion
in the present study we found that polymorphisms in the gene for MBl do not 
predispose for severe meningococcal disease necessitating icU-treatment. 
However, snPs in exon 1 may be a risk factor for meningococcal meningitis. MBl-
deficiency is unlikely to be an important cause of familial meningococcal disease. 
MasP2 deficiency is not a frequent cause of meningococcal disease.
in recent years, it has been questioned whether MBl-deficiency should be seen 
as a factor of importance in susceptibility to infectious disease or that it should be 
considered as a redundant molecule with little impact on susceptibility 22,23. evidence 
for the latter notion stems from contradictory results in case-control studies 13-
15,24,25, a large prospective trial in adults that failed to show an association of MBl 
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deficiency with infectious disease 12 and the high worldwide prevalence of multiple 
MBL2 deficiency or low-producing alleles 26. However, this does not exclude an 
effect of MBl-deficiency on specific infectious diseases or in particular patient or age 
groups 27-31. our study does not support a role for MBl-deficiency in susceptibility 
for disease in a group of children with meningococcal infection admitted to a tertiary 
care icU. of the individual snPs, only the regulatory polymorphism H showed a 
(non-significant) trend for preferential transmission to the patients. However, the 
H variant is not linked to MBl-deficiency, in contrast it is associated with higher 
plasma concentrations of MBl (median 1.97, range 0.04-5.99 for HH genotype, 
median 1.53 range 0.04-8.6 for H/l genotype and median 0.95 range 0.04-5.05 
for ll genotype). in addition, we found no evidence that exon 1 polymorphisms, 
that lead to with deficiency of MBl from the plasma, are associated with increased 
susceptibility to meningococcal infection. our findings correspond to the findings 
in two case-control studies concerning meningococcal disease 14,15 and is further 
supported by the observation that the frequency of exon 1 snPs in our patient 
group (36% heterozygous and 5% homozygous) was equal to that in an unselected 
population of 9425 adult Danish patients (37% heterozygous and 5% homozygous) 
12. our study contrasts with the study of Hibberd et al., who studied the role of 
exon 1 polymorphisms in meningococcal disease in a group of patients similar in 
age and race. of interest, frequency of the exon 1 polymorphisms in our patient 
group was significantly different from the control group in the study of Hibberd (22.1 
% heterozygotes, P = 0.002 and 1.5 % homozygotes, P = 0.04; χ2-test) 13. This 
indicates that, had we used the same control group, we would have confirmed the 
results in the Hibberd study. However, the control group in the Hibberd study may 
have been subject to selection bias as only patients without infectious disease were 
chosen 13. The design of our study precludes this kind of selection, giving stronger 
support to our conclusions.
We classified our patients in four clinically relevant groups, based on the presence 
or absence of shock or meningitis, and confirmed that this classification reliably 
distinguishes patients with severe disease from those with mild disease 32. in a 
subgroup analysis, we found that exon 1 snPs were associated with a significantly 
increased relative risk for meningitis. in these patients, also a lower median plasma 
concentration of MBl in comparison with the other groups was found, which 
supports this observation and indicates that the presence of these exon 1 snPs 
directly affected MBl plasma concentration. Reportedly, terminal complement 
pathway deficiencies predispose to less severe manifestations of meningococcal 
disease 11. it is tempting to speculate that MBl-deficiency, similar to these terminal 
complement deficiencies, predisposes to less severe disease. of note, this finding 
was done in a subgroup (n = 38) and should be confirmed in a larger cohort of 
249
patients with only meningococcal meningitis. 
MBl might be especially important in young children where it functions as an ante-
antibody 29,33. Therefore, we analysed whether exon 1 snPs were associated with 
susceptibility for disease in patients between 0.5 and 3 years old, but we found no 
increase in risk. 
The group of patients included in this study is clinically highly relevant, as icU 
patients have more severe disease and higher mortality rates than patients 
not necessitating icU treatment, and comprises the complete spectrum of 
meningococcal disease 1. However, it is skewed on two sides. Patients with mild 
disease not necessitating icU treatment and - for obvious reasons - patients with a 
fatal course were not included. Because exon 1 polymorphisms did not predispose 
to disease in the most severely ill patients (the shock patients) it is unlikely that 
inclusion of fatalities and their parents would have changed the results. as we found 
that exon 1 snPs increased susceptibility to meningococcal meningitis, inclusion 
of non-icU patients with meningitis might have strengthened our results for this 
group.
We confirmed earlier observations that MBl-plasma concentration is mostly 
determined by exon 1 snPs, and that there is a moderate effect of the ‘X’ snP in 
the promoter region 34. MBl/MasP2-activity (the ability of MBl to bind mannan and 
activate c4 via MasP2) was completely dependent on MBl-plasma concentration. 
The observation that there were no discrepancies between plasma concentration 
and activity suggests that there were no MasP-2 deficient patients in our population 
35. This indicates that MasP-2 deficiency is not a frequent cause of meningococcal 
disease. 
Previous reports have implicated MBl as a predisposing factor for familial 
meningococcal disease 36,37. We found a high number of patients (10 %) with 
a positive family history, from which 66 % had a first degree relative with 
meningococcal infection. frequency of exon 1 snPs in these patients with familial 
meningococcal disease was equal to that in the other patients, no patients were 
homozygous. This indicates that MBl-deficiency is not a major cause of familial 
meningococcal disease in patients admitted to an icU. However, the high number 
of patients with a positive family history suggests that there are other, not yet 
defined, genetic factors that predispose to meningococcal infection, in addition to 
environmental and exposure factors.  
in conclusion, mutations in the gene for MBl do not predispose for severe 
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meningococcal disease necessitating icU-treatment. exon 1 polymorphism in our 
study predisposed to development of meningococcal meningitis, it is conceivable 
that MBl-deficiency is a susceptibility factor for mild meningococcal disease in 
children.
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innate cytokine production capacity and clinical manifestation 
of meningococcal disease 17
aBsTRacT
We analyzed the role of the innate production capacity for tumor necrosis factor 
(Tnf), interleukin 1β (il-1β), il-12 and il-10 in the clinical presentation and severity 
of meningococcal disease. 
Whole blood cultures from survivors of severe meningococcal disease obtained 
median 5.4 years after hospitalization were stimulated with meningococcal 
lipopolysaccharide and heat-killed Neisseria meningitidis bacteria. 
113 survivors of meningococcal disease were included. We classified these patients 
according to clinical manifestation in four groups: shock (n = 43), both shock and 
meningitis (n = 11), bacteraemia (neither shock nor meningitis, n = 24) and distinct 
meningitis (n = 35). 
The classification into four groups stratifies these patients according to disease 
severity. no differences in whole blood cytokine production were found between 
the patients in these four groups. However, within the group of patients that had 
presented with shock, interleukin 1β and the interleukin 1β / interleukin 10 ratio 
were negatively correlated with disease severity (R = -0.35, P = 0.03 and R = -0.33, 
P = 0.04, respectively, PRisM score).
clinical manifestation of meningococcal disease cannot be explained by the innate 
production capacity of whole blood cultures for the cytokines Tnf, il-1β, il-10 and 
il-12. in patients that presented with shock, a low production capacity for interleukin 
1β and a low interleukin il-1β / interleukin 10 production ratio was associated with 
more severe disease. 
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17
inTRoDUcTion
invasive meningococcal disease occurs when, after penetration of the 
nasopharyngeal mucosa, a pathogenic strain of Neisseria meningitidis invades 
the bloodstream. as published over 20 years ago 1, invasive disease can present 
with distinct clinical manifestations defined by the presence or absence of shock 
or meningitis. This classification is pathophysiologically based on the rapidity 
of, and the compartment in which, meningococcal proliferation occurs. During 
meningococcal septic shock, meningococci multiplicate seemingly unimpeded in 
the bloodstream. as a consequence, a systemic inflammatory response (siRs) is 
provoked by massive and systemic activation of a range of inflammatory systems. 
among these the cytokine network is of particular interest. When outgrowth in the 
bloodstream is restricted, meningococci seeded into the subarachnoideal space 
can proliferate within that compartment. in this case, meningococcal meningitis 
with a localized inflammatory response develops 2.
Various components of the innate immune response are assumed to play a role 
in the control of outgrowth of meningococci in the bloodstream. one of these is 
the capacity to mount a cytokine profile that brings an adequate cellular defence 
mechanism into action. cytokines influence meningococcal disease in a complex 
fashion during the early stage of infection, throughout clinically overt disease as 
well as during repair and recovery. early studies found evidence that high levels 
of the pro-inflammatory cytokines tumor necrosis factor-α (TNF) and interleukin-
1β (IL-1β) elicited shock and disseminated intravascular coagulation (DIC) 3-5, but 
these cytokines were difficult to measure because of their short half-life. later 
studies showed that other cytokines like il-6, il-12 and particularly il-10, an anti-
inflammatory cytokine responsible for the inactivation of monocytes 6, were more 
accurately measured and reflected the severity of disease better 7-9. nowadays, 
the concept is that the balance between anti- and pro-inflammatory cytokines is a 
reliable marker for outcome 10,11.
Due to various polymorphisms in the genes for cytokines, their receptors, the 
intracellular pathways leading to cytokine production and post-transcriptional 
events, there are significant inter-individual differences in the amounts of 
cytokines produced after a certain stimulus. for meningococcal disease, various 
polymorphisms in the genes for cytokines or their receptors have been associated 
with altered risk for disease or disease severity and outcome 12. We hypothesised 
that upon contact with meningococci, the innate capacity to produce high amounts 
of pro-inflammatory cytokines or low amounts of anti-inflammatory cytokines, 
protects against the rapid outgrowth of bacteria in the bloodstream and determines 
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the clinical manifestation and severity of disease that develops.
To test this hypothesis we measured the in-vitro production of TNF, IL-1β, IL-12 and 
il-10 in whole blood cultures stimulated with purified meningococcal lPs and with 
heat-killed (HK) meningococci in 113 survivors of meningococcal disease. 
PaTienTs anD MeTHoDs
ethics
studies were done after approval of the local ethical committee and informed 
consent was obtained from and for all patients and parents.
Patients
Between 1990 and 2005, 236 patients aged between 0.1 and 22.7 years with 
meningococcal disease were admitted to the icU of the Radboud University 
nijmegen Medical centre, either transferred from other hospitals or as a primary 
admission. Diagnosis of meningococcal disease was made on typical presentation. 
infection with N. meningitidis was considered proven when there was a positive 
culture of blood, skin biopsy or csf or when gram-negative diplococci were seen 
in gram-stained biopsies or csf.
of the 236 patients, 22 (9.3 %) died. from 37 survivors the address could not be 
retrieved. The remaining 177 patients (or their parents) were invited to participate 
in the study; 62 of them did not respond or declined to participate, in two patients 
the whole blood stimulation was unsuccessful. Thus, 113 patients (63 males, 50 
females) took part in the study. The median age of the patients at admission to the 
icU was 3.4 years (range 0.1 – 22.7 years). The delay between admission and 
participation was median 5.4 years (range 0.4 – 14.3 years). The median age at 
inclusion in the study was 8.9 years (range 1.3 - 36.4 years). 
Patient data were collected by retrospective chart analysis when admission was 
before 2002 (n = 102) and by prospective analysis after this date (n = 11). Patients 
were divided in four groups based on clinical manifestation (shock, shock plus 
meningitis, bacteremia, or meningitis). shock was defined as systolic arterial 
pressure below the fifth percentile for age despite adequate volume expansion 
requiring prolonged (>12 hours) vasopressive (i.e. (nor)epinephrine or dopamine) 
support 13. Meningitis was diagnosed when there were > 105 leukocytes/l in csf 
or when there were clinical signs of meningitis. Meningococcal bacteremia was 
diagnosed in patients having a typical presentation of meningococcal disease 
(sudden onset of fever and a purperic rash) in the absence of shock or meningitis. 
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PRisM scores were calculated from data during the first 24 hrs of icU admission 
14,15. Data on sequelae were also obtained. 
Whole blood cultures 
sterile, endotoxin-free heparinized blood from all 113 patients was diluted 1:1 in 
RPMi 1640 and incubated in polypropylene cryotubes (nalgene nUnc, Roskilde, 
Denmark) with RPMi (blank), with 1x107/ml heat-killed (HK) serogroup B N. 
meningitidis H44/76 and with 10 ng/ml purified lPs (matching the amount of lPs 
present on HK bacteria) isolated by phenol extraction from this strain 16. Meningococci 
and meningococcal lPs were a kind gift of Dr. P. van der ley, at the netherlands 
Vaccine institute. samples were incubated for 20 hrs at 37 °c, centrifuged at 3500 
RPM whereafter the plasma was collected and stored for analysis at –80 °c. in the 
control (unstimulated) samples median cytokine concentrations were equal to the 
lower detection limit of the multiplex cytokine assay. 
cytokine analysis
Tnf, il-1β, il-10 and il-12 were measured using commercially available Bio-Plex 
protein array system (Bio-Rad laboratories, inc.) 17. lower limits of detection were 
8 pg/ml for Tnf, il-1β, il-12 and il-10.
statistical analysis 
Tests were performed using graph Pad Prism 4 software. χ2 and Mann-Whitney 
test for non-parametrical data were used to compare the different patient groups. 
spearman correlation was used to calculate correlation coefficients and R-square 
values. Bonferroni correction for multiple testing was used for the analyses in Table 
1; P < 0.083 was considered significant.
ResUlTs
Patient characteristics
The clinical characteristics of the patients according to their clinical manifestation 
are shown in table 1. Patients with meningococcal septic shock (s) were most 
severely ill, as evidenced by the lowest blood pressure, the highest lactate 
concentrations, the most severe Dic with lowest platelet numbers and lowest 
fibrinogen concentrations, the highest PRisM-score, the longest stay in the icU 
and the highest number of sequelae. of note, patients with shock also had the 
lowest cRP concentrations at admission and the shortest time from onset of 
symptoms to admission. The latter two parameters indicate a very rapid course and 
fulminant disease. Patients with shock plus meningitis (s+M) had a lower disease 
severity and less fulminant disease than the patients with shock alone. Disease 
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severity in this group was higher than in the patients with bacteraemia (B), but the 
time from first symptom to presentation was similar. Patients with meningococcal 
meningitis (M) had the lowest disease severity and the longest duration between 
onset of symptoms to admission, reflecting less fulminant disease (Table 1, figure 
1). These data indicate that the simple classification of patients in these four 
groups is clinically relevant and reflects severity and fulminancy of the disease. no 
differences were found in any of the clinical characteristics between the male and 
female patients (not shown). 
cytokine production in whole blood cultures
in unstimulated whole blood cultures no or only limited cytokine production 
occurred. after stimulation with purified meningococcal lPs, substantial amounts 
of Tnf, il-1β, il-12 and il-10 were produced. as expected 18, HK N. meningitidis 
was a more potent inducer of cytokines (Table 2). The production of TNF, IL-1β, 
il-12 and il-10 after stimulation with meningococcal lPs was highly correlated to 
cytokine production by HK N. meningitidis (spearman R respectively 0.84, 0.76, 
0.81 and 0.74; all P < 0.0001). There was no relation between age at inclusion 
shock shock and 
meningitis
bacteraemia meningitis
n 43 11 24 35
m / f (n) 26/17 5/6 13/11 18/17
age admission (y) 2.4 (0.5-15)* 2.5 (0.1-14) 3.4 (0.3-8)* 5.1 (0.4-22)
age inclusion (y) 8.4 (1.4-29) * 9.2 (4.5-22) 7.4 (2.1-14) * 12.4 (2.5-36)
T1 (h) 12 (3.5-20)* 14 (6-24)* 14 (2.8-48)* 23 (10-72)
T2 (h) 16 (6-38)* 18 (11-27)* 18 (3-51)* 25 (12-44)
Proven N. men (%) 95 % 100 % 83 % 86 %
group B (%) 82 % 81 % 81 % 88 %
PRisM 16 (6-34)#,* 12 (6-26)#,* 6 (0-25)* 3 (0-14)
MaP (mmHg) 60 (35-89)#,* 59 (42-100)* 75 (53-141) 78 (57-112) )
CRP (mg/l) 61 (9-154)µµ 78 (34-150) 87 (2-174) 147 (37-237)
lactate (mmol/l) 4.1 (1.5-10.8)#,* 2.3 (1.2-6.9) 2.0 (1.0-5.3) 2.8 (0.9-4.8)
fibrinogen (g/l) 1.6 (0.1-3.8)#,* 2.1 (0.8-4.6)* 2.9 (0.8-6.3) 4.1 (2.2-6.8)
Platelets (109/l) 70 (10-276)&,#,*, 159 (39-284)& 159 (24-291) 188 (69-432)
Days in icU 7 (1-30)#,* 6 (2-9)#,* 2 (1-9) 1 (1-4)
sequelae (%) 77 % (40 %)#,* 36 % (0 %) 33 % (0 %) 20 % (0 %)
Patients were dived into four groups, based on clinical presentation. Presented are medians and ranges, 
unless otherwise indicated). group B indicates percentage of serogroup group B N. meningitidis, rest was 
group c, no other serogroups isolated. sequelae indicate all sequelae reported by patients or parents; 
severe sequelae, defined as severe scars, amputations, paralysis or prolonged hypocortisism is shown 
between brackets. m = males, f = females, T1 = time from first symptom to admission to the initial hospital, 
T2 = time from first symptom to admission at the icU of the Radboud University nijmegen Medical centre, 
N. men = Neisseria meningitidis, PRisM = pediatric risk of mortality, MaP = mean arterial pressure, cRP 
= C-reactive protein. Differences were tested for significance using Mann-Whitney test or χ2-test when 
appropriate, and corrected for multiple testing using Bonferroni correction: P < 0.0083 was considered 
significant. * indicates significance for the comparison with the meningitis group, # indicates significance 
for comparison with the bacteraemia group, & indicates significance for the comparison with the shock and 
meningitis group 
Table 1. Patient data according to presentation
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and the amounts of Tnf, il-1β and il-12 produced; there was a weak negative 
correlation between il-10 and age at inclusion (spearman R = -0.21, P = .03). 
induction of il-1β production after stimulation with lPs in female patients was 73 % 
lower than male patients (P = 0.02), no significant differences were seen between 
males and females for the other cytokines or for HK N. meningitidis. 
The production of Tnf, il-1β and il-12 after stimulation with lPs and HK 
meningococci was strongly correlated. in contrast, il-10 production correlated 
only weakly with the production of these cytokines (Table 3), suggesting a different 
regulation mechanism for the production of il-10 as compared to that for Tnf, il-
1β or il-12.
no significant differences in whole blood cytokine production, stimulated either with 
meningococcal lPs (figure 2) or with HK N. meningitidis (data not shown), were 
found between patients stratified according to their clinical manifestation. There 
was also no difference for the Tnf/il-10 ratio and the il-1β/il-10 ratio.
similarly, no significant significant correlation existed between the production of 
Presented are medians and ranges, differences between lPs and N. meningitidis were all significant (P < 
.001, by Mann-Whitney test).
Tnf (pg/ml) IL-1β (pg/mL) il-12 (pg/ml) il-10 (pg/ml)
Meningococcal lPs 3660 
(237-15473)
8075 
(940-30147)
27 
(8-257)
1063 
(118-3225)
HK n. meningitidis 7259 
(990-23665)
19624 
(3478-90653)
44 
(12-323)
1566 
(297-10326)
Table 2. 
cytokine production by whole blood cultures stimulated for 20 hrs with  purified meningococcal 
lPs or HK Neisseria meningitidis 
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the measured cytokines or the ratio of Tnf-to-il-10 or il-1β-to-il-10, and disease 
severity as expressed by the PRisM-score for all patients combined. However, 
for the group of patients with shock, the severity of disease correlated negatively 
and significantly with the IL-1β production (R = -0.35, P = 0.03, R = -0.21, P = 
0.17, for stimulation with lPs and HK N. meningitidis, respectively). in this group 
no correlation was found between PRisM and il-10 (R = -0.02 P = 0.89 and R = 
0.23, P = 0.14 for lPs and HK N. meningitidis, respectively). However, there was 
a significant negative correlation between disease severity and the ratio of il-1β/
il-10 production (R = -0.33, P = 0.04 and R = -0.36, P = 0.02 for lPs and HK N. 
meningitidis respectively). The Tnf- and il-12 production, and the Tnf/il10 ratio 
were not correlated with disease severity.
Tnf (pg/ml) il-1β (pg/ml) il-12 (pg/ml)
il-1β R = 0.59 (P < .0001)
R2 = 0.35
il-12 0.60 (P < .0001)
R2 = 0.36
0.48 (P < .0001)
R2 = 0.23
il-10 0.27 (P = .006)
R2 = 0.07
0.26 (P = .008)
R2 = 0.07
0.25 (P = .009)
R2 = 0.06
Table 3.
Spearman correlation coefficient for production of TNF, IL-1β, IL-12 and IL-10 by whole blood 
cultures stimulated for 20 hrs with meningococcal lPs
Figure 2
cytokine production after stimulation with meningococcal lPs by whole blood cultures of survivors of 
meningococcal disease according to patient groups shock (s), shock and meningitis (s+M), bacteraemia 
(B) and meningitis. Bars indicate medians. Differences between groups were tested using Mann-Whitney 
test, no significant differences for any of the cytokines were found. 
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The il-1β production and the il-1β-to-il-10 ratio in shock patients showed also a 
significant correlation with other parameters of disease severity, like platelet count 
and serum lactate concentration (figure 3). no significant correlation was found 
with admission values of blood pressure, fibrinogen or the number of days spent in 
icU.
DiscUssion
in the present study we made two major observations. first, in contrast to our 
hypothesis, we found that the clinical manifestation of meningococcal disease 
cannot be explained by the innate production capacity of the cytokines Tnf, il-
1β, il-10 and il-12 in whole blood cultures. second, in patients that presented 
with shock, a low production capacity for il-1β and a low ratio of il-1β-to-il-10 
production was associated with more severe disease.
in 1983, Bøvre and Høiby introduced a simple system that classified patients based 
on the absence or presence of shock and meningitis 1. We confirmed that this 
classification reliably distinguishes patients with a rapid evolution of disease due to 
the rapid outgrowth of meningococci in the bloodstream, from those who had a less 
fast evolution thanks to a better control 19-21. This makes this classification ideally 
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Figure 3
correlation of il-1β and the IL-1β/IL-10 ratio with PRISM, platelet count (x109/l) and lactate (mmol/l) 
concentrations, after stimulation of whole blood cultures with meningococcal lPs. R indicates spearman 
correlation coefficient. for visual purposes, one outlier was removed from the graphs showing the il-1β/il-
10 ratio, this outlier was not excluded from the correlation analysis. PRisM = Pediatric risk of mortality.
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fitted for the study of factors that determine early outgrowth of meningococci.
our study population is clinically highly relevant and reflects the complete spectrum 
of invasive meningococcal disease. However, it is skewed on two sides. on one side, 
patients with meningitis or bacteremia and a mild course are not included because 
these patients are not referred to an icU. on the other side, we miss - for obvious 
reasons - the most severely ill shock patients, i.e. those who died. nonetheless, 
we excellently characterized the patients with regard to clinical manifestation and 
severity of disease and therefore believe that the conclusions drawn are solid. The 
age of the patients, at the time the stimulation tests were performed, was median 
5.4 years older than the age at disease onset. This gap however, probably did not 
affect the results because age had only a minor effect on cytokine production. 
in order to mimic the in vivo situation as closely as possible we used for the in vitro 
whole blood stimulation experiments, HK N. meningitidis and purified meningococcal 
lPs  concentrations comparable to those encountered in vivo during disease 19-21. in 
addition, we chose to incubate for 20 hrs to allow measurement of TNF, IL-1β, IL-12 
and il-10 in the same culture. We confirmed that HK N. meningitidis is more potent 
stimulus than purified meningococcal lPs 18. in addition, we found that cytokine 
production after stimulation with HK N. meningitidis and lPs are strongly correlated, 
suggesting that lPs is the dominant cytokine-inducing moiety of meningococci 18,22. 
furthermore, we found a positive correlation between the amount of Tnf, il-1β and 
il-12 produced, suggesting that production of these cytokines shares at least some 
regulatory pathways. in contrast, il-10 did not follow this pattern, indicating that il-
10 production is regulated by different mechanisms 23.
our results differ from those of Westendorp et al. who studied Tnf and il-10 
production in relatives of 61 patients with meningococcal disease and found low 
Tnf and high il-10 production correlating with severe disease 24. Westendorp 
however, used lPs derived from E.coli in concentrations (1000 ng/ml) far exceeding 
those encountered in genuine disease. in contrast, we studied patients and used 
HK meningococci and meningococcal lPs in clinically relevant concentrations 22. 
We believe that these modifications and the larger number of patients (n = 113) 
evaluated, give stronger support to our conclusions.
our in vitro whole blood culture system has two limitations. first, it does not contain 
cells not present in blood (such as endothelial cells, and Kupfer cells in the liver) that 
in vivo may have been responsible for cytokine production 25,26. second, information 
about the early kinetics of cytokine production is missed as only  the amount (and 
ratio) of cytokines accumulated in the culture after 20 hrs is measured. However, 
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we speculate that other non-cytokine components of the innate immune system, 
either alone or in synergy with bacterial factors, may be more relevant for the 
early outgrowth of meningococci and hence the type of disease that develops. of 
interest, whole blood killing of meningococci is critically dependent on a functional 
complement system 27,28. 
once meningococcal septic shock has been established, multiple factors including 
the delay to effective treatment 29-31, bacterial properties 32 and host polymorphisms 
12 influence disease severity. We show in the present study, that a low production 
capacity for il-1β and a low ratio of il-1β-to-il-10 production is associated with 
more severe disease. This finding is supported by the studies of Read et al. 32,33 
who found that variations in the promotor gene for il-1β, causing less production, 
are associated with increased mortality. Moreover, a genetically high production 
capacity for il-1 receptor antagonist (il-1Ra), the major inhibitor of il-1β action, 
has also been shown to predispose to more severe disease 32,34,35. Taken together, 
these findings are consistent with a crucial and protective role for il-1β in the 
progression of meningococcal septic shock. 
When produced in excessive amounts, il-1β is believed to be deleterious 5,36. 
This seems to contrast with our finding of a harmful effect of less il-β production 
and a lower ratio of il-1β-to-il-10 production as assessed in-vitro. This paradox 
has puzzled various authors before 24,32,37,38. one of the explanations is that the 
ineffective early immune response results in higher bacterial outgrowth and 
hence more severe disease. However, our finding that outgrowth of meningococci 
(as defined by type of presentation) is not influenced by the capacity to mount a 
certain pro- or anti-inflammatory cytokine response, refutes this opinion. Rather, 
our findings underscore the importance of a balanced pro- and anti-inflammatory 
reaction not only during the very early stage after bacterial invasion, but also during 
the subsequent progression of disease 10,11,39. When at any moment during the 
course of the disease this balance is lost, the inflammatory response runs out of 
bounds and high plasma concentrations of cytokines accompany severe disease 
irrespective of the innate production capacity for these cytokines.
in sum, our study indicates that the clinical manifestation of meningococcal disease 
is not determined by the innate production capacity for the cytokines Tnf, il-1β, 
il-10 and il-12 as measured in whole blood cultures. However, disease severity 
in patients with meningococcal septic shock is positively influenced by the capacity 
to mount an adequate il-1β response. This latter finding may possibly explain the 
failure of adjunctive therapies in sepsis aimed at inhibiting IL-1β 40,41. 
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summary and general Discussion 18
The dreadful consequences of meningococccal septic shock are due to the 
breakdown of homeostasis by a massive inflammatory response with the cytokine 
network and the complement system as key players. Understanding what happens 
and how this happens is a prerequisite to find treatments that are able to modulate 
this response in a way that preserves the beneficial bactericidal effects of the 
inflammatory response while attenuating the detrimental systemic effects.
in textbooks on infectious diseases and host defence, it is generally accepted 
that the inflammatory events during meningococcal and other gram-negative 
septic shock are primarily elicited by the lipopolysaccharide (lPs) component of 
the bacterial outer membrane. in chapters 2 - 4, we used a genetically modified 
meningococcus (H44/76lpxA or H44/76[plaK33]) that is deficient for lPs to study 
the relative importance of lPs versus non lPs components of meningococci in the 
induction of cytokines and the activation of complement. 
in chapter 2 we demonstrated that non-lPs components of meningococci are 
responsible for a substantial part of tumor necrosis factor (Tnf)-α and interleukin 
(il)-1β production and virtually all interferon (ifn)-γ production in human peripheral 
blood mononuclear cells. in addition, experiments with mice showed that lPs-
deficient meningococci were able to induce cytokine production and death, albeit 
that approximately 100-fold more lPs-deficient meningococci were needed to 
cause mortality in mice than 'wild-type' lPs containing meningococci (Neisseria 
meningitidis H44/76). We conclude that N. meningitidis can induce cytokines and 
disease independent of lPs. 
cD14 and TlR4 are reported to be the principle cellular receptors for lPs, 
therefore, in chapter 3, we investigated the role of the cD14-TlR4 receptor 
complex for cytokine induction by meningococcal lPs and non-lPs components 
of meningococci. WT14, a monoclonal antibody against cD14, abolished Tnfα and 
il-1β induction by Escherichia coli lPs in human mononuclear cells, while cytokine 
induction by meningococcal lPs or lPs-containing N. meningitidis H44/76 and 
lPs-deficient H44/76lpxA meningococci was only partly inhibited by anti-cD14. 
experiments with macrophages isolated from TlR4-deficient mice, revealed that 
TlR4 is crucial for cytokine production by meningococcal lPs, but lPs-containing 
or lPs-deficient meningococci were able to induce a significant cytokine response 
in TlR4-deficient macrophages, similar to that of TlR4-containing murine 
macrophages. Thus, N. meningitidis induced cytokines in human PBMcs or murine 
peritoneal macrophages by pathways independent from the lPs receptors cD14 
and TlR4. 
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in chapter 4, we investigated the involvement of lPs and non-lPs components of 
meningococci in complement activation and complement-dependent inflammatory 
effects in a human whole blood model of meningococcal sepsis. The lPs containing 
H44/76 and lPs deficient H44/76lpxA N. meningitidis strains both activated 
complement effectively and to a similar extent. in contrast, purified  meningococcal 
lPs, used at a concentration matched to the amount present in whole bacteria, did 
not induce any complement activation. Both complement receptor-3 up-regulation 
and oxidative burst in neutrophils and monocytes were induced by N. meningitidis 
independent of lPs. Thus, in the whole blood model of meningococcal sepsis, 
complement activation and the immediate complement-dependent inflammatory 
effects of cR3 up-regulation and oxidative burst induced by meningococci occurred 
independent of lPs.
The conclusions from chapters 2 - 4 imply that therapeutic strategies designed to 
block only the effects of lPs or the lPs-receptors cD14 and TlR4 will have a 
partial effect on the induction of cytokines, and will not stop complement activation 
at all. Therefore, it is doubtful that such therapies will modify the course of disease. 
our findings may thus explain the failure of earlier anti-endotoxin therapies to 
influence morbidity or mortality in a positive way. 
in chapter 5 we investigated whether lipoproteins - compounds which had recently 
gained much attention as a promising treatment option for gram-negative sepsis 
because they are able to inhibit cytokine production induced by E. coli lPs - had 
an effect on cytokine production by meningococcal lPs or whole gram-negative 
bacteria. Therefore, we assessed the neutralizing effect of low-density lipoproteins 
(lDl), high-density lipoproteins (HDl), and very low-density lipoproteins (VlDl) on 
lPs- or whole bacteria-induced cytokine production in human mononuclear cells. 
a strong inhibition of E. coli lPs-induced cytokines by lDl and HDl was seen, 
whereas VlDl had a less pronounced effect. in contrast, N. meningitidis lPs, 
in similar concentrations, was neutralized much less effectively than E. coli lPs. 
effective neutralization of meningococcal lPs required a prolonged interaction 
time, a lower concentration of lPs, and higher concentrations of lipoproteins. 
Minimal neutralizing effects of the lipoproteins were observed on whole E. coli or 
N. meningitidis bacteria under all conditions tested. These findings raise questions 
about the rationale for adjuvant treatment of meningococcal and other types of 
gram-negative sepsis with lipoproteins.
an unexpected, but interesting approach to inhibit TlR4 dependent cytokine 
production comes from the lPs-molecule itself. in chapter 6, we investigated novel 
lPs species derived from N. meningitidis H44/76 by insertional inactivation of the 
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lpxL1 and lpxL2 gene that have a lipid a portion consisting of five (pentaacylated 
lpxL1) or four (tetraacylated lpxL2) fatty acids. We found that these novel lPs 
species functioned as lPs antagonists in humans by inhibiting cytokine production 
dependent on toll-like receptor 4 (TlR4). in contrast to the situation in humans, 
lpxL1 lPs was an agonist for cytokine production in peritoneal macrophages of 
mice, and exacerbated arthritis in a murine collagen induced arthritis model. 
although - in the light of the studies presented earlier in this thesis - it is not 
expected that inhibiting lPs or TlR4 alone will have a considerable beneficial 
effect on the course of meningococcal septic shock, the lPs antagonists might be 
useful in other inflammatory diseases that are TlR4 dependent such as rheumatoid 
arthritis, asthma or and inflammatory bowel disease.
 
from chapters 2 - 6 we have learned that it may be unwise to focus only on lPs 
as a disease inducing element of N. meningitidis. The ultimate strategy to stop 
the systemic inflammation induced by the meningococcus would neutralise all 
elements of the bacterium that provoke inflammation. future research should focus 
on identifying the non-lPs meningococcal components and their receptors that are 
responsible for the production of cytokines and the activation of complement. it 
may not be possible to find one magic bullit to stop the inflammatory response at 
the level of the bacterium or immune receptors. Maybe we need something more 
like a cluster bomb - multiple molecules that have an effect on multiple components 
of meningococci or multiple cellular and plasmatic receptors. 
in chapter 7 we studied whether cytokine production induced by meningococci is 
influenced by mannose-binding lectin (MBl), a key molecule in the lectin pathway of 
complement activation. We found that MBL significantly augmented IL-1β and IL-10 
production after stimulation with lPs-deficient meningococci, in a dose-dependent 
manner. In contrast, TNFα, IL-6 and IFNγ productions were unaffected. No effect 
of MBl was observed on cytokine induction by meningococcal lPs. We concluded 
that MBl interacted with non-lPs components of N. meningitidis and in this way 
selectively modulated the cytokine response. our findings link the complement 
system to cytokine production. Whether the augmented cytokine production by MBl 
contributes to the defensive function of MBl to meningococcal infections is subject 
to future research. 
chapters 8 - 12 of this thesis focus on complement activation by N. meningitidis in 
vitro as well as in vivo. The importance of the complement system in meningococcal 
disease is emphasized by several observations. complement deficiencies are 
defined risk factors for meningococcal infections, indicating that complement 
is crucial in the initial defence against this bacterium. on the other hand, during 
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fulminant meningococcal sepsis, disease severity, tissue damage, and outcome are 
closely related to the degree of complement activation. Thus, with respect to the 
pathogenesis of meningococcal disease, the complement system has been aptly 
named a double-edged sword.
in chapter 8 we studied the effect of complement inhibition on inflammation and 
bacterial killing in a novel human whole blood model of meningococcal sepsis. We 
found that the mannose-binding lectin and alternative complement pathway were 
crucial for complement activation by N. meningitidis and oxidative burst induced 
in granulocytes and monocytes. inhibition of c5a, using mab 137-26 binding the 
c5a moiety of c5 before cleavage, prohibited cR3 up-regulation, phagocytosis, and 
oxidative burst but had no effect on c5b-9 (Tcc) formation, lysis, and bacterial 
killing. a monoclonal antibody that blocks cleavage of and in this way prevents 
c5a and Tcc formation, showed the same effect on cR3, phagocytosis, and 
oxidative burst as the anti-c5a mab but additionally inhibited Tcc formation, 
lysis, and bacterial killing, consistent with a c5b-9-dependent killing mechanism. 
in conclusion, the anti-c5a mab 137-26 inhibited the potentially harmful effects 
of N meningitidis-induced c5a formation while preserving complement-mediated 
bacterial killing. We suggest that this is an attractive approach for the treatment of 
meningococcal sepsis. 
chapter 9 highlights the importance of the alternative pathway of complement in 
the defence against meningoccoci. We describe 2 cases of meningococcal septic 
shock, 1 of them fatal, in 2 children of a Turkish family. in the surviving patient, 
alternative pathway activation was absent and factor D plasma concentrations were 
undetectable. Mutation analysis of the factor D gene revealed a T638 > g (Val213 > 
gly) and a T640 > c (cys214 > arg) mutation in the genomic Dna from the patient, 
both in homozygous form. in vitro incubation of factor-D deficient plasma of the 
boy with serogroup B N. meningitidis showed normal MBl-mediated complement 
activation but no formation of the alternative pathway c3-convertase c3bBbP, and 
severely decreased c3bc formation and terminal complement activation. The defect 
was restored after supplementation with factor D. Thus, factor D deficiency leads 
to reduced alternative-pathway dependent complement activation by meningococci, 
and in this way to an increased susceptibility to invasive disease. 
in chapter 10 we investigated in patients with meningococcal septic shock and 
meningococcal disease without shock to what extent the alternative and lectin 
pathways of complement contribute to the systemic activation of complement 
and the ensuing tissue damage. in the patients with meningcoccal septic shock, 
high systemic concentrations of complement activation products c3bc (indicating 
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common pathway activation) and Tcc (terminal pathway activation) were seen. 
systemic activation of complement excellently correlated with disease severity 
and parameters of Dic. We also found high concentrations of c3bBbP, indicating 
alternative pathway activation. Two of the shock patients were MBl-deficient and 
had much lower circulating values of c3bc and Tcc than MBl-sufficient patients 
that presented with shock. interestingly, these MBl-deficient patients had relatively 
low disease severity and mild disseminated intravascular coagulation (Dic). This 
indicates that MBl is critical for the systemic activation of complement during 
meningococcal septic shock. 
in chapter 11 the restriction fragment length polymorphism genotyping method we 
used for determination of MBl genotypes is presented. We developed a PcR-RflP 
method for the X/Y promoter polymorphism of the MBL gene that works with the 
previously described PcR-RflP method for the three exon 1 variants to detect the 
mutations in the MBL gene that cause MBl deficiency.
chapter 12 provides a concise review of the diverse actions of the complement 
system in sepsis, emphasising on the defence against infection and the damage 
done by uncontrolled systemic activation of the complement system.
The data from chapters 8 - 12 show that MBl the and alternative pathway are 
crucial for the activation of complement during meningococcal septic shock. 
inhibition of c5a may be an attractive approach to diminish the devastating effects 
of septic shock especially because it preserves complement-mediated bacterial 
killing. it is interesting that the activation of complement was closely related to the 
development of disseminated intravascular coagulation (Dic) and thrombcytopenia. 
Dic is caused by activation of the coagulatory system and causes much of the 
severe sequelae associated with meningococcal disease such as amputations. This 
may be mediated by c5a-induced upregulation of tissue factor, but is incompletely 
understood. The pathogenesis of Dic and ways to influence the morbidity associated 
with it deserves further exploration. 
in chapters 13 - 15 we studied various new mediators in patients with meningococcal 
septic shock. 
Vascular endothelial growth factor (Vegf) is a central factor in angiogenesis 
and is an important mediator of vascular permeability. in chapter 13, patients 
with meningococcal infection were investigated in the early phase of invasive 
meningococcal disease. Vegf plasma concentrations were increased and were 
highest in the presence of shock compared with patients presenting without shock. 
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Vegf concentration at admission correlated with the severity of disease and 
the amount of fluids administered in the first 24 h. in all patients, a decrease in 
Vegf was associated with a decrease in fluid intake during t = 24 to 48 h. The 
results suggest that microvascular permeability in sepsis is closely linked to the 
plasma concentration of Vegf. The role of Vegf in sepsis-associated increased 
microvascular permeability needs further exploration and may represent a new 
therapeutic target.
in chapter 14 we studied macrophage migration inhibitory factor (Mif), a mediator 
of innate immunity and important in the pathogenesis of septic shock in-vivo in 
patients with meningococcal disease, in human experimental endotoxaemia and 
in whole blood cultures. Using a newly developed sensitive and specific enzyme-
linked immunosorbent assay (elisa), we found that Mif was increased in patients 
with meningococcal disease and highest in the presence of shock. Mif could not 
be detected in a human endotoxaemia model although high concentrations of TNFα 
were found. in addition, Mif was not produced by whole blood cells incubated 
with lPs or meningococci. Therefore, it can be questioned whether Mif in human 
sepsis is induced by lPs or Tnfα. our observations suggest that Mif plays a role 
in the development of shock in patients with sepsis, mediated in concert with other 
pathological events. 
chapter 15 studied the long pentraxin PTX3, an important element of the innate 
immune system and a potential candidate as a diagnostic tool in inflammatory 
conditions. We found high plasma concentrations of PTX3 at admission in patients 
with meningococcal disease. concentrations were significantly higher in patients 
with shock compared to patients without shock. in contrast, cRP at admission was 
lower in the shock group as compared to the no shock group. High PTX3 or low 
cRP concentration at admission discriminated well between presence and absence 
of shock, but PTX3 did not correlate with disease severity (PRisM) and days spent 
in icU. in conclusion, PTX3 was an early indicator of shock in patients with severe 
meningococcal disease that followed a pattern of induction distinct from cRP. 
in the part of the thesis presented in chapters 13 - 15 we identified 2 mediators, 
Vegf and Mif - that had not been previously studied in meningococcal disease - as 
possible mediators of tissue damage, both mediating different disease mechanisms. 
Because both Vegf and Mif are induced very early in the course of disease, they 
are primary mediators, which hold a promise for therapeutic interventions. However, 
it should be noted that the pathogenesis of sepsis and septic shock is complex 
and involves multiple mediators at multiple time points. Thus, therapies aimed at 
modulating the course of sepsis would most likely require a multi-target approach 
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and should attack mediators upstream in the inflammatory reaction. 
although it is a possible prognostic factor, The pathophysiological role of PTX3 in 
meningococcal disease is unknown. PTX3 binds to meningococci and the gram-
negative outer membrane protein ompa. future research will be aimed to explore 
whether PTX3 is important in the early defence against meningcococci.
one of the most intriguing aspects of meningococcal disease is that although 
carriage rates for meningcococci in some age groups exceed 20 %, only a minority 
of people ever get disease. even more peculiar is perhaps that clinical manifestation 
of disease is so diverse. 
in chapter 16 we studied the role of MBl genotype, MBl plasma concentration 
and MBl/MasP2-activity in susceptibility to and clinical presentation of disease 
in a case-parent study including 120 patients with meningococcal disease and 
parents. genotype for MBl was assessed using line probe assay. no transmission 
disequilibrium was found for the single nucleotide polymorphisms (snPs) in the 
MBL2 gene using transmission disequilibrium testing. The exon1 snPs combined 
were also not associated with an increased risk for disease. However, subgroup 
analysis showed increased risk for meningococcal meningitis associated with 
the exon 1 snPs. in addition, MBl plasma concentrations in meningitis patients 
were significantly lower than in patients with shock or bacteraemia. We concluded 
that polymorphisms in the gene for MBl do not predispose for invasive severe 
meningococcal disease, but snPs in exon 1 may be a risk factor for meningococcal 
meningitis. 
our findings contrast with previous studies on MBl and susceptibility to 
meningococcal disease. We believe that these findings of an association between 
MBl-deficiency and susceptibility to meningococcal disease can be explained 
by the use of flawed control groups with unusual low numbers of MBl-deficient 
individuals. The case-parent design of our study precludes such a matching bias, 
but has the problem of lower power. Thus, we cannot exclude that MBl-deficiency 
has a small effect on susceptibility to meningococcal disease which is only apparent 
in patients with meningococcal meningitis. 
in chapter 17 we analyzed the role of the innate production capacity for Tnf, 
il-1β, il-12 and il-10 in the clinical presentation and severity of meningococcal 
disease. Whole blood cultures from 113 survivors of meningococcal disease 
obtained median 5.4 years after hospitalization were stimulated with meningococcal 
lipopolysaccharide and heat-killed Neisseria meningitidis bacteria. Patients were 
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classified according to clinical manifestation in four groups: shock, both shock and 
meningitis, bacteraemia (neither shock nor meningitis) and distinct meningitis. no 
differences in whole blood cytokine production were found between the patients in 
these four groups. However, within the group of patients that had presented with 
shock, interleukin 1β (il-1β) and the il-1β / il-10 ratio were negatively correlated 
with disease severity. Thus, patients with meningococcal septic shock had a more 
severe course of disease when the production capacity for il-1β was lower. This 
latter finding may possibly explain the failure of adjunctive therapies in sepsis 
aimed at inhibiting IL-1β. 
We could not explain the differences in clinical manifestation of meningococcal 
disease by the innate cytokine response in whole blood. other non-cytokine 
components of the innate immune system, such as the complement system, either 
alone or in synergy with bacterial factors, may be more relevant for the early 
outgrowth of meningococci and hence the type of disease that develops. 
future research should focus on identifying the hosts genetic and functional factors 
that determine susceptibility to and clinical course of meningococcal disease. in this 
way we may be able to predict the clinical course of a patient in an early stage of 
the infection and select the patients at high risk for a deleterious course. in addition, 
if we could identify patients at high risk for developing meningococcal disease, e.g. 
by national screening programs, and would be able to vaccinate only people at risk, 
large scale vaccination campaigns may become unnecessary.
a final remark. Meningococcal disease is a serious problem in the netherlands 
and other industrialised countries, and every effort should be made to save all the 
patients we can. However, the core of the problem lies in the third world, especially 
africa - the ‘meningitis belt’ - and asia. in these countries, meningococcal disease 
is a disease of the underprivileged. The questions in these countries are different: 
are there enough vaccines, are there enough antibiotics, is there a hospital, is there 
any help at all? although the inequity between the western and third world lies at 
the base of this problem and is not easily solved, we should also make every effort 
we can to help the people in those countries with resources and research. 
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Meningokokken septische shock is een ernstige infectieziekte die vaak, in korte tijd, 
fataal afloopt. De heftige ontstekingsreactie tijdens deze ziekte wordt aangezet door 
complement-activatie en cytokine-productie en heeft primair tot doel bacteriegroei 
te remmen.  De ontstekingsreactie leidt echter ook tot ernstige verstoring van 
de homeostase met hierbij gedissemineerde intravasale stolling (Dis)en shock 
en daardoor uitval van meerdere organen. Hoe deze reactie precies verloopt, is 
slechts ten dele bekend. Betere behandeling van de ziekte door beteugeling van de 
ontstekingsreactie zodanig dat de gunstige effecten van deze reactie intact blijven, 
vereist meer kennis over wat er precies gebeurt en hoe dit wordt veroorzaakt.
leerboeken over infectieziekten vertellen ons dat de ontstekingsreactie bij 
meningokokken septische shock wordt veroorzaakt door lipopolysaccharide (lPs), 
een component van de bacteriële buitenmembraan. Door gebruik te maken van 
een genetisch gemodificeerde meningokok (H44/76lpxA of H44/76[pLAK33]) die 
geen lPs in zijn buitenmembraan heeft, onderzochten we (in hoofdstuk 2-4) het 
relatieve belang van het ‘lPs deel’ en van de ‘niet-lPs delen’ van de meningokok 
bij de activatie van complement en inductie van cytokine productie.
in hoofdstuk 2 laten we zien dat een belangrijk deel van de tumor-necrosis factor 
(TNF)-α en interleukine (IL)-1β productie en vrijwel alle interferon (IFN)-γ productie 
van menselijke mononucleaire bloedcellen na contact met meningokokken op 
rekening komt van de niet-lPs delen van de meningokok. De lPs-deficiente 
meningokokken konden ook cytokine productie en mortaliteit veroorzaken in een 
muis-model van meningokokken sepsis. echter, de dosis die hiervoor nodig was, 
lag honderd maal hoger dan wanneer ‘wild-type’ lPs bevattende meningokokken 
werden gebruikt. Hieruit concluderen we dat N. meningitidis cytokine-productie en 
ziekte kan induceren, onafhankelijk van lPs.
Volgens de literatuur zijn cD14 en TlR4 belangrijkste cellulaire receptoren voor het 
lPs; dit was de reden om in hoofdstuk 3 te onderzoeken wat de rol is van cD14 en 
TlR4 bij de cytokine inductie door niet-lPs componenten van meningokokken. een 
monoklonaal antilichaam gericht tegen CD14 bleek de TNFα en IL-1β productie 
door menselijke mononucleaire bloedcellen na stimulatie met E. coli lPs volledig 
te blokkeren. cytokine inductie door lPs van meningokokken, lPs-bevattende 
H44/76 meningokokken en lPs-deficiente H44/76lpxA meningokokken werd echter 
slechts gedeeltelijk geremd. experimenten met macrofagen geïsoleerd van TlR4-
deficiënte muizen wezen uit dat TlR4 cruciaal is voor de inductie van cytokinen 
door meningokokken lPs. echter, complete lPs bevattende meningokokken en 
lPs-deficiënte meningokokken gaven in TlR4-deficiënte muizen macrofagen 
beiden een krachtige cytokine respons, vergelijkbaar met de respons in macrofagen 
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van TlR4 bevattende muizen. Dit betekent dat N. meningitidis cytokine productie 
kan induceren in humane mononucleaire bloedcellen of muizen macrofagen 
onafhankelijk van de lPs receptoren cD14 en TlR4. 
in hoofdstuk 4 onderzochten we het belang van lPs en van de niet-lPs 
bestanddelen van de meningokok bij de activatie van complement en de 
complement-afhankelijke ontstekingsreactie in menselijk bloed. We vonden dat 
de lPs bevattende H44/76 meningokokken en de lPs-deficiente H44/76lpxA 
meningokokken beiden krachtig complement activeerden. gezuiverd lPs van 
meningokokken, gebruikt in hoeveelheden vergelijkbaar met de hoeveelheid 
aanwezig op complete meningokokken, was een relatief zwakke activator van 
complement. opregulatie van de complement receptor-3 op leukocyten en productie 
van vrije zuurstofradicalen door leukocyten gebeurde onafhankelijk van lPs. 
complement activatie en de complement afhankelijke leukocyten activatie uitgelokt 
door de meningokok geschiedt in menselijk bloed dus onafhankelijk van lPs. 
De resultaten van de onderzoeken in hoofdstuk 2-4, impliceren dat behandeling-
strategieën gericht op het blokkeren van lPs of de lPs-receptoren cD14 en TlR4, 
slechts een gedeeltelijk effect zullen hebben op de productie van cytokinen, en 
geen effect op de activatie van complement. om deze reden valt het te betwijfelen 
dat zulke therapieën het ziekte beloop kunnen modificeren. Het is aannemelijk dat 
dit één van de oorzaken is waardoor anti-endotoxine therapieën er niet in geslaagd 
zijn de afloop van meningokokken septische shock te verbeteren. 
in hoofdstuk 5 onderzochten we of lipoproteinen, stoffen die door hun remmende 
effect op E.coli lPs geïnduceerde cytokine productie aandacht hebben gekregen 
als eventuele behandelingsmogelijkheid van gram-negatieve sepsis, ook een 
remmend effect hebben op cytokine inductie door meningokokken lPs of complete 
gram-negatieve bacteriën. Hiertoe bestudeerden we het effect van low-density 
(lDl), high density (HDl) en very low density (VlDl) lipoproteinen op cytokine 
productie geïnduceerd door lPs of complete bacteriën in humane mononucleare 
cellen. Het bleek dat de cytokine productie na stimulatie met E. coli lPs krachtig 
werd geremd door lDl en HDl, en iets minder door VlDl. cytokine productie na 
stimulatie met meningokokken lPs werd echter veel minder effectief geremd. Voor 
effectieve neutralisatie van meningokokken lPs was een langere interactie tijd, 
een lagere concentratie van lPs of hogere concentratie van lipoproteinen nodig. 
De cytokine productie na stimulatie met complete gram-negatieve bacteriën, 
E.coli zowel als N. meningitidis, werd slechts minimaal geneutraliseerd door de 
lipoproteinen. onze resultaten zetten vraagtekens bij de rationale om lipoproteinen 
te gebruiken als adjuvante behandeling voor gram-negatieve sepsis. 
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een onverwachte, maar interessante benadering om TlR4-afhankelijke cytokine 
productie te remmen komt vanuit het lPs molecuul zelf. in hoofdstuk 6 hebben we 
meningokokken lPs varianten onderzocht met een lipid a deel dat bestaat uit vijf 
(pentageacyleerd lpxL1 lPs) of vier (tetrageacyleerd lpxL2 lPs) vetzuren. Deze 
nieuwe lPs varianten zijn afkomstig van genetisch gemanipuleerde meningokokken 
waarbij lpxL1 of het lpxL2 gen is geïnactiveerd. Deze lPs mutanten bleken lPs-
geïnduceerde TlR4-afhankelijke cytokine productie door menselijke bloedcellen 
uitstekend te remmen, ze fungeerden als lPs-antagonisten. in tegenstelling tot de 
situatie in mensen was lpxL1 lPs een agonist voor cytokine productie in peritoneaal 
macrofagen van muizen en het zorgde voor een exacerbatie van arthritis in een 
arthritis model in muizen. Hoewel het niet verwacht kan worden dat het remmen 
van lPs of TlR4 alleen een gunstig effect heeft op het beloop van meningokokken 
septische shock, is het wellicht mogelijk dat de onderzochte lPs-varianten 
bruikbaar zijn bij de behandeling van andere TlR4 afhankelijke ontstekingsziekten 
zoals rheumatoide arthritis, asthma of inflammatoire darmziekten. 
Uit de hoofdstukken 2-6 kunnen we afleiden dat het voor beteugeling van de 
ontstekingsreactie bij meningokokkenziekte, onverstandig lijkt de pijlen alleen 
op lPs te richten. Willen we de onwenselijke effecten van de ontstekingsreactie 
remmen dan zullen we de rol hierin van de niet-lPs onderdelen van de meningokok 
beter moeten kennen: wat is de exacte bijdrage, hoe verloopt de herkenning en 
de inductie van ontstekingsstoffen? Het is misschien niet mogelijk om een enkele 
zilveren kogel te vinden die de inflammatoire reactie op het niveau van de bacterie 
kan stoppen; misschien hebben we iets nodig als een clusterbom, dat wil zeggen 
meerdere moleculen die een effect hebben op meerdere bestanddelen van 
meningokokken en hun cellulaire of plasmatische receptoren, om het beloop van 
meningokokkenziekte gunstig kunnen beïnvloeden. 
in hoofdstuk 7 bestudeerden we het effect van mannose-bindend lectine (MBl), 
het sleutelmolecuul voor complement-activatie via de lectine-route, op de 
cytokine productie door menselijke mononucleaire bloedcellen na contact met 
meningokokken. We ontdekten dat MBL de IL-1β- en IL-10-productie uitgelokt door 
LPS-deficiente meningokokken versterkt, maar dat er geen effect was op de TNFα-, 
IL-6- en IFNγ-productie. Ook was er geen effect van MBL op de, veel sterkere, 
cytokine productie na contact met meningokoken lPs. We concludeerden dat 
MBl waarschijnlijk een interactie aangaat met de niet-lPs bestanddelen van de 
meningokok en hierbij de productie van specifieke cytokines beïnvloedt. of de door 
ons ontdekte verbinding tussen het complement-systeem en het cytokine-netwerk 
ook bijdraagt aan de bescherming tegen meningokokkenziekte is onderwerp voor 
toekomstig onderzoek.
284
18
De hoofdstukken 8–12 van dit proefschrift wordt, zowel in-vitro als in-vivo, 
complement-activatie door meningokokken bestudeerd. complement-activatie is een 
evolutionair oud beschermingsmechanisme tegen extracellulaire infecties. Mensen 
met complement-deficiënties hebben veel grotere kans op meningokokkenziekte. 
aan de andere kant is, bij mensen met een normaal complementsysteem, de 
ernst van meningokokkenziekte nauw gerelateerd aan de mate van complement-
activatie. Daarom wordt het complement systeem bij meningokokkenziekte ook wel 
een ‘dubbelzijdig zwaard’ genoemd.
in hoofdstuk 8 bestudeerden we het effect van remming van complement-activatie 
op ontsteking en de bacteriële ‘killing’ in een in-vitro model met menselijk bloed. We 
vonden dat de lectine- en de alternatieve-route essentieel zijn voor complement-
activatie door meningokokken en de complement afhankelijke productie van 
vrije zuurstofradicalen in neutrofiele granulocyten en monocyten. Blokkade van 
complementfactor c5a, door het monoklonaal antilichaam (mab) 137-26, dat het 
c5a-deel van c5 bindt en blokkeert nog voordat c5 gesplitst wordt in c5a en 
c5b, remt de opregulatie van complement Receptor-3 (cR3), de fagocytose en 
de productie van vrije zuurstofradicalen volledig. Daarentegen is er geen effect 
op de vorming van c5b-9 (= Terminaal complement complex (Tcc)), noch op 
lysis en killing van meningokokken. een ander mab dat de splitsing van c5 remt, 
had hetzelfde effect op de opregulatie van cR3, de fagocytose en de productie 
van vrije zuurstofradicalen, maar remde ook Tcc-formatie en lysis en killing van 
bacteriën. Dit betekent dat het anti-c5a mab 137-26 de schadelijke effecten van N. 
meningitidis geïnduceerde vorming van c5a kan remmen terwijl het de complement 
afhankelijke bacteriële killing intact houdt. Dit belooft nieuwe mogelijkheden voor 
de behandeling van meningokokken sepsis.
Hoofdstuk 9 laat zien hoe belangrijk de alternatieve route is voor de afweer tegen 
meningokokken. We beschrijven twee kinderen met meningokokken septische 
shock uit één familie. een van de twee kinderen overleed. in het patiëntje dat 
overleefde bleek er geen alternatieve route activatie. Dit kwam doordat er geen 
factor D (fD) was. Mutatie analyse van het FD-gen liet een T636>g (Val 213 > gly) 
en een T640>c (cys 214 > arg) mutatie zien in het Dna van het patiëntje, beide in 
homozygote vorm. In-vitro incubatie van het Deficiënte plasma met meningokokken 
toonde normale lectine-route activatie, maar geen vorming van het alternatieve 
route c3-convertase c3bBbP, en daardoor ook veel minder vorming van c3bc- en 
Tcc. Dit defect herstelde na toevoeging van extra fD. aldus leidt fD-deficientie tot 
een sterk verminderde alternatieve route activatie na contact met meningokokken, 
en zorgt dit voor een verhoogde vatbaarheid voor deze ziekte.
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in hoofdstuk 10 onderzochten we bij patiënten met meningokokkenziekte in welke 
mate de alternatieve- en de lectine-route bijdragen aan de activatie van complement 
en de hierop volgende weefselschade. in patiënten met meningokokken septische 
shock bleek de plasma concentratie van de complement activatie producten 
c3bc (wijzend op algemene route activatie) en Tcc (wijzend op terminale route 
activatie) sterk verhoogd. Deze systemische activatie van het complement systeem 
correleerde met de ziekte-ernst en parameters voor gedissemineerde intravasale 
stolling (Dis). activatie van de alternatieve route werd aangetoond door het vinden 
van verhoogde c3bBbP concentraties. Twee van de patiënten met shock bleken 
MBl-deficiënt. De twee hadden lagere concentraties van c3bc en Tcc dan de 
overige MBl-sufficiënte shock patiënten. opvallend genoeg hadden deze twee 
MBl-deficiënte patiënten ook minder Dis, en was bij hen de ziekte ernst ook 
minder. Deze observaties laten zien dat ook in-vivo MBl van cruciaal belang is voor 
de systemische complement activatie tijdens meningokokken septische shock.
in hoofdstuk 11 presenteren we een ‘restriction fragment length polymorphism 
(RflP)’ methode voor het genotyperen van de verschillende MBl genotypes. We 
hebben een PcR-RflP methode ontwikkeld voor het X/Y promoter polymorphisme 
in het MBL2 gen om zo de mutaties in het MBl2 gen te kunnen detecteren die 
MBl-deficiëntie veroorzaken. 
Hoofdstuk 12 geeft een literatuur overzicht van de acties van het complement 
systeem tijdens sepsis. Hierin belichten we met name de rol van het complement 
systeem als ‘dubbelzijdig zwaard’.
De resultaten gepresenteerd in hoofdstukken 8 - 12 laten zien dat de alternatieve 
en de lectine-route beide van cruciaal belang zijn voor het activeren van het 
complementsysteem bij meningokokken septische shock. Het blokkeren van c5a 
zou een aantrekkelijke benadering kunnen zijn om de schadelijke effecten van 
complement activatie te verminderen, vooral omdat anti-c5a mab de complement 
gemediëerde bacteriële ‘killing’ intact houdt. interessant is verder dat er een nauwe 
relatie bestaat tussen complement-activatie en de Dis en thrombocytopenie. 
Dis, dat wordt veroorzaakt door activatie van - onder andere - tissue factor, is bij 
meningokokken septische shock de oorzaak van veel ernstige restverschijnselen, 
zoals necrose van extremiteiten. Bij het ontstaan van Dis speelt mogelijk c5a-
gemedieerde opregulatie van tissue factor een rol, maar het proces is tot nu toe 
onvoldoende begrepen. De rol van complement-activatie bij het ontstaan van Dis, 
en de mogelijkheden dit te beïnvloeden, verdienen daarom ook meer onderzoek.
in de hoofdstukken 13 tot en met 15 hebben we verschillende, tot dusver nog niet 
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onderzochte, ontstekingsmediatoren bij meningokokkenziekte bestudeert. 
‘Vascular endothelial growth factor’ (Vegf) is een belangrijke factor bij 
angiogenese en vasculaire permeabiliteit. in hoofdstuk 13 onderzochten we 
patiënten met invasieve meningokokkenziekte in een vroege fase van de opname. 
De plasma concentratie van Vegf was bij hen verhoogd en de hoogste waardes 
werden gevonden in de patiënten met shock. De Vegf-concentratie bij opname 
correleerde met de ernst van de ziekte en de hoeveelheid vocht toegediend in de 
eerste 24 uur. Bij alle patiënten werd de normalisering van de Vegf-concentratie 
na 24 – 48 uur, gevolgd door een afname in de vocht behoefte. Deze resultaten 
suggereren dat microvasculaire permeabiliteit tijdens sepsis mogelijk in verband 
staat met de Vegf-concentratie. Wellicht vormt Vegf een nieuw mikpunt voor 
toekomstige therapieën voor meningokokken septische shock.
in hoofdstuk 14 bestudeerden we ‘Macrophage Migration inhibitory factor’ 
(Mif), in-vivo bij patiënten met meningokokkenziekte en vrijwilligers die in een 
experimentele setting lPs kregen toegediend, en in-vitro in een vol bloed model. 
We gebruikten een nieuw ontwikkelde, zeer gevoelige en specifieke ‘enzyme linked 
immunosorbent assay’ (elisa), en vonden dat de plasmaconcentratie van Mif 
verhoogd was in patiënten met meningokokkenziekte, waarbij de hoogste waarden 
werden gevonden in patiënten met septische shock. Mif kon daarentegen niet 
aangetoond worden tijdens experimentele humane endotoxinaemie, hoewel bij 
deze vrijwilligers wel zeer hoge TNFα concentraties werden gevonden. Ook kon er 
geen Mif productie worden gevonden na stimulatie met lPs of meningokokken in 
het in-vitro model waarbij ook TNFα werd geproduceerd. Onze bevindingen tonen 
aan dat de productie van Mif tijdens sepsis niet afkomstig is van bloedcellen en 
dat deze – in tegenstelling tot wat werd gedacht – niet bepaald wordt door de TNFα 
plasma concentratie. 
in hoofdstuk 15 keken we naar het pentraxine 3 (PTX3). PTX3 lijkt qua vorm en 
functie op c-reactief proteïne (cRP) en heeft een functie bij de klaring van celresten 
en de aangeboren afweer. PTX3 wordt geproduceerd door endotheel cellen, terwijl 
cRP wordt gemaakt door levercellen na stimulatie met il-6. een verhoogde PTX3 
concentratie kan gebruikt worden bij de diagnostiek van ontstekingsziekten. Bij 
patiënten met meningokokkenziekte vonden we hoge PTX3 concentraties op het 
moment van opname. De PTX3 concentraties waren het hoogst in de patiënten met 
shock, dit in tegenstelling tot de cRP-concentratie die het hoogste was bij patiënten 
met meningitis. aldus is PTX3 een vroege indicator voor shock bij patiënten met 
meningokokkenziekte.
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We beschreven in hoofdstuk 13-15 het patroon van Vegf, Mif en PTX3. Vegf 
en Mif zijn twee mediatoren die bij meningokokkenziekte nog niet eerder zijn 
bestudeerd. omdat beiden vroeg in het ziekteproces worden geproduceerd 
en geassocieerd zijn met ernstige weefselschade, spelen ze mogelijk een rol in 
het ontstaan van deze weefselschade en vormen ze hierdoor een mogelijk doel 
van therapie. echter, we weten uit de literatuur dat veel andere mediatoren bij 
meningokokken septische shock een vergelijkbaar patroon volgen. Daarom zullen 
therapieën die bedoeld zijn om het dramatische beloop van meningokokken 
septische shock te keren, waarschijnlijk gericht moeten zijn op meerdere 
van deze mediatoren. De pathofysiologische rol van PTX3 in het beloop van 
meningokokkenziekte dient verder te worden uitgezocht. Uit de literatuur is bekend 
dat PTX3 aan het buitenmembraan proteïne ompa, van meningokokken bindt. 
aldus is PTX3, naast een indicator van ziekte, mogelijk ook van belang voor de 
afweer tegen meningokokken. 
een van de meest intrigerende aspecten van meningokokkenziekte is dat, hoewel 
er veel mensen zijn die meningokokken in hun neus huisvesten (in sommige 
leeftijdsgroepen is dit zelfs 20 %), slechts een klein deel van deze mensen ziek 
wordt. evenzo merkwaardig is dat dezelfde bacterie bij verschillende individuen 
verschillende ziektebeelden kan veroorzaken.
in hoofdstuk 16 bestudeerden we de rol van MBl op de vatbaarheid voor de ziekte 
en het type ziektebeeld dat zich ontwikkelt. Hiertoe deden we een ‘case-parent’ 
studie in 120 patiënten met meningokokkenziekte en hun ouders. MBl genotype 
werd bepaald met behulp van een ‘line probe assay’. We vonden geen transmissie 
disequilibrium voor de verschillende snPs in het MBL2 gen, hetgeen betekent dat 
MBL2 snPs geen verhoogd risico geven op ernstige meningokokkenziekte. De 
combinatie van de verschillende snPs in exon 1 was ook niet geassocieerd met 
een verhoogd risico op meningokokkenziekte. in een subgroep analyse vonden 
we echter wel een verhoogd risico voor meningokokken meningitis geassocieerd 
met de exon 1 snPs. ook was de plasmaconcentratie van MBl in de patiënten 
met meningitis significant lager dan bij patiënten met bacteriemie of shock. aldus 
concluderen we dat polymorphismen in het MBL2 gen niet bijdragen aan een 
verhoogde kans op het krijgen van ernstige invasie meningokokkenziekte, hoewel 
de snPs in exon 1 wel een risico factor voor meningitis zouden kunnen zijn. 
Deze bevindingen verschillen van eerdere studies die wel lieten zien dat exon 1 
polymorphismen in het MBL2 gen geassocieerd waren met een grotere kans op het 
krijgen van meningokokkenziekte. Deze studies hadden als nadeel dat er controle 
groepen werden gebruikt met ongebruikelijke weinig MBl-deficiënte personen. Het 
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‘case-parent’ ontwerp van onze studie voorkomt deze ‘matching bias’, maar heeft 
wel als nadeel dat de statistische ‘power’ minder is. om deze reden kunnen we 
niet geheel uitsluiten dat MBl-deficiëntie een klein effect heeft op vatbaarheid voor 
meningokokkenziekte met name bij patiënten met meningitis. 
in hoofdstuk 17 analyseerden we of de aangeboren productiecapaciteit 
voor de cytokinen TNFα, IL-1β, IL-12 en IL-10 de klinische manifestatie 
van meningokokkenziekte bepaald. Bloed van 113 overlevenden van 
meningokokkenziekte, afgenomen mediaan 5.4 jaar na presentatie op de intensive 
care, werd gestimuleerd met N. meningitidis lPs en hitte gedode N. meningitidis 
bacteriën. De patiënten werden geclassificeerd naar aanleiding van ziekte 
manifestatie in vier groepen: shock, shock met meningitis, meningitis zonder shock 
en bacteriemie (geen shock en geen meningitis). We vonden geen enkel verschil 
in cytokine productie in bloed tussen deze 4 verschillende groepen. in de groep 
van patiënten die zich hadden gepresenteerd met shock vonden we echter wel 
een negatieve correlatie van de IL-1β en de IL-1β / IL-10 ratio met ziekte ernst. 
Dit betekent dat wanneer de aangeboren productiecapaciteit voor IL-1β lager 
is, patiënten met meningokokken septische shock een ernstiger beloop van de 
ziekte hebben. Deze laatste bevinding is wellicht een verklaring voor het falen van 
therapieën die gericht zijn op het remmen van de IL-1β productie tijdens sepsis. 
De verschillende klinische manifestaties van meningokokkenziekte konden 
niet verklaard worden door verschillen in aangeboren productie capaciteit voor 
de verschillende cytokinen die we bestudeerd hebben. andere, niet-cytokine 
onderdelen van het aangeboren immuunsysteem van de gastheer, zoals het 
complement systeem, alleen dan wel in synergie met bacteriële factoren, zijn 
misschien meer relevant voor het type ziekte dat zich ontwikkelt. 
Toekomstig onderzoek moet zich richten op de genetische en functionele 
gastheerfactoren die vatbaarheid voor en klinische manifestatie van 
meningokokkenziekte bepalen. Wellicht kunnen we dan het klinische beloop beter 
voorzien, en de patiënten selecteren die een grote kans hebben op een ernstig 
beloop. als we patiënten met een hoog risico op het krijgen van meningokokkenziekte 
kunnen identificeren, bijvoorbeeld via nationale screeningsprogramma’s, en 
we zouden alleen die mensen hoeven te vaccineren, dan zouden grootschalige 
landelijke vaccinatie campagnes overbodig kunnen worden. 
een laatste opmerking. Meningokokkenziekte is een ernstig probleem in nederland 
en andere geïndustrialiseerde landen; we moeten alles doen om zo veel mogelijk 
patiënten te redden. De kern van het probleem ligt echter ergens anders, namelijk 
in de derde wereld, en dan vooral afrika - de ‘meningitis gordel’ - en azië. in deze 
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landen is meningokokkenziekte een ziekte van minderbedeelden. De vragen in 
deze landen zijn heel anders: zijn er genoeg vaccins, zijn er genoeg antibiotica, 
is er een ziekenhuis, is er sowieso enige vorm van hulp. Hoewel de ongelijkheid 
tussen het westen en de derde wereld de bron van dit probleem vormt, moeten we 
ons uiterste best doen om ook de mensen in die landen te helpen met alle middelen 
die we hebben. 
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